(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
4 November 2004 (04.11.2004)

PCT

(10) International Publication Number
WO 2004/094376 A1

(51) International Patent Classification[7]: C07D 209/16, 209/26, 213/38, C07C 259/06, C07D 403/12, A61K 31/16, A61P 35/00

(21) International Application Number: PCT/US2004/011990

(22) International Filing Date: 16 April 2004 (16.04.2004)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
60/463,479 17 April 2003 (17.04.2003) US
60/484,053 30 June 2003 (30.06.2003) US

(71) Applicant *(for all designated States except US)*: **BAYER PHARMACEUTICALS CORPORATION** [US/US]; 400 Morgan Lane, West Haven, CT 06516 (US).

(72) Inventors; and

(75) Inventors/Applicants *(for US only)*: **WANG, Yamin** [CN/US]; 10 Russet Road, Sandy Hook, CT 06482 (US). **DAI, Miao** [CN/US]; 83-72 Daniels Street, Briarwood, NY 11435 (US). **HATOUM-MOKDAD, Holia** [US/US]; 43 Joseph Lane, Hamden, CT 06514 (US). **HONG, Zhenqiu** [CN/US]; 11A Robert Treat Drive, Milford, CT 06460 (US). **KLUENDER, Harold, C. E.** [US/US]; 27 Academy Road, Trumbull, CT 06611 (US). **LADOUCEUR, Gaetan, H.** [CA/US]; 103 Golden Hill Drive, Guilford, CT 06437 (US). **LI, Tindy** [US/US]; 102 Wharton Place, West Haven, CT 06516 (US). **LOWE, Derek, B.** [US/US]; 31 Bittersweet Lane, Hamden, CT 06518 (US). **MULL, Eric, S.** [US/US]; 1937 Little Meadow Road, Guilford, CT 06437 (US). **SHELEKHIN, Tatiana, E.** [US/US]; 4 High Valley Road, Ridgefield, CT 06877 (US). **SMITH, Roger, A.** [US/US]; 65 Winterhill Road, Madison, CT 06443 (US). **WONG, Wai, C.** [US/US]; 10 Green Haven Road, Trumbull, CT 06611 (US).

(74) Agents: **GREENMAN, Jeffrey, M.** et al.; Bayer Pharmaceuticals Corporation, 400 Morgan Lane, West Haven, CT 06516 (US).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

— *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii)) for the following designations AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW, ARIPO patent (BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG)*

— *as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii)) for all designations*

— *as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii)) for all designations*

— *of inventorship (Rule 4.17(iv)) for US only*

Published:

— *with international search report*

[Continued on next page]

(54) Title: HYDROXAMIC ACIDS USEFUL IN THE TREATMENT OF HYPER-PROLIFERATIVE DISORDERS



(I)

(57) Abstract: This invention relates to a compound of Formula (I) and its use in treating hyper-proliferative disorders.

WO 2004/094376 A1

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

Hydroxamic Acids Useful in the Treatment of Hyper-Proliferative Disorders

Field of the Invention

This invention relates to novel hydroxamic acid compounds, pro-drugs thereof, pharmaceutical compositions containing such compounds and pro-drugs, and the use of those compounds or compositions for treating hyper-proliferative disorders.

Compounds of the Invention

One embodiment of the present invention is a compound of Formula I



(I)

wherein

W is selected from H, $(C_1\text{-}C_6)$alkyl,

O-phenyl optionally substituted with up to 2 substituents each selected independently from R^{12},

phenyl optionally substituted with up to 2 substituents each selected independently from R^{12}, OH, $COOR^7$, $C(O)NHR^7$, $S(O)_2(C_1\text{-}C_3)$alkyl, $NHS(O)_2(C_1\text{-}C_3)$alkyl, $N[(C_1\text{-}C_3)alkyl]_2$, $NH(C_1\text{-}C_3)$alkyl, $NHC(O)(C_1\text{-}C_3)$alkyl,  , and $(C_1\text{-}C_3)$alkoxy substituted with 1 substituent selected from $N[(C_1\text{-}C_3)alkyl]_2$, $NH(C_1\text{-}C_3)$alkyl, and  ,

indolyl optionally substituted with 1 or 2 substituents each selected independently from R^{12}, OH, $C(O)O(C_1\text{-}C_4)$alkyl,

$(C_1\text{-}C_3)$alkyl substituted with 1 or 2 substituents each selected independently from OH, $C(O)R^8$, $(C_1\text{-}C_3)$alkoxy, pyrrolidinyl,  , imidazolyl, $NH(C_1\text{-}C_3)$alkyl, and $N[(C_1\text{-}C_3)alkyl]_2$, and

$(C_1\text{-}C_3)$alkoxy substituted with 1 substituent selected from $NH(C_1\text{-}C_3)$alkyl, $N[(C_1\text{-}C_3)alkyl]_2$, pyrrolidinyl, imidazolyl,  and $(C_1\text{-}C_3)$alkoxy, and

another heteroaryl optionally substituted with up to 3 substituents each independently selected from R^{12};

L is selected from CHR^4, CHR^5-CHR^6, and CHR^5-CH_2-CHR^6;

R^1 is selected from H, $C(O)R^{10}$, $C(O)OR^7$, tetrahydropyranyl, $(C_3$-$C_6)$cycloalkyl,

phenyl optionally substituted with up to 2 substituents each independently selected from R^{12},

pyridyl, optionally substituted with up to 2 substituents each independently selected from R^{12},

$S(O)_2$-phenyl where said phenyl is optionally substituted with 1 or 2 substituents each independently selected from R^{12}, NH_2, $NHC(O)(C_1$-$C_3)$alkyl, $NH(C_1$-$C_3)$alkyl-$N[(C_1$-$C_3)$alkyl$]_2$, $NH(C_1$-$C_3)$alkyl-OH, COOH, OH, and $(C_1$-$C_3)$alkoxy substituted with 1 substituent selected from $N[(C_1$-$C_3)$alkyl$]_2$, OH, and  ,

$S(O)_2(C_1$-$C_3)$alkyl optionally substituted with one phenyl ring,

$(C_1$-$C_6)$alkyl optionally substituted with 1 or 2 substituents each independently selected from OR^{11}, $C(O)R^{10}$, $C(O)OR^7$, $N[(C_1$-$C_3)$alkyl$]_2$, $(C_3$-$C_6)$cycloalkyl, dioxopyrrolidinyl,  , glucopyranosyl, glucopyranosylamino, $(C_1$-$C_3)$alkoxy optionally substituted with 1 or 2 substituents each selected independently from OH,  , and imidazolyl,

O-phenyl optionally substituted with up to two substituents each independently selected from R^{12},

NH_2 where one H is optionally replaced with one substituent selected from $S(O)_2(C_1$-$C_3)$alkyl, $S(O)_2NH(C_1$-$C_3)$alkyl, $S(O)_2CF_3$, $C(O)R^7$, $S(O)_2N[(C_1$-$C_3)$alkyl$]_2$, $C(O)O(C_1$-$C_4)$alkyl, $C(O)NH(C_1$-$C_4)$alkyl, $C(O)N[(C_1$-$C_3)$alkyl$]_2$,  , and $(C_1$-$C_4)$alkyl optionally substituted with one OH group,

phenyl optionally substituted with 1 or 2 substituents each independently selected from R^{12}, OH, S-$(C_1$-$C_3)$alkyl, $C(O)NH_2$, $S(O)_2NH_2$, $C(O)N[(C_1$-$C_3)$alkyl$]_2$, $S(O)_2(C_1$-$C_3)$alkyl, $S(O)_2NHC(O)(C_1$-$C_3)$alkyl, $C(O)(C_1$-$C_3)$alkyl, $C(O)NH(C_1$-$C_3)$alkyl, $NHS(O)_2(C_1$-$C_3)$alkyl, $NHS(O)_2N[(C_1$-$C_3)$alkyl$]_2$, $NHC(O)NH(C_1$-$C_3)$alkyl,

$NHC(O)N[(C_1\text{-}C_3)alkyl]_2$, $NHC(O)NH_2$, $S(O)_2N[(C_1\text{-}C_3)alkyl]_2$, $NHS(O)_2NH(C_1\text{-}C_3)alkyl$, $NHC(O)(C_1\text{-}C_3)alkyl$, $S(O)_2NH(C_1\text{-}C_3)alkyl$ optionally substituted with 1 substituent selected from $(C_1\text{-}C_3)alkoxy$, $NH(C_1\text{-}C_3)alkyl$, $N[(C_1\text{-}C_3)alkyl]_2$, and  ,

$(C_1\text{-}C_3)alkyl$ substituted with one substituent selected from $NHS(O)_2(C_1\text{-}C_3)alkyl$, $NHS(O)_2N[(C_1\text{-}C_3)alkyl]_2$, $NHC(O)NH(C_1\text{-}C_3)alkyl$, $NHC(O)N[(C_1\text{-}C_3)alkyl]_2$, $NHS(O)_2NH(C_1\text{-}C_3)alkyl$, and $NHC(O)(C_1\text{-}C_3)alkyl$, and

$(C_1\text{-}C_3)alkoxy$ substituted with 1 substituent selected from OH, $NH(C_1\text{-}C_3)alkyl$, $N[(C_1\text{-}C_3)alkyl]_2$, $(C_1\text{-}C_3)alkoxy$, and  ,

pyrrolyl optionally substituted with one substituent selected from R^{12}, $C(O)N[(C_1\text{-}C_3)alkyl]_2$, $C(O)NH(C_1\text{-}C_3)alkyl$, $C(O)(C_1\text{-}C_3)alkyl$,  , and $S(O)_2(C_1\text{-}C_3)alkyl$,

pyrazolyl optionally substituted with up to 3 substituents each selected independently from R^{12}, $C(O)N[(C_1\text{-}C_3)alkyl]_2$, $C(O)NH(C_1\text{-}C_3)alkyl$, and  , and

another heteroaryl optionally substituted with up to two substituents each independently selected from R^{12};

R^2 is in each instance selected independently from $(C_1\text{-}C_3)alkyl$, halo, $(C_1\text{-}C_3)alkoxy$, CF_3, NO_2, NH_2, CN, and COOH;

R^3 is selected from H, $(C_1\text{-}C_3)alkyl$, and halo;

R^4 is selected from H and $(C_1\text{-}C_3)alkyl\text{-}OH$;

R^5 is selected from H, OH and $(C_1\text{-}C_3)alkyl$;

R^6 is selected from H, $C(O)OR^7$, $C(O)R^9$, and

$(C_1\text{-}C_6)alkyl$ optionally substituted with one substituent selected from OH, $NHS(O)_2(C_1\text{-}C_3)alkyl$, and $NHC(O)(C_1\text{-}C_3)alkyl$;

R^7 is selected from H and $(C_1\text{-}C_4)alkyl$;

R^8 is selected from OH, NH_2, $N[(C_1\text{-}C_3)alkyl]_2$, morpholinyl, and pyrrolidinyl;

R^9 is selected from NH_2, morpholinyl, $N[(C_1\text{-}C_3)alkyl]_2$, and $NH(C_1\text{-}C_3)alkyl$ optionally substituted with one substituent selected from

OH, COOH, and $N[(C_1\text{-}C_3)alkyl]_2$;

R^{10} is selected from $(C_3\text{-}C_6)$cycloalkyl, morpholinyl, $N[(C_1\text{-}C_4)alkyl]_2$, $(C_1\text{-}C_3)$alkoxy,

heteroaryl optionally substituted with 1 or 2 substituents each independently selected from $(C_1\text{-}C_3)$alkyl, $(C_1\text{-}C_3)$alkoxy, OH, halo and CF_3,

phenyl optionally substituted with 1 or 2 substituents each independently selected from $(C_1\text{-}C_3)$alkyl, $(C_1\text{-}C_3)$alkoxy, OH, halo and CF_3,

$(C_1\text{-}C_3)$alkyl optionally substituted with one substituent selected from phenyl, imidazolyl, and  ,

$NH(C_1\text{-}C_4)$alkyl optionally substituted with 1 phenyl ring optionally substituted with 1 or 2 substituents each independently selected from $(C_1\text{-}C_3)$alkyl, $(C_1\text{-}C_3)$alkoxy, halo and CF_3, and

NH-phenyl where said phenyl is optionally substituted with 1 or 2 substituents each independently selected from $(C_1\text{-}C_3)$alkyl, $(C_1\text{-}C_3)$alkoxy, halo and CF_3;

R^{11} is selected from H, $C(O)N[(C_1\text{-}C_3)alkyl]_2$, C(O)-pyrrolidinyl, C(O)NH-phenyl, and $C(O)NH(C_1\text{-}C_3)$alkyl optionally substituted with 1 phenyl ring;

R^{12} is selected from $(C_1\text{-}C_6)$alkyl, $(C_1\text{-}C_3)$alkoxy, halo, NO_2, CN, CF_3, O-CF_3, and phenyl optionally substituted with up to 2 substituents each selected independently from halo, $(C_1\text{-}C_3)$alkyl, and $(C_1\text{-}C_3)$alkoxy;

X is selected from O, S, CH_2, and NH, and

when X is NH, the H on NH is optionally replaced with $C(O)(C_1\text{-}C_3)$alkyl, $S(O)_2(C_1\text{-}C_3)$alkyl, or $(C_1\text{-}C_6)$alkyl

and when X is O, S, or CH_2, the  moiety is optionally substituted

by replacing any H atom in the  moiety with $(C_1\text{-}C_4)$alkyl;

m is selected from 0, 1 and 2;

n is selected from 1 and 2;

-- -- is selected from a double bond and a single bond;

or a pharmaceutically acceptable salt, ester or carbonate thereof.

The terms identified above have the following meaning throughout:

The term "optionally substituted" means that the moiety so modified may have from none to up to at least the highest number of substituents indicated. The substituent may replace any H atom on the moiety so modified as long as the replacement is chemically possible and chemically stable. When there are two or more substituents on any moiety,

each substituent is chosen independently of any other substituent and can, accordingly, be the same or different.

The terms "(C_1-C_3)alkyl", "(C_1-C_4)alkyl" and "(C_1-C_6)alkyl", mean linear or branched saturated carbon groups having from about 1 to about 3, about 4, or about 6 C atoms, respectively. Such groups include but are not limited to methyl, ethyl, *n*-propyl, isopropyl, *n*-butyl, isobutyl, *sec*-butyl, *tert*-butyl, and the like.

The term "(C_1-C_3)alkoxy" means a linear or branched saturated carbon group having from about 1 to about 3 C atoms, said carbon group being attached to an O atom. The O atom is the point of attachment of the alkoxy substituent to the rest of the molecule. Such groups include but are not limited to methoxy, ethoxy, *n*-propoxy, isopropoxy, and the like.

When an alkyl or an alkoxy group is "optionally substituted", that means that any H atom on any C atom in the group is replaced with a recited substituent as long as the substitution is chemically appropriate for the C atom's location in the molecule, and as long as only about the maximum number of substituents recited replace H atoms in any specific alkoxy group.

The term "(C_3-C_6)cycloalkyl" means the monocyclic analogs of an alkyl group having from about 3 to about 6 C atoms, as defined above. Examples of (C_3-C_6)cycloalkyl groups include but are not limited to cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, and the like.

The term "halo" means an atom selected from Cl, Br, F and I, where Cl, Br and F are preferred.

When "(O)" is used in a chemical formula, it means =O. For example, "C(O)" means a carbonyl group and "$S(O)_2$" means a sulfonyl group.

The formula "$N[(C_1$-$C_3)alkyl]_2$" means that each of the 2 possible alkyl groups attached to the N atom are selected independently from the other so that they may be the same or they may be different.

In the case of $(R^2)_m$, when m is 1 or 2, R^2 is in each instance attached to the core molecule at any available C atom on the phenyl ring. That is, when m is 1, R^2 is attached at any one of the three available C atoms of the phenyl ring. When m is 2, each R^2 group is attached to a separate available C atom selected form the three available C atoms of the phenyl ring, and each R^2 group is selected independently from the other.

The terms "heteroaryl" and "another heteroaryl" (hereafter, severally and collectively "another/heteroaryl") each means an aromatic mono or fused bicyclic ring containing about 5 to about 10 atoms, 1, 2, 3, or 4 of which are each independently selected from N, O and S, the remaining atoms being C, as described further below.

When another/heteroaryl is an aromatic monocyclic ring containing 5 atoms, 1, 2, 3, or 4 of the atoms are each independently selected from N, O and S, and the remaining atoms are C, with the proviso that there is no more than one O atom or one S atom in any ring. The 5 membered heteroaryl is attached to the core molecule at any available C or N atom, and any substituent may be attached to the heteroaryl at any available C or N atom with the proviso that halo, NO_2, CN, O-CF_3, or alkoxy substituents are attached to the ring at any of the ring's available C atoms only. Such 5-membered heteroaryl groups include pyrrolyl, furanyl, thienyl, imidazolyl, pyrazolyl, thiazolyl, isothiazolyl, oxazolyl, isoxazolyl, isothiazolyl, triazolyl, oxadiazolyl, tetrazolyl, and thiadiazolyl, and the like, in all their possible isomeric forms.

When another/heteroaryl is an aromatic monocyclic ring containing 6 atoms, 1 or 2 of the atoms in the ring are N, and the remaining atoms are C. The moiety is attached to the core molecule at any available C atom, and any substituent may be attached to the 6 membered heteroaryl at any available C atom. Such groups include pyridinyl, pyrimidinyl, pyridazinyl, pyrazinyl, and the like, in any possible isomeric form.

When another/heteroaryl is a fused bicyclic ring, it has from 9 to 10 atoms divided into 2 rings that are fused together and 1, 2, 3, or 4 of which are each independently selected from N, O and S with the proviso that there can be no more than one O atom or one S atom in any fused bicyclic ring. The complete fused bicyclic ring system is aromatic. The heteroatoms may be located at any available position on the fused bicyclic moiety. A fused bicyclic heteroaryl is attached to the core molecule through any available C or N atom, and is optionally substituted at any available C or N atom(s) with the recited substituents with the exception that halo, NO_2, CN, O-CF_3, or alkoxy substituents are attached to the ring at any of the ring's available C atoms only. Bicyclic heteroaryl groups include -5-6, and -6-6 fused bicycles. The fused bicycles include, but are not limited to benzofuranyl, quinolinyl, isoquinolinyl, naphthyridinyl, indolyl, indazolyl, isoindolyl, benzoxazolyl, benzothiazolyl, benzimidazolyl, benzothienyl, benzotriazolyl and the like, in any possible isomeric form.

When W is another heteroaryl, indolyl is not included in this group. When W is optionally substituted indolyl, the indolyl moiety may be attached to the rest of the molecule at any available C or N atom, and it may be optionally substituted at any available C or N atom in the indolyl moiety.

When R^1 is (C_1-C_6)alkyl substituted with another heteroaryl, pyrrolyl and pyrazolyl are not included in the another heteroaryl group. When R^1 is (C_1-C_6)alkyl substituted with optionally substituted pyrrolyl or optionally substituted pyrazolyl, the said pyrrolyl or pyrazolyl may be attached to the rest of the molecule at any available C or N atom, and it

may be optionally substituted at any available C or N atom on the ring with the exception that halo, NO_2, CN, O-CF_3, or alkoxy substituents are attached to the ring at any of the ring's available C atoms only.

When a glucopyranosyl group is attached to the rest of the molecule, it is attached through any O atom bonded to the groups pyranyl ring, and when a glucopyranosylamino group is attached to the rest of the molecule, it is attached through its N atom.

When a phenyl ring is substituted with one or more substituent, the substituent(s) may be attached to the phenyl ring at any available C atom. When there is more than 1 substituent on a phenyl ring, each is selected independently from the other so that they may be the same or different.

 means optionally substituted morpholinyl, thiomorpholinyl, piperidinyl or piperazinyl. A  ring may be attached to the rest of the molecule through any available N atom in the  . When a  ring is substituted, the substituent(s) is/are attached to the ring at any of the ring's available C or N atom(s). When there is more than 1 substituent on a ring, each is selected independently from the other so that they may be the same or different.

When n is 1, the W-L-N(R^1)- side chain may be attached to the rest of the molecule at the C1, C2, or C3 atom, preferably at the C1or C2 atom where the carbon atoms are numbered as follows:  .

When n is 2, the W-L-N(R^1)- side chain may be attached to the rest of the molecule at C5, C6, C7, or C8 atom, preferably at C5, or C6 atom where the carbon atoms are numbered as follows:  .

When L is CHR^5-CHR^6 or CHR^5-CH_2-CHR^6, W is linked to these groups at the CHR^5 carbon atom and N(R^1) is linked to these groups at the CHR^6 carbon atom.

Representative compounds of Formula I are shown in Table I. Those compound examples that have characterization data such as HPLC retention time and/or M+H mass

spectroscopy data listed were actually synthesized. Those that do not have characterization data were not synthesized; however, they can be synthesized by following procedures that are well known to those skilled in the art and/or procedures that are disclosed in this application.

5

Table I

Compound Example	Structure	Synthetic sequence	HPLC RT (min) (method)	M+H
1		D, E1, 1	1.65 (A)	391.9
2		D, E, G2, J3, 2	1.53 (A)	420.0
3		D, E, I1, 3	1.70 (A)	362.0
4		D, E, I2, 4	1.68 (A)	362.0
5		D, E, G, J, H2, 5	1.52 (A)	406.0
6		D, E, G, J, H1, 6	1.51 (A)	406.0

Compound Example	Structure	Synthetic sequence	HPLC RT (min) (method)	M+H
7		D, E3, 7	1.63 (A)	391.9
8		D, E, 8	1.73 (A)	362.0
9		D, E, G, J, 9	1.54 (A)	406.0
10		C, G1 (via A), A2, D1, 10	3.72 (A)	561.9
11		C, F, F1 (via B), J2, D2, 11	2.17 (B)	406.5 (-BOC)
12		K, L, E4, 12	1.98 (A)	376.0

Compound Example	Structure	Synthetic sequence	HPLC RT (min) (method)	M+H
13		D, E, M, 13	2.30 (A)	403.9
14		D, E, M1, 14	2.76 (A)	480.0
15		D, E, M2, 15	2.82 (A)	458.0
16		D, E2, 16	1.72 (A)	392.0
17		D, E, M3, 17	2.68 (A)	465.9
18		D, E, M4, 18	2.91 (A)	472.1

Compound Example	Structure	Synthetic sequence	HPLC RT (min) (method)	M+H
19		D, E, N, 19	2.43 (A)	432.9
20		D, E, N1, 20	2.80 (A)	461.0
21		D, E, N2, 21	2.79 (A)	494.9
22		D, E, N3, 22	2.79 (A)	508.9
23		D, E, O, 23	3.11 (A)	501.9

Compound Example	Structure	Synthetic sequence	HPLC RT (min) (method)	M+H
24		D, E, O1, 24	2.49 (A)	439.9
25		D, E, G2, J3, P1, 25	1.68 (A)	420.0
26		D, E, G2, J3, P2, 26	1.68 (A)	420.0
27		D, E, G3, 27	1.83 (A)	420.0
28		D, E, F2, 28	2.15 (A)	504.9
29		D, E, G4, 29	2.27 (A)	476.1

Compound Example	Structure	Synthetic sequence	HPLC RT (min) (method)	M+H
30		D, Q, 30	1.03 (A)	310.0
31		D, Q1, 31	0.76 (A)	324.1
32		D, Q2, F3, J4, 32	1.51 (A)	367.0
33		D, Q3, 33	1.73 (A)	376.0
34		D, E, G, G5, J5, 34	1.82 (A)	420.0
35		D, E, G, G6, J6, 35	1.93 (A)	434.0

Compound Example	Structure	Synthetic sequence	HPLC RT (min) (method)	M+H
36		D, E, G, G7, J7, 36	1.62 (A)	450.0
37		K, L, E4, F4, J8, 37	1.95 (A)	420.0
38		K, L, E4, F4, J8, R1, 38	1.64 (A)	420.0
39		K, L, E4, F4, J8, R2, 39	1.65 (A)	419.9
40		D, E5, 40	1.44 (A)	353.0
41		D, E6, 41	1.44 (A)	352.9

Compound Example	Structure	Synthetic sequence	HPLC RT (min) (method)	M+H
42		D, E7, 42	1.23 (A)	319.0
43		C, G1 (via A), A2, D1, 10, 43	1.70 (A)	362.1
44		C, F, F1 (via B), J2, D2, 11, 44	1.65 (A)	406.1
45		D, E, F2, 28, 45	1.39 (A)	404.7
46		D, E, G4, 29, 46	1.90 (A)	420.0
47				

Compound Example	Structure	Synthetic sequence	HPLC RT (min) (method)	M+H
48				
49				
50				
51		D3, Q7, G8, J9, 51	1.67 (A)	420.2
52				
53		D, E, G, J, S, 53	1.69 (A)	408.0

Compound Example	Structure	Synthetic sequence	HPLC RT (min) (method)	M+H
54				
55				
56				
57				
58				
59				

Compound Example	Structure	Synthetic sequence	HPLC RT (min) (method)	M+H
60				
61				
62				
63				
64				
65				

Compound Example	Structure	Synthetic sequence	HPLC RT (min) (method)	M+H
66				
67				
68				
69				
70				
71				

Compound Example	Structure	Synthetic sequence	HPLC RT (min) (method)	M+H
72		D, E, F5, 72	1.66 (A)	442.0
73				
74		D, E, G12, 74	1.13 (A)	450.1
75				
76				

Compound Example	Structure	Synthetic sequence	HPLC RT (min) (method)	M+H
77				
78				
79				
80				

Compound Example	Structure	Synthetic sequence	HPLC RT (min) (method)	M+H
81		D, E, G9, 81	1.82 (A)	475.2
82				
83		D, E, F2, T, M5, 83	1.33 (A)	447.1
84		D, E, F2, T, O2, 84	0.96 (A)	483.0
85		D, E, F2, T, F99, J52, 85	1.38 (A)	449.2

Compound Example	Structure	Synthetic sequence	HPLC RT (min) (method)	M+H
86				
87				
88				
89				

Compound Example	Structure	Synthetic sequence	HPLC RT (min) (method)	M+H
90				
91				
92				
93		D, E, F6, 93	1.77 (A)	390.0
94		D, E, F7, 94	2.29 (A)	452.0

Compound Example	Structure	Synthetic sequence	HPLC RT (min) (method)	M+H
95		D, E, F8, 95	2.40 (A)	458.1
96				
97				
98				
99				
100				

Compound Example	Structure	Synthetic sequence	HPLC RT (min) (method)	M+H
101				
102				
103				
104				
105				
106				

Compound Example	Structure	Synthetic sequence	HPLC RT (min) (method)	M+H
107				
108				
109				
110				
111				
112				

Compound Example	Structure	Synthetic sequence	HPLC RT (min) (method)	M+H
113				
114				
115				
116				
117				

Compound Example	Structure	Synthetic sequence	HPLC RT (min) (method)	M+H
118				
119				
120				
121				
122				
123				

Compound Example	Structure	Synthetic sequence	HPLC RT (min) (method)	M+H
124				
125				
126				
127				
128		D, E8, 128	1.30 (A)	319.0
129				

Compound Example	Structure	Synthetic sequence	HPLC RT (min) (method)	M+H
130				
131				
132				
133				
134				

Compound Example	Structure	Synthetic sequence	HPLC RT (min) (method)	M+H
135				
136				
137				
138				
139				

Compound Example	Structure	Synthetic sequence	HPLC RT (min) (method)	M+H
140				
141				
142		D, Q4, F9, J10, 142	1.21 (A)	436.0
143		D, Q5, F10, J11, 143	1.82 (A)	439.9
144		D, Q6, F11, J12, 144	1.82 (A)	437.9
145				

Compound Example	Structure	Synthetic sequence	HPLC RT (min) (method)	M+H
146				
147				
148				
149				
150				
151				
152				

Compound Example	Structure	Synthetic sequence	HPLC RT (min) (method)	M+H
153				
154				
155				
156				
157				

Compound Example	Structure	Synthetic sequence	HPLC RT (min) (method)	M+H
158				
159				
160				
161				
162		D, Q37, F38, U1, J37, 162	0.98 (A)	535.0

Compound Example	Structure	Synthetic sequence	HPLC RT (min) (method)	M+H
163				
164				
165		D, E, F2, T, N4, 165	0.98 (A)	476.1
166				
167				

Compound Example	Structure	Synthetic sequence	HPLC RT (min) (method)	M+H
168				
169				
170				
171				
172				

Compound Example	Structure	Synthetic sequence	HPLC RT (min) (method)	M+H
173		D, Q5, F10, J11, R45, 173	1.67 (A)	440.1
174		D, Q5, F10, J11, R46, 174	1.81 (A)	440.1
175		AD, AE, AF, AG,Q64, F167, D5, 175	1.90 (A)	383.1
176		AD, AE, AF, AG, Q63, D4, 176	2.23 (A)	380.0
177		D, Q18, F21, J20, R5. 177	0.99 (A)	415.0
178		D, Q18, F21, J20, R6. 178	0.96 (A)	415.0

Compound Example	Structure	Synthetic sequence	HPLC RT (min) (method)	M+H
179		D, E, V, 179	1.95 (A)	390.0
180		D, E1, G10, J13, 180	1.48 (A)	436.0
181		D, E1, 181	2.43(A)	474.0
182		D, E1, 182	2.45(A)	496.0
183		D, E1, 183	2.63(A)	502.0
184		D, Q5, R47, 184	2.07 (A)	395.9

Compound Example	Structure	Synthetic sequence	HPLC RT (min) (method)	M+H
185		D, Q5, R48, 185	2.10 (A)	395.5
186		D3, Q7, F12, 186	2.27 (A)	404.1
187		D3, Q7, G11, J14, 187	2.12 (A)	434.2
188		D3, Q8, 188	2.53 (A)	408.2
189		D3, Q9, 189	2.60 (A)	410.2
190		D3, Q10, 190	2.28 (A)	406.2

Compound Example	Structure	Synthetic sequence	HPLC RT (min) (method)	M+H
191		D3, Q11, 191	2.33 (A)	406.2
192		D3, Q12, 192	2.40 (A)	394.2
193		D3, Q7, G8, J9, R3, 193	1.83 (A)	420.2
194		D3, Q7, G8, J9, R4, 194	1.84 (A)	420.2
195		D3, Q11, F13, 195	1.79 (A)	434.1
196		D3, Q10, F14, 196	1.75 (A)	434.1

Compound Example	Structure	Synthetic sequence	HPLC RT (min) (method)	M+H
197		D3, Q12, F15, 197	1.86 (A)	422.2
198		D, Q13, 198	1.91 (A)	392.0
199		D, Q4, 199	1.78 (A)	392.0
200		D, Q13, F16, J15, 200	1.44 (A)	436.0
201		D, Q6, 201	1.91 (A)	394.0
202		D, Q5, 202	1.98 (A)	395.9

Compound Example	Structure	Synthetic sequence	HPLC RT (min) (method)	M+H
203		D, Q14, 203	1.62 (A)	322.9
204		D, Q15, 204	1.84 (A)	337.1
205		D, Q16, 205	1.87 (A)	337.1
206		D, Q17, 206	1.87 (A)	337.1
207		D, E, G2, V1, J38, R23, 207	1.89 (A)	434.1
208		D, Q15, F17, J16, 208	1.81 (A)	381.1

Compound Example	Structure	Synthetic sequence	HPLC RT (min) (method)	M+H
209		D, Q16, F18, J17, 209	1.85 (A)	381.1
210		D, Q17, F19, J18, 210	1.83 (A)	381.1
211		D, Q14, F20, J19, 211	1.64 (A)	367.0
212		D, E, G2, V1, J38, R24, 212	1.89 (A)	434.0
213		D, Q18, 213	1.83 (A)	357.0
214		D, Q19, 214	1.76 (A)	353.0

Compound Example	Structure	Synthetic sequence	HPLC RT (min) (method)	M+H
215		D, Q20, 215	1.75 (A)	383.1
216		D, Q21, 216	1.87 (A)	357.0
217		D, Q22, 217	1.98 (A)	351.1
218		D, Q23, 218	1.69 (A)	353.0
219		D, Q24, 219	1.69 (A)	353.0
220		D, Q25, 220	1.90 (A)	357.0
221		D, Q26, 221	1.92 (A)	431.0

Compound Example	Structure	Synthetic sequence	HPLC RT (min) (method)	M+H
222		D, Q18, F21, J20, 222	1.79 (A)	415.0
223		D, Q20, F22, J21, 223	1.72 (A)	441.1
224		D, Q23, F23, J22, 224	1.63 (A)	411.0
225		D, Q19, F24, J23, 225	1.76 (A)	411.0
226		D, Q24, F25, J24, 226	1.64 (A)	411.0
227		D, Q21, F26, J25, 227	1.83 (A)	415.0
228		D, Q25, F27, J26, 228	1.85 (A)	415.0

Compound Example	Structure	Synthetic sequence	HPLC RT (min) (method)	M+H
229		D, Q15, F17, J16, R25, 229	1.92 (A)	381.0
230		D, Q15, F17, J16, R26, 230	1.92 (A)	381.0
231		D, Q27, F28, J27, 231	1.75 (A)	427.0
232		D, Q28, F29, J28, 232	1.90 (A)	395.0
233		D, Q29, F30, J29, 233	1.68 (A)	427.0
234		D, Q30, F31, J30, 234	1.91(A)	395.0

Compound Example	Structure	Synthetic sequence	HPLC RT (min) (method)	M+H
235		D, Q31, F32, J31, 235	1.86 (A)	435.0
236		D, Q32, F33, J32, 236	1.60 (A)	385.0
237		D, Q33, F34, J33, 237	1.59 (A)	385.0
238		D, Q34, F35, J34, 238	1.61 (A)	385.0
239		D, Q35, F36, J35, 239	1.94 (A)	434.9
240		D, E, F39, R27, 240	1.82 (A)	468.1

Compound Example	Structure	Synthetic sequence	HPLC RT (min) (method)	M+H
241		D, E, F39, R28, 241	1.91 (A)	468.1
242		D, Q36, F37, J36, 242	1.73 (A)	381.0
243		D, Q38, F168, W1, 243	1.85 (A)	397.0
244		D, Q38, F168, W2, 244	1.84 (A)	413.0
245		D, Q38, F168, W3, 245	1.94 (A)	413.0
246		D, Q38, F168, W4, 246	2.23 (A)	400.9

Compound Example	Structure	Synthetic sequence	HPLC RT (min) (method)	M+H
247		D, Q38, F168, W, 247	1.96 (A)	383.0
248		D, Q38, F168, W5, 248	2.33 (A)	417.0
249		D, Q38, F168, W6, 249	2.39 (A)	417.0
250		D, Q38, F168, W7, 250	2.26 (A)	397.0
251		D, Q38, F168, W8, 251	1.99 (A)	413.0
252		D, Q38, F168, W9, 252	2.30 (A)	400.9

Compound Example	Structure	Synthetic sequence	HPLC RT (min) (method)	M+H
253		D, Q38, F168, W10, 253	2.30 (A)	417.0
254		D, Q13, F16, J15, R31, 254	1.30 (A)	436.0
255		D, Q13, R29, 255	1.83 (A)	392.0
256		D, Q13, R30, 256	1.85 (A)	392.0
257		D, Q13, F16, J15, R32, 257	1.23 (A)	436.0
258		D, E, F98, X7, 258	1.19 (A)	511.9
259		D, E, F98, X8, 259	1.36 (A)	554.0

Compound Example	Structure	Synthetic sequence	HPLC RT (min) (method)	M+H
260		D, E, F98, X9, 260	0.99 (A)	497.9
261		D, E, F2, T, O2, R33, 261	0.97 (A)	483.1
262		D, E, F2, T, O2, R34, 262	0.97 (A)	483.1
263		D, E, F98, X7, R35, 263	0.99 (A)	512.0
264		D, E, F98, X7, R36, 264	0.95 (A)	512.0
265		D, E, A3, 265	3.06 (A)	462.0

Compound Example	Structure	Synthetic sequence	HPLC RT (min) (method)	M+H
266		D, E, F40, 266	2.13 (A)	470.1
267		D, E, F41, 267	2.20 (A)	468.1
268		D, E, F42, 268	2.11 (A)	498.1
269		D, E, F43, 269	2.04 (A)	418.1
270		D, E, F44, 270	2.02 (A)	404.0
271		D, E, F45, 271	2.30 (A)	466.1

Compound Example	Structure	Synthetic sequence	HPLC RT (min) (method)	M+H
272		D, E, F46, 272	1.95 (A)	484.1
273		D, E, F47, 273	2.35 (A)	502.1
274		D, E, F48, 274	1.92 (A)	484.1
275		D, E, F49, 275	2.16 (A)	444.2
276		D, E, F50, 276	2.16 (A)	482.3
277		D, E, F51, 277	2.08 (A)	486.2

Compound Example	Structure	Synthetic sequence	HPLC RT (min) (method)	M+H
278		D, E, F52, 278	2.11 (A)	418.1
279		D, E, F53, 279	2.39 (A)	446.1
280		D, E, F54, 280	2.14 (A)	440.9
281		D, E, F55, 281	1.91 (A)	416.1
282		D, E, F56, 282	2.09 (A)	453.1
283		D, E, F57, 283	2.22 (A)	456.1

Compound Example	Structure	Synthetic sequence	HPLC RT (min) (method)	M+H
284		D, E, F58, 284	2.04 (A)	458.0
285		D, E, F59, 285	1.95 (A)	442.0
286		D, E, G, J, U2, 286	2.19 (A)	482.1
287		D, E, G, J, U, 287	2.25 (A)	516.2
288		D, E, G, J, U3, 288	2.31 (A)	516.2
289		D, E, G, J, U4, 289	2.32 (A)	516.1

Compound Example	Structure	Synthetic sequence	HPLC RT (min) (method)	M+H
290		D, E, F60, 290	1.67 (A)	456.1
291		D, E, G, J, U5, 291	2.46 (A)	496.1
292		D, E, G, J, U6, 292	2.28 (A)	496.1
293		D, E, G, J, U7, 293	2.28 (A)	496.1
294		D, E, F61, 294	1.96 (A)	468.0
295		D, E, F62, 295	2.22 (A)	466.1

Compound Example	Structure	Synthetic sequence	HPLC RT (min) (method)	M+H
296		D, E, F39, 296	1.94 (A)	468.0
297		D, E, F63, 297	2.02 (A)	509.1
298		D, E, F6, R7, 298	1.68 (A)	390.0
299		D, E, F6, R8, 299	1.70 (A)	390.0
300		D, E, F54, R9, 300	2.00 (A)	440.9
301		D, E, F64, 301	2.02 (A)	455.0

Compound Example	Structure	Synthetic sequence	HPLC RT (min) (method)	M+H
302		D, E, F54, R10, 302	2.00 (A)	440.9
303		D, Q24, F25, J24, R11, 303	1.73 (A)	411.1
304		D, Q24, F25, J24, R12, 304	1.74 (A)	411.1
305		D, E, F65, 305	2.25 (A)	482.1
306		D, E, F66, 306	2.43 (A)	496.1
307		D, E, F67, 307	2.02 (A)	459.0
308		D, E, F68, 308	2.05 (A)	519.0

Compound Example	Structure	Synthetic sequence	HPLC RT (min) (method)	M+H
309		D, E, F69, 309	1.17 (A)	512.1
310		D, E, F70, 310	1.95 (A)	466.0
311		D, E, F71, 311	2.08 (A)	442.1
312		D, E, F72, X1, 312	1.92 (A)	498.0
313		D, E, F73, 313	2.42 (A)	498.1
314		D, E, F72, X3, 314	1.19 (A)	512.0

Compound Example	Structure	Synthetic sequence	HPLC RT (min) (method)	M+H
315		D, E, F63, R13, 315	2.01 (A)	509.2
316		D, E, F63, R14, 316	2.01 (A)	509.1
317		D, E, F72, X4, 317	1.50 (A)	554.0
318		D, E, F74, 318	1.10 (A)	456.1
319		D, E, F75, 319	2.37 (A)	491.0
320		D, E, F76, 320	1.74 (A)	567.3

Compound Example	Structure	Synthetic sequence	HPLC RT (min) (method)	M+H
321		D, E, F77, X5, 321	1.26 (A)	512.1
322		D, E, F78, 322	2.22 (A)	526.1
323		D, E, F77, X6, 323	1.38 (A)	498.1
324		D, E, F72, X1, R15, 324	1.92 (A)	498.1
325		D, E, F72, X1, R16, 325	1.93 (A)	498.1
326		D, E, F72, X3, R17, 326	0.96 (A)	512.0

Compound Example	Structure	Synthetic sequence	HPLC RT (min) (method)	M+H
327		D, E, F72, X3, R18, 327	0.96 (A)	512.1
328		D, Q37, 328	1.02 (A)	378.6
329		D, Q1, F79, J40, 329	1.02 (A)	368.1
330		D, Q, F80, J41, 330	1.06 (A)	354.1
331		D, Q37, F38, J42, 331	0.87 (A)	422.0
332		D, Q40, 332	1.88 (A)	364.9

Compound Example	Structure	Synthetic sequence	HPLC RT (min) (method)	M+H
333		D, Q41, 333	2.07 (A)	398.8
334		D, Q42, 334	1.16 (A)	377.7
335		D, Q40, F82, J43, 335	1.98 (A)	408.9
336		D, Q41, F83, J44, 336	2.12 (A)	442.9
337		D, Q42, F84, J45, 337	1.30 (A)	421.9
338		D, Q43, 338	0.78 (A)	324.0

Compound Example	Structure	Synthetic sequence	HPLC RT (min) (method)	M+H
339		D, Q44, 339	0.81 (A)	324.0
340		D, Q45, 340	0.87 (A)	310.0
341		D, Q44, F85, J46, 341	1.08 (A)	368.0
342		D, Q43, F86, J47, 342	1.03 (A)	368.0
343		D, Q45, F87, J48, 343	1.10 (A)	354.0
344		D, Q46, 344	0.86 (A)	324.9
345		D, Q46, F88, J49, 345	0.99 (A)	368.9

Compound Example	Structure	Synthetic sequence	HPLC RT (min) (method)	M+H
346		D, Q47, 346	1.19 (A)	312.9
347		D, Q48, 347	0.96 (A)	298.9
348		D, Q49, 348	1.03 (A)	342.0
349		D, Q48, F89, J50, 349	0.28 (A)	343.0
350		D, Q27, F28, J27, R39, 350	1.61 (A)	427.0
351		D, Q27, F28, J27, R40, 351	1.58 (A)	427.0
352		D, Q47,F90, J51, 352	1.12 (A)	356.9

Compound Example	Structure	Synthetic sequence	HPLC RT (min) (method)	M+H
353		D, E, F91, 353	2.49 (A)	530.0
354		D, E, F92, 354	2.74 (A)	466.0
355		D, E, F93, 355	2.78 (A)	486.0
356		D, E, F94 (via AH1), 356	2.44 (A)	523.0
357		D, E, F95 (via AH2), 357	2.32 (A)	509.0

Compound Example	Structure	Synthetic sequence	HPLC RT (min) (method)	M+H
358		D, E, F96 (via AH), 358	2.07 (A)	545.1
359		D, E, F97 (via AH3), 359	1.21 (A)	559.1
360		D, E, F96 (via AH), R41, 360	2.08 (A)	545.1
361		D, E, F96 (via AH), R42, 361	2.07 (A)	545.1

Compound Example	Structure	Synthetic sequence	HPLC RT (min) (method)	M+H
362		D, E, O3, Y, Z1, 362	2.73 (A)	589.3
363		D, E, O3, Y, Z, J53, 363	2.19 (A)	562.0
364				
365				

Compound Example	Structure	Synthetic sequence	HPLC RT (min) (method)	M+H
366				
367				
368		D, Q50, F100, J54, 368	1.92 (A)	406.1
369				
370		D, Q51, F101, J55, 370	1.67 (A)	420.1
371				

Compound Example	Structure	Synthetic sequence	HPLC RT (min) (method)	M+H
372				
373				
374				
375				
376				
377				
378				
379		D, Q52, F102, J56, 379	1.03 (A)	436.0

Compound Example	Structure	Synthetic sequence	HPLC RT (min) (method)	M+H
380				
381				
382				
383				
384				
385				
386				

Compound Example	Structure	Synthetic sequence	HPLC RT (min) (method)	M+H
387				
388				
389				
390				
391				
392				
393				

Compound Example	Structure	Synthetic sequence	HPLC RT (min) (method)	M+H
394				
395				
396				
397				
398				
399				
400				

Compound Example	Structure	Synthetic sequence	HPLC RT (min) (method)	M+H
401				
402				
403		D, E, F103 (AH4), 403	2.02 (A)	531.1
404				
405				
406				

Compound Example	Structure	Synthetic sequence	HPLC RT (min) (method)	M+H
407				
408				
409		D, E, F104, 409	2.32 (A)	491.1
410				
411		D, E, F105, 411	2.65 (A)	491.1

Compound Example	Structure	Synthetic sequence	HPLC RT (min) (method)	M+H
412				
413				
414				
415				
416				
417				
418				

Compound Example	Structure	Synthetic sequence	HPLC RT (min) (method)	M+H
419				
420				
421				
422				
423				
424				
425				

Compound Example	Structure	Synthetic sequence	HPLC RT (min) (method)	M+H
426				
427				
428		D, E, F106 (via AH5), 428	1.26 (A)	574.0
429		D, E, F107 (via AH6), 429	2.51(A)	538.2
430		D, E, F171 (via AH7), 430	2.07 (A)	552.2

Compound Example	Structure	Synthetic sequence	HPLC RT (min) (method)	M+H
431		D, E, F108 (via AH8), 431	1.93 (A)	495.1
432		D, E, F109 (via AH9), 432	2.63 (A)	588.1
433				
434				

Compound Example	Structure	Synthetic sequence	HPLC RT (min) (method)	M+H
435				
436				
437				

Compound Example	Structure	Synthetic sequence	HPLC RT (min) (method)	M+H
438				
439				
440				

Compound Example	Structure	Synthetic sequence	HPLC RT (min) (method)	M+H
441				
442				
443				

Compound Example	Structure	Synthetic sequence	HPLC RT (min) (method)	M+H
444				
445				
446		D, E, F2, T, N5, 446	1.67(A)	504.2
447		D, E, F2, T, N6, 447	1.07 (A)	518.1

Compound Example	Structure	Synthetic sequence	HPLC RT (min) (method)	M+H
448		D, E, F2, T, AA, 448	1.22 (A)	512.1
449				
450				
451				
452				
453		D, E, F110, 453	1.14 (A)	512.1

Compound Example	Structure	Synthetic sequence	HPLC RT (min) (method)	M+H
454				
455				
456		D, E, F111, 456	0.94 (A)	567.3
457				
458				
459				
460		D, Q53, 460	1.19 (A)	394.0

Compound Example	Structure	Synthetic sequence	HPLC RT (min) (method)	M+H
461				
462		D, E, X, 462	3.46 (A)	505.0
463		D, E, X2, 463	3.49 (A)	506.0
464				
465				
466				
467				

Compound Example	Structure	Synthetic sequence	HPLC RT (min) (method)	M+H
468				
469		D, E, F112, 469	1.27 (A)	490.1
470		D, E, F113, 470	2.26 (A)	470.1
471		D, E, F114, 471	1.05 (A)	557.9
472		D, E, F115, 472	2.43 (A)	504.1
473		D, E, F116, 473	1.02 (A)	484.0

Compound Example	Structure	Synthetic sequence	HPLC RT (min) (method)	M+H
474				
475		D, E, F117, 475	2.25 (A)	470.1
476		D, E, F118, 476	1.32 (A)	471.0
477		D, E, F119, 477	0.99 (A)	460.0
478				
479				

Compound Example	Structure	Synthetic sequence	HPLC RT (min) (method)	M+H
480				
481				
482				
483		D, Q13, F120, 483	2.11 (A)	470.9
484		D, Q13, F120, R43, 484	2.11 (A)	470.9
485		D, Q13, F120, R44, 485	2.12 (A)	470.9

Compound Example	Structure	Synthetic sequence	HPLC RT (min) (method)	M+H
486		D, Q13, F121, 486	1.84 (A)	420.1
487		D, Q13, F121, R21, 487	1.79 (A)	420.1
488		D, Q13, F121, R22, 488	1.80 (A)	420.1
489		D, Q54, F122, 489	2.27 (A)	454.9
490		D, Q54, F122, R37, 490	2.25 (A)	454.9
491		D, Q54, F122, R38, 491	2.26 (A)	454.9
492		D, Q55, 492	1.80 (A)	363.0

Compound Example	Structure	Synthetic sequence	HPLC RT (min) (method)	M+H
493		D, Q56, 493	1.72 (A)	363.0
494				
495				
496				
497				
498				
499		D, Q57, 499	1.07 (A)	363.1

Compound Example	Structure	Synthetic sequence	HPLC RT (min) (method)	M+H
500				
501		D, E, F69, R19, 501	0.95 (A)	512.1
502		D, E, F69, R20, 502	1.01 (A)	512.1
503		D, E, F123, 503	1.97 (A)	470.1
504		D, E, O4, 504	2.26(A)	558.9
505		D, E, O4, AB, 505	3.62 (A)	517.1

Compound Example	Structure	Synthetic sequence	HPLC RT (min) (method)	M+H
506		D, E, F124 (via AH10), 506	2.17 (A)	545.1
507		D, Q51, F125, 507	2.25 (A)	455.0,
508		D, Q51, 508	1.08 (A)	375.9
509		D, Q50, 509	1.46 (A)	362.0
510		D, Q52, 510	0.93 (A)	392.0
511		D, E, O3, Y, 511	2.73(A)	518.0

Compound Example	Structure	Synthetic sequence	HPLC RT (min) (method)	M+H
512		D, E, O4, AB, AC, 512	3.08(A)	561.1
513		D, Q58, F169, 513	2.09 (A)	404.1
514		D, Q58, F169, R49, 514	2.02 (A)	404.1
515		D, Q58, F169, R50, 515	2.05 (A)	404.1
516		D, Q54, F127, 516	2.01 (A)	404.1
517		D, Q54, F127, R51, 517	1.85 (A)	404.1
518		D, Q54, F127, R52, 518	1.80 (A)	404.1

Compound Example	Structure	Synthetic sequence	HPLC RT (min) (method)	M+H
519		D, Q58, F128, 519	2.29 (A)	454.9
520		D, Q58, F128, R53, 520		
521		D, Q58, F128, R54, 521		
522		D, Q59, F129, 522	2.29 (A)	474.9
523		D, Q59, F129, R55, 523	2.28 (A)	474.9
524		D, Q59, F129, R56, 524	2.30 (A)	474.9

Compound Example	Structure	Synthetic sequence	HPLC RT (min) (method)	M+H
525		D, Q60, F130, 525	2.20 (A)	458.9
526		D, Q60, F130, R57, 526	2.17 (A)	458.9
527		D, Q60, F130, R58, 527	2.19 (A)	458.9
528		D, E, F76, R59, 528	1.66 (A)	567.3
529		D, E, F76, R60, 529	1.65 (A)	567.3

Compound Example	Structure	Synthetic sequence	HPLC RT (min) (method)	M+H
530		D, Q59, F131, 530	1.94 (A)	601.4
531		D, Q59, F131, R61, 531	1.93 (A)	601.4
532		D, Q59, F131, R62, 532	1.94 (A)	601.4
533		D, Q60, F132, 533	1.85 (A)	585.3

Compound Example	Structure	Synthetic sequence	HPLC RT (min) (method)	M+H
534		D, Q60, F132, R63, 534	1.90 (A)	585.2
535		D, Q60, F133, R64, 535	1.89 (A)	585.2
536		D, Q54, F133, 536	1.89 (A)	581.3
537		D, Q54, F133, R65, 537	1.78 (A)	581.3

Compound Example	Structure	Synthetic sequence	HPLC RT (min) (method)	M+H
538		D, Q54, F133, R66, 538	1.94 (A)	581.2
539		D, Q13, F134, 539	1.86 (A)	597.2
540		D, Q13, F134, R67, 540	1.84 (A)	597.2
541		D, Q13, F134, R68, 541	1.84 (A)	597.2

Compound Example	Structure	Synthetic sequence	HPLC RT (min) (method)	M+H
542		D, Q58, F135, 542	1.95 (A)	581.3
543		D, Q58, F135, R69, 543	1.98 (A)	581.2
544		D, Q58, F135, R70, 544	1.99 (A)	581.2
545		D, E, F123, R71, 545	1.80 (A)	470.1

Compound Example	Structure	Synthetic sequence	HPLC RT (min) (method)	M+H
546		D, E, F123, R72, 546	1.77 (A)	470.1
547		D, Q58, F136, 547	2.07 (A)	484.1
548		D, Q58, F136, R73, 548	2.12 (A)	484.2
549		D, Q58, F136, R74, 549	2.12 (A)	484.2
550		D, Q13, F137, 550	1.97 (A)	500.0

Compound Example	Structure	Synthetic sequence	HPLC RT (min) (method)	M+H
551		D, Q13, F137, R75, 551	1.99 (A)	500.0
552		D, Q13, F137, R76, 552	1.99 (A)	500.0
553		D, Q59, F138, 553	2.16 (A)	504.0
554		D, Q59, F138, R77, 554	2.17 (A)	504.2
555		D, Q59, F138, R78, 555	2.17 (A)	504.2

Compound Example	Structure	Synthetic sequence	HPLC RT (min) (method)	M+H
556		D, Q60, F139, 556	2.04 (A)	488.1
557		D, Q60, F139, R79, 557	2.00 (A)	488.1
558		D, Q60, F139, R80, 558	1.88 (A)	488.1
559		D, Q54, F140, 559	2.11 (A)	484.1
560		D, Q54, F140, R81, 560	1.92 (A)	484.1

Compound Example	Structure	Synthetic sequence	HPLC RT (min) (method)	M+H
561		D, Q54, F140, R82, 561	1.96 (A)	484.1
562		D, Q54, F141, J57, 562	1.88 (A)	420.1
563		D, Q54, F141, J57, R83, 563	1.87 (A)	420.1
564		D, Q54, F141, J57, R84, 564	1.88 (A)	420.1
565		D, Q60, F142, J58, 565	1.75 (A)	424.0
566		D, Q60, F142, J58, R85, 566	1.72 (A)	424.0
567		D, Q60, F142, J58, R86, 567	1.69 (A)	424.0

Compound Example	Structure	Synthetic sequence	HPLC RT (min) (method)	M+H
568		D, Q59, F143, J59, 568	1.90 (A)	440.1
569		D, Q59, F143, J59, R87, 569	1.95 (A)	439.9
570		D, Q59, F143, J59, R88, 570	1.95 (A)	439.9
571		D, E, G, G5, J5, R89, 571	1.84 (A)	420.1
572		D, E, G, G5, J5, R90, 572	1.87 (A)	420.1
573		D, E, F2, T, O5, 573	1.64 (A)	537.0

Compound Example	Structure	Synthetic sequence	HPLC RT (min) (method)	M+H
574		D, E, F144, 574	2.50 (A)	505.1
575		D, E, O3, Y, Z2, 575	2.44(A)	629.4
576		D, Q61, 576	2.08 (A)	392.0
577		D, Q62, 577	2.59 (A)	410.0
578		D, E, F145, 578	1.93 (A)	456.1
579		D, E, F146, 579	1.76 (A)	474.1

Compound Example	Structure	Synthetic sequence	HPLC RT (min) (method)	M+H
580		D, E, F147, 580	2.10 (A)	490.0
581		D, E, F148, 581	2.42 (A)	470.1
582		D, E, F149, 582	2.45 (A)	470.1
583		D, E, F150, 583	1.69 (A)	486.1
584		D, E, F151, 584	2.02 (A)	488.0
585		D, E, F152, 585	2.54 (A)	504.1

Compound Example	Structure	Synthetic sequence	HPLC RT (min) (method)	M+H
586		D, E, F153, 586	2.47 (A)	484.1
587		D, E, F154, 587	1.81 (A)	500.2
588		D, E, F155, 588	2.14 (A)	484.0
589		D, E, F156, 589	2.13 (A)	484.0
590		D, E, F157, 590	1.82 (A)	488.1

Compound Example	Structure	Synthetic sequence	HPLC RT (min) (method)	M+H
591		D, E, F158, 591	2.53 (A)	504.1
592		D, E, F159, 592	2.46 (A)	484.2
593		D, E, F160, 593	1.80 (A)	500.1
594		D, E, F161, 594	2.09 (A)	470.0
595		D, E, F162, 595	1.97 (A)	474.0

Compound Example	Structure	Synthetic sequence	HPLC RT (min) (method)	M+H
596		D, E, F163, 596	2.07 (A)	491.0
597		D, E, F164, 597	2.03 (A)	470.0
598		D, E, F165, 598	1.90 (A)	486.0
599		D, E, F166, 599	1.91 (A)	456.0
600				

Compound Example	Structure	Synthetic sequence	HPLC RT (min) (method)	M+H
601				
602				
603				
604				
605				

Compound Example	Structure	Synthetic sequence	HPLC RT (min) (method)	M+H
606				
607				
608				
609				
610				

Compound Example	Structure	Synthetic sequence	HPLC RT (min) (method)	M+H
611				
612				
613				
614				
615				
616				
617				

Compound Example	Structure	Synthetic sequence	HPLC RT (min) (method)	M+H
618				
619		D, Q60, 619	2.02 (A)	379.9
620		D, Q59, 620	2.14 (A)	395.9
621		D, Q54, 621	2.00 (A)	376.1
622		D, Q58, 622	2.07 (A)	376.1
623				
624				

Compound Example	Structure	Synthetic sequence	HPLC RT (min) (method)	M+H
625				
626				
627				
628				
629				

Compound Example	Structure	Synthetic sequence	HPLC RT (min) (method)	M+H
630				
631				
632				
633				
634				
635				

Compound Example	Structure	Synthetic sequence	HPLC RT (min) (method)	M+H
636				
637				
638				
639				
640				
641				

Compound Example	Structure	Synthetic sequence	HPLC RT (min) (method)	M+H
642				
643				
644				
645				
646				
647				

Compound Example	Structure	Synthetic sequence	HPLC RT (min) (method)	M+H
648				
649				
650				
651				
652				
653				

Compound Example	Structure	Synthetic sequence	HPLC RT (min) (method)	M+H
654				
655				
656				
657				
658				

Compound Example	Structure	Synthetic sequence	HPLC RT (min) (method)	M+H
659				
660				
661				
662				
663				
664				

Compound Example	Structure	Synthetic sequence	HPLC RT (min) (method)	M+H
665				
666				
667				
668				
669				

Compound Example	Structure	Synthetic sequence	HPLC RT (min) (method)	M+H
670				
671				
672				
673				
674				

Compound Example	Structure	Synthetic sequence	HPLC RT (min) (method)	M+H
675				
676				
677				
678				
679				

Compound Example	Structure	Synthetic sequence	HPLC RT (min) (method)	M+H
680				
681				
682				
683				
684				

Compound Example	Structure	Synthetic sequence	HPLC RT (min) (method)	M+H
685				
686				
687				
688				
689				

Compound Example	Structure	Synthetic sequence	HPLC RT (min) (method)	M+H
690				
691				
692				
693				
694				
695				

Compound Example	Structure	Synthetic sequence	HPLC RT (min) (method)	M+H
696				
697				
698				
699				
700				

Compound Example	Structure	Synthetic sequence	HPLC RT (min) (method)	M+H
701				
702				
703				
704				
705				

Compound Example	Structure	Synthetic sequence	HPLC RT (min) (method)	M+H
706				
707				
708				
709				
710				

Compound Example	Structure	Synthetic sequence	HPLC RT (min) (method)	M+H
711				
712				
713				
714				
715				

Compound Example	Structure	Synthetic sequence	HPLC RT (min) (method)	M+H
716				
717				
718				
719				
720				

Compound Example	Structure	Synthetic sequence	HPLC RT (min) (method)	M+H
721				
722				
723				
724				
725				

Compound Example	Structure	Synthetic sequence	HPLC RT (min) (method)	M+H
726				
727				
728				
729				
730				

Compound Example	Structure	Synthetic sequence	HPLC RT (min) (method)	M+H
731				
732				
733				
734				
735				

Compound Example	Structure	Synthetic sequence	HPLC RT (min) (method)	M+H
736				
737				
738				
739				
740				

Compound Example	Structure	Synthetic sequence	HPLC RT (min) (method)	M+H
741				
742				
743				
744				
745				

Compound Example	Structure	Synthetic sequence	HPLC RT (min) (method)	M+H
746				
747				
748				
749				
750				

Compound Example	Structure	Synthetic sequence	HPLC RT (min) (method)	M+H
751				
752				
753				
754				
755				

Compound Example	Structure	Synthetic sequence	HPLC RT (min) (method)	M+H
756				
757				
758				
759				
760				

Compound Example	Structure	Synthetic sequence	HPLC RT (min) (method)	M+H
761				
762				
763				
764				
765				

Compound Example	Structure	Synthetic sequence	HPLC RT (min) (method)	M+H
766				
767				
768				
769				
770				

Compound Example	Structure	Synthetic sequence	HPLC RT (min) (method)	M+H
771				
772				
773				
774				
775				
776				

Compound Example	Structure	Synthetic sequence	HPLC RT (min) (method)	M+H
777				
778				
779				
780				
781				
782				

Compound Example	Structure	Synthetic sequence	HPLC RT (min) (method)	M+H
783				
784				
785				
786				
787				
788				

Compound Example	Structure	Synthetic sequence	HPLC RT (min) (method)	M+H
789				
790				
791				
792				
793				

Compound Example	Structure	Synthetic sequence	HPLC RT (min) (method)	M+H
794				
795				
796		D, Q60, R91, 796	1.93 (A)	380.0
797		D, Q60, R92, 797	1.92 (A)	380.0
798		D, Q59, R93, 798	2.04 (A)	396.0
799		D, Q59, R94, 799	2.06 (A)	396.0
800		D, Q54, R95, 800	2.03 (A)	376.1

Compound Example	Structure	Synthetic sequence	HPLC RT (min) (method)	M+H
801		D, Q54, R96, 801	2.03 (A)	376.0
802		D, Q58, R97, 802	2.01 (A)	376.1
803		D, Q58, R98, 803	2.00 (A)	376.0
804		D, Q60, F170, 804	1.92 (A)	408.0
805		D, Q60, F170, R99, 805	1.90 (A)	408.0
806		D, Q60, F170, R100, 806	1.90 (A)	408.0
807		D, Q52, R101, 807	1.97 (A)	392.0

Compound Example	Structure	Synthetic sequence	HPLC RT (min) (method)	M+H
808		D, Q52, R102, 808	2.20 (A)	392.0

The chemical names for the compounds shown in Table I are provided below in Table 2.

Table 2

Compound Example	IUPAC Name
1	(2E)-N-hydroxy-3-(1-{[(1S)-2-hydroxy-1-(1H-indol-3-ylmethyl)ethyl]amino}-2,3-dihydro-1H-inden-5-yl)acrylamide
2	(2E)-N-hydroxy-3-(1-{(3-hydroxypropyl)[2-(1H-indol-3-yl)ethyl]amino}-2,3-dihydro-1H-inden-5-yl)acrylamide
3	(2E)-N-hydroxy-3-((1S)-1-{[2-(1H-indol-3-yl)ethyl]amino}-2,3-dihydro-1H-inden-5-yl)acrylamide
4	(2E)-N-hydroxy-3-((1R)-1-{[2-(1H-indol-3-yl)ethyl]amino}-2,3-dihydro-1H-inden-5-yl)acrylamide
5	(2E)-N-hydroxy-3-((1R)-1-{(2-hydroxyethyl)[2-(1H-indol-3-yl)ethyl]amino}-2,3-dihydro-1H-inden-5-yl)acrylamide
6	(2E)-N-hydroxy-3-((1S)-1-{(2-hydroxyethyl)[2-(1H-indol-3-yl)ethyl]amino}-2,3-dihydro-1H-inden-5-yl)acrylamide
7	(2E)-N-hydroxy-3-(1-{[(1R)-2-hydroxy-1-(1H-indol-3-ylmethyl)ethyl]amino}-2,3-dihydro-1H-inden-5-yl)acrylamide
8	(2E)-N-hydroxy-3-(1-{[2-(1H-indol-3-yl)ethyl]amino}-2,3-dihydro-1H-inden-5-yl)acrylamide
9	(2E)-N-hydroxy-3-(1-{(2-hydroxyethyl)[2-(1H-indol-3-yl)ethyl]amino}-2,3-dihydro-1H-inden-5-yl)acrylamide
10	tert-butyl 3-[2-((tert-butoxycarbonyl){5-[(1E)-3-(hydroxyamino)-3-oxoprop-1-en-1-yl]-2,3-dihydro-1H-inden-2-yl}amino)ethyl]-1H-indole-1-carboxylate
11	(2E)-3-{2-[{2-[1-(2,2-dimethylpropanoyl)-1H-indol-3-yl]ethyl}(2-hydroxyethyl)amino]-2,3-dihydro-1H-inden-5-yl}-N-hydroxyacrylamide
12	(2E)-N-hydroxy-3-(5-{[2-(1H-indol-3-yl)ethyl]amino}-5,6,7,8-tetrahydronaphthalen-2-yl)acrylamide
13	(2E)-3-(1-{acetyl[2-(1H-indol-3-yl)ethyl]amino}-2,3-dihydro-1H-inden-5-yl)-N-hydroxyacrylamide

Compound Example	IUPAC Name
14	(2E)-N-hydroxy-3-{1-[[2-(1H-indol-3-yl)ethyl](phenylacetyl)amino]-2,3-dihydro-1H-inden-5-yl}acrylamide
15	N-{5-[(1E)-3-(hydroxyamino)-3-oxoprop-1-en-1-yl]-2,3-dihydro-1H-inden-1-yl}-N-[2-(1H-indol-3-yl)ethyl]cyclopentanecarboxamide
16	(2E)-N-hydroxy-3-((1S)-1-{[(1S)-2-hydroxy-1-(1H-indol-3-ylmethyl)ethyl]amino}-2,3-dihydro-1H-inden-5-yl)acrylamide
17	N-{5-[(1E)-3-(hydroxyamino)-3-oxoprop-1-en-1-yl]-2,3-dihydro-1H-inden-1-yl}-N-[2-(1H-indol-3-yl)ethyl]benzamide
18	N-{5-[(1E)-3-(hydroxyamino)-3-oxoprop-1-en-1-yl]-2,3-dihydro-1H-inden-1-yl}-N-[2-(1H-indol-3-yl)ethyl]cyclohexanecarboxamide
19	(2E)-3-(1-{[(ethylamino)carbonyl][2-(1H-indol-3-yl)ethyl]amino}-2,3-dihydro-1H-inden-5-yl)-N-hydroxyacrylamide
20	(2E)-3-(1-{[(tert-butylamino)carbonyl][2-(1H-indol-3-yl)ethyl]amino}-2,3-dihydro-1H-inden-5-yl)-N-hydroxyacrylamide
21	(2E)-3-(1-{[(benzylamino)carbonyl][2-(1H-indol-3-yl)ethyl]amino}-2,3-dihydro-1H-inden-5-yl)-N-hydroxyacrylamide
22	(2E)-N-hydroxy-3-[1-([2-(1H-indol-3-yl)ethyl]{[(2-phenylethyl)amino]carbonyl}amino)-2,3-dihydro-1H-inden-5-yl]acrylamide
23	(2E)-N-hydroxy-3-{1-[[2-(1H-indol-3-yl)ethyl](phenylsulfonyl)amino]-2,3-dihydro-1H-inden-5-yl}acrylamide
24	(2E)-N-hydroxy-3-{1-[[2-(1H-indol-3-yl)ethyl](methylsulfonyl)amino]-2,3-dihydro-1H-inden-5-yl}acrylamide
25	(2E)-N-hydroxy-3-((1S)-1-{(3-hydroxypropyl)[2-(1H-indol-3-yl)ethyl]amino}-2,3-dihydro-1H-inden-5-yl)acrylamide
26	(2E)-N-hydroxy-3-((1R)-1-{(3-hydroxypropyl)[2-(1H-indol-3-yl)ethyl]amino}-2,3-dihydro-1H-inden-5-yl)acrylamide
27	(2E)-N-hydroxy-3-{1-[[2-(1H-indol-3-yl)ethyl](2-methoxyethyl)amino]-2,3-dihydro-1H-inden-5-yl}acrylamide
28	tert-butyl (2-{{5-[(1E)-3-(hydroxyamino)-3-oxoprop-1-en-1-yl]-2,3-dihydro-1H-inden-1-yl}[2-(1H-indol-3-yl)ethyl]amino}ethyl)carbamate
29	tert-butyl N-{5-[(1E)-3-(hydroxyamino)-3-oxoprop-1-en-1-yl]-2,3-dihydro-1H-inden-1-yl}-N-[2-(1H-indol-3-yl)ethyl]glycinate
30	(2E)-N-hydroxy-3-{1-[(pyridin-3-ylmethyl)amino]-2,3-dihydro-1H-inden-5-yl}acrylamide
31	(2E)-N-hydroxy-3-{1-[(2-pyridin-3-ylethyl)amino]-2,3-dihydro-1H-inden-5-yl}acrylamide
32	(2E)-N-hydroxy-3-{1-[(2-hydroxyethyl)(2-methylbenzyl)amino]-2,3-dihydro-1H-inden-5-yl}acrylamide
33	(2E)-N-hydroxy-3-{1-[[2-(1H-indol-3-yl)ethyl](methyl)amino]-2,3-dihydro-1H-inden-5-yl}acrylamide
34	(2E)-N-hydroxy-3-(1-{(2-hydroxyethyl)[2-(1-methyl-1H-indol-3-yl)ethyl]amino}-2,3-dihydro-1H-inden-5-yl)acrylamide

Compound Example	IUPAC Name
35	(2E)-3-{1-[[2-(1-ethyl-1H-indol-3-yl)ethyl](2-hydroxyethyl)amino]-2,3-dihydro-1H-inden-5-yl}-N-hydroxyacrylamide
36	(2E)-N-hydroxy-3-[1-((2-hydroxyethyl){2-[1-(2-hydroxyethyl)-1H-indol-3-yl]ethyl}amino)-2,3-dihydro-1H-inden-5-yl]acrylamide
37	(2E)-N-hydroxy-3-(5-{(2-hydroxyethyl)[2-(1H-indol-3-yl)ethyl]amino}-5,6,7,8-tetrahydronaphthalen-2-yl)acrylamide
38	(2E)-N-hydroxy-3-((5R)-5-{(2-hydroxyethyl)[2-(1H-indol-3-yl)ethyl]amino}-5,6,7,8-tetrahydronaphthalen-2-yl)acrylamide
39	(2E)-N-hydroxy-3-((5S)-5-{(2-hydroxyethyl)[2-(1H-indol-3-yl)ethyl]amino}-5,6,7,8-tetrahydronaphthalen-2-yl)acrylamide
40	(2E)-3-(1-{[(1R)-1-benzyl-2-hydroxyethyl]amino}-2,3-dihydro-1H-inden-5-yl)-N-hydroxyacrylamide
41	(2E)-3-(1-{[(1S)-1-benzyl-2-hydroxyethyl]amino}-2,3-dihydro-1H-inden-5-yl)-N-hydroxyacrylamide
42	(2E)-N-hydroxy-3-(1-{[1-(hydroxymethyl)-2-methylbutyl]amino}-2,3-dihydro-1H-inden-5-yl)acrylamide
43	(2E)-N-hydroxy-3-(2-{[2-(1H-indol-3-yl)ethyl]amino}-2,3-dihydro-1H-inden-5-yl)acrylamide
44	(2E)-N-hydroxy-3-(2-{(2-hydroxyethyl)[2-(1H-indol-3-yl)ethyl]amino}-2,3-dihydro-1H-inden-5-yl)acrylamide trifluoroacetate (salt)
45	(2E)-3-(1-{(2-aminoethyl)[2-(1H-indol-3-yl)ethyl]amino}-2,3-dihydro-1H-inden-5-yl)-N-hydroxyacrylamide
46	N-{5-[(1E)-3-(hydroxyamino)-3-oxoprop-1-en-1-yl]-2,3-dihydro-1H-inden-1-yl}-N-[2-(1H-indol-3-yl)ethyl]glycine
47	(2E)-N-hydroxy-3-(1-{[3-(1H-imidazol-1-yl)propanoyl][2-(1H-indol-3-yl)ethyl]amino}-2,3-dihydro-1H-inden-5-yl)acrylamide
48	(2E)-N-hydroxy-3-(1-{[2-(1H-indol-3-yl)ethyl][3-(4-methylpiperazin-1-yl)propanoyl]amino}-2,3-dihydro-1H-inden- 5-yl)acrylamide
49	(2E)-N-hydroxy-3-{1-[[2-(1H-indol-3-yl)ethyl](3-morpholin-4-ylpropanoyl)amino]-2,3-dihydro-1H-inden-5-yl}acrylamide
50	(2E)-3-(1-{(benzylsulfonyl)[2-(1H-indol-3-yl)ethyl]amino}- 2,3-dihydro-1H-inden-5-yl)-N-hydroxyacrylamide
51	(2E)-N-hydroxy-3-(1-{(2-hydroxyethyl)[2-(1H-indol-3-yl)ethyl]amino}-2,3-dihydro-1H-inden-5-yl)but-2-enamide
52	(2Z)-3-chloro-N-hydroxy-3-(1-{(2-hydroxyethyl)[2-(1H-indol-3-yl)ethyl]amino}-2,3-dihydro-1H-inden-5-yl)acrylamide
53	N-hydroxy-3-(1-{(2-hydroxyethyl)[2-(1H-indol-3-yl)ethyl]amino}-2,3-dihydro-1H-inden-5-yl)propanamide
54	3-(6-chloro-1-{(2-hydroxyethyl)[2-(1H-indol-3-yl)ethyl]amino}-2,3-dihydro-1H-inden-5-yl)-N-hydroxypropanamide
55	3-(4-chloro-1-{(2-hydroxyethyl)[2-(1H-indol-3-yl)ethyl]amino}-2,3-dihydro-1H-inden-5-yl)-N-hydroxypropanamide

Compound Example	IUPAC Name
56	N-hydroxy-3-(1-{(2-hydroxyethyl)[2-(1H-indol-3-yl)ethyl]amino}-6-methoxy-2,3-dihydro-1H-inden-5-yl)propanamide
57	3-(4,6-dichloro-1-{(2-hydroxyethyl)[2-(1H-indol-3-yl)ethyl]amino}-2,3-dihydro-1H-inden-5-yl)-N-hydroxypropanamide
58	N-hydroxy-3-(1-{(2-hydroxyethyl)[2-(1H-indol-3-yl)ethyl]amino}-4-methyl-2,3-dihydro-1H-inden-5-yl)propanamide
59	N-hydroxy-3-(1-{(2-hydroxyethyl)[2-(1H-indol-3-yl)ethyl]amino}-6-methyl-2,3-dihydro-1H-inden-5-yl)propanamide
60	N-hydroxy-3-[1-{(2-hydroxyethyl)[2-(1H-indol-3-yl)ethyl]amino}-6-(trifluoromethyl)-2,3-dihydro-1H-inden-5-yl]propanamide
61	N-hydroxy-3-(1-{(2-hydroxyethyl)[2-(1H-indol-3-yl)ethyl]amino}-6-nitro-2,3-dihydro-1H-inden-5-yl)propanamide
62	3-(6-amino-1-{(2-hydroxyethyl)[2-(1H-indol-3-yl)ethyl]amino}-2,3-dihydro-1H-inden-5-yl)-N-hydroxypropanamide
63	3-(6-cyano-1-{(2-hydroxyethyl)[2-(1H-indol-3-yl)ethyl]amino}-2,3-dihydro-1H-inden-5-yl)-N-hydroxypropanamide
64	6-[3-(hydroxyamino)-3-oxopropyl]-3-{(2-hydroxyethyl)[2-(1H-indol-3-yl)ethyl]amino}indane-5-carboxylic acid
65	6-[(1E)-3-(hydroxyamino)-3-oxoprop-1-en-1-yl]-3-{(2-hydroxyethyl)[2-(1H-indol-3-yl)ethyl]amino}indane-5-carboxylic acid
66	(2E)-N-hydroxy-3-(1-{(2-hydroxyethyl)[2-(1H-indol-3-yl)ethyl]amino}-6-nitro-2,3-dihydro-1H-inden-5-yl)acrylamide
67	(2E)-3-(6-chloro-1-{(2-hydroxyethyl)[2-(1H-indol-3-yl)ethyl]amino}-2,3-dihydro-1H-inden-5-yl)-N-hydroxyacrylamide
68	(2E)-3-(6-cyano-1-{(2-hydroxyethyl)[2-(1H-indol-3-yl)ethyl]amino}-2,3-dihydro-1H-inden-5-yl)-N-hydroxyacrylamide
69	(2E)-3-(6-amino-1-{(2-hydroxyethyl)[2-(1H-indol-3-yl)ethyl]amino}-2,3-dihydro-1H-inden-5-yl)-N-hydroxyacrylamide
70	(2E)-3-(4,6-dichloro-1-{(2-hydroxyethyl)[2-(1H-indol-3-yl)ethyl]amino}-2,3-dihydro-1H-inden-5-yl)-N-hydroxyacrylamide
71	(2E)-3-(4-chloro-1-{(2-hydroxyethyl)[2-(1H-indol-3-yl)ethyl]amino}-2,3-dihydro-1H-inden-5-yl)-N-hydroxyacrylamide
72	(2E)-N-hydroxy-3-(1-{(1H-imidazol-4-ylmethyl)[2-(1H-indol-3-yl)ethyl]amino}-2,3-dihydro-1H-inden-5-yl)acrylamide
73	(2E)-3-(1-{(2,3-dihydroxypropyl)[2-(1H-indol-3-yl)ethyl]amino}-2,3-dihydro-1H-inden-5-yl)-N-hydroxyacrylamide
74	(2E)-N-hydroxy-3-(1-{[2-(2-hydroxyethoxy)ethyl][2-(1H-indol-3-yl)ethyl]amino}-2,3-dihydro-1H-inden-5-yl)acrylamide
75	(2E)-3-(1-{[2-(2,3-dihydroxypropoxy)ethyl][2-(1H-indol-3-yl)ethyl]amino}-2,3-dihydro-1H-inden-5-yl)-N-hydroxyacrylamide
76	(2E)-N-hydroxy-3-(1-{[2-(1H-indol-3-yl)ethyl][2-(2-morpholin-4-ylethoxy)ethyl]amino}-2,3-dihydro-1H-inden-5-yl)acrylamide

Compound Example	IUPAC Name
77	(2E)-N-hydroxy-3-(1-{[2-(1H-imidazol-5-ylmethoxy)ethyl][2-(1H-indol-3-yl)ethyl]amino}-2,3-dihydro-1H-inden-5-yl)acrylamide
78	2-{{5-[(1E)-3-(hydroxyamino)-3-oxoprop-1-en-1-yl]-2,3-dihydro-1H-inden-1-yl}[2-(1H-indol-3-yl)ethyl]amino}ethyl diethylcarbamate
79	2-{{5-[(1E)-3-(hydroxyamino)-3-oxoprop-1-en-1-yl]-2,3-dihydro-1H-inden-1-yl}[2-(1H-indol-3-yl)ethyl]amino}ethyl pyrrolidine-1-carboxylate
80	2-{{5-[(1E)-3-(hydroxyamino)-3-oxoprop-1-en-1-yl]-2,3-dihydro-1H-inden-1-yl}[2-(1H-indol-3-yl)ethyl]amino}ethyl benzylcarbamate
81	(2E)-N-hydroxy-3-{1-[[2-(1H-indol-3-yl)ethyl](2-morpholin-4-ylethyl)amino]-2,3-dihydro-1H-inden-5-yl}acrylamide
82	(2E)-3-(1-{[2-(diethylamino)ethyl][2-(1H-indol-3-yl)ethyl]amino}-2,3-dihydro-1H-inden-5-yl)-N-hydroxyacrylamide
83	(2E)-3-(1-{[2-(acetylamino)ethyl][2-(1H-indol-3-yl)ethyl]amino}-2,3-dihydro-1H-inden-5-yl)-N-hydroxyacrylamide
84	(2E)-N-hydroxy-3-[1-([2-(1H-indol-3-yl)ethyl]{2-[(methylsulfonyl)amino]ethyl}amino)-2,3-dihydro-1H-inden-5-yl]acrylamide
85	(2E)-N-hydroxy-3-(1-{{2-[(2-hydroxyethyl)amino]ethyl}[2-(1H-indol-3-yl)ethyl]amino}-2,3-dihydro-1H-inden-5-yl)acrylamide
86	N-(2-{{5-[(1E)-3-(hydroxyamino)-3-oxoprop-1-en-1-yl]-2,3-dihydro-1H-inden-1-yl}[2-(1H-indol-3-yl)ethyl]amino}ethyl)-beta-D-glucopyranosylamine
87	(2E)-3-(1-{[2-(beta-D-glucopyranosyloxy)ethyl][2-(1H-indol-3-yl)ethyl]amino}-2,3-dihydro-1H-inden-5-yl)-N-hydroxyacrylamide
88	(2E)-N-hydroxy-3-(1-{[2-(1H-indol-3-yl)ethyl][2-(4-methylpiperazin-1-yl)ethyl]amino}-2,3-dihydro-1H-inden- 5-yl)acrylamide
89	(2E)-3-(1-{[2-(4-acetylpiperazin-1-yl)ethyl][2-(1H-indol-3-yl)ethyl]amino}-2,3-dihydro-1H-inden-5-yl)-N-hydroxyacrylamide
90	(2E)-N-hydroxy-3-[1-([2-(1H-indol-3-yl)ethyl]{2-[4-(methylsulfonyl)piperazin-1-yl]ethyl}amino)-2,3-dihydro-1H-inden-5-yl]acrylamide
91	(2E)-N-hydroxy-3-{1-[[2-(1H-indol-3-yl)ethyl](3-morpholin-4-yl-3-oxopropyl)amino]-2,3-dihydro-1H-inden-5-yl}acrylamide
92	N,N-diethyl-N3-{5-[(1E)-3-(hydroxyamino)-3-oxoprop-1-en-1-yl]-2,3-dihydro-1H-inden-1-yl}-N3-[2-(1H-indol-3-yl)ethyl]-beta-alaninamide
93	(2E)-3-(1-{ethyl[2-(1H-indol-3-yl)ethyl]amino}-2,3-dihydro-1H-inden-5-yl)-N-hydroxyacrylamide
94	(2E)-3-(1-{benzyl[2-(1H-indol-3-yl)ethyl]amino}-2,3-dihydro-1H-inden-5-yl)-N-hydroxyacrylamide
95	(2E)-3-(1-{(cyclohexylmethyl)[2-(1H-indol-3-yl)ethyl]amino}-2,3-dihydro-1H-inden-5-yl)-N-hydroxyacrylamide
96	(2E)-3-(1-{cyclohexyl[2-(1H-indol-3-yl)ethyl]amino}-2,3-dihydro-1H-inden-5-yl)-N-hydroxyacrylamide

Compound Example	IUPAC Name
97	(2E)-N-hydroxy-3-{1-[[2-(1H-indol-3-yl)ethyl](pyridin-2-ylmethyl)amino]-2,3-dihydro-1H-inden-5-yl}acrylamide
98	(2E)-N-hydroxy-3-{1-[[2-(1H-indol-3-yl)ethyl](phenyl)amino]-2,3-dihydro-1H-inden-5-yl}acrylamide
99	(2E)-N-hydroxy-3-{1-[[2-(1H-indol-3-yl)ethyl](pyridin-2-yl)amino]-2,3-dihydro-1H-inden-5-yl}acrylamide
100	(2E)-N-hydroxy-3-{1-[[2-(1H-indol-3-yl)ethyl](tetrahydro-2H-pyran-4-yl)amino]-2,3-dihydro-1H-inden-5-yl}acrylamide
101	(2E)-N-hydroxy-3-(1-{[2-hydroxy-1-(hydroxymethyl)-2-phenylethyl]amino}-2,3-dihydro-1H-inden-5-yl)acrylamide
102	(2E)-N-hydroxy-3-(1-{[2-hydroxy-1-(hydroxymethyl)-2-(4-nitrophenyl)ethyl]amino}-2,3-dihydro-1H-inden-5-yl)acrylamide
103	(2E)-N-hydroxy-3-[1-({2-hydroxy-1-(hydroxymethyl)-2-[4-(methylsulfonyl)phenyl]ethyl}amino)-2,3-dihydro-1H-inden-5-yl]acrylamide
104	(2E)-3-(1-{[1-(4-chlorobenzyl)-2-hydroxyethyl]amino}-2,3-dihydro-1H-inden-5-yl)-N-hydroxyacrylamide
105	(2E)-N-hydroxy-3-(1-{[2-hydroxy-1-(4-hydroxybenzyl)ethyl]amino}-2,3-dihydro-1H-inden-5-yl)acrylamide
106	(2E)-N-hydroxy-3-(1-{[2-hydroxy-1-(1H-imidazol-4-ylmethyl)ethyl]amino}-2,3-dihydro-1H-inden-5-yl)acrylamide
107	(2E)-N-hydroxy-3-(1-{[2-hydroxy-1-(4-methoxybenzyl)ethyl]amino}-2,3-dihydro-1H-inden-5-yl)acrylamide
108	(2E)-N-hydroxy-3-(1-{[3-hydroxy-1-(hydroxymethyl)-3-(4-nitrophenyl)propyl]amino}-2,3-dihydro-1H-inden-5-yl)acrylamide
109	(2E)-N-hydroxy-3-{1-[(2-hydroxy-1-phenylethyl)amino]-2,3-dihydro-1H-inden-5-yl}acrylamide
110	(2E)-N-hydroxy-3-(1-{[3-hydroxy-1-(5-methyl-2-thienyl)propyl]amino}-2,3-dihydro-1H-inden-5-yl)acrylamide
111	(2E)-N-hydroxy-3-{1-[(3-hydroxy-1-pyridin-3-ylpropyl)amino]-2,3-dihydro-1H-inden-5-yl}acrylamide
112	(2E)-3-[1-({1-[4-(dimethylamino)phenyl]-3-hydroxypropyl}amino)-2,3-dihydro-1H-inden-5-yl]-N-hydroxyacrylamide
113	(2E)-3-(1-{[1-(4-fluorophenyl)-3-hydroxypropyl]amino}-2,3- dihydro-1H-inden-5-yl)-N-hydroxyacrylamide
114	(2E)-3-(1-{[1-(3,4-dimethoxyphenyl)-3-hydroxypropyl]amino}-2,3-dihydro-1H-inden-5-yl)-N-hydroxyacrylamide
115	(2E)-3-(1-{[1-(1-benzofuran-2-yl)-3-hydroxypropyl]amino}-2,3-dihydro-1H-inden-5-yl)-N-hydroxyacrylamide
116	(2E)-3-(1-{[1-(1-benzothien-3-yl)-3-hydroxypropyl]amino}-2,3-dihydro-1H-inden-5-yl)-N-hydroxyacrylamide
117	(2E)-N-hydroxy-3-{1-[(3-hydroxy-1-quinolin-3-ylpropyl)amino]-2,3-dihydro-1H-inden-5-yl}acrylamide

Compound Example	IUPAC Name
118	(2E)-N-hydroxy-3-{1-[(2-hydroxy-1-pyridin-3-ylethyl)amino]-2,3-dihydro-1H-inden-5-yl}acrylamide
119	tert-butyl N-{5-[(1E)-3-(hydroxyamino)-3-oxoprop-1-en-1-yl]-2,3-dihydro-1H-inden-1-yl}tyrosinate
120	N-{5-[(1E)-3-(hydroxyamino)-3-oxoprop-1-en-1-yl]-2,3-dihydro-1H-inden-1-yl}tyrosine
121	tert-butyl N-{5-[(1E)-3-(hydroxyamino)-3-oxoprop-1-en-1-yl]-2,3-dihydro-1H-inden-1-yl}tryptophanate
122	N-{5-[(1E)-3-(hydroxyamino)-3-oxoprop-1-en-1-yl]-2,3-dihydro-1H-inden-1-yl}tryptophan
123	Nalpha-{5-[(1E)-3-(hydroxyamino)-3-oxoprop-1-en-1-yl]-2,3-dihydro-1H-inden-1-yl}-N-(2-hydroxyethyl)tryptophanamide
124	(2E)-N-hydroxy-3-(1-{[1-(1H-indol-3-ylmethyl)-2-morpholin-4-yl-2-oxoethyl]amino}-2,3-dihydro-1H-inden-5-yl)acrylamide
125	N-[2-(dimethylamino)ethyl]-Nalpha-{5-[(1E)-3-(hydroxyamino)-3-oxoprop-1-en-1-yl]-2,3-dihydro-1H-inden-1-yl}tryptophanamide
126	Nalpha-{5-[(1E)-3-(hydroxyamino)-3-oxoprop-1-en-1-yl]-2,3-dihydro-1H-inden-1-yl}tryptophanamide
127	N-{5-[(1E)-3-(hydroxyamino)-3-oxoprop-1-en-1-yl]-2,3-dihydro-1H-inden-1-yl}tryptophylglycine
128	(2E)-N-hydroxy-3-(1-{[(1S)-1-(hydroxymethyl)-3-methylbutyl]amino}-2,3-dihydro-1H-inden-5-yl)acrylamide
129	(2E)-N-hydroxy-3-(1-{[1-(hydroxymethyl)-2-methylpropyl]amino}-2,3-dihydro-1H-inden-5-yl)acrylamide
130	(2E)-N-hydroxy-3-{1-[(2-hydroxyethyl)amino]-2,3-dihydro-1H-inden-5-yl}acrylamide
131	tert-butyl N-{5-[(1E)-3-(hydroxyamino)-3-oxoprop-1-en-1-yl]-2,3-dihydro-1H-inden-1-yl}serinate
132	(2E)-N-hydroxy-3-(1-{[2-hydroxy-1-(hydroxymethyl)ethyl]amino}-2,3-dihydro-1H-inden-5-yl)acrylamide
133	N-{5-[(1E)-3-(hydroxyamino)-3-oxoprop-1-en-1-yl]-2,3-dihydro-1H-inden-1-yl}serine
134	(3-{2-[{5-[(1E)-3-(hydroxyamino)-3-oxoprop-1-en-1-yl]-2,3-dihydro-1H-inden-1-yl}(2-hydroxyethyl)amino]ethyl}-1H-indol-1-yl)acetic acid
135	(2E)-N-hydroxy-3-[1-((2-hydroxyethyl){2-[1-(2-oxo-2-pyrrolidin-1-ylethyl)-1H-indol-3-yl]ethyl}amino)-2,3-dihydro-1H-inden-5-yl]acrylamide
136	(2E)-3-{1-[(2-{1-[2-(diethylamino)-2-oxoethyl]-1H-indol-3-yl}ethyl)(2-hydroxyethyl)amino]-2,3-dihydro-1H-inden-5-yl}-N-hydroxyacrylamide
137	(2E)-3-{1-[{2-[1-(2-amino-2-oxoethyl)-1H-indol-3-yl]ethyl}(2-hydroxyethyl)amino]-2,3-dihydro-1H-inden-5-yl}-N-hydroxyacrylamide
138	(2E)-3-{1-[{2-[1-(2,3-dihydroxypropyl)-1H-indol-3-yl]ethyl}(2-hydroxyethyl)amino]-2,3-dihydro-1H-inden-5-yl}-N-hydroxyacrylamide

Compound Example	IUPAC Name
139	(2E)-N-hydroxy-3-[1-((2-hydroxyethyl){2-[1-(2-morpholin-4-ylethyl)-1H-indol-3-yl]ethyl}amino)-2,3-dihydro-1H-inden-5-yl]acrylamide
140	(2E)-N-hydroxy-3-{1-[(2-hydroxyethyl)(2-{1-[2-(1H-imidazol-5-yl)ethyl]-1H-indol-3-yl}ethyl)amino]-2,3-dihydro-1H-inden-5-yl}acrylamide
141	(2E)-N-hydroxy-3-(1-{(2-hydroxyethyl)[2-(5-methyl-1H-indol-3-yl)ethyl]amino}-2,3-dihydro-1H-inden-5-yl)acrylamide
142	(2E)-N-hydroxy-3-(1-{(2-hydroxyethyl)[2-(5-methoxy-1H-indol-3-yl)ethyl]amino}-2,3-dihydro-1H-inden-5-yl)acrylamide
143	(2E)-3-{1-[[2-(5-chloro-1H-indol-3-yl)ethyl](2-hydroxyethyl)amino]-2,3-dihydro-1H-inden-5-yl}-N-hydroxyacrylamide
144	(2E)-3-{1-[[2-(5-fluoro-2-methyl-1H-indol-3-yl)ethyl](2-hydroxyethyl)amino]-2,3-dihydro-1H-inden-5-yl}-N-hydroxyacrylamide
145	(2E)-N-hydroxy-3-(6-{(2-hydroxyethyl)[2-(1H-indol-3-yl)ethyl]amino}-5,6,7,8-tetrahydronaphthalen-2-yl)acrylamide
146	(2E)-N-hydroxy-3-(6-{[2-(1H-indol-3-yl)ethyl]amino}-5,6,7,8-tetrahydronaphthalen-2-yl)acrylamide
147	(2E)-N-hydroxy-3-(1-{(2-hydroxyethyl)[2-(1H-indol-3-yl)ethyl]amino}-6,7-dimethyl-2,3-dihydro-1H-inden-5-yl)acrylamide
148	(2E)-3-(6,7-dichloro-1-{(2-hydroxyethyl)[2-(1H-indol-3-yl)ethyl]amino}-2,3-dihydro-1H-inden-5-yl)-N-hydroxyacrylamide
149	(2E)-N-hydroxy-3-(1-{(2-hydroxyethyl)[2-(1H-indol-3-yl)ethyl]amino}-7-methyl-2,3-dihydro-1H-inden-5-yl)acrylamide
150	(2E)-N-hydroxy-3-(1-{(2-hydroxyethyl)[2-(2-thienyl)ethyl]amino}-2,3-dihydro-1H-inden-5-yl)acrylamide
151	(2E)-N-hydroxy-3-[1-((2-hydroxyethyl){2-[3-(trifluoromethyl)phenyl]ethyl}amino)-2,3-dihydro-1H-inden-5-yl]acrylamide
152	(2E)-N-hydroxy-3-{1-[(2-hydroxyethyl)(2-{4-[(methylsulfonyl)amino]phenyl}ethyl)amino]-2,3-dihydro-1H-inden-5-yl}acrylamide
153	(2E)-3-{1-[(4-cyanobenzyl)(2-hydroxyethyl)amino]-2,3-dihydro-1H-inden-5-yl}-N-hydroxyacrylamide
154	(2E)-3-{1-[[4-(ethylamino)benzyl](2-hydroxyethyl)amino]-2,3-dihydro-1H-inden-5-yl}-N-hydroxyacrylamide
155	N-ethyl-4-{[{5-[(1E)-3-(hydroxyamino)-3-oxoprop-1-en-1-yl]-2,3-dihydro-1H-inden-1-yl}(2-hydroxyethyl)amino]methyl}benzamide
156	4-{[{5-[(1E)-3-(hydroxyamino)-3-oxoprop-1-en-1-yl]-2,3-dihydro-1H-inden-1-yl}(2-hydroxyethyl)amino]methyl}benzoic acid
157	(2E)-N-hydroxy-3-[1-((2-hydroxyethyl){2-[1-(2-methoxyethyl)-1H-indol-3-yl]ethyl}amino)-2,3-dihydro-1H-inden-5-yl]acrylamide
158	(2E)-3-{1-[(2-{1-[2-(dimethylamino)ethyl]-1H-indol-3-yl}ethyl)(2-hydroxyethyl)amino]-2,3-dihydro-1H-inden-5-yl}-N-hydroxyacrylamide

Compound Example	IUPAC Name
159	(2E)-N-hydroxy-3-[1-((2-hydroxyethyl){2-[1-(2-pyrrolidin-1-ylethyl)-1H-indol-3-yl]ethyl}amino)-2,3-dihydro-1H-inden-5-yl]acrylamide
160	(2E)-N-hydroxy-3-[1-((2-hydroxyethyl){2-[5-(2-methoxyethoxy)-1H-indol-3-yl]ethyl}amino)-2,3-dihydro-1H-inden-5-yl]acrylamide
161	(2E)-3-{1-[(2-{5-[2-(dimethylamino)ethoxy]-1H-indol-3-yl}ethyl)(2-hydroxyethyl)amino]-2,3-dihydro-1H-inden-5-yl}-N-hydroxyacrylamide
162	(2E)-N-hydroxy-3-[1-((2-hydroxyethyl){2-[5-(2-morpholin-4-ylethoxy)-1H-indol-3-yl]ethyl}amino)-2,3-dihydro-1H-inden-5-yl]acrylamide
163	(2E)-N-hydroxy-3-[1-((2-hydroxyethyl){2-[5-(2-pyrrolidin-1-ylethoxy)-1H-indol-3-yl]ethyl}amino)-2,3-dihydro-1H-inden-5-yl]acrylamide
164	(2E)-N-hydroxy-3-{1-[(2-hydroxyethyl)(2-{5-[2-(1H-imidazol-5-yl)ethoxy]-1H-indol-3-yl}ethyl)amino]-2,3-dihydro-1H-inden-5-yl}acrylamide
165	(2E)-3-(1-{(2-{[(ethylamino)carbonyl]amino}ethyl)[2-(1H-indol-3-yl)ethyl]amino}-2,3-dihydro-1H-inden-5-yl)-N-hydroxyacrylamide
166	(2E)-N-hydroxy-3-[1-((2-hydroxyethyl){2-[1-(3-morpholin-4-yl-3-oxopropyl)-1H-indol-3-yl]ethyl}amino)-2,3-dihydro-1H-inden-5-yl]acrylamide
167	N-ethyl-Nalpha-{5-[(1E)-3-(hydroxyamino)-3-oxoprop-1-en-1-yl]-2,3-dihydro-1H-inden-1-yl}tryptophanamide
168	Nalpha-{5-[(1E)-3-(hydroxyamino)-3-oxoprop-1-en-1-yl]-2,3-dihydro-1H-inden-1-yl}-N,N-dimethyltryptophanamide
169	(2E)-3-(1-{{[(4-fluorophenyl)amino]carbonyl}[2-(1H-indol-3-yl)ethyl]amino}-2,3-dihydro-1H-inden-5-yl)-N-hydroxyacrylamide
170	2-{{5-[(1E)-3-(hydroxyamino)-3-oxoprop-1-en-1-yl]-2,3-dihydro-1H-inden-1-yl}[2-(1H-indol-3-yl)ethyl]amino}ethyl ethylcarbamate
171	2-{{5-[(1E)-3-(hydroxyamino)-3-oxoprop-1-en-1-yl]-2,3-dihydro-1H-inden-1-yl}[2-(1H-indol-3-yl)ethyl]amino}ethyl phenylcarbamate
172	(2E)-N-hydroxy-3-(1-{[2-(1H-indol-3-yl)-1-methylethyl]amino}-2,3-dihydro-1H-inden-5-yl)acrylamide
173	(2E)-3-{(1S)-1-[[2-(5-chloro-1H-indol-3-yl)ethyl](2-hydroxyethyl)amino]-2,3-dihydro-1H-inden-5-yl}-N-hydroxyacrylamide
174	(2E)-3-{(1R)-1-[[2-(5-chloro-1H-indol-3-yl)ethyl](2-hydroxyethyl)amino]-2,3-dihydro-1H-inden-5-yl}-N-hydroxyacrylamide
175	(2E)-3-(1-{ethyl[2-(3-methylphenyl)ethyl]amino}-4-fluoro-2,3-dihydro-1H-inden-5-yl)-N-hydroxyacrylamide
176	(2E)-3-(4-fluoro-1-{[2-(1H-indol-3-yl)ethyl]amino}-2,3-dihydro-1H-inden-5-yl)-N-hydroxyacrylamide
177	(2E)-3-{(1S)-1-[[2-(2-chlorophenyl)ethyl](3-hydroxypropyl)amino]-2,3-dihydro-1H-inden-5-yl}-N-hydroxyacrylamide
178	(2E)-3-{(1R)-1-[[2-(2-chlorophenyl)ethyl](3-hydroxypropyl)amino]-2,3-dihydro-1H-inden-5-yl}-N-hydroxyacrylamide
179	(2E)-N-hydroxy-3-(1-{methyl[2-(1-methyl-1H-indol-3-yl)ethyl]amino}-2,3-dihydro-1H-inden-5-yl)acrylamide

Compound Example	IUPAC Name
180	(2E)-N-hydroxy-3-(1-{(2-hydroxyethyl)[2-hydroxy-1-(1H-indol-3-ylmethyl)ethyl]amino}-2,3-dihydro-1H-inden-5-yl)acrylamide
181	N-{(1R)-5-[(1E)-3-(hydroxyamino)-3-oxoprop-1-en-1-yl]-2,3-dihydro-1H-inden-1-yl}-N-[(1S)-2-hydroxy-1-(1H-indol-3-ylmethyl)ethyl]cyclobutanecarboxamide
182	N-{(1R)-5-[(1E)-3-(hydroxyamino)-3-oxoprop-1-en-1-yl]-2,3-dihydro-1H-inden-1-yl}-N-[(1S)-2-hydroxy-1-(1H-indol-3-ylmethyl)ethyl]benzamide
183	N-{(1R)-5-[(1E)-3-(hydroxyamino)-3-oxoprop-1-en-1-yl]-2,3-dihydro-1H-inden-1-yl}-N-[(1S)-2-hydroxy-1-(1H-indol-3-ylmethyl)ethyl]cyclohexanecarboxamide
184	(2E)-3-((1S)-1-{[2-(5-chloro-1H-indol-3-yl)ethyl]amino}-2,3-dihydro-1H-inden-5-yl)-N-hydroxyacrylamide
185	(2E)-3-((1R)-1-{[2-(5-chloro-1H-indol-3-yl)ethyl]amino}-2,3-dihydro-1H-inden-5-yl)-N-hydroxyacrylamide
186	(2E)-3-(1-{ethyl[2-(1H-indol-3-yl)ethyl]amino}-2,3-dihydro-1H-inden-5-yl)-N-hydroxybut-2-enamide
187	(2E)-N-hydroxy-3-(1-{(3-hydroxypropyl)[2-(1H-indol-3-yl)ethyl]amino}-2,3-dihydro-1H-inden-5-yl)but-2-enamide
188	(2E)-3-(1-{[2-(5-fluoro-2-methyl-1H-indol-3-yl)ethyl]amino}-2,3-dihydro-1H-inden-5-yl)-N-hydroxybut-2-enamide
189	(2E)-3-(1-{[2-(5-chloro-1H-indol-3-yl)ethyl]amino}-2,3-dihydro-1H-inden-5-yl)-N-hydroxybut-2-enamide
190	(2E)-N-hydroxy-3-(1-{[2-(5-methoxy-1H-indol-3-yl)ethyl]amino}-2,3-dihydro-1H-inden-5-yl)but-2-enamide
191	(2E)-N-hydroxy-3-(1-{[2-(6-methoxy-1H-indol-3-yl)ethyl]amino}-2,3-dihydro-1H-inden-5-yl)but-2-enamide
192	(2E)-3-(1-{[2-(6-fluoro-1H-indol-3-yl)ethyl]amino}-2,3-dihydro-1H-inden-5-yl)-N-hydroxybut-2-enamide
193	(2E)-N-hydroxy-3-((1S)-1-{(2-hydroxyethyl)[2-(1H-indol-3-yl)ethyl]amino}-2,3-dihydro-1H-inden-5-yl)but-2-enamide
194	(2E)-N-hydroxy-3-((1R)-1-{(2-hydroxyethyl)[2-(1H-indol-3-yl)ethyl]amino}-2,3-dihydro-1H-inden-5-yl)but-2-enamide
195	(2E)-3-(1-{ethyl[2-(6-methoxy-1H-indol-3-yl)ethyl]amino}-2,3-dihydro-1H-inden-5-yl)-N-hydroxybut-2-enamide
196	(2E)-3-(1-{ethyl[2-(5-methoxy-1H-indol-3-yl)ethyl]amino}-2,3-dihydro-1H-inden-5-yl)-N-hydroxybut-2-enamide
197	(2E)-3-(1-{ethyl[2-(6-fluoro-1H-indol-3-yl)ethyl]amino}-2,3-dihydro-1H-inden-5-yl)-N-hydroxybut-2-enamide
198	(2E)-N-hydroxy-3-(1-{[2-(6-methoxy-1H-indol-3-yl)ethyl]amino}-2,3-dihydro-1H-inden-5-yl)acrylamide
199	(2E)-N-hydroxy-3-(1-{[2-(5-methoxy-1H-indol-3-yl)ethyl]amino}-2,3-dihydro-1H-inden-5-yl)acrylamide

Compound Example	IUPAC Name
200	(2E)-N-hydroxy-3-(1-{(2-hydroxyethyl)[2-(6-methoxy-1H-indol-3-yl)ethyl]amino}-2,3-dihydro-1H-inden-5-yl)acrylamide
201	(2E)-3-(1-{[2-(5-fluoro-2-methyl-1H-indol-3-yl)ethyl]amino}-2,3-dihydro-1H-inden-5-yl)-N-hydroxyacrylamide
202	(2E)-3-(1-{[2-(5-chloro-1H-indol-3-yl)ethyl]amino}-2,3-dihydro-1H-inden-5-yl)-N-hydroxyacrylamide
203	(2E)-N-hydroxy-3-{1-[(2-phenylethyl)amino]-2,3-dihydro-1H-inden-5-yl}acrylamide
204	(2E)-N-hydroxy-3-(1-{[2-(2-methylphenyl)ethyl]amino}-2,3-dihydro-1H-inden-5-yl)acrylamide
205	(2E)-N-hydroxy-3-(1-{[2-(4-methylphenyl)ethyl]amino}-2,3-dihydro-1H-inden-5-yl)acrylamide
206	(2E)-N-hydroxy-3-(1-{[2-(3-methylphenyl)ethyl]amino}-2,3-dihydro-1H-inden-5-yl)acrylamide
207	(2E)-N-hydroxy-3-((1S)-1-{(3-hydroxypropyl)[2-(1-methyl-1H-indol-3-yl)ethyl]amino}-2,3-dihydro-1H-inden-5-yl)acrylamide
208	(2E)-N-hydroxy-3-(1-{(2-hydroxyethyl)[2-(2-methylphenyl)ethyl]amino}-2,3-dihydro-1H-inden-5-yl)acrylamide
209	(2E)-N-hydroxy-3-(1-{(2-hydroxyethyl)[2-(4-methylphenyl)ethyl]amino}-2,3-dihydro-1H-inden-5-yl)acrylamide
210	(2E)-N-hydroxy-3-(1-{(2-hydroxyethyl)[2-(3-methylphenyl)ethyl]amino}-2,3-dihydro-1H-inden-5-yl)acrylamide
211	(2E)-N-hydroxy-3-{1-[(2-hydroxyethyl)(2-phenylethyl)amino]-2,3-dihydro-1H-inden-5-yl}acrylamide
212	(2E)-N-hydroxy-3-((1R)-1-{(3-hydroxypropyl)[2-(1-methyl-1H-indol-3-yl)ethyl]amino}-2,3-dihydro-1H-inden-5-yl)acrylamide
213	(2E)-3-(1-{[2-(2-chlorophenyl)ethyl]amino}-2,3-dihydro-1H-inden-5-yl)-N-hydroxyacrylamide
214	(2E)-N-hydroxy-3-(1-{[2-(2-methoxyphenyl)ethyl]amino}-2,3-dihydro-1H-inden-5-yl)acrylamide
215	(2E)-3-(1-{[2-(2,3-dimethoxyphenyl)ethyl]amino}-2,3-dihydro-1H-inden-5-yl)-N-hydroxyacrylamide
216	(2E)-3-(1-{[2-(3-chlorophenyl)ethyl]amino}-2,3-dihydro-1H-inden-5-yl)-N-hydroxyacrylamide
217	(2E)-3-(1-{[2-(3,4-dimethylphenyl)ethyl]amino}-2,3-dihydro-1H-inden-5-yl)-N-hydroxyacrylamide
218	(2E)-N-hydroxy-3-(1-{[2-(3-methoxyphenyl)ethyl]amino}-2,3-dihydro-1H-inden-5-yl)acrylamide
219	(2E)-N-hydroxy-3-(1-{[2-(4-methoxyphenyl)ethyl]amino}-2,3-dihydro-1H-inden-5-yl)acrylamide
220	(2E)-3-(1-{[2-(4-chlorophenyl)ethyl]amino}-2,3-dihydro-1H-inden-5-yl)-N-hydroxyacrylamide

Compound Example	IUPAC Name
221	(2E)-3-(1-{[2-(3-bromo-4-methoxyphenyl)ethyl]amino}-2,3-dihydro-1H-inden-5-yl)-N-hydroxyacrylamide
222	(2E)-3-{1-[[2-(2-chlorophenyl)ethyl](3-hydroxypropyl)amino]-2,3-dihydro-1H-inden-5-yl}-N-hydroxyacrylamide
223	(2E)-3-{1-[[2-(2,3-dimethoxyphenyl)ethyl](3-hydroxypropyl)amino]-2,3-dihydro-1H-inden-5-yl}-N-hydroxyacrylamide
224	(2E)-N-hydroxy-3-(1-{(3-hydroxypropyl)[2-(3-methoxyphenyl)ethyl]amino}-2,3-dihydro-1H-inden-5-yl)acrylamide
225	(2E)-N-hydroxy-3-(1-{(3-hydroxypropyl)[2-(2-methoxyphenyl)ethyl]amino}-2,3-dihydro-1H-inden-5-yl)acrylamide
226	(2E)-N-hydroxy-3-(1-{(3-hydroxypropyl)[2-(4-methoxyphenyl)ethyl]amino}-2,3-dihydro-1H-inden-5-yl)acrylamide
227	(2E)-3-{1-[[2-(3-chlorophenyl)ethyl](3-hydroxypropyl)amino]-2,3-dihydro-1H-inden-5-yl}-N-hydroxyacrylamide
228	(2E)-3-{1-[[2-(4-chlorophenyl)ethyl](3-hydroxypropyl)amino]-2,3-dihydro-1H-inden-5-yl}-N-hydroxyacrylamide
229	(2E)-N-hydroxy-3-((1S)-1-{(2-hydroxyethyl)[2-(2-methylphenyl)ethyl]amino}-2,3-dihydro-1H-inden-5-yl)acrylamide
230	(2E)-N-hydroxy-3-((1R)-1-{(2-hydroxyethyl)[2-(2-methylphenyl)ethyl]amino}-2,3-dihydro-1H-inden-5-yl)acrylamide
231	(2E)-3-{1-[[2-(2,5-dimethoxyphenyl)ethyl](2-hydroxyethyl)amino]-2,3-dihydro-1H-inden-5-yl}-N-hydroxyacrylamide
232	(2E)-3-{1-[[2-(2,5-dimethylphenyl)ethyl](2-hydroxyethyl)amino]-2,3-dihydro-1H-inden-5-yl}-N-hydroxyacrylamide
233	(2E)-3-{1-[[2-(3,5-dimethoxyphenyl)ethyl](2-hydroxyethyl)amino]-2,3-dihydro-1H-inden-5-yl}-N-hydroxyacrylamide
234	(2E)-3-{1-[[2-(2,4-dimethylphenyl)ethyl](2-hydroxyethyl)amino]-2,3-dihydro-1H-inden-5-yl}-N-hydroxyacrylamide
235	(2E)-3-{1-[[2-(2,6-dichlorophenyl)ethyl](2-hydroxyethyl)amino]-2,3-dihydro-1H-inden-5-yl}-N-hydroxyacrylamide
236	(2E)-3-{1-[[2-(2-fluorophenyl)ethyl](2-hydroxyethyl)amino]-2,3-dihydro-1H-inden-5-yl}-N-hydroxyacrylamide
237	(2E)-3-{1-[[2-(3-fluorophenyl)ethyl](2-hydroxyethyl)amino]-2,3-dihydro-1H-inden-5-yl}-N-hydroxyacrylamide
238	(2E)-3-{1-[[2-(4-fluorophenyl)ethyl](2-hydroxyethyl)amino]-2,3-dihydro-1H-inden-5-yl}-N-hydroxyacrylamide
239	(2E)-N-hydroxy-3-((1R)-1-{(4-hydroxybenzyl)[2-(1H-indol-3-yl)ethyl]amino}-2,3-dihydro-1H-inden-5-yl)acrylamide
240	(2E)-N-hydroxy-3-((1R)-1-{(4-hydroxybenzyl)[2-(1H-indol-3-yl)ethyl]amino}-2,3-dihydro-1H-inden-5-yl)acrylamide
241	(2E)-N-hydroxy-3-((1S)-1-{(4-hydroxybenzyl)[2-(1H-indol-3-yl)ethyl]amino}-2,3-dihydro-1H-inden-5-yl)acrylamide

Compound Example	IUPAC Name
242	(2E)-N-hydroxy-3-{1-[(2-hydroxyethyl)(3-phenylpropyl)amino]-2,3-dihydro-1H-inden-5-yl}acrylamide
243	(2E)-N-hydroxy-3-(1-{(2-hydroxyethyl)[2-(2-methylphenoxy)ethyl]amino}-2,3-dihydro-1H-inden-5-yl)acrylamide
244	(2E)-N-hydroxy-3-(1-{(2-hydroxyethyl)[2-(2-methoxyphenoxy)ethyl]amino}-2,3-dihydro-1H-inden-5-yl)acrylamide
245	(2E)-N-hydroxy-3-(1-{(2-hydroxyethyl)[2-(4-methoxyphenoxy)ethyl]amino}-2,3-dihydro-1H-inden-5-yl)acrylamide
246	(2E)-3-{1-[[2-(2-fluorophenoxy)ethyl](2-hydroxyethyl)amino]-2,3-dihydro-1H-inden-5-yl}-N-hydroxyacrylamide
247	(2E)-N-hydroxy-3-{1-[(2-hydroxyethyl)(2-phenoxyethyl)amino]-2,3-dihydro-1H-inden-5-yl}acrylamide
248	(2E)-3-{1-[[2-(2-chlorophenoxy)ethyl](2-hydroxyethyl)amino]-2,3-dihydro-1H-inden-5-yl}-N-hydroxyacrylamide
249	(2E)-3-{1-[[2-(4-chlorophenoxy)ethyl](2-hydroxyethyl)amino]-2,3-dihydro-1H-inden-5-yl}-N-hydroxyacrylamide
250	(2E)-N-hydroxy-3-(1-{(2-hydroxyethyl)[2-(3-methylphenoxy)ethyl]amino}-2,3-dihydro-1H-inden-5-yl)acrylamide
251	(2E)-N-hydroxy-3-(1-{(2-hydroxyethyl)[2-(3-methoxyphenoxy)ethyl]amino}-2,3-dihydro-1H-inden-5-yl)acrylamide
252	(2E)-3-{1-[[2-(3-fluorophenoxy)ethyl](2-hydroxyethyl)amino]-2,3-dihydro-1H-inden-5-yl}-N-hydroxyacrylamide
253	(2E)-3-{1-[[2-(3-chlorophenoxy)ethyl](2-hydroxyethyl)amino]-2,3-dihydro-1H-inden-5-yl}-N-hydroxyacrylamide
254	(2E)-N-hydroxy-3-((1S)-1-{(2-hydroxyethyl)[2-(6-methoxy-1H-indol-3-yl)ethyl]amino}-2,3-dihydro-1H-inden-5-yl)acrylamide
255	(2E)-N-hydroxy-3-((1R)-1-{[2-(6-methoxy-1H-indol-3-yl)ethyl]amino}-2,3-dihydro-1H-inden-5-yl)acrylamide
256	(2E)-N-hydroxy-3-((1S)-1-{[2-(6-methoxy-1H-indol-3-yl)ethyl]amino}-2,3-dihydro-1H-inden-5-yl)acrylamide
257	(2E)-N-hydroxy-3-((1R)-1-{(2-hydroxyethyl)[2-(6-methoxy-1H-indol-3-yl)ethyl]amino}-2,3-dihydro-1H-inden-5-yl)acrylamide
258	5-({{5-[(1E)-3-(hydroxyamino)-3-oxoprop-1-en-1-yl]-2,3-dihydro-1H-inden-1-yl}[2-(1H-indol-3-yl)ethyl]amino}methyl)-N,N-dimethyl-1H-pyrrole-3-carboxamide
259	(2E)-N-hydroxy-3-[1-([2-(1H-indol-3-yl)ethyl]{[4-(morpholin-4-ylcarbonyl)-1H-pyrrol-2-yl]methyl}amino)-2,3-dihydro-1H-inden-5-yl]acrylamide
260	5-({{5-[(1E)-3-(hydroxyamino)-3-oxoprop-1-en-1-yl]-2,3-dihydro-1H-inden-1-yl}[2-(1H-indol-3-yl)ethyl]amino}methyl)-N-methyl-1H-pyrrole-3-carboxamide
261	(2E)-N-hydroxy-3-[1-([2-(1H-indol-3-yl)ethyl]{2-[(methylsulfonyl)amino]ethyl}amino)-2,3-dihydro-1H-inden-5-yl]acrylamide

Compound Example	IUPAC Name
262	(2E)-N-hydroxy-3-[1-([2-(1H-indol-3-yl)ethyl]{2-[(methylsulfonyl)amino]ethyl}amino)-2,3-dihydro-1H-inden-5-yl]acrylamide
263	5-({{(1S)-5-[(1E)-3-(hydroxyamino)-3-oxoprop-1-en-1-yl]-2,3-dihydro-1H-inden-1-yl}[2-(1H-indol-3-yl)ethyl]amino}methyl)-N,N-dimethyl-1H-pyrrole-3-carboxamide
264	5-({{(1R)-5-[(1E)-3-(hydroxyamino)-3-oxoprop-1-en-1-yl]-2,3-dihydro-1H-inden-1-yl}[2-(1H-indol-3-yl)ethyl]amino}methyl)-N,N-dimethyl-1H-pyrrole-3-carboxamide
265	tert-butyl {5-[(1E)-3-(hydroxyamino)-3-oxoprop-1-en-1-yl]-2,3-dihydro-1H-inden-1-yl}[2-(1H-indol-3-yl)ethyl]carbamate
266	(2E)-3-(1-{(2-fluorobenzyl)[2-(1H-indol-3-yl)ethyl]amino}-2,3-dihydro-1H-inden-5-yl)-N-hydroxyacrylamide
267	(2E)-3-(1-{butyl[2-(1H-indol-3-yl)ethyl]amino}-2,3-dihydro-1H-inden-5-yl)-N-hydroxyacrylamide
268	(2E)-N-hydroxy-3-(1-{(2-hydroxy-3-methoxybenzyl)[2-(1H-indol-3-yl)ethyl]amino}-2,3-dihydro-1H-inden-5-yl)acrylamide
269	(2E)-3-(1-{butyl[2-(1H-indol-3-yl)ethyl]amino}-2,3-dihydro-1H-inden-5-yl)-N-hydroxyacrylamide
270	(2E)-N-hydroxy-3-{1-[[2-(1H-indol-3-yl)ethyl](propyl)amino]-2,3-dihydro-1H-inden-5-yl}acrylamide
271	(2E)-N-hydroxy-3-{1-[[2-(1H-indol-3-yl)ethyl](2-phenylethyl)amino]-2,3-dihydro-1H-inden-5-yl}acrylamide
272	(2E)-3-(1-{(2,5-dihydroxybenzyl)[2-(1H-indol-3-yl)ethyl]amino}-2,3-dihydro-1H-inden-5-yl)-N-hydroxyacrylamide
273	(2E)-3-(1-{(5-chloro-2-hydroxybenzyl)[2-(1H-indol-3-yl)ethyl]amino}-2,3-dihydro-1H-inden-5-yl)-N-hydroxyacrylamide
274	(2E)-3-(1-{(2,3-dihydroxybenzyl)[2-(1H-indol-3-yl)ethyl]amino}-2,3-dihydro-1H-inden-5-yl)-N-hydroxyacrylamide
275	(2E)-3-(1-{(cyclopentylmethyl)[2-(1H-indol-3-yl)ethyl]amino}-2,3-dihydro-1H-inden-5-yl)-N-hydroxyacrylamide
276	(2E)-N-hydroxy-3-(1-{(2-hydroxy-3-methylbenzyl)[2-(1H-indol-3-yl)ethyl]amino}-2,3-dihydro-1H-inden-5-yl)acrylamide
277	(2E)-3-(1-{(5-fluoro-2-hydroxybenzyl)[2-(1H-indol-3-yl)ethyl]amino}-2,3-dihydro-1H-inden-5-yl)-N-hydroxyacrylamide
278	(2E)-N-hydroxy-3-{1-[[2-(1H-indol-3-yl)ethyl](isobutyl)amino]-2,3-dihydro-1H-inden-5-yl}acrylamide
279	(2E)-3-(1-{(3,3-dimethylbutyl)[2-(1H-indol-3-yl)ethyl]amino}-2,3-dihydro-1H-inden-5-yl)-N-hydroxyacrylamide
280	(2E)-N-hydroxy-3-{1-[[2-(1H-indol-3-yl)ethyl](1H-pyrrol-2-ylmethyl)amino]-2,3-dihydro-1H-inden-5-yl}acrylamide
281	(2E)-3-(1-{(cyclopropylmethyl)[2-(1H-indol-3-yl)ethyl]amino}-2,3-dihydro-1H-inden-5-yl)-N-hydroxyacrylamide

Compound Example	IUPAC Name
282	(2E)-N-hydroxy-3-{1-[[2-(1H-indol-3-yl)ethyl](pyridin-4-ylmethyl)amino]-2,3-dihydro-1H-inden-5-yl}acrylamide
283	(2E)-N-hydroxy-3-(1-{[2-(1H-indol-3-yl)ethyl][(1-methyl-1H-imidazol-2-yl)methyl]amino}-2,3-dihydro-1H-inden-5-yl)acrylamide
284	(2E)-N-hydroxy-3-{1-[[2-(1H-indol-3-yl)ethyl](2-thienylmethyl)amino]-2,3-dihydro-1H-inden-5-yl}acrylamide
285	(2E)-3-(1-{(2-furylmethyl)[2-(1H-indol-3-yl)ethyl]amino}-2,3-dihydro-1H-inden-5-yl)-N-hydroxyacrylamide
286	(2E)-N-hydroxy-3-{1-[[2-(1H-indol-3-yl)ethyl](2-phenoxyethyl)amino]-2,3-dihydro-1H-inden-5-yl}acrylamide
287	(2E)-3-(1-{[2-(2-chlorophenoxy)ethyl][2-(1H-indol-3-yl)ethyl]amino}-2,3-dihydro-1H-inden-5-yl)-N-hydroxyacrylamide
288	(2E)-3-(1-{[2-(3-chlorophenoxy)ethyl][2-(1H-indol-3-yl)ethyl]amino}-2,3-dihydro-1H-inden-5-yl)-N-hydroxyacrylamide
289	(2E)-3-(1-{[2-(4-chlorophenoxy)ethyl][2-(1H-indol-3-yl)ethyl]amino}-2,3-dihydro-1H-inden-5-yl)-N-hydroxyacrylamide
290	(2E)-N-hydroxy-3-(1-{[2-(1H-indol-3-yl)ethyl][(2-methyl-1H-imidazol-4-yl)methyl]amino}-2,3-dihydro-1H-inden-5-yl)acrylamide
291	(2E)-N-hydroxy-3-(1-{[2-(1H-indol-3-yl)ethyl][2-(2-methylphenoxy)ethyl]amino}-2,3-dihydro-1H-inden-5-yl)acrylamide
292	(2E)-N-hydroxy-3-(1-{[2-(1H-indol-3-yl)ethyl][2-(3-methylphenoxy)ethyl]amino}-2,3-dihydro-1H-inden-5-yl)acrylamide
293	(2E)-N-hydroxy-3-(1-{[2-(1H-indol-3-yl)ethyl][2-(4-methylphenoxy)ethyl]amino}-2,3-dihydro-1H-inden-5-yl)acrylamide
294	(2E)-N-hydroxy-3-(1-{(3-hydroxybenzyl)[2-(1H-indol-3-yl)ethyl]amino}-2,3-dihydro-1H-inden-5-yl)acrylamide
295	(2E)-N-hydroxy-3-{1-[[2-(1H-indol-3-yl)ethyl](3-methylbenzyl)amino]-2,3-dihydro-1H-inden-5-yl}acrylamide
296	(2E)-N-hydroxy-3-(1-{(4-hydroxybenzyl)[2-(1H-indol-3-yl)ethyl]amino}-2,3-dihydro-1H-inden-5-yl)acrylamide
297	(2E)-3-(1-{[4-(acetylamino)benzyl][2-(1H-indol-3-yl)ethyl]amino}-2,3-dihydro-1H-inden-5-yl)-N-hydroxyacrylamide
298	(2E)-3-((1S)-1-{ethyl[2-(1H-indol-3-yl)ethyl]amino}-2,3-dihydro-1H-inden-5-yl)-N-hydroxyacrylamide
299	(2E)-3-((1R)-1-{ethyl[2-(1H-indol-3-yl)ethyl]amino}-2,3-dihydro-1H-inden-5-yl)-N-hydroxyacrylamide
300	(2E)-N-hydroxy-3-{(1S)-1-[[2-(1H-indol-3-yl)ethyl](1H-pyrrol-2-ylmethyl)amino]-2,3-dihydro-1H-inden-5-yl}acrylamide
301	(2E)-N-hydroxy-3-(1-{[2-(1H-indol-3-yl)ethyl][(1-methyl-1H-pyrrol-2-yl)methyl]amino}-2,3-dihydro-1H-inden-5-yl)acrylamide
302	(2E)-N-hydroxy-3-{(1R)-1-[[2-(1H-indol-3-yl)ethyl](1H-pyrrol-2-ylmethyl)amino]-2,3-dihydro-1H-inden-5-yl}acrylamide

Compound Example	IUPAC Name
303	(2E)-N-hydroxy-3-((1S)-1-{(3-hydroxypropyl)[2-(4-methoxyphenyl)ethyl]amino}-2,3-dihydro-1H-inden-5-yl)acrylamide
304	(2E)-N-hydroxy-3-((1R)-1-{(3-hydroxypropyl)[2-(4-methoxyphenyl)ethyl]amino}-2,3-dihydro-1H-inden-5-yl)acrylamide
305	(2E)-N-hydroxy-3-{1-[[2-(1H-indol-3-yl)ethyl](4-methoxybenzyl)amino]-2,3-dihydro-1H-inden-5-yl}acrylamide
306	(2E)-3-(1-{(4-ethoxybenzyl)[2-(1H-indol-3-yl)ethyl]amino}-2,3-dihydro-1H-inden-5-yl)-N-hydroxyacrylamide
307	(2E)-N-hydroxy-3-{1-[[2-(1H-indol-3-yl)ethyl](1,3-thiazol-2-ylmethyl)amino]-2,3-dihydro-1H-inden-5-yl}acrylamide
308	(2E)-N-hydroxy-3-[1-([2-(1H-indol-3-yl)ethyl]{[1-(methylsulfonyl)-1H-pyrrol-2-yl]methyl}amino)-2,3-dihydro-1H-inden-5-yl]acrylamide
309	(2E)-N-hydroxy-3-(1-{[4-(2-hydroxyethoxy)benzyl][2-(1H-indol-3-yl)ethyl]amino}-2,3-dihydro-1H-inden-5-yl)acrylamide
310	(2E)-3-(1-{[(4-cyano-1H-pyrrol-2-yl)methyl][2-(1H-indol-3-yl)ethyl]amino}-2,3-dihydro-1H-inden-5-yl)-N-hydroxyacrylamide
311	(2E)-N-hydroxy-3-(1-{(1H-imidazol-2-ylmethyl)[2-(1H-indol-3-yl)ethyl]amino}-2,3-dihydro-1H-inden-5-yl)acrylamide
312	5-({{5-[(1E)-3-(hydroxyamino)-3-oxoprop-1-en-1-yl]-2,3-dihydro-1H-inden-1-yl}[2-(1H-indol-3-yl)ethyl]amino}methyl)-N-methyl-1H-pyrrole-2-carboxamide
313	(2E)-N-hydroxy-3-(1-{[2-(1H-indol-3-yl)ethyl][4-(methylthio)benzyl]amino}-2,3-dihydro-1H-inden-5-yl)acrylamide
314	5-({{5-[(1E)-3-(hydroxyamino)-3-oxoprop-1-en-1-yl]-2,3-dihydro-1H-inden-1-yl}[2-(1H-indol-3-yl)ethyl]amino}methyl)-N,N-dimethyl-1H-pyrrole-2-carboxamide
315	(2E)-3-((1S)-1-{[4-(acetylamino)benzyl][2-(1H-indol-3-yl)ethyl]amino}-2,3-dihydro-1H-inden-5-yl)-N-hydroxyacrylamide
316	(2E)-3-((1R)-1-{[4-(acetylamino)benzyl][2-(1H-indol-3-yl)ethyl]amino}-2,3-dihydro-1H-inden-5-yl)-N-hydroxyacrylamide
317	(2E)-N-hydroxy-3-[1-([2-(1H-indol-3-yl)ethyl]{[5-(morpholin-4-ylcarbonyl)-1H-pyrrol-2-yl]methyl}amino)-2,3-dihydro-1H-inden-5-yl]acrylamide
318	(2E)-N-hydroxy-3-(1-{[2-(1H-indol-3-yl)ethyl][(4-methyl-1H-imidazol-5-yl)methyl]amino}-2,3-dihydro-1H-inden-5-yl)acrylamide
319	(2E)-N-hydroxy-3-{1-[[2-(1H-indol-3-yl)ethyl](1H-indol-3-ylmethyl)amino]-2,3-dihydro-1H-inden-5-yl}acrylamide
320	(2E)-3-(1-{{4-[2-(diethylamino)ethoxy]benzyl}[2-(1H-indol-3-yl)ethyl]amino}-2,3-dihydro-1H-inden-5-yl)-N-hydroxyacrylamide
321	4-({{5-[(1E)-3-(hydroxyamino)-3-oxoprop-1-en-1-yl]-2,3-dihydro-1H-inden-1-yl}[2-(1H-indol-3-yl)ethyl]amino}methyl)-N,N-dimethyl-1H-pyrrole-2-carboxamide
322	(2E)-N-hydroxy-3-(1-{[2-(1H-indol-3-yl)ethyl][4-(2-methoxyethoxy)benzyl]amino}-2,3-dihydro-1H-inden-5-yl)acrylamide

Compound Example	IUPAC Name
323	4-({{5-[(1E)-3-(hydroxyamino)-3-oxoprop-1-en-1-yl]-2,3-dihydro-1H-inden-1-yl}[2-(1H-indol-3-yl)ethyl]amino}methyl)-N-methyl-1H-pyrrole-2-carboxamide
324	5-({{(1R)-5-[(1E)-3-(hydroxyamino)-3-oxoprop-1-en-1-yl]-2,3-dihydro-1H-inden-1-yl}[2-(1H-indol-3-yl)ethyl]amino}methyl)-N-methyl-1H-pyrrole-2-carboxamide
325	5-({{(1S)-5-[(1E)-3-(hydroxyamino)-3-oxoprop-1-en-1-yl]-2,3-dihydro-1H-inden-1-yl}[2-(1H-indol-3-yl)ethyl]amino}methyl)-N-methyl-1H-pyrrole-2-carboxamide
326	5-({{(1R)-5-[(1E)-3-(hydroxyamino)-3-oxoprop-1-en-1-yl]-2,3-dihydro-1H-inden-1-yl}[2-(1H-indol-3-yl)ethyl]amino}methyl)-N,N-dimethyl-1H-pyrrole-2-carboxamide
327	5-({{(1S)-5-[(1E)-3-(hydroxyamino)-3-oxoprop-1-en-1-yl]-2,3-dihydro-1H-inden-1-yl}[2-(1H-indol-3-yl)ethyl]amino}methyl)-N,N-dimethyl-1H-pyrrole-2-carboxamide
328	(2E)-N-hydroxy-3-(1-{[2-(5-hydroxy-1H-indol-3-yl)ethyl]amino}-2,3-dihydro-1H-inden-5-yl)acrylamide
329	(2E)-N-hydroxy-3-{1-[(2-hydroxyethyl)(2-pyridin-3-ylethyl)amino]-2,3-dihydro-1H-inden-5-yl}acrylamide
330	(2E)-N-hydroxy-3-(1-{(2-hydroxyethyl)[2-(5-hydroxy-1H-indol-3-yl)ethyl]amino}-2,3-dihydro-1H-inden-5-yl)acrylamide
331	(2E)-N-hydroxy-3-(1-{(2-hydroxyethyl)[2-(5-hydroxy-1H-indol-3-yl)ethyl]amino}-2,3-dihydro-1H-inden-5-yl)acrylamide
332	(2E)-3-{1-[(1-benzothien-3-ylmethyl)amino]-2,3-dihydro-1H-inden-5-yl}-N-hydroxyacrylamide
333	(2E)-3-(1-{[(5-chloro-1-benzothien-3-yl)methyl]amino}-2,3-dihydro-1H-inden-5-yl)-N-hydroxyacrylamide
334	(2E)-N-hydroxy-3-[1-({[6-(trifluoromethyl)pyridin-3-yl]methyl}amino)-2,3-dihydro-1H-inden-5-yl]acrylamide
335	(2E)-3-{1-[(1-benzothien-3-ylmethyl)(2-hydroxyethyl)amino]-2,3-dihydro-1H-inden-5-yl}-N-hydroxyacrylamide
336	(2E)-3-{1-[[(5-chloro-1-benzothien-3-yl)methyl](2-hydroxyethyl)amino]-2,3-dihydro-1H-inden-5-yl}-N-hydroxyacrylamide
337	(2E)-N-hydroxy-3-[1-((2-hydroxyethyl){[6-(trifluoromethyl)pyridin-3-yl]methyl}amino)-2,3-dihydro-1H-inden-5-yl]acrylamide
338	(2E)-N-hydroxy-3-{1-[(2-pyridin-4-ylethyl)amino]-2,3-dihydro-1H-inden-5-yl}acrylamide
339	(2E)-N-hydroxy-3-{1-[(2-pyridin-2-ylethyl)amino]-2,3-dihydro-1H-inden-5-yl}acrylamide
340	(2E)-N-hydroxy-3-{1-[(pyridin-2-ylmethyl)amino]-2,3-dihydro-1H-inden-5-yl}acrylamide
341	(2E)-N-hydroxy-3-{1-[(2-hydroxyethyl)(2-pyridin-2-ylethyl)amino]-2,3-dihydro-1H-inden-5-yl}acrylamide

Compound Example	IUPAC Name
342	(2E)-N-hydroxy-3-{1-[(2-hydroxyethyl)(2-pyridin-4-ylethyl)amino]-2,3-dihydro-1H-inden-5-yl}acrylamide
343	(2E)-N-hydroxy-3-{1-[(2-hydroxyethyl)(pyridin-2-ylmethyl)amino]-2,3-dihydro-1H-inden-5-yl}acrylamide
344	(2E)-N-hydroxy-3-(1-{[(5-methylpyrazin-2-yl)methyl]amino}-2,3-dihydro-1H-inden-5-yl)acrylamide
345	(2E)-N-hydroxy-3-(1-{(2-hydroxyethyl)[(5-methylpyrazin-2-yl)methyl]amino}-2,3-dihydro-1H-inden-5-yl)acrylamide
346	(2E)-N-hydroxy-3-(1-{[(5-methyl-2-furyl)methyl]amino}-2,3-dihydro-1H-inden-5-yl)acrylamide
347	(2E)-3-{1-[(2-furylmethyl)amino]-2,3-dihydro-1H-inden-5-yl}-N-hydroxyacrylamide
348	(2E)-3-(1-{[2-(3,5-dimethylisoxazol-4-yl)ethyl]amino}-2,3-dihydro-1H-inden-5-yl)-N-hydroxyacrylamide
349	(2E)-3-{1-[(2-furylmethyl)(2-hydroxyethyl)amino]-2,3-dihydro-1H-inden-5-yl}-N-hydroxyacrylamide
350	(2E)-3-{(1S)-1-[[2-(2,5-dimethoxyphenyl)ethyl](2-hydroxyethyl)amino]-2,3-dihydro-1H-inden-5-yl}-N-hydroxyacrylamide
351	(2E)-3-{(1R)-1-[[2-(2,5-dimethoxyphenyl)ethyl](2-hydroxyethyl)amino]-2,3-dihydro-1H-inden-5-yl}-N-hydroxyacrylamide
352	(2E)-N-hydroxy-3-(1-{(2-hydroxyethyl)[(5-methyl-2-furyl)methyl]amino}-2,3-dihydro-1H-inden-5-yl)acrylamide
353	(2E)-N-hydroxy-3-(1-{[2-(1H-indol-3-yl)ethyl][4-(methylsulfonyl)benzyl]amino}-2,3-dihydro-1H-inden-5-yl)acrylamide
354	(2E)-N-hydroxy-3-{1-[[2-(1H-indol-3-yl)ethyl](4-methylbenzyl)amino]-2,3-dihydro-1H-inden-5-yl}acrylamide
355	(2E)-3-(1-{(4-chlorobenzyl)[2-(1H-indol-3-yl)ethyl]amino}-2,3-dihydro-1H-inden-5-yl)-N-hydroxyacrylamide
356	N-ethyl-4-({{5-[(1E)-3-(hydroxyamino)-3-oxoprop-1-en-1-yl]-2,3-dihydro-1H-inden-1-yl}[2-(1H-indol-3-yl)ethyl]amino}methyl)benzamide
357	4-({{5-[(1E)-3-(hydroxyamino)-3-oxoprop-1-en-1-yl]-2,3-dihydro-1H-inden-1-yl}[2-(1H-indol-3-yl)ethyl]amino}methyl)-N-methylbenzamide
358	(2E)-N-hydroxy-3-[1-([2-(1H-indol-3-yl)ethyl]{4-[(methylsulfonyl)amino]benzyl}amino)-2,3-dihydro-1H-inden-5-yl]acrylamide
359	(2E)-N-hydroxy-3-{1-[[2-(1H-indol-3-yl)ethyl](4-{[(methylsulfonyl)amino]methyl}benzyl)amino]-2,3-dihydro-1H-inden-5-yl}acrylamide
360	(2E)-N-hydroxy-3-[(1S)-1-([2-(1H-indol-3-yl)ethyl]{4-[(methylsulfonyl)amino]benzyl}amino)-2,3-dihydro-1H-inden-5-yl]acrylamide
361	(2E)-N-hydroxy-3-[(1R)-1-([2-(1H-indol-3-yl)ethyl]{4-[(methylsulfonyl)amino]benzyl}amino)-2,3-dihydro-1H-inden-5-yl]acrylamide

Compound Example	IUPAC Name
362	(2E)-3-(1-{({4-[2-(dimethylamino)ethoxy]phenyl}sulfonyl)[2-(1H-indol-3-yl)ethyl]amino}-2,3-dihydro-1H-inden-5-yl)-N-hydroxyacrylamide
363	(2E)-N-hydroxy-3-(1-{{[4-(2-hydroxyethoxy)phenyl]sulfonyl}[2-(1H-indol-3-yl)ethyl]amino}-2,3-dihydro-1H-inden-5-yl)acrylamide
364	(2E)-3-(1-{({4-[2-(dimethylamino)ethoxy]phenyl}sulfonyl)[2-(6-methoxy-1H-indol-3-yl)ethyl]amino}-2,3-dihydro-1H-inden-5-yl)-N-hydroxyacrylamide
365	(2E)-3-{1-[[2-(5-chloro-1H-indol-3-yl)ethyl]({4-[2-(dimethylamino)ethoxy]phenyl}sulfonyl)amino]-2,3-dihydro-1H-inden-5-yl}-N-hydroxyacrylamide
366	(2E)-3-(1-{({4-[2-(dimethylamino)ethoxy]phenyl}sulfonyl)[2-(2-methylphenyl)ethyl]amino}-2,3-dihydro-1H-inden-5-yl)-N-hydroxyacrylamide
367	(2E)-3-(1-{[(4-{[2-(dimethylamino)ethyl]amino}phenyl)sulfonyl][2-(1H-indol-3-yl)ethyl]amino}-2,3-dihydro-1H-inden-5-yl)-N-hydroxyacrylamide
368	(2E)-N-hydroxy-3-(1-{(2-hydroxyethyl)[2-(1H-indol-1-yl)ethyl]amino}-2,3-dihydro-1H-inden-5-yl)acrylamide
369	(2E)-N-hydroxy-3-(1-{(3-hydroxypropyl)[2-(1H-indol-1-yl)ethyl]amino}-2,3-dihydro-1H-inden-5-yl)acrylamide
370	(2E)-N-hydroxy-3-(1-{(2-hydroxyethyl)[2-(3-methyl-1H-indol-1-yl)ethyl]amino}-2,3-dihydro-1H-inden-5-yl)acrylamide
371	(2E)-N-hydroxy-3-(1-{(2-hydroxyethyl)[2-(2-methyl-1H-indol-1-yl)ethyl]amino}-2,3-dihydro-1H-inden-5-yl)acrylamide
372	(2E)-3-{1-[[2-(2,3-dimethyl-1H-indol-1-yl)ethyl](2-hydroxyethyl)amino]-2,3-dihydro-1H-inden-5-yl}-N-hydroxyacrylamide
373	(2E)-3-(1-{ethyl[2-(1H-indol-1-yl)ethyl]amino}-2,3-dihydro-1H-inden-5-yl)-N-hydroxyacrylamide
374	(2E)-N-hydroxy-3-{1-[[2-(1H-indol-1-yl)ethyl](1H-pyrrol-2-ylmethyl)amino]-2,3-dihydro-1H-inden-5-yl}acrylamide
375	N-hydroxy-3-(1-{(2-hydroxyethyl)[2-(1H-indol-1-yl)ethyl]amino}-2,3-dihydro-1H-inden-5-yl)propanamide
376	(2E)-3-{1-[[2-(6-fluoro-2-methyl-1H-indol-1-yl)ethyl](2-hydroxyethyl)amino]-2,3-dihydro-1H-inden-5-yl}-N-hydroxyacrylamide
377	(2E)-N-hydroxy-3-(1-{(2-hydroxyethyl)[2-(1H-indol-1-yl)ethyl]amino}-2,3-dihydro-1H-inden-5-yl)but-2-enamide
378	(2E)-3-(1-{(cyclopropylmethyl)[2-(1H-indol-1-yl)ethyl]amino}-2,3-dihydro-1H-inden-5-yl)-N-hydroxyacrylamide
379	(2E)-N-hydroxy-3-(1-{(2-hydroxyethyl)[2-(5-methoxy-1H-indol-1-yl)ethyl]amino}-2,3-dihydro-1H-inden-5-yl)acrylamide
380	(2E)-N-hydroxy-3-(1-{(2-hydroxyethyl)[2-(6-methoxy-1H-indol-1-yl)ethyl]amino}-2,3-dihydro-1H-inden-5-yl)acrylamide
381	(2E)-3-(1-{[4-(acetylamino)benzyl][2-(1H-indol-1-yl)ethyl]amino}-2,3-dihydro-1H-inden-5-yl)-N-hydroxyacrylamide

Compound Example	IUPAC Name
382	(2E)-N-hydroxy-3-(1-{[(1S)-2-hydroxy-1-(1H-indol-1-ylmethyl)ethyl]amino}-2,3-dihydro-1H-inden-5-yl)acrylamide
383	(2E)-N-hydroxy-3-{1-[[(1S)-2-hydroxy-1-(1H-indol-1-ylmethyl)ethyl](methyl)amino]-2,3-dihydro-1H-inden-5-yl}acrylamide
384	(2E)-N-hydroxy-3-(1-{[4-(2-hydroxyethoxy)benzyl][2-(1H-indol-1-yl)ethyl]amino}-2,3-dihydro-1H-inden-5-yl)acrylamide
385	(2E)-N-hydroxy-3-(1-{[2-(1H-indol-1-yl)ethyl][4-(2-methoxyethoxy)benzyl]amino}-2,3-dihydro-1H-inden-5-yl)acrylamide
386	(2E)-3-(1-{{4-[2-(dimethylamino)ethoxy]benzyl}[2-(1H-indol-1-yl)ethyl]amino}-2,3-dihydro-1H-inden-5-yl)-N-hydroxyacrylamide
387	5-({{5-[(1E)-3-(hydroxyamino)-3-oxoprop-1-en-1-yl]-2,3-dihydro-1H-inden-1-yl}[2-(1H-indol-1-yl)ethyl]amino}methyl)-N-methyl-1H-pyrrole-2-carboxamide
388	5-({{5-[(1E)-3-(hydroxyamino)-3-oxoprop-1-en-1-yl]-2,3-dihydro-1H-inden-1-yl}[2-(1H-indol-1-yl)ethyl]amino}methyl)-N,N-dimethyl-1H-pyrrole-2-carboxamide
389	(2E)-N-hydroxy-3-[1-([2-(1H-indol-1-yl)ethyl]{[5-(morpholin-4-ylcarbonyl)-1H-pyrrol-2-yl]methyl}amino)-2,3-dihydro-1H-inden-5-yl]acrylamide
390	5-({{5-[(1E)-3-(hydroxyamino)-3-oxoprop-1-en-1-yl]-2,3-dihydro-1H-inden-1-yl}[2-(1H-indol-1-yl)ethyl]amino}methyl)-N,N-dimethyl-1H-pyrrole-3-carboxamide
391	(2E)-N-hydroxy-3-(1-{[2-(1H-indol-1-yl)ethyl][(1-methyl-1H-pyrrol-2-yl)methyl]amino}-2,3-dihydro-1H-inden-5-yl)acrylamide
392	(2E)-3-(1-{[2-(acetylamino)ethyl][2-(1H-indol-1-yl)ethyl]amino}-2,3-dihydro-1H-inden-5-yl)-N-hydroxyacrylamide
393	(2E)-N-hydroxy-3-[1-([2-(1H-indol-1-yl)ethyl]{2-[(methylsulfonyl)amino]ethyl}amino)-2,3-dihydro-1H-inden-5-yl]acrylamide
394	N-hydroxy-3-(1-{(2-hydroxyethyl)[2-(1H-indol-3-yl)ethyl]amino}-2,3-dihydro-1H-inden-5-yl)butanamide
395	N-hydroxy-3-{1-[[2-(1H-indol-3-yl)ethyl](1H-pyrrol-2-ylmethyl)amino]-2,3-dihydro-1H-inden-5-yl}butanamide
396	N-hydroxy-3-(1-{(2-hydroxyethyl)[2-(1-methyl-1H-indol-3-yl)ethyl]amino}-2,3-dihydro-1H-inden-5-yl)butanamide
397	(2E)-3-{1-[[2-(1,2-dimethyl-1H-indol-3-yl)ethyl](2-hydroxyethyl)amino]-2,3-dihydro-1H-inden-5-yl}-N-hydroxyacrylamide
398	(2E)-N-hydroxy-3-(1-{(2-hydroxyethyl)[2-(6-methoxy-1-methyl-1H-indol-3-yl)ethyl]amino}-2,3-dihydro-1H-inden-5-yl)acrylamide
399	(2E)-N-hydroxy-3-(1-{(2-hydroxyethyl)[2-(1H-indol-2-yl)ethyl]amino}-2,3-dihydro-1H-inden-5-yl)acrylamide
400	(2E)-N-hydroxy-3-{1-[[2-(1H-indol-2-yl)ethyl](1H-pyrrol-2-ylmethyl)amino]-2,3-dihydro-1H-inden-5-yl}acrylamide
401	(2E)-N-hydroxy-3-(1-{(2-hydroxyethyl)[2-(5-methoxy-1H-indol-2-yl)ethyl]amino}-2,3-dihydro-1H-inden-5-yl)acrylamide

Compound Example	IUPAC Name
402	(2E)-N-hydroxy-3-(1-{(2-hydroxyethyl)[2-(6-methoxy-1H-indol-2-yl)ethyl]amino}-2,3-dihydro-1H-inden-5-yl)acrylamide
403	(2E)-3-(1-{[4-(aminosulfonyl)benzyl][2-(1H-indol-3-yl)ethyl]amino}-2,3-dihydro-1H-inden-5-yl)-N-hydroxyacrylamide
404	(2E)-N-hydroxy-3-[1-([2-(1H-indol-3-yl)ethyl]{4-[(methylamino)sulfonyl]benzyl}amino)-2,3-dihydro-1H-inden-5-yl]acrylamide
405	(2E)-3-(1-{{4-[(acetylamino)sulfonyl]benzyl}[2-(1H-indol-3-yl)ethyl]amino}-2,3-dihydro-1H-inden-5-yl)-N-hydroxyacrylamide
406	(2E)-3-(1-{[3-(aminosulfonyl)benzyl][2-(1H-indol-3-yl)ethyl]amino}-2,3-dihydro-1H-inden-5-yl)-N-hydroxyacrylamide
407	(2E)-N-hydroxy-3-[1-([2-(1H-indol-3-yl)ethyl]{3-[(methylamino)sulfonyl]benzyl}amino)-2,3-dihydro-1H-inden-5-yl]acrylamide
408	(2E)-3-(1-{{3-[(acetylamino)sulfonyl]benzyl}[2-(1H-indol-3-yl)ethyl]amino}-2,3-dihydro-1H-inden-5-yl)-N-hydroxyacrylamide
409	(2E)-N-hydroxy-3-{1-[[2-(1H-indol-3-yl)ethyl](1H-indol-6-ylmethyl)amino]-2,3-dihydro-1H-inden-5-yl}acrylamide
410	(2E)-3-(1-{(1H-benzimidazol-6-ylmethyl)[2-(1H-indol-3-yl)ethyl]amino}-2,3-dihydro-1H-inden-5-yl)-N-hydroxyacrylamide
411	(2E)-N-hydroxy-3-{1-[[2-(1H-indol-3-yl)ethyl](1H-indol-5- ylmethyl)amino]-2,3-dihydro-1H-inden-5-yl}acrylamide
412	(2E)-3-{1-[[2-(4,5-dimethyl-1H-pyrrol-3-yl)ethyl](2-hydroxyethyl)amino]-2,3-dihydro-1H-inden-5-yl}-N-hydroxyacrylamide
413	(2E)-N-hydroxy-3-(1-{(2-hydroxyethyl)[2-(2,4,5-trimethyl-1H-pyrrol-3-yl)ethyl]amino}-2,3-dihydro-1H-inden-5-yl)acrylamide
414	(2E)-N-hydroxy-3-(1-{(2-hydroxyethyl)[2-(4-morpholin-4-ylphenyl)ethyl]amino}-2,3-dihydro-1H-inden-5-yl)acrylamide
415	(2E)-N-hydroxy-3-(1-{(2-hydroxyethyl)[2-(4-piperazin-1-ylphenyl)ethyl]amino}-2,3-dihydro-1H-inden-5-yl)acrylamide
416	(2E)-N-hydroxy-3-[1-((2-hydroxyethyl){2-[4-(4-methylpiperazin-1-yl)phenyl]ethyl}amino)-2,3-dihydro-1H-inden-5-yl]acrylamide
417	(2E)-3-{1-[(2-{4-[2-(dimethylamino)ethoxy]phenyl}ethyl)(2-hydroxyethyl)amino]-2,3-dihydro-1H-inden-5-yl}-N-hydroxyacrylamide
418	(2E)-N-hydroxy-3-{1-[(2-hydroxyethyl)(2-{4-[2-(methylamino)ethoxy]phenyl}ethyl)amino]-2,3-dihydro-1H-inden-5-yl}acrylamide
419	(2E)-N-hydroxy-3-(1-{(2-hydroxyethyl)[2-(3-methyl-1H-indol-2-yl)ethyl]amino}-2,3-dihydro-1H-inden-5-yl)acrylamide
420	(2E)-3-{1-[[2-(1H-benzimidazol-2-yl)ethyl](2-hydroxyethyl)amino]-2,3-dihydro-1H-inden-5-yl}-N-hydroxyacrylamide
421	(2E)-N-hydroxy-3-(1-{(2-hydroxyethyl)[2-(5-methoxy-1H-benzimidazol-2-yl)ethyl]amino}-2,3-dihydro-1H-inden-5-yl)acrylamide

Compound Example	IUPAC Name
422	(2E)-N-hydroxy-3-(1-{(2-hydroxyethyl)[2-(5-methyl-1H-benzimidazol-2-yl)ethyl]amino}-2,3-dihydro-1H-inden-5-yl)acrylamide
423	(2E)-3-{1-[[2-(5,6-difluoro-1H-benzimidazol-2-yl)ethyl](2-hydroxyethyl)amino]-2,3-dihydro-1H-inden-5-yl}-N-hydroxyacrylamide
424	(2E)-3-{1-[[2-(1,3-benzoxazol-2-yl)ethyl](2-hydroxyethyl)amino]-2,3-dihydro-1H-inden-5-yl}-N-hydroxyacrylamide
425	(2E)-3-{1-[[2-(5-chloro-1,3-benzoxazol-2-yl)ethyl](2-hydroxyethyl)amino]-2,3-dihydro-1H-inden-5-yl}-N-hydroxyacrylamide
426	(2E)-3-{1-[[2-(1,3-benzothiazol-2-yl)ethyl](2-hydroxyethyl)amino]-2,3-dihydro-1H-inden-5-yl}-N-hydroxyacrylamide
427	(2E)-3-{1-[[2-(6-chloro-1,3-benzothiazol-2-yl)ethyl](2-hydroxyethyl)amino]-2,3-dihydro-1H-inden-5-yl}-N-hydroxyacrylamide
428	(2E)-3-(1-{(4-{[(dimethylamino)sulfonyl]amino}benzyl)[2-(1H-indol-3-yl)ethyl]amino}-2,3-dihydro-1H-inden-5-yl)-N-hydroxyacrylamide
429	(2E)-3-(1-{(4-{[(ethylamino)carbonyl]amino}benzyl)[2-(1H-indol-3-yl)ethyl]amino}-2,3-dihydro-1H-inden-5-yl)-N-hydroxyacrylamide
430	(2E)-3-(1-{[4({[(ethylamino)carbonyl]amino}methyl)benzyl][2-(1H-indol-3-yl)ethyl]amino}-2,3-dihydro-1H-inden-5-yl)-N-hydroxyacrylamide
431	4-({{5-[(1E)-3-(hydroxyamino)-3-oxoprop-1-en-1-yl]-2,3-dihydro-1H-inden-1-yl}[2-(1H-indol-3-yl)ethyl]amino}methyl)benzamide
432	(2E)-3-(1-{[4-({[(dimethylamino)sulfonyl]amino}methyl)benzyl][2-(1H-indol-3-yl)ethyl]amino}-2,3-dihydro-1H-inden-5-yl)-N-hydroxyacrylamide
433	(2E)-3-(1-{{4-[(acetylamino)methyl]benzyl}[2-(1H-indol-3-yl)ethyl]amino}-2,3-dihydro-1H-inden-5-yl)-N-hydroxyacrylamide
434	(2E)-N-hydroxy-3-{1-[[2-(1H-indol-3-yl)ethyl](3-{[(2-methoxyethyl)amino]sulfonyl}benzyl)amino]-2,3-dihydro-1H-inden-5-yl}acrylamide
435	(2E)-3-(1-{[3-({[2-(dimethylamino)ethyl]amino}sulfonyl)benzyl][2-(1H-indol-3-yl)ethyl]amino}-2,3-dihydro-1H-inden-5-yl)- N-hydroxyacrylamide
436	(2E)-3-(1-{[3-({[2-(diethylamino)ethyl]amino}sulfonyl)benzyl][2-(1H-indol-3-yl)ethyl]amino}-2,3-dihydro-1H-inden-5-yl)-N-hydroxyacrylamide
437	(2E)-N-hydroxy-3-{1-[[2-(1H-indol-3-yl)ethyl](3-{[(2-morpholin-4-ylethyl)amino]sulfonyl}benzyl)amino]-2,3-dihydro-1H-inden-5-yl}acrylamide
438	(2E)-N-hydroxy-3-{1-[[2-(1H-indol-3-yl)ethyl](3-{[(2-piperazin-1-ylethyl)amino]sulfonyl}benzyl)amino]-2,3-dihydro-1H-inden-5-yl}acrylamide
439	(2E)-N-hydroxy-3-(1-{[2-(1H-indol-3-yl)ethyl][3-({[2-(4-methylpiperazin-1-yl)ethyl]amino}sulfonyl)benzyl]amino}-2,3-dihydro-1H-inden-5-yl)acrylamide
440	(2E)-N-hydroxy-3-{1-[[2-(1H-indol-3-yl)ethyl](4-{[(2-methoxyethyl)amino]sulfonyl}benzyl)amino]-2,3-dihydro-1H-inden-5-yl}acrylamide
441	(2E)-3-(1-{[4-({[2-(dimethylamino)ethyl]amino}sulfonyl)benzyl][2-(1H-indol-3-yl)ethyl]amino}-2,3-dihydro-1H-inden-5-yl)-N-hydroxyacrylamide

Compound Example	IUPAC Name
442	(2E)-N-hydroxy-3-{1-[[2-(1H-indol-3-yl)ethyl](4-{[(2-morpholin-4-ylethyl)amino]sulfonyl}benzyl)amino]-2,3-dihydro-1H-inden-5-yl}acrylamide
443	(2E)-N-hydroxy-3-{1-[[2-(1H-indol-3-yl)ethyl](4-{[(2-piperazin-1-ylethyl)amino]sulfonyl}benzyl)amino]-2,3-dihydro-1H-inden-5-yl}acrylamide
444	(2E)-N-hydroxy-3-(1-{[2-(1H-indol-3-yl)ethyl][4-({[2-(4-methylpiperazin-1-yl)ethyl]amino}sulfonyl)benzyl]amino}-2,3-dihydro-1H-inden-5-yl)acrylamide
445	(2E)-3-(1-{[4-({[2-(diethylamino)ethyl]amino}sulfonyl)benzyl][2-(1H-indol-3-yl)ethyl]amino}-2,3-dihydro-1H-inden-5-yl)-N-hydroxyacrylamide
446	(2E)-3-(1-{(2-{[(diethylamino)carbonyl]amino}ethyl)[2-(1H-indol-3-yl)ethyl]amino}-2,3-dihydro-1H-inden-5-yl)-N-hydroxyacrylamide
447	N-(2-{{5-[(1E)-3-(hydroxyamino)-3-oxoprop-1-en-1-yl]-2,3-dihydro-1H-inden-1-yl}[2-(1H-indol-3-yl)ethyl]amino}ethyl)morpholine-4-carboxamide
448	(2E)-3-(1-{(2-{[(dimethylamino)sulfonyl]amino}ethyl)[2-(1H-indol-3-yl)ethyl]amino}-2,3-dihydro-1H-inden-5-yl)-N-hydroxyacrylamide
449	(2E)-N-hydroxy-3-{1-[(2-(1H-indol-3-yl)-1-{[(methylsulfonyl)amino]methyl}ethyl)amino]-2,3-dihydro-1H-inden-5-yl}acrylamide
450	(2E)-3-(1-{[2-(acetylamino)-1-(1H-indol-3-ylmethyl)ethyl]amino}-2,3-dihydro-1H-inden-5-yl)-N-hydroxyacrylamide
451	(2E)-N-hydroxy-3-(1-{[2-(1H-indol-3-yl)ethyl][4-(2-morpholin-4-ylethoxy)benzyl]amino}-2,3-dihydro-1H-inden-5-yl)acrylamide
452	(2E)-3-(1-{{4-[2-(dimethylamino)ethoxy]benzyl}[2-(1H-indol-3-yl)ethyl]amino}-2,3-dihydro-1H-inden-5-yl)-N-hydroxyacrylamide
453	(2E)-N-hydroxy-3-(1-{[3-(2-hydroxyethoxy)benzyl][2-(1H-indol-3-yl)ethyl]amino}-2,3-dihydro-1H-inden-5-yl)acrylamide
454	(2E)-N-hydroxy-3-(1-{[2-(1H-indol-3-yl)ethyl][3-(2-morpholin-4-ylethoxy)benzyl]amino}-2,3-dihydro-1H-inden-5-yl)acrylamide
455	(2E)-3-(1-{{3-[2-(dimethylamino)ethoxy]benzyl}[2-(1H-indol-3-yl)ethyl]amino}-2,3-dihydro-1H-inden-5-yl)-N-hydroxyacrylamide
456	(2E)-3-(1-{{3-[2-(diethylamino)ethoxy]benzyl}[2-(1H-indol-3-yl)ethyl]amino}-2,3-dihydro-1H-inden-5-yl)-N-hydroxyacrylamide
457	(2E)-N-hydroxy-3-(1-{[2-(4-phenyl-1H-1,2,3-triazol-1-yl)ethyl]amino}-2,3-dihydro-1H-inden-5-yl)acrylamide
458	(2E)-N-hydroxy-3-(1-{(2-hydroxyethyl)[2-(4-phenyl-1H-1,2,3-triazol-1-yl)ethyl]amino}-2,3-dihydro-1H-inden-5-yl)acrylamide
459	(2E)-N-hydroxy-3-{1-[[2-(1H-indol-3-yl)ethyl](2H-tetrazol-5-ylmethyl)amino]-2,3-dihydro-1H-inden-5-yl}acrylamide
460	(2E)-3-(1-{[3-(5-fluoro-1H-indol-3-yl)propyl]amino}-2,3-dihydro-1H-inden-5-yl)-N-hydroxyacrylamide
461	(2E)-3-{1-[[3-(5-fluoro-1H-indol-3-yl)propyl](2-hydroxyethyl)amino]-2,3-dihydro-1H-inden-5-yl}-N-hydroxyacrylamide

Compound Example	IUPAC Name
462	N-{5-[(1E)-3-(hydroxyamino)-3-oxoprop-1-en-1-yl]-2,3-dihydro-1H-inden-1-yl}-N-[2-(1H-indol-3-yl)ethyl]-1H-indole-2-carboxamide
463	N-{5-[(1E)-3-(hydroxyamino)-3-oxoprop-1-en-1-yl]-2,3-dihydro-1H-inden-1-yl}-N-[2-(1H-indol-3-yl)ethyl]-1-benzofuran-2-carboxamide
464	(2E)-N-hydroxy-3-(1-{[2-(1H-indol-3-yl)ethyl][(3-methyl-1H-pyrazol-5-yl)methyl]amino}-2,3-dihydro-1H-inden-5-yl)acrylamide
465	(2E)-3-(1-{[(3-tert-butyl-1H-pyrazol-5-yl)methyl][2-(1H-indol-3-yl)ethyl]amino}-2,3-dihydro-1H-inden-5-yl)-N-hydroxyacrylamide
466	(2E)-3-(1-{[(4-bromo-1H-pyrazol-5-yl)methyl][2-(1H-indol-3-yl)ethyl]amino}-2,3-dihydro-1H-inden-5-yl)-N-hydroxyacrylamide
467	(2E)-N-hydroxy-3-(1-{[2-(1H-indol-3-yl)ethyl][(3-propyl-1H-pyrazol-5-yl)methyl]amino}-2,3-dihydro-1H-inden-5-yl)acrylamide
468	(2E)-N-hydroxy-3-{1-[[2-(1H-indol-3-yl)ethyl](1H-pyrazol-5-ylmethyl)amino]-2,3-dihydro-1H-inden-5-yl}acrylamide
469	(2E)-3-(1-{[(4-chloro-1-methyl-1H-pyrazol-3-yl)methyl][2-(1H-indol-3-yl)ethyl]amino}-2,3-dihydro-1H-inden-5-yl)-N-hydroxyacrylamide
470	(2E)-3-(1-{[(1,3-dimethyl-1H-pyrazol-4-yl)methyl][2-(1H-indol-3-yl)ethyl]amino}-2,3-dihydro-1H-inden-5-yl)-N-hydroxyacrylamide
471	(2E)-3-(1-{{[5-chloro-1-methyl-3-(trifluoromethyl)-1H-pyrazol-4-yl]methyl}[2-(1H-indol-3-yl)ethyl]amino}-2,3-dihydro-1H-inden-5-yl)-N-hydroxyacrylamide
472	(2E)-3-(1-{[(5-chloro-1,3-dimethyl-1H-pyrazol-4-yl)methyl][2-(1H-indol-3-yl)ethyl]amino}-2,3-dihydro-1H-inden-5-yl)- N-hydroxyacrylamide
473	(2E)-N-hydroxy-3-(1-{[2-(1H-indol-3-yl)ethyl][(1,3,5-trimethyl-1H-pyrazol-4-yl)methyl]amino}-2,3-dihydro-1H-inden-5-yl)acrylamide
474	(2E)-N-hydroxy-3-(1-{[2-(1H-indol-3-yl)ethyl][(5-methoxy-1,3-dimethyl-1H-pyrazol-4-yl)methyl]amino}-2,3-dihydro-1H-inden-5-yl)acrylamide
475	(2E)-3-(1-{[(1,5-dimethyl-1H-pyrazol-4-yl)methyl][2-(1H-indol-3-yl)ethyl]amino}-2,3-dihydro-1H-inden-5-yl)-N-hydroxyacrylamide
476	(2E)-3-(1-{[(3,5-dimethylisoxazol-4-yl)methyl][2-(1H-indol-3-yl)ethyl]amino}-2,3-dihydro-1H-inden-5-yl)-N-hydroxyacrylamide
477	(2E)-N-hydroxy-3-{1-[[2-(1H-indol-3-yl)ethyl](1,2,3-thiadiazol-4-ylmethyl)amino]-2,3-dihydro-1H-inden-5-yl}acrylamide
478	(2E)-N-hydroxy-3-(1-{(2-hydroxy-2-methylpropyl)[2-(1H-indol-3-yl)ethyl]amino}-2,3-dihydro-1H-inden-5-yl)acrylamide
479	(2E)-N-hydroxy-3-{1-[[2-(1H-indol-3-yl)ethyl](1H-indol-3-ylmethyl)amino]-2,3-dihydro-1H-inden-5-yl}acrylamide
480	(2E)-N-hydroxy-3-{1-[[2-(1H-indol-3-yl)ethyl](1H-indol-4-ylmethyl)amino]-2,3-dihydro-1H-inden-5-yl}acrylamide
481	(2E)-N-hydroxy-3-{1-[[2-(1H-indol-3-yl)ethyl](1H-indol-7-ylmethyl)amino]-2,3-dihydro-1H-inden-5-yl}acrylamide

Compound Example	IUPAC Name
482	(2E)-3-(1-{[2-(2,5-dioxopyrrolidin-1-yl)ethyl][2-(1H-indol-3-yl)ethyl]amino}-2,3-dihydro-1H-inden-5-yl)-N-hydroxyacrylamide
483	(2E)-N-hydroxy-3-{1-[[2-(6-methoxy-1H-indol-3-yl)ethyl](1H-pyrrol-2-ylmethyl)amino]-2,3-dihydro-1H-inden-5-yl}acrylamide
484	(2E)-N-hydroxy-3-{1-[[2-(6-methoxy-1H-indol-3-yl)ethyl](1H-pyrrol-2-ylmethyl)amino]-2,3-dihydro-1H-inden-5-yl}acrylamide
485	(2E)-N-hydroxy-3-{1-[[2-(6-methoxy-1H-indol-3-yl)ethyl](1H-pyrrol-2-ylmethyl)amino]-2,3-dihydro-1H-inden-5-yl}acrylamide
486	(2E)-3-(1-{ethyl[2-(6-methoxy-1H-indol-3-yl)ethyl]amino}-2,3-dihydro-1H-inden-5-yl)-N-hydroxyacrylamide
487	(2E)-3-(1-{ethyl[2-(6-methoxy-1H-indol-3-yl)ethyl]amino}-2,3-dihydro-1H-inden-5-yl)-N-hydroxyacrylamide
488	(2E)-3-(1-{ethyl[2-(6-methoxy-1H-indol-3-yl)ethyl]amino}-2,3-dihydro-1H-inden-5-yl)-N-hydroxyacrylamide
489	(2E)-N-hydroxy-3-{1-[[2-(6-methyl-1H-indol-3-yl)ethyl](1H-pyrrol-2-ylmethyl)amino]-2,3-dihydro-1H-inden-5-yl}acrylamide
490	(2E)-N-hydroxy-3-{1-[[2-(6-methyl-1H-indol-3-yl)ethyl](1H-pyrrol-2-ylmethyl)amino]-2,3-dihydro-1H-inden-5-yl}acrylamide
491	(2E)-N-hydroxy-3-{1-[[2-(6-methyl-1H-indol-3-yl)ethyl](1H-pyrrol-2-ylmethyl)amino]-2,3-dihydro-1H-inden-5-yl}acrylamide
492	(2E)-N-hydroxy-3-(1-{[2-(1H-indazol-1-yl)ethyl]amino}-2,3-dihydro-1H-inden-5-yl)acrylamide
493	(2E)-N-hydroxy-3-(1-{[2-(2H-indazol-2-yl)ethyl]amino}-2,3-dihydro-1H-inden-5-yl)acrylamide
494	(2E)-N-hydroxy-3-(1-{(2-hydroxyethyl)[2-(1H-indazol-1-yl)ethyl]amino}-2,3-dihydro-1H-inden-5-yl)acrylamide
495	(2E)-3-(1-{[2-(1H-1,2,3-benzotriazol-1-yl)ethyl]amino}-2,3-dihydro-1H-inden-5-yl)-N-hydroxyacrylamide
496	(2E)-3-{1-[[2-(1H-1,2,3-benzotriazol-1-yl)ethyl](2-hydroxyethyl)amino]-2,3-dihydro-1H-inden-5-yl}-N-hydroxyacrylamide
497	(2E)-N-hydroxy-3-(1-{[2-(1H-indazol-3-yl)ethyl]amino}-2,3-dihydro-1H-inden-5-yl)acrylamide
498	(2E)-N-hydroxy-3-(1-{(2-hydroxyethyl)[2-(1H-indazol-3-yl)ethyl]amino}-2,3-dihydro-1H-inden-5-yl)acrylamide
499	(2E)-3-(1-{[2-(1H-benzimidazol-1-yl)ethyl]amino}-2,3-dihydro-1H-inden-5-yl)-N-hydroxyacrylamide
500	(2E)-3-{1-[[2-(1H-benzimidazol-1-yl)ethyl](2-hydroxyethyl)amino]-2,3-dihydro-1H-inden-5-yl}-N-hydroxyacrylamide
501	(2E)-N-hydroxy-3-(1-{[4-(2-hydroxyethoxy)benzyl][2-(1H-indol-3-yl)ethyl]amino}-2,3-dihydro-1H-inden-5-yl)acrylamide
502	(2E)-N-hydroxy-3-(1-{[4-(2-hydroxyethoxy)benzyl][2-(1H-indol-3-yl)ethyl]amino}-2,3-dihydro-1H-inden-5-yl)acrylamide

Compound Example	IUPAC Name
503	(2E)-3-(1-{[(1-ethyl-1H-pyrazol-4-yl)methyl][2-(1H-indol-3-yl)ethyl]amino}-2,3-dihydro-1H-inden-5-yl)-N-hydroxyacrylamide
504	(2E)-3-(1-{{[4-(acetylamino)phenyl]sulfonyl}[2-(1H-indol-3-yl)ethyl]amino}-2,3-dihydro-1H-inden-5-yl)-N-hydroxyacrylamide
505	(2E)-3-(1-{[(4-aminophenyl)sulfonyl][2-(1H-indol-3-yl)ethyl]amino}-2,3-dihydro-1H-inden-5-yl)-N-hydroxyacrylamide
506	(2E)-N-hydroxy-3-[1-([2-(1H-indol-3-yl)ethyl]{3-[(methylsulfonyl)amino]benzyl}amino)-2,3-dihydro-1H-inden-5-yl]acrylamide
507	(2E)-N-hydroxy-3-{1-[[2-(3-methyl-1H-indol-1-yl)ethyl](1H-pyrrol-2-ylmethyl)amino]-2,3-dihydro-1H-inden-5-yl}acrylamide
508	(2E)-N-hydroxy-3-(1-{[2-(3-methyl-1H-indol-1-yl)ethyl]amino}-2,3-dihydro-1H-inden-5-yl)acrylamide
509	(2E)-N-hydroxy-3-(1-{[2-(1H-indol-1-yl)ethyl]amino}-2,3-dihydro-1H-inden-5-yl)acrylamide
510	(2E)-N-hydroxy-3-(1-{[2-(5-methoxy-1H-indol-1-yl)ethyl]amino}-2,3-dihydro-1H-inden-5-yl)acrylamide
511	(2E)-N-hydroxy-3-(1-{[(4-hydroxyphenyl)sulfonyl][2-(1H-indol-3-yl)ethyl]amino}-2,3-dihydro-1H-inden-5-yl)acrylamide
512	(2E)-N-hydroxy-3-(1-{({4-[(2-hydroxyethyl)amino]phenyl}sulfonyl)[2-(1H-indol-3-yl)ethyl]amino}-2,3-dihydro-1H-inden-5-yl)acrylamide
513	(2E)-3-(1-{ethyl[2-(1-methyl-1H-indol-3-yl)ethyl]amino}-2,3-dihydro-1H-inden-5-yl)-N-hydroxyacrylamide
514	(2E)-3-(1-{ethyl[2-(1-methyl-1H-indol-3-yl)ethyl]amino}-2,3-dihydro-1H-inden-5-yl)-N-hydroxyacrylamide
515	(2E)-3-(1-{ethyl[2-(1-methyl-1H-indol-3-yl)ethyl]amino}-2,3-dihydro-1H-inden-5-yl)-N-hydroxyacrylamide
516	(2E)-3-(1-{ethyl[2-(6-methyl-1H-indol-3-yl)ethyl]amino}-2,3-dihydro-1H-inden-5-yl)-N-hydroxyacrylamide
517	(2E)-3-(1-{ethyl[2-(6-methyl-1H-indol-3-yl)ethyl]amino}-2,3-dihydro-1H-inden-5-yl)-N-hydroxyacrylamide
518	(2E)-3-(1-{ethyl[2-(6-methyl-1H-indol-3-yl)ethyl]amino}-2,3-dihydro-1H-inden-5-yl)-N-hydroxyacrylamide
519	(2E)-N-hydroxy-3-{1-[[2-(1-methyl-1H-indol-3-yl)ethyl](1H-pyrrol-2-ylmethyl)amino]-2,3-dihydro-1H-inden-5-yl}acrylamide
520	(2E)-N-hydroxy-3-{1-[[2-(1-methyl-1H-indol-3-yl)ethyl](1H-pyrrol-2-ylmethyl)amino]-2,3-dihydro-1H-inden-5-yl}acrylamide
521	(2E)-N-hydroxy-3-{1-[[2-(1-methyl-1H-indol-3-yl)ethyl](1H-pyrrol-2-ylmethyl)amino]-2,3-dihydro-1H-inden-5-yl}acrylamide
522	(2E)-3-{1-[[2-(6-chloro-1H-indol-3-yl)ethyl](1H-pyrrol-2-ylmethyl)amino]-2,3-dihydro-1H-inden-5-yl}-N-hydroxyacrylamide

Compound Example	IUPAC Name
523	(2E)-3-{1-[[2-(6-chloro-1H-indol-3-yl)ethyl](1H-pyrrol-2-ylmethyl)amino]-2,3-dihydro-1H-inden-5-yl}-N-hydroxyacrylamide
524	(2E)-3-{1-[[2-(6-chloro-1H-indol-3-yl)ethyl](1H-pyrrol-2-ylmethyl)amino]-2,3-dihydro-1H-inden-5-yl}-N-hydroxyacrylamide
525	(2E)-3-{1-[[2-(6-fluoro-1H-indol-3-yl)ethyl](1H-pyrrol-2-ylmethyl)amino]-2,3-dihydro-1H-inden-5-yl}-N-hydroxyacrylamide
526	(2E)-3-{1-[[2-(6-fluoro-1H-indol-3-yl)ethyl](1H-pyrrol-2-ylmethyl)amino]-2,3-dihydro-1H-inden-5-yl}-N-hydroxyacrylamide
527	(2E)-3-{1-[[2-(6-fluoro-1H-indol-3-yl)ethyl](1H-pyrrol-2-ylmethyl)amino]-2,3-dihydro-1H-inden-5-yl}-N-hydroxyacrylamide
528	(2E)-3-(1-{{4-[2-(diethylamino)ethoxy]benzyl}[2-(1H-indol-3-yl)ethyl]amino}-2,3-dihydro-1H-inden-5-yl)-N-hydroxyacrylamide
529	(2E)-3-(1-{{4-[2-(diethylamino)ethoxy]benzyl}[2-(1H-indol-3-yl)ethyl]amino}-2,3-dihydro-1H-inden-5-yl)-N-hydroxyacrylamide
530	(2E)-3-[1-([2-(6-chloro-1H-indol-3-yl)ethyl]{4-[2-(diethylamino)ethoxy]benzyl}amino)-2,3-dihydro-1H-inden-5-yl]-N-hydroxyacrylamide
531	(2E)-3-[1-([2-(6-chloro-1H-indol-3-yl)ethyl]{4-[2-(diethylamino)ethoxy]benzyl}amino)-2,3-dihydro-1H-inden-5-yl]-N-hydroxyacrylamide
532	(2E)-3-[1-([2-(6-chloro-1H-indol-3-yl)ethyl]{4-[2-(diethylamino)ethoxy]benzyl}amino)-2,3-dihydro-1H-inden-5-yl]-N-hydroxyacrylamide
533	(2E)-3-(1-{{4-[2-(diethylamino)ethoxy]benzyl}[2-(6-fluoro-1H-indol-3-yl)ethyl]amino}-2,3-dihydro-1H-inden-5-yl)-N-hydroxyacrylamide
534	(2E)-3-(1-{{4-[2-(diethylamino)ethoxy]benzyl}[2-(6-fluoro-1H-indol-3-yl)ethyl]amino}-2,3-dihydro-1H-inden-5-yl)-N-hydroxyacrylamide
535	(2E)-3-(1-{{4-[2-(diethylamino)ethoxy]benzyl}[2-(6-fluoro-1H-indol-3-yl)ethyl]amino}-2,3-dihydro-1H-inden-5-yl)-N-hydroxyacrylamide
536	(2E)-3-(1-{{4-[2-(diethylamino)ethoxy]benzyl}[2-(6-methyl-1H-indol-3-yl)ethyl]amino}-2,3-dihydro-1H-inden-5-yl)-N-hydroxyacrylamide
537	(2E)-3-(1-{{4-[2-(diethylamino)ethoxy]benzyl}[2-(6-methyl-1H-indol-3-yl)ethyl]amino}-2,3-dihydro-1H-inden-5-yl)-N-hydroxyacrylamide
538	(2E)-3-(1-{{4-[2-(diethylamino)ethoxy]benzyl}[2-(6-methyl-1H-indol-3-yl)ethyl]amino}-2,3-dihydro-1H-inden-5-yl)-N-hydroxyacrylamide
539	(2E)-3-(1-{{4-[2-(diethylamino)ethoxy]benzyl}[2-(6-methoxy-1H-indol-3-yl)ethyl]amino}-2,3-dihydro-1H-inden-5-yl)-N-hydroxyacrylamide
540	(2E)-3-(1-{{4-[2-(diethylamino)ethoxy]benzyl}[2-(6-methoxy-1H-indol-3-yl)ethyl]amino}-2,3-dihydro-1H-inden-5-yl)-N-hydroxyacrylamide
541	(2E)-3-(1-{{4-[2-(diethylamino)ethoxy]benzyl}[2-(6-methoxy-1H-indol-3-yl)ethyl]amino}-2,3-dihydro-1H-inden-5-yl)-N-hydroxyacrylamide
542	(2E)-3-(1-{{4-[2-(diethylamino)ethoxy]benzyl}[2-(1-methyl-1H-indol-3-yl)ethyl]amino}-2,3-dihydro-1H-inden-5-yl)-N-hydroxyacrylamide

Compound Example	IUPAC Name
543	(2E)-3-(1-{{4-[2-(diethylamino)ethoxy]benzyl}[2-(1-methyl-1H-indol-3-yl)ethyl]amino}-2,3-dihydro-1H-inden-5-yl)-N-hydroxyacrylamide
544	(2E)-3-(1-{{4-[2-(diethylamino)ethoxy]benzyl}[2-(1-methyl-1H-indol-3-yl)ethyl]amino}-2,3-dihydro-1H-inden-5-yl)-N-hydroxyacrylamide
545	(2E)-3-(1-{[(1-ethyl-1H-pyrazol-4-yl)methyl][2-(1H-indol-3-yl)ethyl]amino}-2,3-dihydro-1H-inden-5-yl)-N-hydroxyacrylamide
546	(2E)-3-(1-{[(1-ethyl-1H-pyrazol-4-yl)methyl][2-(1H-indol-3-yl)ethyl]amino}-2,3-dihydro-1H-inden-5-yl)-N-hydroxyacrylamide
547	(2E)-3-(1-{[(1-ethyl-1H-pyrazol-4-yl)methyl][2-(1-methyl-1H-indol-3-yl)ethyl]amino}-2,3-dihydro-1H-inden-5-yl)-N-hydroxyacrylamide
548	(2E)-3-(1-{[(1-ethyl-1H-pyrazol-4-yl)methyl][2-(1-methyl-1H-indol-3-yl)ethyl]amino}-2,3-dihydro-1H-inden-5-yl)-N-hydroxyacrylamide
549	(2E)-3-(1-{[(1-ethyl-1H-pyrazol-4-yl)methyl][2-(1-methyl-1H-indol-3-yl)ethyl]amino}-2,3-dihydro-1H-inden-5-yl)-N-hydroxyacrylamide
550	(2E)-3-(1-{[(1-ethyl-1H-pyrazol-4-yl)methyl][2-(6-methoxy-1H-indol-3-yl)ethyl]amino}-2,3-dihydro-1H-inden-5-yl)-N-hydroxyacrylamide
551	(2E)-3-(1-{[(1-ethyl-1H-pyrazol-4-yl)methyl][2-(6-methoxy-1H-indol-3-yl)ethyl]amino}-2,3-dihydro-1H-inden-5-yl)-N-hydroxyacrylamide
552	(2E)-3-(1-{[(1-ethyl-1H-pyrazol-4-yl)methyl][2-(6-methoxy-1H-indol-3-yl)ethyl]amino}-2,3-dihydro-1H-inden-5-yl)-N-hydroxyacrylamide
553	(2E)-3-(1-{[2-(6-chloro-1H-indol-3-yl)ethyl][(1-ethyl-1H-pyrazol-4-yl)methyl]amino}-2,3-dihydro-1H-inden-5-yl)-N-hydroxyacrylamide
554	(2E)-3-(1-{[2-(6-chloro-1H-indol-3-yl)ethyl][(1-ethyl-1H-pyrazol-4-yl)methyl]amino}-2,3-dihydro-1H-inden-5-yl)-N-hydroxyacrylamide
555	(2E)-3-(1-{[2-(6-chloro-1H-indol-3-yl)ethyl][(1-ethyl-1H-pyrazol-4-yl)methyl]amino}-2,3-dihydro-1H-inden-5-yl)-N-hydroxyacrylamide
556	(2E)-3-(1-{[(1-ethyl-1H-pyrazol-4-yl)methyl][2-(6-fluoro-1H-indol-3-yl)ethyl]amino}-2,3-dihydro-1H-inden-5-yl)-N-hydroxyacrylamide
557	(2E)-3-(1-{[(1-ethyl-1H-pyrazol-4-yl)methyl][2-(6-fluoro-1H-indol-3-yl)ethyl]amino}-2,3-dihydro-1H-inden-5-yl)-N-hydroxyacrylamide
558	(2E)-3-(1-{[(1-ethyl-1H-pyrazol-4-yl)methyl][2-(6-fluoro-1H-indol-3-yl)ethyl]amino}-2,3-dihydro-1H-inden-5-yl)-N-hydroxyacrylamide
559	(2E)-3-(1-{[(1-ethyl-1H-pyrazol-4-yl)methyl][2-(6-methyl-1H-indol-3-yl)ethyl]amino}-2,3-dihydro-1H-inden-5-yl)-N-hydroxyacrylamide
560	(2E)-3-(1-{[(1-ethyl-1H-pyrazol-4-yl)methyl][2-(6-methyl-1H-indol-3-yl)ethyl]amino}-2,3-dihydro-1H-inden-5-yl)-N-hydroxyacrylamide
561	(2E)-3-(1-{[(1-ethyl-1H-pyrazol-4-yl)methyl][2-(6-methyl-1H-indol-3-yl)ethyl]amino}-2,3-dihydro-1H-inden-5-yl)-N-hydroxyacrylamide
562	(2E)-N-hydroxy-3-(1-{(2-hydroxyethyl)[2-(6-methyl-1H-indol-3-yl)ethyl]amino}-2,3-dihydro-1H-inden-5-yl)acrylamide
563	(2E)-N-hydroxy-3-(1-{(2-hydroxyethyl)[2-(6-methyl-1H-indol-3-yl)ethyl]amino}-2,3-dihydro-1H-inden-5-yl)acrylamide

Compound Example	IUPAC Name
564	(2E)-N-hydroxy-3-(1-{(2-hydroxyethyl)[2-(6-methyl-1H-indol-3-yl)ethyl]amino}-2,3-dihydro-1H-inden-5-yl)acrylamide
565	(2E)-3-{1-[[2-(6-fluoro-1H-indol-3-yl)ethyl](2-hydroxyethyl)amino]-2,3-dihydro-1H-inden-5-yl}-N-hydroxyacrylamide
566	(2E)-3-{1-[[2-(6-fluoro-1H-indol-3-yl)ethyl](2-hydroxyethyl)amino]-2,3-dihydro-1H-inden-5-yl}-N-hydroxyacrylamide
567	(2E)-3-{1-[[2-(6-fluoro-1H-indol-3-yl)ethyl](2-hydroxyethyl)amino]-2,3-dihydro-1H-inden-5-yl}-N-hydroxyacrylamide
568	(2E)-3-{1-[[2-(6-chloro-1H-indol-3-yl)ethyl](2-hydroxyethyl)amino]-2,3-dihydro-1H-inden-5-yl}-N-hydroxyacrylamide
569	(2E)-3-{1-[[2-(6-chloro-1H-indol-3-yl)ethyl](2-hydroxyethyl)amino]-2,3-dihydro-1H-inden-5-yl}-N-hydroxyacrylamide
570	(2E)-3-{1-[[2-(6-chloro-1H-indol-3-yl)ethyl](2-hydroxyethyl)amino]-2,3-dihydro-1H-inden-5-yl}-N-hydroxyacrylamide
571	(2E)-N-hydroxy-3-(1-{(2-hydroxyethyl)[2-(1-methyl-1H-indol-3-yl)ethyl]amino}-2,3-dihydro-1H-inden-5-yl)acrylamide
572	(2E)-N-hydroxy-3-(1-{(2-hydroxyethyl)[2-(1-methyl-1H-indol-3-yl)ethyl]amino}-2,3-dihydro-1H-inden-5-yl)acrylamide
573	(2E)-N-hydroxy-3-{1-[[2-(1H-indol-3-yl)ethyl](2-{[(trifluoromethyl)sulfonyl]amino}ethyl)amino]-2,3-dihydro-1H-inden-5-yl}acrylamide
574	(2E)-N-hydroxy-3-(1-{[2-(1H-indol-3-yl)ethyl][(1-methyl-1H-indol-2-yl)methyl]amino}-2,3-dihydro-1H-inden-5-yl)acrylamide
575	(2E)-N-hydroxy-3-[1-([2-(1H-indol-3-yl)ethyl]{[4-(2-piperidin-1-ylethoxy)phenyl]sulfonyl}amino)-2,3-dihydro-1H-inden-5-yl]acrylamide
576	(2E)-N-hydroxy-3-(1-{[2-(6-methoxy-1H-indol-1-yl)ethyl]amino}-2,3-dihydro-1H-inden-5-yl)acrylamide
577	(2E)-3-(1-{[3-(7-chloro-1H-indol-3-yl)propyl]amino}-2,3-dihydro-1H-inden-5-yl)-N-hydroxyacrylamide
578	(2E)-N-hydroxy-3-(1-{[2-(1H-indol-3-yl)ethyl][(3-methyl-1H-pyrazol-4-yl)methyl]amino}-2,3-dihydro-1H-inden-5-yl)acrylamide
579	(2E)-3-(1-{[2-(6-fluoro-1H-indol-3-yl)ethyl][(3-methyl-1H-pyrazol-4-yl)methyl]amino}-2,3-dihydro-1H-inden-5-yl)-N-hydroxyacrylamide
580	(2E)-3-(1-{[2-(6-chloro-1H-indol-3-yl)ethyl][(3-methyl-1H-pyrazol-4-yl)methyl]amino}-2,3-dihydro-1H-inden-5-yl)-N-hydroxyacrylamide
581	(2E)-N-hydroxy-3-(1-{[2-(6-methyl-1H-indol-3-yl)ethyl][(3-methyl-1H-pyrazol-4-yl)methyl]amino}-2,3-dihydro-1H-inden-5-yl)acrylamide
582	(2E)-N-hydroxy-3-(1-{[2-(1-methyl-1H-indol-3-yl)ethyl][(3-methyl-1H-pyrazol-4-yl)methyl]amino}-2,3-dihydro-1H-inden-5-yl)acrylamide
583	(2E)-N-hydroxy-3-(1-{[2-(6-methoxy-1H-indol-3-yl)ethyl][(3-methyl-1H-pyrazol-4-yl)methyl]amino}-2,3-dihydro-1H-inden-5-yl)acrylamide

Compound Example	IUPAC Name
584	(2E)-3-(1-{[(1,5-dimethyl-1H-pyrazol-4-yl)methyl][2-(6-fluoro-1H-indol-3-yl)ethyl]amino}-2,3-dihydro-1H-inden-5-yl)-N-hydroxyacrylamide
585	(2E)-3-(1-{[2-(6-chloro-1H-indol-3-yl)ethyl][(1,5-dimethyl-1H-pyrazol-4-yl)methyl]amino}-2,3-dihydro-1H-inden-5-yl)-N-hydroxyacrylamide
586	(2E)-3-(1-{[(1,5-dimethyl-1H-pyrazol-4-yl)methyl][2-(6-methyl-1H-indol-3-yl)ethyl]amino}-2,3-dihydro-1H-inden-5-yl)-N-hydroxyacrylamide
587	(2E)-3-(1-{[(1,5-dimethyl-1H-pyrazol-4-yl)methyl][2-(6-methoxy-1H-indol-3-yl)ethyl]amino}-2,3-dihydro-1H-inden-5-yl)-N-hydroxyacrylamide
588	(2E)-3-(1-{[(1,5-dimethyl-1H-pyrazol-4-yl)methyl][2-(1-methyl-1H-indol-3-yl)ethyl]amino}-2,3-dihydro-1H-inden-5-yl)-N-hydroxyacrylamide
589	(2E)-3-(1-{[(1,3-dimethyl-1H-pyrazol-4-yl)methyl][2-(1-methyl-1H-indol-3-yl)ethyl]amino}-2,3-dihydro-1H-inden-5-yl)-N-hydroxyacrylamide
590	(2E)-3-(1-{[(1,3-dimethyl-1H-pyrazol-4-yl)methyl][2-(6-fluoro-1H-indol-3-yl)ethyl]amino}-2,3-dihydro-1H-inden-5-yl)-N-hydroxyacrylamide
591	(2E)-3-(1-{[2-(6-chloro-1H-indol-3-yl)ethyl][(1,3-dimethyl-1H-pyrazol-4-yl)methyl]amino}-2,3-dihydro-1H-inden-5-yl)-N-hydroxyacrylamide
592	(2E)-3-(1-{[(1,3-dimethyl-1H-pyrazol-4-yl)methyl][2-(6-methyl-1H-indol-3-yl)ethyl]amino}-2,3-dihydro-1H-inden-5-yl)-N-hydroxyacrylamide
593	(2E)-3-(1-{[(1,3-dimethyl-1H-pyrazol-4-yl)methyl][2-(6-methoxy-1H-indol-3-yl)ethyl]amino}-2,3-dihydro-1H-inden-5-yl)-N-hydroxyacrylamide
594	(2E)-N-hydroxy-3-(1-{[2-(1-methyl-1H-indol-3-yl)ethyl][(1-methyl-1H-pyrazol-4-yl)methyl]amino}-2,3-dihydro-1H-inden-5-yl)acrylamide
595	(2E)-3-(1-{[2-(6-fluoro-1H-indol-3-yl)ethyl][(1-methyl-1H-pyrazol-4-yl)methyl]amino}-2,3-dihydro-1H-inden-5-yl)-N-hydroxyacrylamide
596	(2E)-3-(1-{[2-(6-chloro-1H-indol-3-yl)ethyl][(1-methyl-1H-pyrazol-4-yl)methyl]amino}-2,3-dihydro-1H-inden-5-yl)-N-hydroxyacrylamide
597	(2E)-N-hydroxy-3-(1-{[2-(6-methyl-1H-indol-3-yl)ethyl][(1-methyl-1H-pyrazol-4-yl)methyl]amino}-2,3-dihydro-1H-inden-5-yl)acrylamide
598	(2E)-N-hydroxy-3-(1-{[2-(6-methoxy-1H-indol-3-yl)ethyl][(1-methyl-1H-pyrazol-4-yl)methyl]amino}-2,3-dihydro-1H-inden-5-yl)acrylamide
599	(2E)-N-hydroxy-3-(1-{[2-(1H-indol-3-yl)ethyl][(1-methyl-1H-pyrazol-4-yl)methyl]amino}-2,3-dihydro-1H-inden-5-yl)acrylamide
600	(2E)-3-(1-{[2-(6-fluoro-1H-indol-3-yl)ethyl][(4-hydroxyphenyl)sulfonyl]amino}-2,3-dihydro-1H-inden-5-yl)-N-hydroxyacrylamide
601	(2E)-3-(1-{[2-(6-chloro-1H-indol-3-yl)ethyl][(4-hydroxyphenyl)sulfonyl]amino}-2,3-dihydro-1H-inden-5-yl)-N-hydroxyacrylamide
602	(2E)-N-hydroxy-3-(1-{[(4-hydroxyphenyl)sulfonyl][2-(6-methyl-1H-indol-3-yl)ethyl]amino}-2,3-dihydro-1H-inden-5-yl)acrylamide
603	(2E)-N-hydroxy-3-(1-{[(4-hydroxyphenyl)sulfonyl][2-(6-methoxy-1H-indol-3-yl)ethyl]amino}-2,3-dihydro-1H-inden-5-yl)acrylamide

Compound Example	IUPAC Name
604	(2E)-N-hydroxy-3-(1-{[(4-hydroxyphenyl)sulfonyl][2-(1-methyl-1H-indol-3-yl)ethyl]amino}-2,3-dihydro-1H-inden-5-yl)acrylamide
605	(2E)-3-(1-{(4-{[(ethylamino)carbonyl]amino}benzyl)[2-(6-fluoro-1H-indol-3-yl)ethyl]amino}-2,3-dihydro-1H-inden-5-yl)-N-hydroxyacrylamide
606	(2E)-3-{1-[[2-(6-chloro-1H-indol-3-yl)ethyl](4-{[(ethylamino)carbonyl]amino}benzyl)amino]-2,3-dihydro-1H-inden-5-yl}-N-hydroxyacrylamide
607	(2E)-3-(1-{(4-{[(ethylamino)carbonyl]amino}benzyl)[2-(6-methyl-1H-indol-3-yl)ethyl]amino}-2,3-dihydro-1H-inden-5-yl)-N-hydroxyacrylamide
608	(2E)-3-(1-{(4-{[(ethylamino)carbonyl]amino}benzyl)[2-(6-methoxy-1H-indol-3-yl)ethyl]amino}-2,3-dihydro-1H-inden-5-yl)-N-hydroxyacrylamide
609	(2E)-3-(1-{(4-{[(ethylamino)carbonyl]amino}benzyl)[2-(1-methyl-1H-indol-3-yl)ethyl]amino}-2,3-dihydro-1H-inden-5-yl)-N-hydroxyacrylamide
610	(2E)-3-(1-{(cyclopropylmethyl)[2-(1-methyl-1H-indol-3-yl)ethyl]amino}-2,3-dihydro-1H-inden-5-yl)-N-hydroxyacrylamide
611	(2E)-3-(1-{(cyclopropylmethyl)[2-(6-fluoro-1H-indol-3-yl)ethyl]amino}-2,3-dihydro-1H-inden-5-yl)-N-hydroxyacrylamide
612	(2E)-3-{1-[[2-(6-chloro-1H-indol-3-yl)ethyl](cyclopropylmethyl)amino]-2,3-dihydro-1H-inden-5-yl}-N-hydroxyacrylamide
613	(2E)-3-(1-{(cyclopropylmethyl)[2-(6-methyl-1H-indol-3-yl)ethyl]amino}-2,3-dihydro-1H-inden-5-yl)-N-hydroxyacrylamide
614	(2E)-3-(1-{(cyclopropylmethyl)[2-(6-methoxy-1H-indol-3-yl)ethyl]amino}-2,3-dihydro-1H-inden-5-yl)-N-hydroxyacrylamide
615	(2E)-3-{1-[[2-(6-fluoro-1H-indol-3-yl)ethyl](methyl)amino]-2,3-dihydro-1H-inden-5-yl}-N-hydroxyacrylamide
616	(2E)-3-{1-[[2-(6-chloro-1H-indol-3-yl)ethyl](methyl)amino]-2,3-dihydro-1H-inden-5-yl}-N-hydroxyacrylamide
617	(2E)-N-hydroxy-3-(1-{methyl[2-(6-methyl-1H-indol-3-yl)ethyl]amino}-2,3-dihydro-1H-inden-5-yl)acrylamide
618	(2E)-N-hydroxy-3-{1-[[2-(6-methoxy-1H-indol-3-yl)ethyl](methyl)amino]-2,3-dihydro-1H-inden-5-yl}acrylamide
619	(2E)-3-(1-{[2-(6-fluoro-1H-indol-3-yl)ethyl]amino}-2,3-dihydro-1H-inden-5-yl)-N-hydroxyacrylamide
620	(2E)-3-(1-{[2-(6-chloro-1H-indol-3-yl)ethyl]amino}-2,3-dihydro-1H-inden-5-yl)-N-hydroxyacrylamide
621	(2E)-N-hydroxy-3-(1-{[2-(6-methyl-1H-indol-3-yl)ethyl]amino}-2,3-dihydro-1H-inden-5-yl)acrylamide
622	(2E)-N-hydroxy-3-(1-{[2-(1-methyl-1H-indol-3-yl)ethyl]amino}-2,3-dihydro-1H-inden-5-yl)acrylamide
623	4-hydroxy-N-{5-[(1E)-3-(hydroxyamino)-3-oxoprop-1-en-1-yl]-2,3-dihydro-1H-inden-1-yl}-N-[2-(1H-indol-3-yl)ethyl]benzamide

Compound Example	IUPAC Name
624	N-[2-(6-fluoro-1H-indol-3-yl)ethyl]-4-hydroxy-N-{5-[(1E)-3-(hydroxyamino)-3-oxoprop-1-en-1-yl]-2,3-dihydro-1H-inden-1-yl}benzamide
625	N-[2-(6-chloro-1H-indol-3-yl)ethyl]-4-hydroxy-N-{5-[(1E)-3-(hydroxyamino)-3-oxoprop-1-en-1-yl]-2,3-dihydro-1H-inden-1-yl}benzamide
626	4-hydroxy-N-{5-[(1E)-3-(hydroxyamino)-3-oxoprop-1-en-1-yl]-2,3-dihydro-1H-inden-1-yl}-N-[2-(6-methyl-1H-indol-3-yl)ethyl]benzamide
627	4-hydroxy-N-{5-[(1E)-3-(hydroxyamino)-3-oxoprop-1-en-1-yl]-2,3-dihydro-1H-inden-1-yl}-N-[2-(6-methoxy-1H-indol-3-yl)ethyl]benzamide
628	4-hydroxy-N-{5-[(1E)-3-(hydroxyamino)-3-oxoprop-1-en-1-yl]-2,3-dihydro-1H-inden-1-yl}-N-[2-(1-methyl-1H-indol-3-yl)ethyl]benzamide
629	(2E)-N-hydroxy-3-{1-[[2-(1-methyl-1H-indol-3-yl)ethyl](1H-pyrazol-4-ylmethyl)amino]-2,3-dihydro-1H-inden-5-yl}acrylamide
630	(2E)-3-{1-[[2-(6-fluoro-1H-indol-3-yl)ethyl](1H-pyrazol-4-ylmethyl)amino]-2,3-dihydro-1H-inden-5-yl}-N-hydroxyacrylamide
631	(2E)-3-{1-[[2-(6-chloro-1H-indol-3-yl)ethyl](1H-pyrazol-4-ylmethyl)amino]-2,3-dihydro-1H-inden-5-yl}-N-hydroxyacrylamide
632	(2E)-N-hydroxy-3-{1-[[2-(6-methyl-1H-indol-3-yl)ethyl](1H-pyrazol-4-ylmethyl)amino]-2,3-dihydro-1H-inden-5-yl}acrylamide
633	(2E)-N-hydroxy-3-{1-[[2-(6-methoxy-1H-indol-3-yl)ethyl](1H-pyrazol-4-ylmethyl)amino]-2,3-dihydro-1H-inden-5-yl}acrylamide
634	(2E)-3-(1-{[2-(6-fluoro-1H-indol-3-yl)ethyl][(3-hydroxyphenyl)sulfonyl]amino}-2,3-dihydro-1H-inden-5-yl)-N-hydroxyacrylamide
635	(2E)-3-(1-{[2-(6-chloro-1H-indol-3-yl)ethyl][(3-hydroxyphenyl)sulfonyl]amino}-2,3-dihydro-1H-inden-5-yl)-N-hydroxyacrylamide
636	(2E)-N-hydroxy-3-(1-{[(3-hydroxyphenyl)sulfonyl][2-(6-methyl-1H-indol-3-yl)ethyl]amino}-2,3-dihydro-1H-inden-5-yl)acrylamide
637	(2E)-N-hydroxy-3-(1-{[(3-hydroxyphenyl)sulfonyl][2-(6-methoxy-1H-indol-3-yl)ethyl]amino}-2,3-dihydro-1H-inden-5-yl)acrylamide
638	(2E)-N-hydroxy-3-(1-{[(3-hydroxyphenyl)sulfonyl][2-(1-methyl-1H-indol-3-yl)ethyl]amino}-2,3-dihydro-1H-inden-5-yl)acrylamide
639	(2E)-N-hydroxy-3-(1-{[(3-hydroxyphenyl)sulfonyl][2-(1H-indol-3-yl)ethyl]amino}-2,3-dihydro-1H-inden-5-yl)acrylamide
640	(2E)-N-hydroxy-3-{1-[[2-(1H-indol-3-yl)ethyl](1H-pyrrol-3-ylmethyl)amino]-2,3-dihydro-1H-inden-5-yl}acrylamide
641	(2E)-3-{1-[[2-(6-fluoro-1H-indol-3-yl)ethyl](1H-pyrrol-3-ylmethyl)amino]-2,3-dihydro-1H-inden-5-yl}-N-hydroxyacrylamide
642	(2E)-3-{1-[[2-(6-chloro-1H-indol-3-yl)ethyl](1H-pyrrol-3-ylmethyl)amino]-2,3-dihydro-1H-inden-5-yl}-N-hydroxyacrylamide
643	(2E)-N-hydroxy-3-{1-[[2-(6-methyl-1H-indol-3-yl)ethyl](1H-pyrrol-3-ylmethyl)amino]-2,3-dihydro-1H-inden-5-yl}acrylamide

Compound Example	IUPAC Name
644	(2E)-N-hydroxy-3-{1-[[2-(1-methyl-1H-indol-3-yl)ethyl](1H-pyrrol-3-ylmethyl)amino]-2,3-dihydro-1H-inden-5-yl}acrylamide
645	(2E)-N-hydroxy-3-(1-{[2-(1H-indol-3-yl)ethyl][(2-methyl-1H-pyrrol-3-yl)methyl]amino}-2,3-dihydro-1H-inden-5-yl)acrylamide
646	(2E)-3-(1-{[2-(6-fluoro-1H-indol-3-yl)ethyl][(2-methyl-1H-pyrrol-3-yl)methyl]amino}-2,3-dihydro-1H-inden-5-yl)-N-hydroxyacrylamide
647	(2E)-3-(1-{[2-(6-chloro-1H-indol-3-yl)ethyl][(2-methyl-1H-pyrrol-3-yl)methyl]amino}-2,3-dihydro-1H-inden-5-yl)-N-hydroxyacrylamide
648	(2E)-N-hydroxy-3-(1-{[2-(6-methyl-1H-indol-3-yl)ethyl][(2-methyl-1H-pyrrol-3-yl)methyl]amino}-2,3-dihydro-1H-inden-5-yl)acrylamide
649	(2E)-N-hydroxy-3-(1-{[2-(1-methyl-1H-indol-3-yl)ethyl][(2-methyl-1H-pyrrol-3-yl)methyl]amino}-2,3-dihydro-1H-inden-5-yl)acrylamide
650	(2E)-3-(1-{[(4-ethyl-1H-pyrrol-3-yl)methyl][2-(1H-indol-3-yl)ethyl]amino}-2,3-dihydro-1H-inden-5-yl)-N-hydroxyacrylamide
651	(2E)-3-(1-{[(4-ethyl-1H-pyrrol-3-yl)methyl][2-(6-fluoro-1H-indol-3-yl)ethyl]amino}-2,3-dihydro-1H-inden-5-yl)-N-hydroxyacrylamide
652	(2E)-3-(1-{[2-(6-chloro-1H-indol-3-yl)ethyl][(4-ethyl-1H-pyrrol-3-yl)methyl]amino}-2,3-dihydro-1H-inden-5-yl)-N-hydroxyacrylamide
653	(2E)-3-(1-{[(4-ethyl-1H-pyrrol-3-yl)methyl][2-(6-methyl-1H-indol-3-yl)ethyl]amino}-2,3-dihydro-1H-inden-5-yl)-N-hydroxyacrylamide
654	(2E)-3-(1-{[(4-ethyl-1H-pyrrol-3-yl)methyl][2-(1-methyl-1H-indol-3-yl)ethyl]amino}-2,3-dihydro-1H-inden-5-yl)-N-hydroxyacrylamide
655	(2E)-3-(1-{[(5-ethyl-1H-pyrrol-3-yl)methyl][2-(1H-indol-3-yl)ethyl]amino}-2,3-dihydro-1H-inden-5-yl)-N-hydroxyacrylamide
656	(2E)-3-(1-{[(5-ethyl-1H-pyrrol-3-yl)methyl][2-(6-fluoro-1H-indol-3-yl)ethyl]amino}-2,3-dihydro-1H-inden-5-yl)-N-hydroxyacrylamide
657	(2E)-3-(1-{[2-(6-chloro-1H-indol-3-yl)ethyl][(5-ethyl-1H-pyrrol-3-yl)methyl]amino}-2,3-dihydro-1H-inden-5-yl)-N-hydroxyacrylamide
658	(2E)-3-(1-{[(5-ethyl-1H-pyrrol-3-yl)methyl][2-(6-methyl-1H-indol-3-yl)ethyl]amino}-2,3-dihydro-1H-inden-5-yl)-N-hydroxyacrylamide
659	(2E)-3-(1-{[(5-ethyl-1H-pyrrol-3-yl)methyl][2-(1-methyl-1H-indol-3-yl)ethyl]amino}-2,3-dihydro-1H-inden-5-yl)-N-hydroxyacrylamide
660	(2E)-3-(1-{[(2,4-dimethyl-1H-pyrrol-3-yl)methyl][2-(1H-indol-3-yl)ethyl]amino}-2,3-dihydro-1H-inden-5-yl)-N-hydroxyacrylamide
661	(2E)-3-(1-{[(2,4-dimethyl-1H-pyrrol-3-yl)methyl][2-(6-fluoro-1H-indol-3-yl)ethyl]amino}-2,3-dihydro-1H-inden-5-yl)-N-hydroxyacrylamide
662	(2E)-3-(1-{[2-(6-chloro-1H-indol-3-yl)ethyl][(2,4-dimethyl-1H-pyrrol-3-yl)methyl]amino}-2,3-dihydro-1H-inden-5-yl)-N-hydroxyacrylamide
663	(2E)-3-(1-{[(2,4-dimethyl-1H-pyrrol-3-yl)methyl][2-(6-methyl-1H-indol-3-yl)ethyl]amino}-2,3-dihydro-1H-inden-5-yl)-N-hydroxyacrylamide

Compound Example	IUPAC Name
664	(2E)-3-(1-{[(2,4-dimethyl-1H-pyrrol-3-yl)methyl][2-(1-methyl-1H-indol-3-yl)ethyl]amino}-2,3-dihydro-1H-inden-5-yl)-N-hydroxyacrylamide
665	(2E)-3-(1-{[(2,5-dimethyl-1H-pyrrol-3-yl)methyl][2-(1H-indol-3-yl)ethyl]amino}-2,3-dihydro-1H-inden-5-yl)-N-hydroxyacrylamide
666	(2E)-3-(1-{[(2,5-dimethyl-1H-pyrrol-3-yl)methyl][2-(6-fluoro-1H-indol-3-yl)ethyl]amino}-2,3-dihydro-1H-inden-5-yl)-N-hydroxyacrylamide
667	(2E)-3-(1-{[2-(6-chloro-1H-indol-3-yl)ethyl][(2,5-dimethyl-1H-pyrrol-3-yl)methyl]amino}-2,3-dihydro-1H-inden-5-yl)-N-hydroxyacrylamide
668	(2E)-3-(1-{[(2,5-dimethyl-1H-pyrrol-3-yl)methyl][2-(6-methyl-1H-indol-3-yl)ethyl]amino}-2,3-dihydro-1H-inden-5-yl)-N-hydroxyacrylamide
669	(2E)-3-(1-{[(2,5-dimethyl-1H-pyrrol-3-yl)methyl][2-(1-methyl-1H-indol-3-yl)ethyl]amino}-2,3-dihydro-1H-inden-5-yl)-N-hydroxyacrylamide
670	(2E)-3-(1-{[(5-chloro-1H-pyrrol-2-yl)methyl][2-(1H-indol-3-yl)ethyl]amino}-2,3-dihydro-1H-inden-5-yl)-N-hydroxyacrylamide
671	(2E)-3-(1-{[(5-chloro-1H-pyrrol-2-yl)methyl][2-(6-fluoro-1H-indol-3-yl)ethyl]amino}-2,3-dihydro-1H-inden-5-yl)-N-hydroxyacrylamide
672	(2E)-3-(1-{[2-(6-chloro-1H-indol-3-yl)ethyl][(5-chloro-1H-pyrrol-2-yl)methyl]amino}-2,3-dihydro-1H-inden-5-yl)-N-hydroxyacrylamide
673	(2E)-3-(1-{[(5-chloro-1H-pyrrol-2-yl)methyl][2-(6-methyl-1H-indol-3-yl)ethyl]amino}-2,3-dihydro-1H-inden-5-yl)-N-hydroxyacrylamide
674	(2E)-3-(1-{[(5-chloro-1H-pyrrol-2-yl)methyl][2-(6-methoxy-1H-indol-3-yl)ethyl]amino}-2,3-dihydro-1H-inden-5-yl)-N-hydroxyacrylamide
675	(2E)-3-(1-{[(5-chloro-1H-pyrrol-2-yl)methyl][2-(1-methyl-1H-indol-3-yl)ethyl]amino}-2,3-dihydro-1H-inden-5-yl)-N-hydroxyacrylamide
676	(2E)-3-(1-{[(5-fluoro-1H-pyrrol-2-yl)methyl][2-(1H-indol-3-yl)ethyl]amino}-2,3-dihydro-1H-inden-5-yl)-N-hydroxyacrylamide
677	(2E)-3-(1-{[2-(6-fluoro-1H-indol-3-yl)ethyl][(5-fluoro-1H-pyrrol-2-yl)methyl]amino}-2,3-dihydro-1H-inden-5-yl)-N-hydroxyacrylamide
678	(2E)-3-(1-{[2-(6-chloro-1H-indol-3-yl)ethyl][(5-fluoro-1H-pyrrol-2-yl)methyl]amino}-2,3-dihydro-1H-inden-5-yl)-N-hydroxyacrylamide
679	(2E)-3-(1-{[(5-fluoro-1H-pyrrol-2-yl)methyl][2-(6-methyl-1H-indol-3-yl)ethyl]amino}-2,3-dihydro-1H-inden-5-yl)-N-hydroxyacrylamide
680	(2E)-3-(1-{[(5-fluoro-1H-pyrrol-2-yl)methyl][2-(6-methoxy-1H-indol-3-yl)ethyl]amino}-2,3-dihydro-1H-inden-5-yl)-N-hydroxyacrylamide
681	(2E)-3-(1-{[(5-fluoro-1H-pyrrol-2-yl)methyl][2-(1-methyl-1H-indol-3-yl)ethyl]amino}-2,3-dihydro-1H-inden-5-yl)-N-

Compound Example	IUPAC Name
	hydroxyacrylamide
682	(2E)-N-hydroxy-3-(1-{[2-(1H-indol-3-yl)ethyl][(5-methyl-1H-pyrrol-2-yl)methyl]amino}-2,3-dihydro-1H-inden-5-yl)acrylamide
683	(2E)-3-(1-{[2-(6-fluoro-1H-indol-3-yl)ethyl][(5-methyl-1H-pyrrol-2-yl)methyl]amino}-2,3-dihydro-1H-inden-5-yl)-N-hydroxyacrylamide
684	(2E)-3-(1-{[2-(6-chloro-1H-indol-3-yl)ethyl][(5-methyl-1H-pyrrol-2-yl)methyl]amino}-2,3-dihydro-1H-inden-5-yl)-N-hydroxyacrylamide
685	(2E)-N-hydroxy-3-(1-{[2-(6-methyl-1H-indol-3-yl)ethyl][(5-methyl-1H-pyrrol-2-yl)methyl]amino}-2,3-dihydro-1H-inden-5-yl)acrylamide
686	(2E)-N-hydroxy-3-(1-{[2-(6-methoxy-1H-indol-3-yl)ethyl][(5-methyl-1H-pyrrol-2-yl)methyl]amino}-2,3-dihydro-1H-inden-5-yl)acrylamide
687	(2E)-N-hydroxy-3-(1-{[2-(1-methyl-1H-indol-3-yl)ethyl][(5-methyl-1H-pyrrol-2-yl)methyl]amino}-2,3-dihydro-1H-inden-5-yl)acrylamide
688	(2E)-3-(1-{[(3-chloro-1H-pyrrol-2-yl)methyl][2-(1H-indol-3-yl)ethyl]amino}-2,3-dihydro-1H-inden-5-yl)-N-hydroxyacrylamide
689	(2E)-3-(1-{[(3-chloro-1H-pyrrol-2-yl)methyl][2-(6-fluoro-1H-indol-3-yl)ethyl]amino}-2,3-dihydro-1H-inden-5-yl)-N-hydroxyacrylamide
690	(2E)-3-(1-{[2-(6-chloro-1H-indol-3-yl)ethyl][(3-chloro-1H-pyrrol-2-yl)methyl]amino}-2,3-dihydro-1H-inden-5-yl)-N-hydroxyacrylamide
691	(2E)-3-(1-{[(3-chloro-1H-pyrrol-2-yl)methyl][2-(6-methyl-1H-indol-3-yl)ethyl]amino}-2,3-dihydro-1H-inden-5-yl)-N-hydroxyacrylamide
692	(2E)-3-(1-{[(3-chloro-1H-pyrrol-2-yl)methyl][2-(6-methoxy-1H-indol-3-yl)ethyl]amino}-2,3-dihydro-1H-inden-5-yl)-N-hydroxyacrylamide
693	(2E)-3-(1-{[(3-chloro-1H-pyrrol-2-yl)methyl][2-(1-methyl-1H-indol-3-yl)ethyl]amino}-2,3-dihydro-1H-inden-5-yl)-N-hydroxyacrylamide
694	(2E)-N-hydroxy-3-(1-{[2-(1H-indol-3-yl)ethyl][(3-methyl-1H-pyrrol-2-yl)methyl]amino}-2,3-dihydro-1H-inden-5-yl)acrylamide
695	(2E)-3-(1-{[2-(6-fluoro-1H-indol-3-yl)ethyl][(3-methyl-1H-pyrrol-2-yl)methyl]amino}-2,3-dihydro-1H-inden-5-yl)-N-hydroxyacrylamide
696	(2E)-3-(1-{[2-(6-chloro-1H-indol-3-yl)ethyl][(3-methyl-1H-pyrrol-2-yl)methyl]amino}-2,3-dihydro-1H-inden-5-yl)-N-hydroxyacrylamide
697	(2E)-N-hydroxy-3-(1-{[2-(6-methyl-1H-indol-3-yl)ethyl][(3-methyl-1H-pyrrol-2-yl)methyl]amino}-2,3-dihydro-1H-inden-5-yl)acrylamide

Compound Example	IUPAC Name
698	(2E)-N-hydroxy-3-(1-{[2-(6-methoxy-1H-indol-3-yl)ethyl][(3-methyl-1H-pyrrol-2-yl)methyl]amino}-2,3-dihydro-1H-inden-5-yl)acrylamide
699	(2E)-N-hydroxy-3-(1-{[2-(1-methyl-1H-indol-3-yl)ethyl][(3-methyl-1H-pyrrol-2-yl)methyl]amino}-2,3-dihydro-1H-inden-5-yl)acrylamide
700	(2E)-3-(1-{[(4-chloro-1H-pyrrol-2-yl)methyl][2-(1H-indol-3-yl)ethyl]amino}-2,3-dihydro-1H-inden-5-yl)-N-hydroxyacrylamide
701	(2E)-3-(1-{[(4-chloro-1H-pyrrol-2-yl)methyl][2-(6-fluoro-1H-indol-3-yl)ethyl]amino}-2,3-dihydro-1H-inden-5-yl)-N-hydroxyacrylamide
702	(2E)-3-(1-{[2-(6-chloro-1H-indol-3-yl)ethyl][(4-chloro-1H-pyrrol-2-yl)methyl]amino}-2,3-dihydro-1H-inden-5-yl)-N-hydroxyacrylamide
703	(2E)-3-(1-{[(4-chloro-1H-pyrrol-2-yl)methyl][2-(6-methyl-1H-indol-3-yl)ethyl]amino}-2,3-dihydro-1H-inden-5-yl)-N-hydroxyacrylamide
704	(2E)-3-(1-{[(4-chloro-1H-pyrrol-2-yl)methyl][2-(6-methoxy-1H-indol-3-yl)ethyl]amino}-2,3-dihydro-1H-inden-5-yl)-N-hydroxyacrylamide
705	(2E)-3-(1-{[(4-chloro-1H-pyrrol-2-yl)methyl][2-(1-methyl-1H-indol-3-yl)ethyl]amino}-2,3-dihydro-1H-inden-5-yl)-N-hydroxyacrylamide
706	(2E)-N-hydroxy-3-(1-{[2-(1H-indol-3-yl)ethyl][(4-methyl-1H-pyrrol-2-yl)methyl]amino}-2,3-dihydro-1H-inden-5-yl)acrylamide
707	(2E)-3-(1-{[2-(6-fluoro-1H-indol-3-yl)ethyl][(4-methyl-1H-pyrrol-2-yl)methyl]amino}-2,3-dihydro-1H-inden-5-yl)-N-hydroxyacrylamide
708	(2E)-3-(1-{[2-(6-chloro-1H-indol-3-yl)ethyl][(4-methyl-1H-pyrrol-2-yl)methyl]amino}-2,3-dihydro-1H-inden-5-yl)-N-hydroxyacrylamide
709	(2E)-N-hydroxy-3-(1-{[2-(6-methyl-1H-indol-3-yl)ethyl][(4-methyl-1H-pyrrol-2-yl)methyl]amino}-2,3-dihydro-1H-inden-5-yl)acrylamide
710	(2E)-N-hydroxy-3-(1-{[2-(6-methoxy-1H-indol-3-yl)ethyl][(4-methyl-1H-pyrrol-2-yl)methyl]amino}-2,3-dihydro-1H-inden-5-yl)acrylamide
711	(2E)-N-hydroxy-3-(1-{[2-(1-methyl-1H-indol-3-yl)ethyl][(4-methyl-1H-pyrrol-2-yl)methyl]amino}-2,3-dihydro-1H-inden-5-yl)acrylamide
712	(2E)-3-(1-{[(3,4-dimethyl-1H-pyrrol-2-yl)methyl][2-(1H-indol-3-yl)ethyl]amino}-2,3-dihydro-1H-inden-5-yl)-N-hydroxyacrylamide
713	(2E)-3-(1-{[(3,4-dimethyl-1H-pyrrol-2-yl)methyl][2-(6-fluoro-1H-indol-3-yl)ethyl]amino}-2,3-dihydro-1H-inden-5-yl)-N-hydroxyacrylamide
714	(2E)-3-(1-{[2-(6-chloro-1H-indol-3-yl)ethyl][(3,4-dimethyl-1H-pyrrol-2-yl)methyl]amino}-2,3-dihydro-1H-inden-5-yl)-N-hydroxyacrylamide

Compound Example	IUPAC Name
715	(2E)-3-(1-{[(3,4-dimethyl-1H-pyrrol-2-yl)methyl][2-(6-methyl-1H-indol-3-yl)ethyl]amino}-2,3-dihydro-1H-inden-5-yl)-N-hydroxyacrylamide
716	(2E)-3-(1-{[(3,4-dimethyl-1H-pyrrol-2-yl)methyl][2-(6-methoxy-1H-indol-3-yl)ethyl]amino}-2,3-dihydro-1H-inden-5-yl)-N-hydroxyacrylamide
717	(2E)-3-(1-{[(3,4-dimethyl-1H-pyrrol-2-yl)methyl][2-(1-methyl-1H-indol-3-yl)ethyl]amino}-2,3-dihydro-1H-inden-5-yl)-N-hydroxyacrylamide
718	(2E)-3-(1-{[(4-chloro-3-methyl-1H-pyrrol-2-yl)methyl][2-(1H-indol-3-yl)ethyl]amino}-2,3-dihydro-1H-inden-5-yl)-N-hydroxyacrylamide
719	(2E)-3-(1-{[(4-chloro-3-methyl-1H-pyrrol-2-yl)methyl][2-(6-fluoro-1H-indol-3-yl)ethyl]amino}-2,3-dihydro-1H-inden-5-yl)-N-hydroxyacrylamide
720	(2E)-3-(1-{[2-(6-chloro-1H-indol-3-yl)ethyl][(4-chloro-3-methyl-1H-pyrrol-2-yl)methyl]amino}-2,3-dihydro-1H-inden-5-yl)-N-hydroxyacrylamide
721	(2E)-3-(1-{[(4-chloro-3-methyl-1H-pyrrol-2-yl)methyl][2-(6-methyl-1H-indol-3-yl)ethyl]amino}-2,3-dihydro-1H-inden-5-yl)-N-hydroxyacrylamide
722	(2E)-3-(1-{[(4-chloro-3-methyl-1H-pyrrol-2-yl)methyl][2-(6-methoxy-1H-indol-3-yl)ethyl]amino}-2,3-dihydro-1H-inden-5-yl)-N-hydroxyacrylamide
723	(2E)-3-(1-{[(4-chloro-3-methyl-1H-pyrrol-2-yl)methyl][2-(1-methyl-1H-indol-3-yl)ethyl]amino}-2,3-dihydro-1H-inden-5-yl)-N-hydroxyacrylamide
724	(2E)-3-(1-{[(3,4-dichloro-1H-pyrrol-2-yl)methyl][2-(1H-indol-3-yl)ethyl]amino}-2,3-dihydro-1H-inden-5-yl)-N-hydroxyacrylamide
725	(2E)-3-(1-{[(3,4-dichloro-1H-pyrrol-2-yl)methyl][2-(6-fluoro-1H-indol-3-yl)ethyl]amino}-2,3-dihydro-1H-inden-5-yl)-N-hydroxyacrylamide
726	(2E)-3-(1-{[2-(6-chloro-1H-indol-3-yl)ethyl][(3,4-dichloro-1H-pyrrol-2-yl)methyl]amino}-2,3-dihydro-1H-inden-5-yl)-N-hydroxyacrylamide
727	(2E)-3-(1-{[(3,4-dichloro-1H-pyrrol-2-yl)methyl][2-(6-methyl-1H-indol-3-yl)ethyl]amino}-2,3-dihydro-1H-inden-5-yl)-N-hydroxyacrylamide
728	(2E)-3-(1-{[(3,4-dichloro-1H-pyrrol-2-yl)methyl][2-(6-methoxy-1H-indol-3-yl)ethyl]amino}-2,3-dihydro-1H-inden-5-yl)-N-hydroxyacrylamide
729	(2E)-3-(1-{[(3,4-dichloro-1H-pyrrol-2-yl)methyl][2-(1-methyl-1H-indol-3-yl)ethyl]amino}-2,3-dihydro-1H-inden-5-yl)-N-hydroxyacrylamide
730	(2E)-3-(1-{[(5-chloro-3,4-dimethyl-1H-pyrrol-2-yl)methyl][2-(1H-indol-3-yl)ethyl]amino}-2,3-dihydro-1H-inden-5-yl)-N-hydroxyacrylamide
731	(2E)-3-(1-{[(5-chloro-3,4-dimethyl-1H-pyrrol-2-yl)methyl][2-(6-fluoro-1H-indol-3-yl)ethyl]amino}-2,3-dihydro-1H-inden-5-yl)-N-hydroxyacrylamide
732	(2E)-3-(1-{[(5-chloro-3,4-dimethyl-1H-pyrrol-2-yl)methyl][2-(6-chloro-1H-indol-3-yl)ethyl]amino}-2,3-dihydro-1H-inden-5-yl)-N-hydroxyacrylamide

Compound Example	IUPAC Name
733	(2E)-3-(1-{[(5-chloro-3,4-dimethyl-1H-pyrrol-2-yl)methyl][2-(6-methyl-1H-indol-3-yl)ethyl]amino}-2,3-dihydro-1H-inden-5-yl)-N-hydroxyacrylamide
734	(2E)-3-(1-{[(5-chloro-3,4-dimethyl-1H-pyrrol-2-yl)methyl][2-(6-methoxy-1H-indol-3-yl)ethyl]amino}-2,3-dihydro-1H-inden-5-yl)-N-hydroxyacrylamide
735	(2E)-3-(1-{[(5-chloro-3,4-dimethyl-1H-pyrrol-2-yl)methyl][2-(1-methyl-1H-indol-3-yl)ethyl]amino}-2,3-dihydro-1H-inden-5-yl)-N-hydroxyacrylamide
736	(2E)-N-hydroxy-3-(1-{[2-(1H-indol-3-yl)ethyl][(3,4,5-trimethyl-1H-pyrrol-2-yl)methyl]amino}-2,3-dihydro-1H-inden-5-yl)acrylamide
737	(2E)-3-(1-{[2-(6-fluoro-1H-indol-3-yl)ethyl][(3,4,5-trimethyl-1H-pyrrol-2-yl)methyl]amino}-2,3-dihydro-1H-inden-5-yl)-N-hydroxyacrylamide
738	(2E)-3-(1-{[2-(6-chloro-1H-indol-3-yl)ethyl][(3,4,5-trimethyl-1H-pyrrol-2-yl)methyl]amino}-2,3-dihydro-1H-inden-5-yl)-N-hydroxyacrylamide
739	(2E)-N-hydroxy-3-(1-{[2-(6-methyl-1H-indol-3-yl)ethyl][(3,4,5-trimethyl-1H-pyrrol-2-yl)methyl]amino}-2,3-dihydro-1H-inden-5-yl)acrylamide
740	(2E)-N-hydroxy-3-(1-{[2-(6-methoxy-1H-indol-3-yl)ethyl][(3,4,5-trimethyl-1H-pyrrol-2-yl)methyl]amino}-2,3-dihydro-1H-inden-5-yl)acrylamide
741	(2E)-N-hydroxy-3-(1-{[2-(1-methyl-1H-indol-3-yl)ethyl][(3,4,5-trimethyl-1H-pyrrol-2-yl)methyl]amino}-2,3-dihydro-1H-inden-5-yl)acrylamide
742	(2E)-3-(1-{[(4-fluoro-3,5-dimethyl-1H-pyrrol-2-yl)methyl][2-(1H-indol-3-yl)ethyl]amino}-2,3-dihydro-1H-inden-5-yl)-N-hydroxyacrylamide
743	(2E)-3-(1-{[(4-fluoro-3,5-dimethyl-1H-pyrrol-2-yl)methyl][2-(6-fluoro-1H-indol-3-yl)ethyl]amino}-2,3-dihydro-1H-inden-5-yl)-N-hydroxyacrylamide
744	(2E)-3-(1-{[2-(6-chloro-1H-indol-3-yl)ethyl][(4-fluoro-3,5-dimethyl-1H-pyrrol-2-yl)methyl]amino}-2,3-dihydro-1H-inden-5-yl)-N-hydroxyacrylamide
745	(2E)-3-(1-{[(4-fluoro-3,5-dimethyl-1H-pyrrol-2-yl)methyl][2-(6-methyl-1H-indol-3-yl)ethyl]amino}-2,3-dihydro-1H-inden-5-yl)-N-hydroxyacrylamide
746	(2E)-3-(1-{[(4-fluoro-3,5-dimethyl-1H-pyrrol-2-yl)methyl][2-(6-methoxy-1H-indol-3-yl)ethyl]amino}-2,3-dihydro-1H-inden-5-yl)-N-hydroxyacrylamide
747	(2E)-3-(1-{[(4-fluoro-3,5-dimethyl-1H-pyrrol-2-yl)methyl][2-(1-methyl-1H-indol-3-yl)ethyl]amino}-2,3-dihydro-1H-inden-5-yl)-N-hydroxyacrylamide
748	(2E)-3-(1-{[(4,5-dimethyl-1H-pyrrol-2-yl)methyl][2-(1H-indol-3-yl)ethyl]amino}-2,3-dihydro-1H-inden-5-yl)-N-hydroxyacrylamide
749	(2E)-3-(1-{[(4,5-dimethyl-1H-pyrrol-2-yl)methyl][2-(6-fluoro-1H-indol-3-yl)ethyl]amino}-2,3-dihydro-1H-inden-5-yl)-N-hydroxyacrylamide

Compound Example	IUPAC Name
750	(2E)-3-(1-{[2-(6-chloro-1H-indol-3-yl)ethyl][(4,5-dimethyl-1H-pyrrol-2-yl)methyl]amino}-2,3-dihydro-1H-inden-5-yl)-N-hydroxyacrylamide
751	(2E)-3-(1-{[(4,5-dimethyl-1H-pyrrol-2-yl)methyl][2-(6-methyl-1H-indol-3-yl)ethyl]amino}-2,3-dihydro-1H-inden-5-yl)-N-hydroxyacrylamide
752	(2E)-3-(1-{[(4,5-dimethyl-1H-pyrrol-2-yl)methyl][2-(6-methoxy-1H-indol-3-yl)ethyl]amino}-2,3-dihydro-1H-inden-5-yl)-N-hydroxyacrylamide
753	(2E)-3-(1-{[(4,5-dimethyl-1H-pyrrol-2-yl)methyl][2-(1-methyl-1H-indol-3-yl)ethyl]amino}-2,3-dihydro-1H-inden-5-yl)-N-hydroxyacrylamide
754	(2E)-3-(1-{[(4,5-dichloro-1H-pyrrol-2-yl)methyl][2-(1H-indol-3-yl)ethyl]amino}-2,3-dihydro-1H-inden-5-yl)-N-hydroxyacrylamide
755	(2E)-3-(1-{[(4,5-dichloro-1H-pyrrol-2-yl)methyl][2-(6-fluoro-1H-indol-3-yl)ethyl]amino}-2,3-dihydro-1H-inden-5-yl)-N-hydroxyacrylamide
756	(2E)-3-(1-{[2-(6-chloro-1H-indol-3-yl)ethyl][(4,5-dichloro-1H-pyrrol-2-yl)methyl]amino}-2,3-dihydro-1H-inden-5-yl)-N-hydroxyacrylamide
757	(2E)-3-(1-{[(4,5-dichloro-1H-pyrrol-2-yl)methyl][2-(6-methyl-1H-indol-3-yl)ethyl]amino}-2,3-dihydro-1H-inden-5-yl)-N-hydroxyacrylamide
758	(2E)-3-(1-{[(4,5-dichloro-1H-pyrrol-2-yl)methyl][2-(6-methoxy-1H-indol-3-yl)ethyl]amino}-2,3-dihydro-1H-inden-5-yl)-N-hydroxyacrylamide
759	(2E)-3-(1-{[(4,5-dichloro-1H-pyrrol-2-yl)methyl][2-(1-methyl-1H-indol-3-yl)ethyl]amino}-2,3-dihydro-1H-inden-5-yl)-N-hydroxyacrylamide
760	(2E)-3-(1-{[(3,5-dimethyl-1H-pyrrol-2-yl)methyl][2-(1H-indol-3-yl)ethyl]amino}-2,3-dihydro-1H-inden-5-yl)-N-hydroxyacrylamide
761	(2E)-3-(1-{[(3,5-dimethyl-1H-pyrrol-2-yl)methyl][2-(6-fluoro-1H-indol-3-yl)ethyl]amino}-2,3-dihydro-1H-inden-5-yl)-N-hydroxyacrylamide
762	(2E)-3-(1-{[2-(6-chloro-1H-indol-3-yl)ethyl][(3,5-dimethyl-1H-pyrrol-2-yl)methyl]amino}-2,3-dihydro-1H-inden-5-yl)-N-hydroxyacrylamide
763	(2E)-3-(1-{[(3,5-dimethyl-1H-pyrrol-2-yl)methyl][2-(6-methyl-1H-indol-3-yl)ethyl]amino}-2,3-dihydro-1H-inden-5-yl)-N-hydroxyacrylamide
764	(2E)-3-(1-{[(3,5-dimethyl-1H-pyrrol-2-yl)methyl][2-(6-methoxy-1H-indol-3-yl)ethyl]amino}-2,3-dihydro-1H-inden-5-yl)-N-hydroxyacrylamide
765	(2E)-3-(1-{[(3,5-dimethyl-1H-pyrrol-2-yl)methyl][2-(1-methyl-1H-indol-3-yl)ethyl]amino}-2,3-dihydro-1H-inden-5-yl)-N-hydroxyacrylamide
766	4-[([2-(6-fluoro-1H-indol-3-yl)ethyl]{5-[(1E)-3-(hydroxyamino)-3-oxoprop-1-en-1-yl]-2,3-dihydro-1H-inden-1-yl}amino)sulfonyl]benzoic acid
767	4-[([2-(6-chloro-1H-indol-3-yl)ethyl]{5-[(1E)-3-(hydroxyamino)-3-oxoprop-1-en-1-yl]-2,3-dihydro-1H-inden-1-yl}amino)sulfonyl]benzoic acid

Compound Example	IUPAC Name
768	4-({{5-[(1E)-3-(hydroxyamino)-3-oxoprop-1-en-1-yl]-2,3-dihydro-1H-inden-1-yl}[2-(6-methyl-1H-indol-3-yl)ethyl]amino}sulfonyl)benzoic acid
769	4-({{5-[(1E)-3-(hydroxyamino)-3-oxoprop-1-en-1-yl]-2,3-dihydro-1H-inden-1-yl}[2-(6-methoxy-1H-indol-3-yl)ethyl]amino}sulfonyl)benzoic acid
770	4-({{5-[(1E)-3-(hydroxyamino)-3-oxoprop-1-en-1-yl]-2,3-dihydro-1H-inden-1-yl}[2-(1-methyl-1H-indol-3-yl)ethyl]amino}sulfonyl)benzoic acid
771	4-({{5-[(1E)-3-(hydroxyamino)-3-oxoprop-1-en-1-yl]-2,3-dihydro-1H-inden-1-yl}[2-(1H-indol-3-yl)ethyl]amino}sulfonyl)benzoic acid
772	4-({{5-[(1E)-3-(hydroxyamino)-3-oxoprop-1-en-1-yl]-2,3-dihydro-1H-inden-1-yl}[2-(1H-indol-3-yl)ethyl]amino}methyl)-N-methyl-1H-pyrazole-5-carboxamide
773	4-[([2-(6-fluoro-1H-indol-3-yl)ethyl]{5-[(1E)-3-(hydroxyamino)-3-oxoprop-1-en-1-yl]-2,3-dihydro-1H-inden-1-yl}amino)methyl]-N-methyl-1H-pyrazole-5-carboxamide
774	4-[([2-(6-chloro-1H-indol-3-yl)ethyl]{5-[(1E)-3-(hydroxyamino)-3-oxoprop-1-en-1-yl]-2,3-dihydro-1H-inden-1-yl}amino)methyl]-N-methyl-1H-pyrazole-5-carboxamide
775	4-({{5-[(1E)-3-(hydroxyamino)-3-oxoprop-1-en-1-yl]-2,3-dihydro-1H-inden-1-yl}[2-(6-methyl-1H-indol-3-yl)ethyl]amino}methyl)-N-methyl-1H-pyrazole-5-carboxamide
776	4-({{5-[(1E)-3-(hydroxyamino)-3-oxoprop-1-en-1-yl]-2,3-dihydro-1H-inden-1-yl}[2-(6-methoxy-1H-indol-3-yl)ethyl]amino}methyl)-N-methyl-1H-pyrazole-5-carboxamide
777	4-({{5-[(1E)-3-(hydroxyamino)-3-oxoprop-1-en-1-yl]-2,3-dihydro-1H-inden-1-yl}[2-(1-methyl-1H-indol-3-yl)ethyl]amino}methyl)-N-methyl-1H-pyrazole-5-carboxamide
778	(2E)-N-hydroxy-3-[1-([2-(1H-indol-3-yl)ethyl]{[5-(morpholin-4-ylcarbonyl)-1H-pyrazol-4-yl]methyl}amino)-2,3-dihydro-1H-inden-5-yl]acrylamide
779	(2E)-3-[1-([2-(6-fluoro-1H-indol-3-yl)ethyl]{[5-(morpholin-4-ylcarbonyl)-1H-pyrazol-4-yl]methyl}amino)-2,3-dihydro-1H-inden-5-yl]-N-hydroxyacrylamide
780	(2E)-3-[1-([2-(6-chloro-1H-indol-3-yl)ethyl]{[5-(morpholin-4-ylcarbonyl)-1H-pyrazol-4-yl]methyl}amino)-2,3-dihydro-1H-inden-5-yl]-N-hydroxyacrylamide
781	(2E)-N-hydroxy-3-[1-([2-(6-methyl-1H-indol-3-yl)ethyl]{[5-(morpholin-4-ylcarbonyl)-1H-pyrazol-4-yl]methyl}amino)-2,3-dihydro-1H-inden-5-yl]acrylamide
782	(2E)-N-hydroxy-3-[1-([2-(6-methoxy-1H-indol-3-yl)ethyl]{[5-(morpholin-4-ylcarbonyl)-1H-pyrazol-4-yl]methyl}amino)-2,3-dihydro-1H-inden-5-yl]acrylamide
783	(2E)-N-hydroxy-3-[1-([2-(1-methyl-1H-indol-3-yl)ethyl]{[5-(morpholin-4-ylcarbonyl)-1H-pyrazol-4-yl]methyl}amino)-2,3-dihydro-1H-inden-5-yl]acrylamide
784	N-{5-[(1E)-3-(hydroxyamino)-3-oxoprop-1-en-1-yl]-2,3-dihydro-1H-inden-1-yl}-N-[2-(1H-indol-3-yl)ethyl]-1H-pyrrole-2-carboxamide

Compound Example	IUPAC Name
785	N-{5-[(1E)-3-(hydroxyamino)-3-oxoprop-1-en-1-yl]-2,3-dihydro-1H-inden-1-yl}-N-[2-(1H-indol-3-yl)ethyl]-5-methyl-1H-pyrrole-2-carboxamide
786	N-{5-[(1E)-3-(hydroxyamino)-3-oxoprop-1-en-1-yl]-2,3-dihydro-1H-inden-1-yl}-N-[2-(1H-indol-3-yl)ethyl]-1H-imidazole-2-carboxamide
787	N-{5-[(1E)-3-(hydroxyamino)-3-oxoprop-1-en-1-yl]-2,3-dihydro-1H-inden-1-yl}-N-[2-(1H-indol-3-yl)ethyl]-2-furamide
788	N-{5-[(1E)-3-(hydroxyamino)-3-oxoprop-1-en-1-yl]-2,3-dihydro-1H-inden-1-yl}-N-[2-(1H-indol-3-yl)ethyl]thiophene-2-carboxamide
789	(2E)-3-(1-{[(4-acetyl-1H-pyrrol-2-yl)methyl][2-(1H-indol-3-yl)ethyl]amino}-2,3-dihydro-1H-inden-5-yl)-N-hydroxyacrylamide
790	(2E)-N-hydroxy-3-(1-{[2-(6-methoxy-1H-indol-3-yl)ethyl][(2-methyl-1H-pyrrol-3-yl)methyl]amino}-2,3-dihydro-1H-inden-5-yl)acrylamide
791	(2E)-N-hydroxy-3-{1-[[2-(6-methoxy-1H-indol-3-yl)ethyl](1H-pyrrol-3-ylmethyl)amino]-2,3-dihydro-1H-inden-5-yl}acrylamide
792	(2E)-3-(1-{[(4-ethyl-1H-pyrrol-3-yl)methyl][2-(6-methoxy-1H-indol-3-yl)ethyl]amino}-2,3-dihydro-1H-inden-5-yl)-N-hydroxyacrylamide
793	(2E)-3-(1-{[(5-ethyl-1H-pyrrol-3-yl)methyl][2-(6-methoxy-1H-indol-3-yl)ethyl]amino}-2,3-dihydro-1H-inden-5-yl)-N-hydroxyacrylamide
794	(2E)-3-(1-{[(2,4-dimethyl-1H-pyrrol-3-yl)methyl][2-(6-methoxy-1H-indol-3-yl)ethyl]amino}-2,3-dihydro-1H-inden-5-yl)-N-hydroxyacrylamide
795	(2E)-3-(1-{[(2,5-dimethyl-1H-pyrrol-3-yl)methyl][2-(6-methoxy-1H-indol-3-yl)ethyl]amino}-2,3-dihydro-1H-inden-5-yl)-N-hydroxyacrylamide
796	(2E)-3-(1-{[2-(6-fluoro-1H-indol-3-yl)ethyl]amino}-2,3-dihydro-1H-inden-5-yl)-N-hydroxyacrylamide
797	(2E)-3-(1-{[2-(6-fluoro-1H-indol-3-yl)ethyl]amino}-2,3-dihydro-1H-inden-5-yl)-N-hydroxyacrylamide
798	(2E)-3-(1-{[2-(6-chloro-1H-indol-3-yl)ethyl]amino}-2,3-dihydro-1H-inden-5-yl)-N-hydroxyacrylamide
799	(2E)-3-(1-{[2-(6-chloro-1H-indol-3-yl)ethyl]amino}-2,3-dihydro-1H-inden-5-yl)-N-hydroxyacrylamide
800	(2E)-N-hydroxy-3-(1-{[2-(6-methyl-1H-indol-3-yl)ethyl]amino}-2,3-dihydro-1H-inden-5-yl)acrylamide
801	(2E)-N-hydroxy-3-(1-{[2-(6-methyl-1H-indol-3-yl)ethyl]amino}-2,3-dihydro-1H-inden-5-yl)acrylamide
802	(2E)-N-hydroxy-3-(1-{[2-(1-methyl-1H-indol-3-yl)ethyl]amino}-2,3-dihydro-1H-inden-5-yl)acrylamide
803	(2E)-N-hydroxy-3-(1-{[2-(1-methyl-1H-indol-3-yl)ethyl]amino}-2,3-dihydro-1H-inden-5-yl)acrylamide
804	(2E)-3-(1-{ethyl[2-(6-fluoro-1H-indol-3-yl)ethyl]amino}-2,3-dihydro-1H-inden-5-yl)-N-hydroxyacrylamide

Compound Example	IUPAC Name
805	(2E)-3-(1-{ethyl[2-(6-fluoro-1H-indol-3-yl)ethyl]amino}-2,3-dihydro-1H-inden-5-yl)-N-hydroxyacrylamide
806	(2E)-3-(1-{ethyl[2-(6-fluoro-1H-indol-3-yl)ethyl]amino}-2,3-dihydro-1H-inden-5-yl)-N-hydroxyacrylamide
807	(2E)-N-hydroxy-3-(1-{[2-(5-methoxy-1H-indol-1-yl)ethyl]amino}-2,3-dihydro-1H-inden-5-yl)acrylamide
808	(2E)-N-hydroxy-3-(1-{[2-(5-methoxy-1H-indol-1-yl)ethyl]amino}-2,3-dihydro-1H-inden-5-yl)acrylamide

The compounds of this invention may contain one or more asymmetric centers, depending upon the location and nature of the various substituents desired. Asymmetric carbon atoms may be present in the (*R*) or (*S*) configuration. In certain instances, asymmetry may also be present due to restricted rotation about a given bond, for example, the central bond adjoining two substituted aromatic rings of the specified compounds. Substituents on a ring may also be present in either cis or trans form, and a substituent on a double bond may be present in either =*Z*- or =*E*- form. It is intended that all such configurations (including enantiomers and diastereomers) are included within the scope of the present invention. Preferred compounds are those with the absolute configuration of the compound of this invention which produces the more desirable biological activity. Separated, pure or partially purified isomers or racemic mixtures of the compounds of this invention are also included within the scope of the present invention. The purification of said isomers and the separation of said isomeric mixtures can be accomplished by standard techniques known in the art.

For the compounds containing one or more asymmetric centers, (±), (+), or (-) is used to describe the racemic mixture, the enantiomer with the positive optical rotation, or the negative rotation, respectively. In the absence of any (+) or (-) sign before a structure or a chemical name, the compound described is a racemic mixture with the relative stereochemistry shown. The exceptions are examples 1, 7, 16, 40, 41, 42, and 128 and their corresponding chiral intermediates. The absolute stereochemistry is depicted by the structures and/or IUPAC names.

Pharmaceutically acceptable salts of these compounds are also within the scope of this invention. The term "pharmaceutically acceptable salt" refers to a relatively non-toxic, inorganic or organic salt of a compound of the present invention. For example, see S. M. Berge, *et al.* "Pharmaceutical Salts," J. Pharm. Sci., 66: 1-19, 1977.

Representative salts of the compounds of this invention include the conventional non-toxic salts and the quaternary ammonium salts that are formed, for example, from inorganic or organic acids or bases by means well known in the art. For example, such acid addition salts include acetate, adipate, alginate, ascorbate, aspartate, benzoate, benzenesulfonate, bisulfate, butyrate, citrate, camphorate, camphorsulfonate, cinnamate, cyclopentanepropionate, digluconate, dodecylsulfate, ethanesulfonate, fumarate, glucoheptanoate, glycerophosphate, hemisulfate, heptanoate, hexanoate, hydrochloride, hydrobromide, hydroiodide, 2-hydroxyethanesulfonate, itaconate, lactate, maleate, mandelate, methanesulfonate, 2-naphthalenesulfonate, nicotinate, nitrate, oxalate, pamoate, pectinate, persulfate, 3-phenylpropionate, picrate, pivalate, propionate, succinate, sulfonate, tartrate, thiocyanate, tosylate, and undecanoate.

Base salts include alkali metal salts such as potassium and sodium salts, alkaline earth metal salts such as calcium and magnesium salts, and ammonium salts with organic bases such as dicyclohexylamine and *N*-methyl-D-glucamine. Additionally, basic nitrogen containing groups may be quaternized with such agents as lower alkyl halides such as methyl, ethyl, propyl, and butyl chlorides, bromides and iodides; dialkyl sulfates like dimethyl, diethyl, and dibutyl sulfate; and diamyl sulfates, long chain halides such as decyl, lauryl, myristyl and strearyl chlorides, bromides and iodides, aralkyl halides like benzyl and phenethyl bromides and others.

Pro-drugs of the present invention

It is anticipated that pro-drug forms of the compounds identified above will prove useful in certain circumstances, and such compounds are also intended to fall within the scope of the invention. A pro-drug, for the purpose of this invention, is a compound that is converted into its parent compound by one or more metabolic processes within a patient's body. Such conversion processes include the major drug biotransformation reactions described in *Goodman and Gilman's The Pharmacological Basis of Therapeutics* (Ninth Edition), editor Molinoff *et al.*, publ. by McGraw-Hill, pages 11-13, (1996), which is hereby incorporated by reference, including, but not by way of limitation, hydrolysis in the stomach, gut or plasma.

A pro-drug compound may have advantages over its parent compound in that it may be better absorbed, better distributed, and/or it may more readily penetrate the central nervous system, be more slowly metabolized or cleared, and the like. Pro-drug forms may also have formulation advantages in terms of crystallinity or water solubility. Accordingly, a pro-drug of this invention may have a chemical structure that enhances the properties of the parent compound into which it may be metabolized. Additional examples of such enhanced

properties include those described in, for example, *"Pharmaceutical Dosage Form and Drug Delivery Systems"* (Sixth Edition), edited by Ansel *et al.*, publ. by Williams & Wilkins, pgs. 27-29, **(1995)**, which is incorporated herein by reference.

Examples of pro-drugs include parent compounds identified in the Tables above that have one or more hydroxyl groups where the hydroxyl groups on these compounds are converted to ester or carbonate groups. Such esters include alkyl esters such as methyl, ethyl, propyl, isopropyl, butyl, isobutyl, pentyl and alkyl-phenyl esters, and the like. Specific examples of esters include acetate and benzoate. Examples of the carbonates of the compounds of this invention include pharmaceutically acceptable carbonates such as methyl, ethyl, propyl, isopropyl, butyl, isobutyl or pentyl carbonate. Specific examples of carbonates include *O*-C(=O)-CH_2CH_3 (ethyl carbonate) and *O*-C(=O)-$CH(CH_3)_2$ (isopropyl carbonate).

These ester or carbonate group(s) may be hydrolyzed at physiological pH values, may be cleaved by endogenous esterases or lipases, or otherwise may be cleaved *in vivo* to release the parent compound as the active material for treating hyper-proliferative disorders. (*See, e.g.,* U.S. Patent No. 4,942,184, U.S. Patent No. 4,960,790, U.S. Patent No. 5,817,840, and U.S. Patent No. 5824701, all of which are incorporated herein by reference in their entirety, including references therein.)

Unless the context clearly indicates to the contrary, whenever the term "compounds of this invention," "compounds of the present invention", and the like, are used herein, they are intended to include the chemically feasible pharmaceutically acceptable salts and/or esters as well as all stereoisomeric forms of the referenced compounds.

Method of making the compounds of the present invention

In general, the compounds used in this invention may be prepared by standard techniques known in the art, by known processes analogous thereto, and/or by the processes described herein, using starting materials which are either commercially available or producible according to routine, conventional chemical methods. The particular process to be utilized in the preparation of the compounds of this invention depends upon the specific compound desired. Such factors as whether the amine is substituted or not, the selection of the specific substituents possible at various locations on the molecule, and the like, each play a role in the path to be followed in the preparation of the specific compounds of this invention. Those factors are readily recognized by one of ordinary skill in the art.

The following preparative methods are presented to aid the reader in the synthesis of the compounds of the present invention.

Abbreviations and Acronyms

When the following abbreviations and symbols are used herein, they have the following meaning:

$[\alpha]_D$	optical rotation
AcOH	acetic acid
Boc	*tert*-butylcarboxy
DIBAL	diisobutylaluminum hydride
DMAP	4-dimethylaminopyridine
DMF	*N,N*-dimethylformamide
DIPEA	diisopropylethylamine
DMSO	dimethylsulfoxide
DPPP	bis(diphenylphosphino)propane
EA	elemental analysis
ES	electrospray
Et_3N	triethylamine
Et_2O	diethyl ether
EtOAc	ethyl acetate
GC-MS	Gas chromatography -mass spectrometry
h	hour
Hex	Hexanes
HPLC	high performance liquid chromatography
iPrOH	2-propanol
LC-MS	Liquid Chromatography/Mass Spectrometry
Me	methyl
MeOH	methanol
min	minutes
$NaBH(OAc)_3$	sodium triacetoxyborohydride
NMR	Nuclear Magnetic Resonance Spectroscopy

OTBDMS	*tert*-butyl(dimethyl)silyloxy
OMe	methoxy
$Pd(OAc)_2$	palladium (II) acetate
PyBOP	Bromotripyrrolidinophosphonium hexafluorophosphate
R_f	TLC Retention Factor
RT	retention time (HPLC)
rt	room temperature
TBDMS	*tert*-butyldimethylsilyl
THF	tetrahydrofuran
TLC	thin layer chromatography

Experimental Procedures:

LC-MS methods

Method A:

HPLC - electrospray mass spectra (HPLC ES-MS) were obtained using a Hewlett-Packard 1100 HPLC equipped with a quaternary pump, a variable wavelength detector set at 254 nm, a YMC pro C-18 column (2 x 23 mm, 120A), and a Finnigan LCQ ion trap mass spectrometer with electrospray ionization. Spectra were scanned from 120-1200 amu using a variable ion time according to the number of ions in the source. The eluents were A: 2% acetonitrile in water with 0.02% TFA and B: 2% water in acetonirile with 0.018% TFA. Gradient elution from 10% B to 95% over 3.5 minutes at a flowrate of 1.0 mL/min was used with an initial hold of 0.5 minutes and a final hold at 95% B of 0.5 minutes. Total run time was 6.5 minutes.

Method B:

HPLC - electrospray mass spectra (HPLC ES-MS) were obtained using a Gilson HPLC system equipped with two Gilson 306 pumps, a Gilson 215 Autosampler, a Gilson diode array detector, a YMC Pro C-18 column (2 x 23mm, 120 A), and a Micromass LCZ single quadrupole mass spectrometer with z-spray electrospray ionization. Spectra were scanned from 120-800 amu over 1.5 seconds. ELSD (Evaporative Light Scattering Detector) data was also acquired as an analog channel. The eluents were A: 2% acetonitrile in water with 0.02% TFA and B: 2% water in acetonirile with 0.018% TFA. Gradient elution from 10% B to 90% over 3.5 minutes at a flowrate of 1.5 mL/min was used

with an initial hold of 0.5 minutes and a final hold at 90% B of 0.5 minutes. Total run time was 4.8 minutes.

NMR methods

Proton (^{1}H) nuclear magnetic resonance (NMR) spectra were measured with a Varian Mercury (300 MHz) or a Bruker Avance (500 MHz) spectrometer with either Me_4Si (δ 0.00) or residual protonated solvent ($CHCl_3$ δ 7.26; MeOH δ 3.30; DMSO δ 2.49) as standard. The NMR data of the synthesized examples, some of which are not disclosed in the following detailed charaterizations, are in agreements with their corresponding structural assignments.

Optical rotation

Optical rotations of the purified enantiomers were measured with a Perkin-Elmer 241 polarimeter under the Na D line at room temperature. [α]D was calculated and presented with the solvent and concentration used (g/100 mL).

Elemental analyses were conducted by Robertson Microlit Labs, Madison NJ. The results of elemental analyses, if conducted but not disclosed in the following detailed charaterizations, are in agreements with their corresponding structural assignments.

The general synthesis of a compound of this invention is described below in Flow Diagrams I –X. This illustration of the synthesis of indane derived compounds could be applied to the synthesis of tetrahydronaphthalene derived compounds as well by substituting appropriate starting materials. The starting materials and/or intermediates are either commercially available or are prepared in similar manners as described in the literature procedures or the procedures described in the specific examples.

The right-hand portion of the compounds of Formula (I), the optionally substituted phenyl propenoate moiety, may be constructed by forming connection A or connection B, described further below. The left-hand portion may be constructed by forming connection C or connection D. These connections are followed by hydroxamic acid formation.



(I)

It should be apparent to those skilled in the art that the sequence of the synthetic steps is dependent on starting material availability and functional group compatibility and could vary from compound to compound (see, e.g., Table I, "Synthetic sequence" column for examples of the sequence of steps followed to provide the specific Compound Example). Protection and deprotection reactions could be involved in addition to the following reactions, as would be obvious to one skilled in the art. The groups and terms R^1, R^2, R^3, R^{12}, m, L, and W used below are as defined previously unless specified otherwise.

Connection A

Connection A is the coupling of the optionally substituted indane portion of the molecule to the optionally substituted propenoate portion of the molecule. It can be formed by using metal-mediated cross-coupling reactions such as Heck Reaction as illustrated in Flow Diagram I.

Flow Diagram I



Y = Br, I, OTf, N_2^+, Cl
R^3 = H, or $(C_1$-$C_3)$alkyl
R = methyl or ethyl

Alternatively, Connection A can be formed via the intermediate propynoate followed by halogenation of the propynoate as illustrated in Flow Diagram II.

Flow Diagram II



Y = Br, I, OTf, N_2^+, Cl
R^3 = halo
R = methyl or ethyl

Connection B

Connection B is the coupling of the optionally substituted indane aldehyde or ketone to the acetate portion of the molecule. It can be formed by using olefination reaction such as Wittig reaction or Horner-Emmons reaction as illustrated in Flow Diagram III.

Flow Diagram III



R^3 = H or (C_1-C_3)alkyl
R = methyl or ethyl

Connection C

Connection C is the coupling of the optionally substituted indanone to the optionally substituted amine. It can be formed via the reductive amination of optionally substituted indanones or a sequential reduction and displacement as illustrated in Flow Diagram IV. The optionally substituted amines are either commercially available or are prepared in similar manners as described in the specific procedures listed below or the literature procedures (for example, Journal of Organic Chemistry (2003), 68(12), 4938-4940.)

Flow Diagram IV



U = leaving groups such as OMs, OTs, Cl, Br

Connection D

Connection D is the coupling of the optionally substituted aminoindane to the optionally substituted alkyl groups. It can be formed via either the reductive amination or *N*-alkylation as illustrated in Flow Diagram V.

Flow Diagram V



Z = leaving group such as Br, I, OTs

Hydroxamic acid formation

Hydroxamic acids could be formed via several pathways as illustrated in Flow Diagram VI.

Flow Diagram VI



PG = protecting group such as TBDMS, THP

Further manipulations

If the following functional groups are present in the molecule, the transformations listed in Flow Diagram VII could be conducted.

Flow Diagram VII



When R^1 is (C_1-C_6)alkyl optionally substituted with optionally substituted phenyl, optionally substituted pyrrolyl, optionally substituted pyrazolyl, or optionally substituted another heteroaryl, R^1 is often attached to its linked N atom via a reductive amination reaction between an aldehyde and optionally substituted amino-indane (Flow Diagram VIII).

The aldehydes are either commercially available or are prepared in similar manners as described in the literature procedures [for example, Canadian Journal of Chemistry (1990), 68(5), 791-4; Canadian Journal of Chemistry (1995), 73(5), 675-84; Tetrahedron (2001), 57(15), 3063-3067. Canadian Journal of Chemistry (1978), 56(5), 654-7; Canadian Journal of Chemistry (1981), 59(17), 2673-6; Tetrahedron Letters (2002), 43(20), 3673-3675; Canadian Journal of Chemistry (1980), 58(23), 2527-30; Bioorganic & Medicinal Chemistry Letters (1994), 4(21), 2627-30; Chemicke Zvesti (1983), 37(2), 251-62.], the general synthetic sequence shown in Flow Diagram IX and X, or the specific procedures below. For the purpose of clear illustration, only the 1,4-substitution pattern is shown in Flow Diagrams IX and X. However, the synthetic sequence can be applied to 1, 2- or 1, 3-substitution pattern as well.

Flow Diagram VIII



Flow Diagram IX



Flow Diagram X



R^a = H or (C1-C3) alkyl
R^c = H or (C1-C3) alkyl
R = H, methyl or ethyl
R'= methyl or ethyl

The following specific examples are presented to illustrate the invention, but they should not be construed as limiting the scope of the invention in any way. In the tables listing the intermediates, those compounds that have characterization data such as HPLC retention time, M+H mass spectroscopy data, TLC R_f value, or NMR data listed were actually synthesized. Those that do not have characterization data were not synthesized; however, they can be synthesized by following procedures that are well known to those skilled in the art and/or procedures that are disclosed in this application.

Experimental Examples of the Invention

Intermediate A

tert-Butyl 3-(2-bromoethyl)-1*H*-indole-1-carboxylate



Ethyl 1*H*-indol-3-ylacetate (2.5 g, 12.3 mmol) was dissolved in THF (60 mL) and to the resulting solution was added Di-tert-butyl carbonate (2.9 g, 16.6 mmol), Et_3N (1.89 mL), and DMAP (150 mg, 1.23 mmol). The reaction was stirred for 16 h at rt. The solvent was removed under vacuum and the residue was re-dissolved in Et_2O and saturated $NaHCO_3$ was added and the mixture was stirred vigorously for 30 min. The organic phase was collected, and dried over Na_2SO_4. The solvent was removed by vacuum. The crude product was purified further by passing it through a plug of silica using Et_2O as eluent. The solvent was removed under vacuum to give tert-butyl 3-(2-ethoxy-2-oxoethyl)-1*H*-indole-1-carboxylate as an oil (3.73 g, 99%): ^1H NMR ($CDCl_3$) δ 8.14 (m, 1H), 7.54 (m, 2H), 7.32 (m, 1H), 7.24 (m, 2H), 4.19 (q, 2H), 3.71 (s, 1H), 1.68 (s, 9H), 1.29 (t, 3H).

The following intermediate compounds are synthesized in a similar manner:

Inter-mediate	Structure	^{1}H NMR
A1		($CDCl_3$) δ 8.14 (m, 1H), 7.55 (m, 2H), 7.22-7.34 (m, 2H), 4.19 (q, 2H), 3.72 (s, 2H), 1.68 (s, 9H), 1.29 (t, 3H)
A2		(CD_2Cl_2) δ 8.10 (m, 1H), 7.34 (m, 2H), 7.29 (m, 3H), 7.21 (m, 1H), 7.08 (m, 1H), 3.08 (m, 6H), 2.92 (m, 3H), 1.67 (s, 9H), 1.46 (br s, 9H).
A3		HPLC RT: 3.87 (A) M+H: 460.9

Intermediate B

tert-Butyl 3-(2-oxoethyl)-1*H*-indole-1-carboxylate



Intermediate A1 (*tert*-Butyl 3-(2-ethoxy-2-oxoethyl)-1*H*-indole-1-carboxylate) (1.5 g. 4.94 mmol) was dissolved in THF(30 mL) and the resulting mixture was cooled to -78°C. DIBAL (1M in Hex, 738 mg, 5.19 mmol) was added dropwise to the solution. No reaction occurred after the addition of the first equivalent of DIBAL was added. More DIBAL was added (1107 mg, 7.79 mmol) to the reaction. The reaction was then quenched with MeOH at -78°C to limit alcohol formation even though there was still starting material. A saturated

solution of Rochelle's salt (sodium potassium tartrate) was added to the reaction. This mixture was extracted with EtOAc. The organic layer was collected and dried over Na_2SO_4. The solvent was then removed under vacuum. The crude product was purified by silica gel chromatography using 5-10 % EtOAc in Hex as eluent to give tert-butyl 3-(2-oxoethyl)-1*H*-indole-1-carboxylate as an oil (215 mg, 17% yield): ^{1}H-NMR δ (CD_2Cl_2) 9.78 (m, 1H), 8.18 (m, 1H), 7.61 (m, 1H), 7.47 (m, 1H), 7.37 (m, 1H), 7.27 (m, 1H), 3.80 (m, 2H), 1.70 (m, 9H).

Intermediate C

5-Bromo-2,3-dihydro-1*H*-inden-2-ylamine hydrochloride



2-Aminoindane hydrochloride (4.12 g, 24.3 mmol) and water (40 mL) were mixed and the resulting mixture was heated to 60°C. Bromine (4.07 g, 25.5 mmol) was added dropwise over 45 min and the reaction mixture was stirred for an additional hour before it was cooled in an ice-bath. The solid formed was filtered and washed with water, Et_2O, and then dried under vacuum to give 5-bromo-2-indane as the hydrochloride salt (3.8 g, 63%). ^{1}H-NMR: (DMSO-d6) δ 8.08 (br s, 3H), 7.49 (m, 1H), 7.36 (m, 1H), 7.23 (d, 1H), 4.00 (br s, 1H), 3.25 (m, 2H), 2.92 (m, 2H).

Intermediate D

Methyl (2*E*)-3-(1-oxo-2,3-dihydro-1*H*-inden-5-yl)-2-propenoate



To a solution of 5-bromo-1-indanone (1.50 g, 71.0 mmol) in CH_3CN (45 mL) and Et_3N (45 mL) was added $Pd(OAc)_2$ (0.957 g, 4.2 mmol), PPh_3 (2.793g, 10.7 mmol), methyl acrylate (16 mL, 177.7 mmol). The reaction mixture was heated to 85 °C under argon for 16 h. The mixture was cool to rt and the solvent was evaporated in vacuo. The resulting black residue was taken up in CH_2Cl_2 and filtered through Celite. The filtrate was washed with 2N HCl, saturated aqueous $NaHCO_3$, and brine. It was then dried over $MgSO_4$ and concentrated in vacuo. The resulting yellow crude solid was triturated with Et_2O to yield methyl (2*E*)-3-(1-oxo-2,3-dihydro-1*H*-inden-5-yl)-2-propenoate (13.23 g, 86%): TLC R_f=0.35 (25%EtOAc in Hex), ^{1}H-NMR (CD_2Cl_2) δ 7.72 (d, 1H), 7.7(s, 1H), 7.65 (s, 1H), 7.54-7.57(m, 1H), 6.5 (d, 1H), 3.80 (s, 3H), 3.16 (t, 2H) and 2.70 (t, 2H).

The following compounds are synthesized in a similar manner:

Inter-mediate	Structure	HPLC RT (min) (method)	M+H
D1		4.98 (A)	583.1 (+Na)
D2		3.06 (B)	505.6
D3		2.30 (B)	231.3
D4		2.31 (A)	379.0
D5		^{1}H-NMR (DMSO-*d6*) δ 7.79 (d, 1H), 7.35 (t, 1H), 7.13 (t, 1H), 6.95 (m, 4H), 6.51 (d, 1H), 4.58 (t, 1H), 3.79 (s, 3H), 2.99 (m, 1H), 2.77 (m, 2H), 2.62 (m, 5H),	

Inter-mediate	Structure	HPLC RT (min) (method)	M+H
		2.31 (s, 3H), 2.21 (m, 1H), 2.01 (m, 1H), 1.09 (t, 3H).	

Intermediate E

Methyl (2*E*)-3-(1-{[2-(1*H*-indol-3-yl)ethyl]amino}-2,3-dihydro-1*H*-inden-5-yl)-2-propenoate



A mixture of Intermediate D [methyl ((2*E*)-3-(1-oxo-2,3-dihydro-1*H*-inden-5-yl)-2-propenoate)] (1.00 g, 4.62 mmol), tryptamine (0.78 g, 4.86 mmol), toluenesulfonic acid (0.02 g, 0.14 mmol) and toluene (25 mL) in a 100 mL round bottle flask with a Dean-Stark condenser was heated to reflux for 3 h. The crude mixture was concentrated under vacuum to give a black residue. It was dissolved with dichloroethane (20 mL) and $NaBH(OAc)_3$ (0.98 g, 4.62 mmol) was added. The mixture was stirred overnight at rt. The reaction was quenched with saturated $NaHCO_3$ and extracted with CH_2Cl_2 twice. The combined organic layer was washed with brine and dried over Na_2SO_4. The solvent was evaporated to give the crude product as a dark residue. It was purified with 40 M Biotage eluting with MeOH (with 2M NH_3)/CH_2Cl_2 (5/95) to obtain methyl (2*E*)-3-(1-{[2-(1*H*-indol-3-yl)ethyl]amino}-2,3-dihydro-1*H*-inden-5-yl)-2-propenoate as a brown solid (0.68 g, 40 %): LC/MS [M+H] 361.0, RT 2.27 min (method A). ^{1}H-NMR (DMSO-*d6*) δ 10.76 (s, 1H), 7.63 (d, 1H), 7.56 (s, 1H), 7.49 (m, 2H), 7.34 (m, 2H), 7.13 (d,1H), 7.05 (m, 1H), 6.95 (m, 1H), 6.58 (d, 1H), 4.23 (t, 1H), 3.70 (s, 3H), 2.92 (m, 5H), 2.73 (m, 1H), 2.33 (m, 1H), 1.80 (m, 1H).

The following compounds are synthesized in a similar manner. For intermediates E4, E5, E6, and E7, a mixture of *n*-butanol and toluene is used as the solvent for the Schiff base formation.

Intermediate E is also formed in a similar manner as described in the synthesis of intermediate Q with the alternative work up as an HCl salt.

Inter-mediate	Structure	HPLC RT (min) (method)	M+H
E1[a, b]		2.11 (A)	391.0
E2[a, b]		2.13 (A)	391.0
E3[a]		2.12 (A)	391.0
E4		2.24 (A)	375.0
E5[a]		2.26 (A)	351.9
E6[a]		2.15 (A)	351.9
E7[a]		2.02 (A)	318.0

Inter-mediate	Structure	HPLC RT (min) (method)	M+H
E8		1.99 (A)	317.9

a. The absolute configuration of the indane chiral center is tentatively assigned based the facial selectivity observed by Stalker et al. in *Tetrahedron*, **2002**, *58*, 4837-4849.

b. E1 and E2 are formed in the same reaction and E2 is isolated as the minor isomer.

Intermediate F

5-Bromo-*N*-(2-{[tert-butyl(dimethyl)silyl]oxy}ethyl)-2-indanamine



Intermediate C (5- Bromo-2-indanamine) (226 mg, 1.07 mmol), {[tert-butyl(dimethyl)silyl]oxy} acetaldehyde (186 mg, 1.07 mmol) and dichloroethane (10 mL) was placed in a flask along with AcOH (73 uL, 1.28 mmol), followed by the immediate addition of $NaBH(OAc)_3$ (316 mg, 1.49 mmol). The mixture was stirred for 1h at rt. The reaction was quenched with saturated $NaHCO_3$, and extracted with CH_2Cl_2. The organic layer was collected and dried over Na_2SO_4. The solvent was removed under vacuum to give 5-bromo-*N*-(2-{[tert-butyl(dimethyl)silyl]oxy}ethyl)-2-indanamine as an oil (384 mg, 97%). It was used for further reactions without purification: ^{1}H-NMR (CD_2Cl_2) δ 7.26 (m, 1H), 7.17 (m, 1H), 6.99 (m, 1H), 3.64 (m, 2H), 3.56 (m, 1H), 3.04 (m, 2H), 2.57-2.70 (m, 4H), 0.83 (s, 9H), 0.01 (s, 6H).

The following compounds are synthesized in a similar manner.

Inter-mediate	Structure	HPLC RT (min) (method)	M+H
F1		3.56 (A)	613.1
F2		2.60 (A)	504.1
F3		3.64 (A)	480.1
F4		2.94 (A)	533.0
F5		2.08 (A)	441.1

Inter-mediate	Structure	HPLC RT (min) (method)	M+H
F6		2.30 (A)	389.1
F7		2.53 (A)	451.0
F8		2.69 (A)	457.2
F9		2.96 (A)	549.2
F10		3.52 (A)	353.1
F11		3.52 (A)	351.1

Inter-mediate	Structure	HPLC RT (min) (method)	M+H
F12		2.49 (A)	403.0
F13		2.86 (A)	433.2
F14		2.82 (A)	433.2
F15		2.19 (B)	421.2
F16		2.91 (A)	549.4

Inter-mediate	Structure	HPLC RT (min) (method)	M+H
F17		3.63 (A)	494.1
F18		3.63 (A)	494.1
F19		3.63 (A)	494.1
F20		3.02 (A)	480.1

Inter-mediate	Structure	HPLC RT (min) (method)	M+H
F21		3.24 (A)	528.1
F22		3.07 (A)	554.2
F23		3.04 (A)	524.2
F24		3.09 (A)	524.2
F25		3.03 (A)	524.2
F26		3.27 (A)	528.1

Inter-mediate	Structure	HPLC RT (min) (method)	M+H
F27		3.14 (A)	528.3
F28		3.02 (A)	540.1
F29		3.16 (A)	508.2
F30		3.00 (A)	540.1
F31		3.16 (A)	508.2

Inter-mediate	Structure	HPLC RT (min) (method)	M+H
F32		3.22 (A)	548.2
F33		3.03 (A)	498.1
F34		3.02 (A)	498.1
F35		3.01 (A)	498.1

Inter-mediate	Structure	HPLC RT (min) (method)	M+H
F36		3.18 (A)	548.1
F37		3.17 (A)	494.2
F38		2.73 (A)	534.7
F39		2.37 (A)	467.1
F40		2.59 (A)	469.0

Inter-mediate	Structure	HPLC RT (min) (method)	M+H
F41		2.50 (A)	467.0
F42		2.58 (A)	497.1
F43		2.50 (A)	417.2
F44		2.38 (A)	403.1
F45		2.62 (A)	465.1
F46		2.45 (A)	483.0

Inter-mediate	Structure	HPLC RT (min) (method)	M+H
F47		2.75 (A)	501.1
F48		2.53 (A)	483.1
F49		2.70 (A)	443.1
F50		2.71 (A)	481.1
F51		2.65 (A)	485.1
F52		2.55 (A)	417.1

Inter-mediate	Structure	HPLC RT (min) (method)	M+H
F53		2.64 (A)	445.2
F54		2.56 (A)	439.9
F55		2.43 (A)	415.1
F56		2.44 (A)	452.2
F57		2.64 (A)	455.1
F58		2.49 (A)	457.1

Inter-mediate	Structure	HPLC RT (min) (method)	M+H
F59		2.48 (A)	441.0
F60		2.02 (A)	455.2
F61		2.38 (A)	467.1
F62		2.63 (A)	465.1
F63		2.50 (A)	508.1
F64		2.33 (A)	454.1

Inter-mediate	Structure	HPLC RT (min) (method)	M+H
F65		2.69 (A)	481.0
F66		2.68 (A)	495.1
F67		2.61 (A)	458.0
F68		2.57 (A)	518.0
F69		2.53 (A)	511.1
F70		2.21 (A)	464.9
F71		2.66 (A)	441.1

Inter-mediate	Structure	HPLC RT (min) (method)	M+H
F72		2.34 (A)	484.0
F73		2.82 (A)	497.0
F74		2.23 (A)	455.1
F75		2.73 (A)	490.0
F76		2.19 (A)	566.2
F77		2.36 (A)	484.0

Inter-mediate	Structure	HPLC RT (min) (method)	M+H
F78		2.66 (A)	525.1
F79		2.51 (A)	481.1
F80		2.92 (A)	467.2
F81		2.73 (A)	534.7
F82		3.35 (A)	522.1

Inter-mediate	Structure	HPLC RT (min) (method)	M+H
F83		3.57 (A)	556.1
F84		3.70 (A)	535.0
F85		2.96 (A)	481.2
F86		2.42 (A)	481.5

Inter-mediate	Structure	HPLC RT (min) (method)	M+H
F87		2.96 (A)	467.3
F88		3.22 (A)	482.1
F89		2.88 (A)	456.1
F90		2.96 (A)	470.1

Inter-mediate	Structure	HPLC RT (min) (method)	M+H
F91		2.56 (A)	529.0
F92		2.71 (A)	465.0
F93		2.78 (A)	485.1
F94		2.12 (A)	522.0

Inter-mediate	Structure	HPLC RT (min) (method)	M+H
F95		2.02 (A)	508.0
F96		2.53 (A)	544.1
F97		2.55 (A)	558.1
F98		2.24 (A)	484.0

Inter-mediate	Structure	HPLC RT (min) (method)	M+H
F99		2.22 (A)	562.2
F100		3.39 (A)	519.0
F101		3.43 (A)	533.2
F102		3.06 (A)	549.2
F103		2.86 (A)	530.1

Inter-mediate	Structure	HPLC RT (min) (method)	M+H
F104		2.19 (A)	490.1
F105		2.58 (A)	490.1
F106		2.60 (A)	573.0
F107		1.69 (A)	537.1

Inter-mediate	Structure	HPLC RT (min) (method)	M+H
F108		2.79 (A)	494.1
F109		1.69 (A)	587.1
F110		1.99 (A)	511.1
F111		0.93 (A)	566.3
F112		1.36(A)	489.0

Inter-mediate	Structure	HPLC RT (min) (method)	M+H
F113		2.80 (A)	469.1
F114		2.96 (A)	556.9
F115		2.53 (A)	502.9
F116		1.12 (A)	483.1
F117		2.80 (A)	469.1

Inter-mediate	Structure	HPLC RT (min) (method)	M+H
F118		2.92 (A)	470.1
F119		2.35 (A)	458.9
F120		1.69 (A)	469.9
F121		1.14 (A)	419.1
F122		2.58 (A)	453.9
F123		2.26 (A)	469.1

Inter-mediate	Structure	HPLC RT (min) (method)	M+H
F124		1.10 (A)	544.0
F125		3.23 (A)	454.1
F126		1.14 (A)	419.1
F127		2.42 (A)	403.1
F128		2.68 (A)	453.9
F129		2.65 (A)	473.9

Inter-mediate	Structure	HPLC RT (min) (method)	M+H
F130		2.59 (A)	457.9
F131		2.31 (A)	600.4
F132		2.23 (A)	584.2
F133		2.20 (A)	580.3

Inter-mediate	Structure	HPLC RT (min) (method)	M+H
F134		2.14 (A)	596.3
F135		2.32 (A)	580.1
F136		2.56 (A)	483.0
F137		2.37 (A)	499.0

Inter-mediate	Structure	HPLC RT (min) (method)	M+H
F138		2.58 (A)	503.0
F139		2.44 (A)	487.1
F140		2.50 (A)	483.2
F141		3.08 (A)	533.2
F142		3.03 (A)	537.2

Inter-mediate	Structure	HPLC RT (min) (method)	M+H
F143		3.14 (A)	553.3
F144		2.96 (A)	504.1
F145		2.42 (A)	455.0
F146		2.80 (A)	473.1
F147		2.89 (A)	489.1

Inter-mediate	Structure	HPLC RT (min) (method)	M+H
F148		2.32 (A)	469.1
F149		2.87 (A)	469.1
F150		2.74 (A)	485.1
F151		2.43 (A)	487.0
F152		2.92 (A)	503.2

Inter-mediate	Structure	HPLC RT (min) (method)	M+H
F153		2.31 (A)	483.2
F154		2.78 (A)	499.1
F155		2.51 (A)	483.0
F156		2.52 (A)	483.0
F157		2.41 (A)	487.1

Inter-mediate	Structure	HPLC RT (min) (method)	M+H
F158		2.50 (A)	502.9
F159		2.28 (A)	483.2
F160		2.76 (A)	499.1
F161		2.49 (A)	469.0
F162		2.35 (A)	473.1

Inter-mediate	Structure	HPLC RT (min) (method)	M+H
F163		2.50 (A)	490.0
F164		2.45 (A)	469.0
F165		2.33 (A)	485.0
F166		2.38 (A)	455.0
F167		^{1}H-NMR (DMSO-*d6*) δ 7.37 (t, 1H), 7.10 (t, 1H), 6.92 (m, 3H), 6.76 (d, 1H), 4.49 (t, 1H), 2.90 (m, 1H),	

Inter-mediate	Structure	HPLC RT (min) (method)	M+H
		2.72 (m, 2H), 2.55 (m, 5H), 2.24 (s, 3H), 2.14 (m, 1H), 1.90 (m, 1H), 0.99 (t, 3H).	
F168		2.56 (A)	420.1
F169		2.48 (A)	403.1
F170		2.41 (A)	407.1
F171		2.88 (A)	551.2

Intermediate G

Methyl (2*E*)-3-(1-{(2-{[*tert*-butyl(dimethyl)silyl]oxy}ethyl)[2-(1*H*-indol-3-yl)ethyl]amino}-2,3-dihydro-1*H*-inden-5-yl)-2-propenoate



To a mixture of intermediate E (methyl (2*E*)-3-(1-{[2-(1*H*-indol-3-yl)ethyl]amino}-2,3-dihydro-1*H*-inden-5-yl)-2-propenoate) (0.49 g, 1.35 mmol), (2-bromoethoxy)-tert-butyldimethylsilane (0.65 g, 2.71 mmol) and *N*,*N*'-diisopropylethylamine (0.35 g, 2.71 mmol) in DMF (10 mL) was added a catalytic amount of KI. This mixture was heated at 80 °C overnight. The reaction was cooled to rt and quenched with water and extracted with CH_2Cl_2 twice. The combined organic layer was washed with water and dried over Na_2SO_4. The solvent was removed under vacuum to obtain the crude product. It was then purified with 25S Biotage eluting with 15 % EtOAc in hexanes to yield methyl (2*E*)-3-(1-{(2-{[tert-butyl(dimethyl)silyl]oxy}ethyl)[2-(1*H*-indol-3-yl)ethyl]amino}-2,3-dihydro-1*H*-inden-5-yl)-2-propenoate as a yellow oil (0.48 g, 67 %): LC/MS [M+H] 519.1, RT 2.90 min (method A); ^{1}H-NMR (CD_3OD) δ 7.67 (d, 1H), 7.40 (s, 1H), 7.33 (m, 4H), 7.03 (m, 2H), 6.89 (m, 1H), 6.47 (d, 1H), 4.65 (t, 1H), 3.76 (s, 3H), 3.63 (m, 2H), 2.90 (m, 6H), 2.64 (m, 2H), 2.24 (m, 1H), 2.02 (m, 1H), 0.85 (s, 9H), 0.00 (s, 6H).

The following compounds are synthesized in a similar manner. In the case of Intermediate G1, Intermediate A and C are used as starting materials. In the case of intermediate G5, G6, and G7, NaH is used as the base and intermediate G is used as the starting material. Intermediate G is also synthesized by a reductive amination reaction between intermediate E and {[tert-butyl(dimethyl)silyl]oxy} acetaldehyde.

Inter-mediate	Structure	HPLC RT (min) (method)	M+H

Inter-mediate	Structure	HPLC RT (min) (method)	M+H
G1		2.79 (A)	455.1
G2		2.99 (A)	533.1
G3		2.44 (A)	419.1
G4		2.74 (A)	475.1
G5		3.14 (A)	533.1
G6		3.28 (A)	547.2

Inter-mediate	Structure	HPLC RT (min) (method)	M+H
G7		3.81 (A)	677.3
G8		2.45 (B)	533.3
G9		2.22 (A)	474.2
G10			549.0
G11		2.26 (B)	547.3

Inter-mediate	Structure	HPLC RT (min) (method)	M+H
G12		1.11 (A)	449.1

Intermediates H1 and H2

Chiral separation of (±) (*E*)-3-(1-{(2-hydroxy-ethyl)-[2-(1*H*-indol-3-yl)-ethyl]-amino}-indan-5-yl)-acrylic acid methyl ester

Intermediate H1 Intermediate H2



Racemic Intermediate J (methyl (2*E*)-3-(1-{(2-hydroxyethyl)[2-(1*H*-indol-3-yl)ethyl]amino}-2,3-dihydro-1*H*-inden-5-yl)-2-propenoate) (0.31 g) was separated with ChiralPAK AD-H using 25-40 % iPrOH in hexane with 0.1 % Et_3N (flow rate = 15 mL/min, 250 uL/injection) to obtain first peak (RT = 18.73 min, 105 mg): $[\alpha]_D$ (MeOH) = +70.2 (c 1.0). Second peak (RT = 22.93 min, 103 mg): $[\alpha]_D$ (MeOH) = -67.9 (c 1.0). The overall recovery yield was 67 %.

Intermediates I1 and I2

Chiral separation of (±) (*E*)-3-{1-[2-(1*H*-indol-3-yl)-ethylamino]-indan-5-yl}-acrylic acid methyl ester

Intermediate I1 Intermediate I2



Racemic Intermediate E (methyl (2*E*)-3-(1-{[2-(1*H*-indol-3-yl)ethyl]amino}-2,3-dihydro-1*H*-inden-5-yl)-2-propenoate) (0.28 g) was separated with ChiralPAK AD-H using 20-28 % MeOH/EtOH (1/1) in hexane with 0.1 % Et_3N (flow rate = 15 mL/min, 250

uL/injection) to obtain the first peak (RT = 6.70 min, 100 mg) and the second peak (RT = 8.10 min, 85 mg). The overall recovery yield was 66 %.

Intermediate J

Methyl (2*E*)-3-(1-{(2-hydroxyethyl)[2-(1*H*-indol-3-yl)ethyl]amino}-2,3-dihydro-1*H*-inden-5-yl)-2-propenoate



To a solution of Intermediate G (methyl (2*E*)-3-(1-{(2-{[tert-butyl(dimethyl)silyl]oxy}ethyl)[2-(1*H*-indol-3-yl)ethyl]amino}-2,3-dihydro-1*H*-inden-5-yl)-2-propenoate) (1.74 g, 3.35 mmol) in MeOH (5 mL) was added 5 % TFA in water (15 mL). The mixture was stirred at 40 °C for 3 h. The reaction was quenched with saturated $NaHCO_3$ and extracted with EtOAc twice. The combined organic layer was washed with brine, dried over Na_2SO_4. The solvent was removed under reduced pressure to give the crude residue. It was purified with 25 M Biotage eluting with 100 % EtOAc to obtain desired product methyl (2*E*)-3-(1-{(2-hydroxyethyl)[2-(1*H*-indol-3-yl)ethyl]amino}-2,3-dihydro-1*H*-inden-5-yl)-2-propenoate as a yellow oil (1.10 g, 80 %): LC/MS [M+H] 405.0, RT 2.26 min (method A). ^{1}H-NMR (CD_3OD) δ 7.68 (d, 1H), 7.43 (s, 1H), 7.30 (m, 4H), 7.03 (m, 2H), 6.90 (m, 1H), 6.50 (d, 1H), 4.66 (t, 1H), 3.79 (s, 3H), 3.61 (m, 2H), 2.92 (m, 8H), 2.28 (m, 1H), 2.06 (m, 1H).

The following compounds are synthesized in a similar manner:

Inter-mediate	Structure	HPLC RT (min) (method)	M+H
J1		0.52 (A)	256.0
J2		3.19 (B)	499.5

Inter-mediate	Structure	HPLC RT (min) (method)	M+H
J3		2.17 (A)	419.0
J4		2.16 (A)	366.0
J5		2.84 (A)	419.1
J6		2.42 (A)	433.1
J7		2.70 (A)	449.1
J8		2.23 (A)	419.0

Inter-mediate	Structure	HPLC RT (min) (method)	M+H
J9		2.81 (A)	419.2
J10		2.10 (A)	435.1
J11		2.30 (A)	439.1
J12		2.29 (A)	437.0
J13		2.09 (A)	435.0
J14		2.81 (A)	433.1

Inter-mediate	Structure	HPLC RT (min) (method)	M+H
J15		2.14 (A)	435.1
J16		2.44 (A)	380.2
J17		2.46 (A)	380.2
J18		2.45 (A)	380.2
J19		2.28 (A)	366.1
J20		2.24 (A)	414.2
J21		2.19 (A)	440.1

Inter-mediate	Structure	HPLC RT (min) (method)	M+H
J22		2.17 (A)	410.1
J23		2.23 (A)	410.1
J24		2.16 (A)	410.1
J25		2.28 (A)	414.2
J26		2.30 (A)	414.2
J27		2.20 (A)	426.0

Inter-mediate	Structure	HPLC RT (min) (method)	M+H
J28		2.35 (A)	394.1
J29		2.19 (A)	426.0
J30		2.36 (A)	394.0
J31		2.30 (A)	434.0
J32		2.16 (A)	384.0
J33		2.17 (A)	384.0

Inter-mediate	Structure	HPLC RT (min) (method)	M+H
J34		2.18 (A)	384.0
J35		2.38 (A)	434.0
J36		2.24 (A)	380.0
J37		1.68 (A)	534.1
J38		2.36 (A)	433.2
J40		0.98 (A)	366.7

Inter-mediate	Structure	HPLC RT (min) (method)	M+H
J41		1.56 (A)	352.8
J42		1.96 (A)	421.1
J43		2.46 (A)	407.9
J44		2.60 (A)	441.9
J45		TLC R_f = 0.14 (EtOAc:hexanes, 3:7)	
J46		1.99 (A)	367.0

Inter-mediate	Structure	HPLC RT (min) (method)	M+H
J47		1.18 (A)	367.0
J48		2.03 (A)	353.0
J49		1.38 (A)	368.1
J50		1.84 (A)	341.9
J51		2.01 (A)	356.0
J52		2.18 (A)	448.2

Inter-mediate	Structure	HPLC RT (min) (method)	M+H
J53		3.32 (A)	561.0
J54		1.70 (A)	404.9
J55		2.51 (A)	419.0
J56		1.32 (A)	435.0
J57		2.34 (A)	419.1
J58		2.30 (A)	423.0
J59		2.41 (A)	438.9

Intermediate K

5-Oxo-5,6,7,8-tetrahydro-2-naphthalenyl trifluoromethanesulfonate



6-Hydroxy-1-tetralone (1.00 g, 6.17 mmol), and Et_3N (1.72 mL, 12.33 mmol) were dissolved in CH_2Cl_2 (30 mL) at rt. The resulting solution was cooled to 0 °C at which time trifluoromethanesulfonic anhydride (1.56 g , 9.25 mmol) was added dropwise. The reaction was stirred for 20 min at which time a solution of saturated $NaHCO_3$ was added. The bi-phasic mixture was vigorously stirred for 10 min then diluted with CH_2Cl_2. The organic layer was collected and washed with 1N HCl and brine. The organic phase was collected, dried over Na_2SO_4, and filtered. After removal of the solvent under vacuum, the crude oil was purified by silica gel chromatography using 20% EtOAc in Hex as eluent give the 5-oxo-5,6,7,8-tetrahydro-2-naphthalenyl trifluoromethanesulfonate as a near colorless oil (1.32 g, 73% yield): ^1H NMR (CD_2Cl_2) δ 8.10 (m, 1H), 7.23 (m, 2H), 3.04 (dd, 2H), 2.68 (dd, 2H), 2.19 (m, 2H).

Intermediate L

Methyl (2*E*)-3-(5-oxo-5,6,7,8-tetrahydro-2-naphthalenyl)-2-propenoate



Intermediate K (5-Oxo-5,6,7,8-tetrahydro-2-naphthalenyl trifluoromethanesulfonate) (1.3 g, 4.42 mmol), methyl acrylate (3.98 mL, 44.2 mmol), Et_3N (1.23 mL, 8.84 mmol), and DPPP (100 mg, 0.24 mmol) were dissolved in DMF (20 mL) at rt. After the solution was degassed with nitrogen for 15 min., $Pd(OAc)_2$ (50 mg, 0.22 mol) was added and the solution was heated to 80 °C for 16 h. The reaction was cooled to rt and the volatile solvents were removed under vacuum. The crude product was purified by silica gel chromatography using 20-30% EtOAc in Hex as eluent to give methyl (2*E*)-3-(5-oxo-5,6,7,8-tetrahydro-2-naphthalenyl)-2-propenoate (670 mg, 66% yield) as a white solid: LC/MS [M+H] 231.1, RT 3.22 min (method A); ^1H NMR (CD_2Cl_2) δ 7.99 (d, 1H), 7.67 (d, 1H), 7.49 (m, 1H), 7.44 (s, 1H), 6.54 (d, 1H), 3.81 (s, 3H), 3.88 (dd, 2H), 2.66 (dd, 2H), 2.16 (m, 2H).

Intermediate M

Methyl (2*E*)-3-(1-{acetyl[2-(1*H*-indol-3-yl)ethyl]amino}-2,3-dihydro-1*H*-inden-5-yl)-2-propenoate



To a solution of Intermediate E (methyl (2*E*)-3-(1-{[2-(1*H*-indol-3-yl)ethyl]amino}-2,3-dihydro-1*H*-inden-5-yl)-2-propenoate) (82 mg, 0.23 mmol) in THF at 0 °C was added acetyl chloride (21 mg, 0.27 mmol) and Et_3N (34 mg, 0.34 mmol). The mixture was stirred at rt overnight. In the morning the reaction was quenched with water. The mixture was extracted with CH_2Cl_2 twice and the combined organic layer was washed with brine and dried over Na_2SO_4. It was concentrated under vacuo to obtain the crude residue. It was then purified with silica gel column chromatography eluting with 80 % EtOAc in Hex to give the desired product as a pair of rotomers (74 mg, 81 %): LC/MS [M+H] 402.9, RT 2.98 min (method A); ^{1}H-NMR (CD_3OD) δ 7.73 (d, *J* = 12 Hz, 1H), 7.56 (s, 1H), 7.50 (m, 1H), 7.28 (m, 2H), 7.10 (m, 4H), 6.57 (dd, *J* = 12 Hz, 3 Hz, 1H), 5.96 and 5.57 (t, 1H), 3.79 (s, 3H), 3.48 (t, 1H), 3.05 (m, 5H), 2.50 (m, 1H), 2.20 (s, 3H), 2.16 (m, 1H).

The following compounds are synthesized in a similar manner:

Inter-mediate	**Structure**	**HPLC RT (min) (method)**	**M+H**
M1		3.96 (A)	479.1
M2		3.57 (A)	457.1

Inter-mediate	Structure	HPLC RT (min) (method)	M+H
M3		3.58 (A)	465.0
M4		3.66 (A)	471.1
M5		2.30 (A)	446.1

Intermediate N

methyl (2*E*)-3-(1-{[(ethylamino)carbonyl][2-(1*H*-indol-3-yl)ethyl]amino}-2,3-dihydro-1*H*-inden-5-yl)acrylate



To a solution of Intermediate E [methyl (2*E*)-3-(1-{[2-(1*H*-indol-3-yl)ethyl]amino}-2,3-dihydro-1*H*-inden-5-yl)-2-propenoate] (88 mg, 0.24 mmol) in CH_2Cl_2 (2 mL) at 0 °C was added ethyl isocyanate (19 mg, 0.27 mmol). The resulting mixture was stirred at rt for 2 hrs. The mixture was then concentrated under vacuum and purified with 25S Biotage eluting with 60 % EtOAc in Hex to obtain the desired product methyl (2*E*)-3-(1-{[(ethylamino)carbonyl][2-(1*H*-indol-3-yl)ethyl]amino}-2,3-dihydro-1*H*-inden-5-yl)acrylate as a yellow solid (100 mg, 95 %): LC/MS [M+H] 432.0, RT 3.10 min (method A).

The following compounds are synthesized in a similar manner:

Inter-mediate	Structure	HPLC RT (min) (method)	M+H
N1		3.54 (A)	460.2
N2		3.43 (A)	493.9
N3		3.65 (A)	508.0
N4		2.41 (A)	475.1
N5		1.35 (A)	503.1

Inter-mediate	Structure	HPLC RT (min) (method)	M+H
N6		1.41 (A)	517.1

Intermediate O

Methyl (2*E*)-3-{1-[[2-(1*H*-indol-3-yl)ethyl](phenylsulfonyl)amino]-2,3-dihydro-1*H*-inden-5-yl}acrylate



To a solution of Intermediate E [methyl (2*E*)-3-(1-{[2-(1*H*-indol-3-yl)ethyl]amino}-2,3-dihydro-1*H*-inden-5-yl)-2-propenoate] (100 mg, 0.28 mmol) in CH_2Cl_2 (2 mL) at 0 °C was added benzenesulfonyl chloride (58 mg, 0.33 mmol) and Et_3N (42 mg, 0.42 mmol) dropwise. The resulting mixture was stirred at rt overnight before it was concentrated under vacuum. The resulting residue was purified with 25S Biotage eluting with 25 % EtOAc in Hex to obtain the desired product methyl (2*E*)-3-{1-[[2-(1*H*-indol-3-yl)ethyl](phenylsulfonyl)amino]-2,3-dihydro-1*H*-inden-5-yl}acrylate as a yellow solid (67 mg, 48 %): LC/MS [M+H] 500.9, RT 3.82 min (method A).

The following compounds are synthesized in a similar manner:

Inter-mediate	Structure	HPLC RT (min) (method)	M+H

Inter-mediate	Structure	HPLC RT (min) (method)	M+H
O1		3.34 (A)	439.0
O2		2.39 (A)	482.0
O3		3.58 (A)	569.8
O4		3.36(A)	558.1
O5		2.68 (A)	536.0

Intermediates P1 and P2

Chiral separation of racemic methyl (2*E*)-3-(1-{(3-hydroxypropyl)[2-(1*H*-indol-3-yl)ethyl]amino}-2,3-dihydro-1*H*-inden-5-yl)acrylate

Intermediate P1



Intermediate P2



Racemic Intermediate J3 methyl (2*E*)-3-(1-{(3-hydroxypropyl)[2-(1*H*-indol-3-yl)ethyl]amino}-2,3-dihydro-1*H*-inden-5-yl)acrylate (0.6 g) was separated with ChiralPAK AD-H using 35-65 % B (B= 1:1 methanol : ethanol) in hexane with 0.1 % Et_3N (flow rate = 15 mL/min, 150 uL/injection) to obtain first peak (RT = 5.35 min, 95 mg). Second peak (RT = 7.98 min, 85 mg): $[\alpha]_D$ = +90.2 (c 1.0, MeOH). The overall recovery yield was 41%.

Intermediate Q

Methyl (2*E*)-3-{1-[(pyridin-3-ylmethyl)amino]-2,3-dihydro-1*H*-inden-5-yl}acrylate



Intermediate D [methyl (2*E*)-3-(1-oxo-2,3-dihydro-1*H*-inden-5-yl)-2-propenoate] (250 mg, 1.16 mmol) was dissolved in CH_2Cl_2, treated with Titanium(IV)methoxide (497 mg, 2.89 mmol, 2.5 eq), molecular sieves (4A, 370 mg), and 3-(methylamine)pyridine (137 mg, 1.27 mmol, 1.1 eq). The reaction mixture was stirred at rt under nitrogen overnight. In the next morning, the mixture was treated with sodium triacetoxyborohydride (610 mg, 2.89 mmol, 2.5 eq) and stirred at rt overnight. It was then diluted with CH_2Cl_2 and MeOH and the reaction was quenched with water and stirred for 30 min. Celite was then added to the emulsion and filtered. The filtrate was then absorbed on silica and purified on the Biotage with 2-3% MeOH in CH_2Cl_2 to afford 340 mg (95% yield) of the product as a solid. R_f = 0.25 (silica, MeOH: CH_2Cl_2, 4:96); LC/MS = 308.9 [(M+H)+, RT = 1.24 min (method A)]; ^1H NMR (DMSO-d_6) δ 1.73-1.86 (m, 1H), 2.26-2.37 (m, 1H), 2.67-2.78 (m, 1H), 2.88-2.97 (m, 1H), 3.70 (s, 3H), 3.76 (d, 1H), 3.82 (d, 1H), 4.13 (t, 1H), 6.58 (d,1H), 7.31-7.35 (m, 1H), 7.41 (d, 1H), 7.52 (d, 1H), 7.57 (s, 1H), 7.64 (d, 1H), 7.77-7.82 (m, 1H), 8.42 (dd, 1H), 8.57 (d, 1H).

Alternatively, 1 N aqueous HCl is used to quench the reaction without the dilution with CH_2Cl_2 and MeOH. The desired product is collected in its hydrochloride salt form. Intermediate E, Q13, Q54, Q58, Q59, and Q60 are prepared as their hydrochloride salts.

The following compounds are synthesized in a similar manner:

Inter-mediate	Structure	HPLC RT (min) (method)	M+H
Q1		1.04 (A)	323.0
Q2		2.29 (A)	321.9
Q3		2.36 (A)	375.0
Q4		2.20 (A)	391.0
Q5		2.94 (A)	395.1
Q6		2.87 (A)	393.0

Inter-mediate	Structure	HPLC RT (min) (method)	M+H
Q7		2.04 (B)	375.2
Q8		2.57 (A)	407.0
Q9		2.63 (A)	409.2
Q10		1.93 (A)	405.2
Q11		2.46 (A)	405.2
Q12		2.52 (A)	393.2

Inter-mediate	Structure	HPLC RT (min) (method)	M+H
Q13		2.24 (A)	391.0
Q14		2.18 (A)	322.1
Q15		2.26 (A)	336.1
Q16		2.30 (A)	336.1
Q17		2.29 (A)	336.1
Q18		2.28 (A)	356.1

Inter-mediate	Structure	HPLC RT (min) (method)	M+H
Q19		2.24 (A)	352.1
Q20		2.21 (A)	382.1
Q21		2.32 (A)	356.1
Q22		2.39 (A)	350.1
Q23		2.19 (A)	352.1
Q24		2.18 (A)	352.1

Inter-mediate	Structure	HPLC RT (min) (method)	M+H
Q25		2.32 (A)	356.0
Q26		2.34 (A)	429.9
Q27		2.25 (A)	382.0
Q28		2.39 (A)	350.0
Q29		2.23 (A)	382.0
Q30		2.38 (A)	350.0

Inter-mediate	Structure	HPLC RT (min) (method)	M+H
Q31		2.32 (A)	390.0
Q32		2.17 (A)	339.9
Q33		2.20 (A)	339.9
Q34		2.20 (A)	339.9
Q35		2.40 (A)	389.9
Q36		1.96 (A)	336.0

Inter-mediate	Structure	HPLC RT (min) (method)	M+H
Q37		2.09 (A)	377.0
Q38		1.25 (A)	261.9
Q40		2.32 (A)	363.6
Q41		2.59 (A)	397.8
Q42		2.05 (A)	376.3
Q43		1.07 (A)	323.0

Inter-mediate	Structure	HPLC RT (min) (method)	M+H
Q44		1.74 (A)	323.1
Q45		2.00 (A)	309.1
Q46		1.88 (A)	323.9
Q47		2.56 (A)	311.9
Q48		2.26 (A)	297.9
Q49		0.47 (A)	341.0
Q50		2.23 (A)	361.0
Q51		2.39 (A)	375.0

Inter-mediate	Structure	HPLC RT (min) (method)	M+H
Q52		1.32 (A)	391.0
Q53		2.88 (A)	393.0
Q54		2.32 (A)	375.0
Q55		2.25 (A)	362.0
Q56		2.31 (A)	361.9
Q57		1.82 (A)	362.1
Q58		1.52 (A)	375.5
Q59		2.51 (A)	395.0

Inter-mediate	Structure	HPLC RT (min) (method)	M+H
Q60		2.43 (A)	379.0
Q61		2.46 (A)	391.1
Q62		2.95(A)	409.0
Q63		2.35 (A)	373.4
Q64		2.45 (A)	347.9

Intermediate R1 and R2

Chiral Separation of (±) methyl (2*E*)-3-(5-{(2-hydroxyethyl)[2-(1*H*-indol-3-yl)ethyl]amino}-5,6,7,8-tetrahydronaphthalen-2-yl)acrylate





Racemic Intermediate J8, methyl (2*E*)-3-(5-{(2-hydroxyethyl)[2-(1*H*-indol-3-yl)ethyl]amino}-5,6,7,8-tetrahydronaphthalen-2-yl)acrylate (0.67 g) was separated with ChiralPAK AD-H 20 x 250 mm using 35-50 % iPrOH in hexane with 0.1 % Et_3N (flow rate = 15 mL/min, 1600 uL/injection, 90 mg/injection) to obtain the first peak (RT = 14.29 min, 295 mg): $[\alpha]_D$ (MeOH) = + 168.7 (c 1.0). Second peak (RT = 17.36 min, 288 mg): $[\alpha]_D$ (MeOH) = - 172.6 (c 1.0). The overall recovery yield was 86%.

Using procedures similar to the above and what is described for intermediate H1, H2, I1, I2, P1 and P2, the following compounds are prepared in a similar manner.

Inter-mediate	Structure	Chiral column	Separation condition	RT (min)	$[\alpha]_D$ (sol-vent)
R3		Chiral PAK AD-H	15-25% MeOH/EtOH (1/1) in hexanes with 0.1% Et_3N	16.62	-66.0 (c 1.0) (MeOH)
R4		Chiral PAK AD-H	15-25% MeOH/EtOH (1/1) in hexane with 0.1% Et_3N	20.12	+66.0 (c 1.0) (MeOH)
R5		Chiral PAK AD-H	20% MeOH/EtOH (1/1) in hexanes with 0.1% Et_3N	5.74	*
R6		Chiral PAK AD-H	20% MeOH/EtOH (1/1) in hexanes with 0.1% Et_3N	6.93	*

Inter-mediate	Structure	Chiral column	Separation condition	RT (min)	$[\alpha]_D$ (sol-vent)
R7	(-) 	Chiral PAK AD-H	10 % B (B = 1:1 MeOH : EtOH) in hexane with 0.1 % Et_3N	12.82	-76.2 (c 1.0) (MeOH)
R8	(+) 	Chiral PAK AD-H	10 % B (B = 1:1 MeOH : EtOH) in hexane with 0.1 % Et_3N	16.21	+87.2 (c 1.0) (MeOH)
R9	(-) 	Chiral PAK AD-H	70 % iPrOH in hexane with 0.1 % Et_3N	17.50	-24.8 (c 1.0) (MeOH)
R10	(+) 	Chiral PAK AD-H	70 % iPrOH in hexane with 0.1 % Et_3N	12.21	+25.6 (c 1.0) (MeOH)
R11	(-) 	Chiral PAK AD-H	25 % B (B = 1:1 MeOH : EtOH) in hexane with 0.1 % Et_3N	8.01	-44.5 (c 1.0) (MeOH)
R12	(+) 	Chiral PAK AD-H	25 % B (B = 1:1 MeOH : EtOH) in hexane	8.01	+48.6 (c 1.0) (MeOH)

Inter-mediate	Structure	Chiral column	Separation condition	RT (min)	$[\alpha]_D$ (sol-vent)
			with 0.1 % Et_3N		
R13	(-) 	Chiral PAK OD-H	15 % B (B = 2:1 MeOH : EtOH) in hexane with 0.1 % Et_3N	35.66	-35.5 (c 1.0) (MeOH)
R14	(+) 	Chiral PAK OD-H	15 % B (B = 2:1 MeOH : EtOH) in hexane with 0.1 % Et_3N	40.8	+39.2 (c 1.0) (MeOH)
R15	(+) 	Chiral PAK AD-H	35 % iPrOH in hexane with 0.1 % Et_2NH	12.20	+22.0 (c 1.0) (MeOH)
R16	(-) 	Chiral PAK AD-H	35 % iPrOH in hexane with 0.1 % Et_2NH	16.01	-21.9 (c 1.0) (MeOH)
R17	(+) 	Chiral PAK AD-H	40 % iPrOH in hexane with 0.1 % Et_2NH	17.48	+36.4 (c 1.0) (MeOH)
R18	(-) 	Chiral PAK AD-H	40 % iPrOH in hexane with 0.1 % Et_2NH	22.87	-34.8 (c 1.0) (MeOH)

Inter-mediate	Structure	Chiral column	Separation condition	RT (min)	$[\alpha]_D$ (sol-vent)
R19		Chiral PAK AD-H	80 % B (B = 2:1 MeOH : EtOH) in hexane with 0.1 % Et_2NH	25.1	+20.4 (c 1.0) (MeOH)
R20		Chiral PAK AD-H	80 % B (B = 2:1 MeOH : EtOH) in hexane with 0.1 % Et_2NH	39.5	-20.8 (c 1.0) (MeOH)
R21		Chiral Pak AD-H	20% EtOH in hexanes with 0.1% Et_2NH	20.30	-69.9 (c 1.1) (MeOH)
R22		Chiral Pak AD-H	20% EtOH in hexanes with 0.1% Et_2NH	26.60	+72.2 (c 1.1) (MeOH)
R23		Chiral Cel OD-H	25-45% (1:1 MeOH-EtOH) in Hexanes with 0.1% Et_3N	11.80	- 63.8 (c 1.1) (MeOH)
R24		Chiral Cel OD-H	25-45% (1:1 MeOH-EtOH) in Hexanes with 0.1% Et_3N	17.00	+ 67.3 (c 1.1) (MeOH)

Inter-mediate	Structure	Chiral column	Separation condition	RT (min)	$[\alpha]_D$ (sol-vent)
R25		Chiral Cel OD-H	15-25% iPrOH in hexanes with 0.1% Et_3N	23.40	- 69.5 (c 1.3) (MeOH)
R26		Chiral Cel OD-H	15-25% iPrOH in hexanes with 0.1% Et_3N	13.4	+ 75.5 (c 1.3) (MeOH)
R27		Chiral Cel OD-H	25% (1:1 MeOH-EtOH) in hexanes with 0.1% Et_3N	20.00	+ 17.9 (c 0.61) (CH_2Cl_2)
R28		Chiral Cel OD-H	25% (1:1 MeOH-EtOH) in hexanes with 0.1% Et_3N	16.20	- 18.6 (c 0.65) (CH_2Cl_2)
R29		Chiral Pak AD-H	35% (1:1 MeOH-EtOH) in hexanes with 0.1% Et_3N	13.00	+20.8 (c 1.3) (MeOH)
R30		Chiral Pak AD-H	35% (1:1 MeOH-EtOH) in hexanes	16.00	-20.7 (c 1.3) (MeOH)

Inter-mediate	Structure	Chiral column	Separation condition	RT (min)	$[\alpha]_D$ (sol-vent)
			with 0.1% Et_3N		
R31		Chiral Pak AD-H	70% 1:1 MeOH-EtOH in hexanes with 0.1% Et_3N	16.60	-72.8 (c 1.3) (MeOH)
R32		Chiral Pak AD-H	70% (1:1 MeOH-EtOH) in hexanes with 0.1% Et_3N	9.00	+ 63.4 (c 1.3) (MeOH)
R33		Chiral Pak AD-H	40% (2:1 MeOH-EtOH) in hexanes with 0.3% Et_2NH	15.50	- 56.7 (c 1.1) (MeOH)
R34		Chiral Pak AD-H	40% (2:1 MeOH-EtOH) in hexanes with 0.3% Et_2NH	22.00	+ 57.2 (c 1.3) (MeOH)
R35		Chiral Pak AD-H	45% (2:1 MeOH-EtOH) in hexanes with 0.3% Et_2NH	14.30	- 7.6 (c 0.9) (MeOH)

Inter-mediate	Structure	Chiral column	Separation condition	RT (min)	$[\alpha]_D$ (sol-vent)
R36		Chiral Pak AD-H	45% (2:1 MeOH-EtOH) in hexanes with 0.3% Et_2NH	19.30	+ 8.0 (c 0.9) (MeOH)
R37		Chiral PAK AD-H	70 % (4:1 iPrOH :MeOH) in hexanes with 0.1 % Et_2NH	16.20	-21.0 (c 1.0) (MeOH)
R38		Chiral PAK AD-H	70 % (4:1 iPrOH :MeOH) in hexanes with 0.1 % Et_2NH	9.08	+20.8 (c 1.0) (MeOH)
R39		Chiral PAK AD-H	25% (MeOH:Et OH, 1:1) in hexane with 0.1 % Et_3N	11.80	-58.1 (c 1.1) (MeOH)
R40		Chiral PAK AD-H	25% (MeOH:Et OH, 1:1) in hexane with 0.1 % Et_3N	17.59	+55.1 (c 1.0) (MeOH)

Inter-mediate	Structure	Chiral column	Separation condition	RT (min)	$[\alpha]_D$ (sol-vent)
R41		Chiral PAK AD	65% iPrOH in hexane with 0.1 % Et_3N	19.92	-28.4 (c 1.4) (MeOH)
R42		Chiral PAK AD	65% iPrOH in hexane with 0.1 % Et_3N	32.82	+30.5 (c 1.3) (MeOH)
R43		Chiral PAK AD-H	70 % (4:1 MeOH : EtOH) in hexanes with 0.1 % Et_2NH	34.40	-21.0 (c 1.0) (MeOH)
R44		Chiral PAK AD-H	70 % (4:1 MeOH : EtOH) in hexanes with 0.1 % Et_2NH	21.06	+20.8 (c 1.0) (MeOH)
R45					-79.3 (c 0.7) (MeOH)
R46					+83.0 (c 1.0) (MeOH)

Inter-mediate	Structure	Chiral column	Separation condition	RT (min)	$[\alpha]_D$ (sol-vent)
R47					-124.0 (c 1.0) (MeOH)
R48					+164.0 (c 1.0) (MeOH)
R49		Chiral Pak AD-H	5% (4:1 iPrOH /MeOH) in hexanes with 0.1% Et_2NH	21.30	+75.5 (c 1.4) (MeOH)
R50		Chiral Pak AD-H	5% (4:1 iPrOH /MeOH) in hexanes with 0.1% Et_2NH	16.70	-74.4 (c 1.4) (MeOH)
R51		Chiral PAK AD-H	15 % EtOH in hexanes with 0.1 % Et_3N	20.40	+66.2 (c 1.0) (MeOH)
R52		Chiral PAK AD-H	15 % EtOH in hexanes with 0.1 % Et_3N	16.70	-70.8 (c 0.8) (MeOH)
R53					

Inter-mediate	Structure	Chiral column	Separation condition	RT (min)	$[\alpha]_D$ (sol-vent)
R54					
R55		Chiral PAK AD-H	50 % (4:1 iPrOH :MeOH) in hexanes with 0.1 % Et_2NH	17.50	+27.0 (c 1.0) (MeOH)
R56		Chiral PAK AD-H	50 % (4:1 iPrOH :MeOH) in hexanes with 0.1 % Et_2NH	33.70	-20.6 (c 1.0) (MeOH)
R57		Chiral Pak AD-H	50% (4:1 iPrOH /MeOH) in hexanes with 0.1% Et_2NH	17.40	+21.8 (c 1.1) (MeOH)
R58		Chiral Pak AD-H	50% (4:1 iPrOH /MeOH) in hexanes with 0.1% Et_2NH	27.70	-23.5 (c 1.1) (MeOH)
R59		Chiral PAK AD-H	60 % B (B = 9:1 EtOH : MeOH) in hexanes with 0.1 % Et_3N	18.70	+17.4 (c 1.0) (MeOH)

Inter-mediate	Structure	Chiral column	Separation condition	RT (min)	$[\alpha]_D$ (sol-vent)
R60		Chiral PAK AD-H	60 % B (B = 9:1 EtOH : MeOH) in hexanes with 0.1 % Et_3N	14.20	-13.6 (c 1.0) (MeOH)
R61		Chiral PaK AD-H	40% (9:1 EtOH/MeOH) in hexanes with Et_3N	23.80	+15.4 (c 1.3) (MeOH)
R62		Chiral PaK AD-H	40% (9:1 EtOH/MeOH) in hexanes with Et_3N	16.20	-19.5 (c 1.3) (MeOH)
R63		Chiral Pak AD-H	35% (9:1 EtOH-MeOH) in hexanes with 0.1% Et_2NH	14.20	+27.3 (c 1.0) (MeOH)
R64		Chiral Pak AD-H	35% (9:1 EtOH-MeOH) in hexanes with 0.1% Et_2NH	7.10	-26.8 (c 1.0) (MeOH)

Inter-mediate	Structure	Chiral column	Separation condition	RT (min)	$[\alpha]_D$ (sol-vent)
R65		Chiral Pak AD-H	100% (2:1 MeOH-iPrOH with 0.1% Et_3N	32.00	+16.5 (c 1.0) (MeOH)
R66		Chiral Pak AD-H	100% (2:1 MeOH-iPrOH with 0.1% Et_3N	14.50	-16.1 (c 1.0) (MeOH)
R67		Chiral Pak AD-H	80% (1:1 MeOH-EtOH) in hexanes with 0.1% Et_2NH	21.81	+21.3 (c 1.0) (MeOH)
R68		Chiral Pak AD-H	80% (1:1 MeOH-EtOH) in hexanes with 0.1% Et_2NH	13.59	-21.7 (c 0.9) (MeOH)
R69		Chiral Pak AD-H	15% iPrOH in hexanes with 0.1% Et_3N	13.17	+24.6 (c 0.8) (MeOH)

Inter-mediate	Structure	Chiral column	Separation condition	RT (min)	$[\alpha]_D$ (sol-vent)
R70		Chiral Pak AD-H	15% iPrOH in hexanes with 0.1% Et_3N	19.37	-25.0 (c 0.6) (MeOH)
R71		Chiral Pak AD	50% (4:1 iPrOH -MeOH) in hexanes with 0.1% Et_2NH	8.79	+19.0 (c 0.1) (MeOH)
R72		Chiral Pak AD	50% (4:1 iPrOH -MeOH) in hexanes with 0.1% Et_2NH	16.63	-15.0 (c 0.1) (MeOH)
R73		Chiral Pak AD-H	20% (1:1 MeOH-EtOH) in hexanes with 0.1% Et_3N	10.00	+13.0 (c 0.1) (MeOH)
R74		Chiral Pak AD-H	20% (1:1 MeOH-EtOH) in hexanes with 0.1% Et_3N	14.50	-10.0 (c 0.1) (MeOH)

Inter-mediate	Structure	Chiral column	Separation condition	RT (min)	$[\alpha]_D$ (sol-vent)
R75		Chiral Pak AD	70% (4:1 MeOH-iPrOH) in hexanes with 0.1% Et_2NH	14.00	+12.0 (c 0.1) (MeOH)
R76		Chiral Pak AD	70% (4:1 MeOH-iPrOH) in hexanes with 0.1% Et_2NH	25.40	-14.0 (c 0.1) (MeOH)
R77		Chiral PAK AD-H	40%(1:1 MeOH-EtOH)/ Hexanes 0.1% Et_3N	11.10	+5.5 (c 1.0) (MeOH)
R78		Chiral PAK AD-H	40%(1:1 MeOH-EtOH)/ Hexanes 0.1% Et_3N	22.80	-4.5 (c 1.0) (MeOH)
R79		Chiral PAK AD-H	40% (1:1 MeOH-EtOH) in hexanes with 0.1% Et_3N	8.10	+5.2 (c 1.0) (MeOH)
R80		Chiral PAK AD-H	40% (1:1 MeOH-EtOH) in hexanes	16.50	-8.7 (c 1.0) (MeOH)

Inter-mediate	Structure	Chiral column	Separation condition	RT (min)	$[\alpha]_D$ (sol-vent)
			with 0.1% Et_3N		
R81		Chiral Pak AD	50% (4:1 iPrOH-MeOH) in hexanes with 0.1% Et_3N	10.30	+15.0 (c 0.1) (MeOH)
R82		Chiral Pak AD	50% (4:1 iPrOH-MeOH) in hexanes with 0.1% Et_3N	20.80	-13.0 (c 0.1) (MeOH)
R83		Chiral PAK AD-H	35 % B (B = 4:1 iPrOH : MeOH) in hexanes with 0.1 % Et_2NH	17.50	+58.5 (c 1.0) (MeOH)
R84		Chiral PAK AD-H	35 % B (B = 4:1 iPrOH : MeOH) in hexanes with 0.1 % Et_2NH	33.70	-64.3 (c 1.0) (MeOH)
R85		Chiral Pak AD-H	40% (4:1 iPrOH /MeOH) in hexanes with Et_2NH	19.10	+70.8 (c 1.1) (MeOH)

Inter-mediate	Structure	Chiral column	Separation condition	RT (min)	$[\alpha]_D$ (sol-vent)
R86		Chiral Pak AD-H	40% (4:1 iPrOH /MeOH) in hexanes with Et_2NH	25.60	-67.6 (c 1.1) (MeOH)
R87		Chiral Pak AD	30% (4:1 iPrOH-MeOH) in hexanes	12.38	+71.6 (c 1.1) (MeOH)
R88		Chiral Pak AD	30% (4:1 iPrOH - MeOH) in hexanes	18.93	-64.4 (c 1.0) (MeOH)
R89		Chiral Cel OD-H	20% (4:1 iPrOH /MeOH) in hexanes with Et_2NH	28.10	+67.2 (c 1.4) (MeOH)
R90		Chiral Cel OD-H	20% (4:1 iPrOH /MeOH) in hexanes with Et_2NH	33.10	-61.2 (c 1.5) (MeOH)
R91		Chiral Pak AD-H	20% (3:1 MeOH-EtOH) in hexanes with 0.1% Et_3N	15.75	+18.8 (c 0.6) (MeOH)
R92		Chiral Pak AD-H	20% (3:1 MeOH-EtOH) in hexanes	20.75	-18.9 (c 0.6) (MeOH)

Inter-mediate	Structure	Chiral column	Separation condition	RT (min)	$[\alpha]_D$ (sol-vent)
			with 0.1% Et_3N		
R93		Chiral PAK AD-H	20 % B (B = 3:1 MeOH : EtOH) in hexanes with 0.1 % Et_3N	18.20	+20.5 (c 1.0) (MeOH)
R94		Chiral PAK AD-H	20 % B (B = 3:1 MeOH : EtOH) in hexanes with 0.1 % Et_3N	23.40	-23.0 (c 1.0) (MeOH)
R95		Chiral Pak AD-H	15% (3:1 MeOH-EtOH) in hexanes with 0.1% Et_3N	27.30	+20.1 (c 0.8) (MeOH)
R96		Chiral Pak AD-H	15% (3:1 MeOH-EtOH) in hexanes with 0.1% Et_3N	33.30	-19.8 (c 0.9) (MeOH)
R97		Chiral Pak AD-H	15% (1:1 MeOH/EtOH) in hexanes with 0.1% Et_2NH	10.00	+18.3 (c 1.3) (MeOH)

Inter-mediate	Structure	Chiral column	Separation condition	RT (min)	$[\alpha]_D$ (sol-vent)
R98		Chiral Pak AD-H	15% (1:1 MeOH/EtOH) in hexanes with 0.1% Et_2NH	14.00	--14.9 (c 1.2) (MeOH)
R99		Chiral Pak AD-H	15% EtOH in Hexanes with 0.1% Et_2NH	14.80	+52.9 (c 1.1) (MeOH)
R100		Chiral Pak AD-H	15% EtOH in Hexanes with 0.1% Et_2NH	11.30	-68.4 (c 1.2) (MeOH)
R101		Chiral Pak AD-H	25% (3:1 MeOH-EtOH) in Hexane with 0.1% Et_3N	19.95	+22.2 (c 1.0) (MeOH)
R102		Chiral Pak AD-H	25% (3:1 MeOH-EtOH) in Hexane with 0.1% Et_3N	26.09	-23.9 (c 1.0) (MeOH)

*The optical rotations were not measured at the methyl ester stage. Assignments were made based on the optical rotation of the final hydroxamic acids.

Intermediate S

Methyl 3-(1-{(2-hydroxyethyl)[2-(1H-indol-3-yl)ethyl]amino}-2,3-dihydro-1H-inden-5-yl)propanoate



To a stirred solution mixture of intermediate J [methyl (2E)-3-(1-{(2-hydroxyethyl)[2-(1H-indol-3-yl)ethyl]amino}-2,3-dihydro-1H-inden-5-yl)acrylate] (300 mg, 0.74 mmol) and CuCl (55 mg, 0.56 mmol) in MeOH (5 mL) and THF (2.5 mL) at 0 °C was added $NaBH_4$ (280 mg, 7.42 mmol). The black mixture was allowed to stir at 0 °C for 1 h. The resulting black precipitate was removed by filtration, and the filtrate was acidified with 1 N HCl solution. White precipitate formed and saturated $NaHCO_3$ was added to dissolve it. The mixture was extracted with EtOAc three times. The combined organic layer was washed with water, dried over Na_2SO_4, filtered and concentrated to obtain a colorless oil. The crude product was resubmitted to the same condition as described above two more times. After the third time, the reaction was worked up as described above and the crude residue was purified with preparative TLC [10 % MeOH (with 2M NH_3) in CH_2Cl_2 to obtain methyl 3-(1-{(2-hydroxyethyl)[2-(1H-indol-3-yl)ethyl]amino}-2,3-dihydro-1H-inden-5-yl)propanoate as a colorless oil (65 mg, 21 %): LC/MS [M+H] 407.1, RT 2.35 min (method A). ^{1}H-NMR (CD_3OD) δ 7.33 (m, 2H), 7.21 (d, J = 5.7 Hz, 1H), 7.05 (m, 5H), 4.62 (t, 1H), 3.62 (s, 3H), 3.58 (m, 2H), 2.86 (m, 12H), 2.22 (m, 1H), 2.02 (m, 1H).

Intermediate T

(Methyl (2E)-3-(1-{(2-aminoethyl)[2-(1H-indol-3-yl)ethyl]amino}-2,3-dihydro-1H-inden-5-yl)acrylate



Intermediate F2 [methyl (2E)-3-(1-{{2-[(tert-butoxycarbonyl)amino]ethyl}[2- (1H-indol-3-yl)ethyl]amino}-2,3-dihydro-1H-inden-5-yl)acrylate] (6.80 g, 13.5 mmol) was dissolved in anhydrous MeOH (20 mL) and cooled to 0 °C. HCl (4N in dioxane, 20 mL) was added to the solution and the resulting mixture was warmed to rt. The reaction was then warmed to 40 °C for 1 h at which time the solvent was removed under vacuum and the crude solid was triturated with Et_2O and collected by filtration. The solid was dissolved in a biphasic mixture of EtOAC/saturated $NaHCO_3$ solution. The organic layer was collected, dried over anhydrous Na_2SO_4, filtered, followed by removal of solvent to give methyl (2E)-3-(1-{(2-aminoethyl)[2-(1H-indol-3-yl)ethyl]amino}-2,3-dihydro-1H-inden-5-yl)acrylate (3.70 g, 68%

yield) as a yellow solid: LC/MS [M+H] 404.1, RT 0.97 min (method A). ^{1}H-NMR (CD_2Cl_2) δ 8.20 (br s, 1H), 7.67 (d, 1H), 7.45-7.29 (m, 5H), 7.13 (m, 1H), 7.03-6.99 (m, 2H), 6.43 (d, 1H), 4.64 (t, 1H), 3.79 (s, 3H), 3.05-2.50, (m, 10H), 2.24 (m, 1H), 2.02 (m, 1H).

Intermediate U

Methyl (2E)-3-(1-{[2-(2-chlorophenoxy)ethyl][2-(1H-indol-3-yl)ethyl]amino}-2,3-dihydro-1H-inden-5-yl)acrylate



To a solution of intermediate J [methyl (2E)-3-(1-{(2-hydroxyethyl)[2-(1H-indol-3-yl)ethyl]amino}-2,3-dihydro-1H-inden-5-yl)acrylate] (150 mg, 0.37 mmol) in THF (3 mL) was added 2-chlorophenol (52 mg, 0.41 mmol), triphenylphosphine (194 mg, 0.74 mmol) and ADDP (187 mg, 0.74 mmol). The mixture was left to stir under nitrogen overnight. HPLC analytical showed complete conversion of starting material to product. Hexane (9 mL) was added to the mixture. The solid was filtered off and the filtrated was concentrated in vacuum. The crude residue was purified with 25 M Biotage eluting with 25 % EtOAc in hexane to obtain methyl (2E)-3-(1-{[2-(2-chlorophenoxy)ethyl][2-(1H-indol-3-yl)ethyl]amino}-2,3-dihydro-1H-inden-5-yl)acrylate as a pale yellow oil (160 mg, 84 %): LC/MS [M+H] 515.1, RT 2.66 min (method A). ^{1}H-NMR (DMSO-*d6*) δ 10.70 (s, 1H), 7.635 (d, *J* = 12 Hz, 1H), 7.54 (s, 1H), 7.47 (d, *J* = 6.3 Hz, 1H), 7.39 (dd, *J* = 6 Hz and 1.2 Hz, 1H), 7.31 (m, 4H), 7.10 (d, *J* = 1.8 Hz, 1H), 7.01 (m, 2H), 6.92 (m, 2H), 6.575 (d, *J* = 12 Hz, 1H), 4.66 (t, 1H), 4.08 (t, 2H), 3.69 (s, 3H), 2.89 (m, 8H), 2.26 (m, 1H), 1.96 (m, 1H).

The following compounds are synthesized in a similar manner as described above.

Inter-mediate	**Structure**	**HPLC RT (min) (method)**	**M+H**

Inter-mediate	Structure	HPLC RT (min) (method)	M+H
U1		TLC: R_f = 0.77 (EtOAc:Hex, 1:1)	
U2		2.69 (A)	481.1
U3		2.71 (A)	515.1
U4		2.69 (A)	515.2
U5		2.70 (A)	495.2

Inter-mediate	Structure	HPLC RT (min) (method)	M+H
U6		2.68 (A)	495.2
U7		2.69 (A)	495.1

Intermediate V

methyl (2E)-3-(1-{methyl[2-(1-methyl-1H-indol-3-yl)ethyl]amino}-2,3-dihydro-1H-inden-5-yl)acrylate



To a cold solution of intermediate E [methyl (2E)-3-(1-{[2-(1H-indol-3-yl)ethyl]amino}-2,3-dihydro-1H-inden-5-yl)acrylate] (1.15 g, 3.19 mmol) in THF (30 mL) was added NaH (0.36 g, 8.93 mmol). The reaction mixture was stirred for 5 min and then MeI (1.36 g, 9.57 mmol) was added. The reaction mixture was stirred at 0^0C for 1 h and then at rt for 2 h. Saturated NH_4Cl and ice water were added and the mixture was extracted with EtOAc. The organic layer was washed with brine, dried over Na_2SO_4, filtered and concentrated down. Chromatography using a Biotage cartridge (25S) with the EtOAc/ Hexane (40%) afforded methyl (2E)-3-(1-{methyl[2-(1-methyl-1H-indol-3-yl)ethyl]amino}-2,3-dihydro-1H-inden-5-yl)acrylate (0.59 g, 47%). LC/MS [M+H] 389.0, RT 2.51 min (method A). ^{1}H-NMR (DMSO-*d6*) δ 7.61 (d, 1H), 7.54 (s, 1H), 7.48 (s, 1H), 7.38 (s, 1H), 7.33 (d, 1H), 7.23 (s, 1H), 7.07 (m, 2H), 6.93 (m, 1H), 6.56 (d, 1H), 4.43 (t, 1H), 3.70 (s, 3H), 3.69 (s, 3H), 2.71 ~ 2.92 (m, 4H), 2.60 (t, 2H), 2.25 (s, 3H), 2.05 (m, 1H), 1.95 (m, 1H).

The following compounds are prepared in a similar manner as described above.

Inter-mediate	Structure	HPLC RT (min) (method)	M+H
V1		3.25 (A)	547.5

Intermediate W

Methyl (2E)-3-{1-[(2-hydroxyethyl)(2-phenoxyethyl)amino]-2,3-dihydro-1H-inden-5-yl}acrylate



Intermediate F168 [methyl (2E)-3-{1-[(2-{[tert-butyl(dimethyl)silyl]oxy}ethyl)(2-hydroxyethyl)amino]-2,3-dihydro-1H-inden-5-yl}acrylate] (120 mg, 0.29 mmol), phenol (32 mg, 0.34 mmol), triphenylphosphine (150 mg, 0.57 mmol), and ADDP (144 mg, 0.57 mmol) were dissolved in CH_2Cl_2 and stirred for 18 h. Hexanes were added to the reaction mixture to precipitate triphenylphosphine oxide. The crude reaction mixture was then filtered and the filtrate was adsorbed onto silica supported tosic acid (Si-Tosic acid) Silicycle inc. (2 g) in a Baker SPE cartridge . The Si-Tosic acid was eluted with CH_2Cl_2 (50 mL), and with MeOH (50 mL) and the eluent was discarded. After 12 h, the Si-Tosic acid was eluted with 2 N NH_3 in MeOH (30 mL) and the eluent was collected and the solvent removed under vacuum. The crude material was dissolved in EtOAc and was washed with saturated $NaHCO_3$ solution, and brine. The organic layer was collected, dried over anhydrous Na_2SO_4, filtered, followed by removal of solvent under vacuum. The product was purified further by 25 M Biotage eluting with 40% EtOAc/hexanes with 1% 2N NH_3 in MeOH added to obtain methyl (2E)-3-{1-[(2-hydroxyethyl)(2-phenoxyethyl)amino]-2,3-dihydro-1H-inden-5-yl}acrylate as a light yellow oil (72 mg, 66% yield): LC/MS [M+H] 382.0, RT 2.19 min

(method A). ^{1}H-NMR (CD_2Cl_2) δ 7.67 (d, 1H), 7.42 (br s, 1H), 7.38 (br s, 2H), 7.28 (m, 2H), 6.95 (m, 1H), 6.89 (m, 2H), 6.43 (m, 1H), 4.63 (t, 1H), 4.10-3.99 (m, 2H), 3.79 (s, 3H), 3.66 (m, 1H), 3.50 (m, 1H), 3.03-2.83 (m, 4H), 2.73 (m, 1H), 2.32 (m, 1H), 2.05 (m, 1H).

The following compounds are prepared in a similar manner as described above.

Inter-mediate	Structure	HPLC RT (min) (method)	M+H
W1		1.30 (A)	396.0
W2		2.18 (A)	412.0
W3		2.16 (A)	412.0
W4		2.19 (A)	399.9
W5		2.32 (A)	416.0

Inter-mediate	Structure	HPLC RT (min) (method)	M+H
W6		2.34 (A)	416.0
W7		2.31 (A)	396.0
W8		2.20 (A)	412.0
W9		2.21 (A)	399.9
W10		2.32 (A)	416.0

Intermediate X

Methyl (2E)-3-(1-{(1H-indol-2-ylcarbonyl)[2-(1H-indol-2- yl)ethyl]amino}-2,3-dihydro-1H-inden-5-yl)acrylate



The HCl salt of intermediate E [Methyl (2*E*)-3-(1-{[2-(1*H*-indol-3-yl)ethyl]amino}-2,3-dihydro-1*H*-inden-5-yl)-2-propenoate hydrochloride] (0.15 g, 0.38 mmol) was dissolved in DMF (5 mL) and 2-indolecarboxylic acid (0.061 g, 0.34 mmol) was added followed by DIPEA (0.18 g, 1.37 mmol) and PyBOP (0.18 g, 0.34 mmol). The resulting mixture was stirred at room overnight, diluted with water and extracted with EtOAc. The organic layer was washed with 0.5 N HCl, water and brine and dried over Na_2SO4. The solvent was evaporated and the residue was purified by 40M Biotage eluting with hexane/EtOAc (6:1) to (3:1) to obtain Methyl (2E)-3-(1-{(1H-indol-2-ylcarbonyl)[2-(1H-indol-2- yl)ethyl]amino}-2,3-dihydro-1H-inden-5-yl)acrylate as a white solid (0.098 g, 57%): LC/MS [M+H] 504.0, RT 3.82 min (method A). ^{1}H-NMR (CD3OD) δ 7.70 (d, 1H), 7.60 (d, 1H), 7.52 (s, 1H), 7.46 (t, 2H), 7.26 (m, 3H), 7.06 (t, 1H), 7.01 (t, 1H), 6.88 (m, 3H), 6.53 (d, 1H), 6.17 (s, 1H), 3.57 (m, 1H), 2.99 (m, 6H), 2.43 (m, 1H), 2.05 (m, 1H).

The following compounds are prepared in a similar manner as described above.

Inter-mediate	**Structure**	**HPLC RT (min) (method)**	**M+H**
X1		2.31 (A)	497.0
X2		3.90 (A)	505.0
X3		2.49 (A)	511.0

Inter-mediate	Structure	HPLC RT (min) (method)	M+H
X4		2.48 (A)	553.0
X5		2.43 (A)	511.1
X6		2.37 (A)	497.1
X7		2.32 (A)	511.0
X8		2.35 (A)	553.0

Inter-mediate	Structure	HPLC RT (min) (method)	M+H
X9		1.58 (A)	497.0

Intermediate Y

Methyl (2E)-3-(1-{[(4-hydroxyphenyl)sulfonyl][2-(1H-indol-3-yl)ethyl]amino}-2,3-dihydro-1H-inden-5-yl)acrylate



To a solution of intermediate O3 [methyl (2E)-3-(1-{{[4-(2-cyanoethoxy)phenyl]sulfonyl}[2-(1H-indol-3-yl)ethyl]amino} -2,3-dihydro-1H-inden-5-yl)acrylate] (0.30 g, 0.53 mmol) in MeOH (10 ml) was added K_2CO_3 (0.29 g, 2.1mmol). The mixture was stirred at rt for 5h under N_2. The reaction mixture was filtered to remove K_2CO_3. The filtrate was concentrated under vacuum to give a yellow residue. The residue was dissolved in CH_2Cl_2 and was washed with saturated $NaHCO_3$, brine and dried over Na_2SO_4. The solvent was evaporated to give methyl (2E)-3-(1-{[(4-hydroxyphenyl)sulfonyl][2-(1H-indol-3-yl)ethyl]amino}-2,3-dihydro-1H-inden-5-yl)acrylate as a dark oil (0.25 g, 91%). LC/MS [M+1] 517.0, RT 3.26 min (Method A).

Intermediate Z

Methyl (2E)-3-(1-{{[4-(2-{[tert-butyl(dimethyl)silyl]oxy}ethoxy)phenyl]sulfonyl}[2-(1H-indol-3-yl)ethyl]amino}-2,3-dihydro-1H-inden-5-yl)acrylate



To a solution of intermediate Y [methyl (2E)-3-(1-{[(4-hydroxyphenyl)sulfonyl][2-(1H-indol-3-yl)ethyl]amino}-2,3-dihydro-1H-inden-5-yl)acrylate] (0.10g, 0.17 mmol) in DMF (2 ml) was added (2-bromoethoxy)(tert-butyl)dimethyl silane (0.06g, 0.26 mmol) and K_2CO_3 (0.096g, 0.70 mmol). The mixture was stirred at 70 °C for 2h. After cooled to rt, the mixture was diluted with EtOAc (20 ml) and washed with H_2O (3x10 mL), brine and dried over Na_2SO_4. The solvent was evaporated to give a 1:1 crude mixture of methyl (2E)-3-(1-{{[4-(2-{[tert-butyl(dimethyl)silyl]oxy}ethoxy) phenyl]sulfonyl}[2-(1H-indol-3-yl)ethyl]amino}-2,3-dihydro-1H-inden-5-yl)acrylate and 2-{[tert-butyl(dimethyl) silyl]oxy} ethyl (2E)-3-(1-{{[4-(2-{[tert -butyl(dimethyl)silyl]oxy} ethoxy) phenyl] sulfonyl}[2-(1H-indol-3-yl)ethyl]amino}-2,3-dihydro-1H-inden-5-yl)acrylate (110 mg). LC/MS [M+H] 675.0, RT 4.78 min and [M+H] 819.3, RT 5.66 min (method A).

The following compounds are prepared in a similar manner as described above.

Inter-mediate	Structure	HPLC RT (min) (method)	M+H
Z1		2.78 (A)	588.1

Inter-mediate	Structure	HPLC RT (min) (method)	M+H
Z2		2.83 (A)	628.4

Intermediate AA

Methyl (2E)-3-(1-{(2-{[(dimethylamino)sulfonyl]amino}ethyl)[2-(1H-indol-3-yl)ethyl]amino}-2,3-dihydro-1H-inden-5-yl)acrylate



Intermediate T [methyl (2E)-3-(1-{(2-aminoethyl)[2-(1H-indol-3-yl)ethyl]amino}-2,3-dihydro-1H-inden-5-yl)acrylate] (150 mg, 0.37 mmol), and Et_3N (80 uL, 0.56 mmol) were dissolved in CH_2Cl_2 (3 mL). The solution was cooled to –40 °C and dimethylsulfamoyl chloride (50 uL, 0.41 mmol) was added. The reaction was warmed to rt and stirred for 18 h. The reaction was diluted with CH_2Cl_2 and washed with saturated $NaHCO_3$ solution and brine. The organic layer was collected, dried over anhydrous Na_2SO_4, filtered, followed by removal of solvent under vacuum. The crude product was purified by silica gel chromatography using 40% EtOAc/hexanes as eluent to obtain methyl (2E)-3-(1-{(2-{[(dimethylamino)sulfonyl]amino}ethyl)[2-(1H-indol-3-yl)ethyl]amino}-2,3-dihydro-1H-inden-5-yl)acrylate (123 mg, 65% yield) as an oily solid: LC/MS [M+H] 511.1, RT 2.36 min (method A).

Intermediate AB

Methyl (2E)-3-(1-{[(4-aminophenyl)sulfonyl][2-(1H-indol-3-yl)ethyl]amino}-2,3-dihydro-1H-inden-5-yl)acrylate



To a solution of intermediate O4 [methyl (2E)-3-(1-{{[4-(acetylamino)phenyl]sulfonyl}[2-(1H-indol-3-yl)ethyl]amino}-2,3-dihydro-1H-inden-5-yl)acrylate] (0.28g, 0.54mmol) in MeOH (10 ml) was slowly added 1M hydrogen chloride in 1,4-dioxane (0.8 ml). The mixture was heated to reflux for 5 h. After cooled to rt, the solvent was evaporated to give a yellow residue. The residue was purified on column chromatography with MeOH-CH_2Cl_2 (5/95, v/v) to give the desired product (0.26g, 90%): LC/MS [M+H] 515.9, RT 3.48 min (method A).

Intermediate AC

Methyl (2E)-3-(1-{({4-[(2-hydroxyethyl)amino]phenyl}sulfonyl)[2-(1H-indol-3-yl)ethyl]amino}-2,3-dihydro-1H-inden-5-yl)acrylate



A solution of intermediate AB [methyl (2E)-3-(1-{[(4-aminophenyl)sulfonyl][2-(1H-indol-3-yl)ethyl]amino}-2,3-dihydro-1H-inden-5-yl)acrylate] (74 mg, 0.14mmol) in MeOH (4 ml) was placed in a 20 ml sealed tube and was bubbled with ethylene oxide for 30 min. The sealed tube was closed and heated at 100 °C for 1h. After cooled to rt, the crude was separated with reverse-phase preparative HPLC to give the desired compound (23mg, 23%) with a 80% purity. No further purification was pursued. LC/MS [M+1] 559.9, RT 2.63 min (method A).

Intermediate AD

1-Bromo-3-(chloromethyl)-2-fluorobenzene



To a solution of 3-bromo-2-fluorophenyl)methanol (820 mg, 4.00mmol) in toluene (10 mL was added thionyl chloride (0.44 mL, 6.00 mmol) and two drops of DMF. The reaction mixture was heated at 90^{0}C for 30 min, cooled to rt and concentrated down to afford intermediate 1-bromo-3-(chloromethyl)-2-fluorobenzene (890 mg, 99%). ^{1}H-NMR (DMSO-*d6*) δ 7.71 (m, 1H), 7.53 (m, 1H), 7.17 (m, 1H), 4.82 (d, 2H).

Intermediate AE

(3-Bromo-2-fluorophenyl)malonic acid



To a cold suspension of NaH (0.07 g, 3.10 mmol) in THF (5 mL) was added dropwise a solution of diethyl malonate (0.47 mL, 3.10 mmol) in THF (5 mL). The reaction was warmed up to rt and stirred for 1 h. Then a solution of intermediate AD [1-bromo-3-(chloromethyl)-2-fluorobenzene] (0.39 g, 1.72 mol) in THF (10 mL) was added dropwise. The reaction mixture was refluxed overnight, cooled and concentrated down. Water was added and extracted with CH_2Cl_2. The organic layer was washed with water, brine dried over Na_2SO_4, filtered and concentrated down. The residue was passed through a short silica gel pad to afford crude intermediate diethyl (3-bromo-2-fluorophenyl)malonate (0.59 g, 68%).

To a solution of diethyl (3-bromo-2-fluorophenyl)malonate (0.58 g, 1.73 mmol) in EtOH (20 mL) was added NaOH (50%, 2 mL). The reaction mixture was refluxed for 3 h, cooled down and concentrated. HCl (1N) was added to change pH to 4 and the mixture was extracted with ether. The organic layer was washed with water, brine, and dried over Na_2SO_4, filtered and concentrated down to afford (3-bromo-2-fluorophenyl)malonic acid as a white solid (0.45 g, 93%). ^{1}H-NMR (DMSO-*d6*) δ 12.91 (S, 2H), 7.54 (m, 1H), 7.30 (m, 1H), 7.06 (m, 1H), 3.57 (t, 1H), 3.07 (d, 2H).

Intermediate AF

(3-Bromo-2-fluorophenyl)acetic acid



The solution of intermediate AE [3-bromo-2-fluorophenyl)malonic acid] (450 mg, 1.55 mmol) in dioxane (10 mL) was refluxed overnight, cooled down and concentrated. Water was added and the mixture was extracted with ether. The organic layer was washed

with water, brine dried over Na_2SO_4, filtered and concentrated down afford (3-bromo-2-fluorophenyl)acetic acid as a white solid (370 mg, 96%). GC/MS [Exact Mass] 246; ^{1}H-NMR (DMSO-*d6*) δ 12.51 (S, 1H), 7.51 (m, 1H), 7.33 (m, 1H), 7.08 (m, 1H), 2.85 (t, 2H), 2.53 (t, 2H).

Intermediate AG

5-Bromo-4-fluoroindan-1-one



To the solution of intermediate AF [(3-bromo-2-fluorophenyl)acetic acid] (150 mg, 0.61 mmol) in CH_2Cl_2 (10 mL) was added thionyl chloride (0.13 mL, 1.82 mmol) and 2 drops of DMF. The mixture was stirred at rt overnight and concentrated down. The residue was dissolved in CH_2Cl_2 (5 mL) and then added to a cold solution of $AlCl_3$ in CH_2Cl_2 (5 mL). The reaction mixture was stirred at 0^{0}C for 20 min and then at rt for 3 h, poured into ice water and the mixture was extracted with CH_2Cl_2. The organic layer was washed with saturated $NaHCO_3$, brine, dried over Na_2SO_4, filtered and concentrated down. Chromatography using a Biotage cartridge (25S) with the EtOAc/ Hexane (10/90) afforded 5-bromo-4-fluoroindan-1-one (120 mg, 86%). GC/MS [Exact Mass] 228; ^{1}H-NMR (DMSO-*d6*) δ 7.74 (m, 1H), 7.40 (d, 1H), 3.12 (t, 2H), 2.68 (m, 2H).

Intermediate AH

N-(4-Formylphenyl)methanesulfonamide



A solution of ethyl 4-aminobenzoate (1.00 g, 6.05 mmol) in pyridine (10 mL) was treated with methanesulfonyl chloride (1.11 g, 9.69 mmol) and stirred at rt for 1 hr. The mixture was diluted with EtOAc and H_2O and the layers were separated. The organic layer was washed with 1 N HCl, brine, and dried over $MgSO_4$. The solvent was removed at reduced pressure and the solid obtained was washed with Et_2O/hexanes to obtain Ethyl 4-[(methylsulfonyl)amino]benzoate as a light pink solid (1.29 g, 88 %): ^{1}H NMR (DMSO-*d6*) δ 10.32 (s, 1H), 7.90 (d, 2H), 7.26 (d, 2H), 4.26 (q, 2H), 3.08 (s, 3H), 1.28 (t, 3H).

A $LiAlH_4$ solution (1.0 M in THF, 6.9 mL, 6.90 mmol) was added to an oven dried flask under nitrogen. The solution was diluted with THF (15 mL) and cooled to 0 °C. A

solution of ethyl 4-[(methylsulfonyl)amino]benzoate (1.29 g, 5.30 mmol) in THF (5 mL) was added dropwise to the LAH solution. After the addition, the reaction was warmed up to rt and stirred for 1 hr. TLC of a small aliquot showed complete reaction. The reaction was then cooled to 0 °C and treated carefully with EtOAc (5 mL), EtOH (5 mL), and 10% $NaHSO_4$ (7 mL). The suspension was filtered through celite and the filtrate was dried over $MgSO_4$. The solvent was removed at reduced pressure to obtain N-[4-(hydroxymethyl)phenyl]methanesulfonamide as a white solid (0.99 g, 93 %): ^{1}H NMR (DMSO-*d6*) δ 9.62 (s, 1H), 7.24 (d, 2H), 7.13 (d, 2H), 5.12 (t, 1H), 4.42 (d, 2H), 2.92 (s, 3H).

N-[4-(hydroxymethyl)phenyl]methanesulfonamide (0.99 g, 4.91 mmol) was dissolved in THF (15 mL) and treated with MnO_2 (1.01 g, 9.83 mmol). The reaction was stirred at 50 °C overnight. The Manganese oxide was then filtered through celite and the filtrate was purified with 40 S Biotage eluting with 40-50% EtOAc in hexanes to obtain *N*-(4-formylphenyl)methanesulfonamide as a white solid (0.64 g, 65 %): ^{1}H NMR (DMSO-*d6*) δ 10.47 (s, 1H), 9.86 (s, 1H), 7.86 (d, 2H), 7.33 (d, 2H), 3.13 (s, 3H).

By following the above procedures and those described for the amide formation (intermediate M, X), the sulfonamide formation (intermediate O), the urea formation (intermediate N), and the sulfonyl urea formation (intermediate AA), the following aldehydes are prepared in similar manners.

Inter-mediate	Structure	TLC R_f (solvent)
AH1		0.33 (EtOAc:hexanes, 1:1)
AH2		0.19 (EtOAc:hexanes, 1:1)

Inter-mediate	Structure	TLC R_f (solvent)
AH3		0.11 (EtOAc:hexanes, 2:3)
AH4		0.26 (EtOAc: CH_2Cl_2, 1:9)
AH5		0.38 (EtOAc:hexanes, 2:3)
AH6		0.20 (EtOAc:hexanes, 2:3)
AH7		0.12 (EtOAc:hexanes, 3:2)
AH8		0.23 (EtOAc:hexanes, 3:2)
AH9		0.39 (EtOAc:hexanes, 2:3)

Inter-mediate	Structure	TLC R_f (solvent)
AH10		0.31 (EtOAc:hexanes, 2:3)

Compound Example 1

(2*E*)-*N*-Hydroxy-3-((1*R*)-1-{[(1S)-2-hydroxy-1-(1*H*-indol-3-ylmethyl)ethyl]amino}-2,3-dihydro-1*H*-inden-5-yl)-2-propenamide



A mixture of Intermediate E1 (methyl (2*E*)-3-((1*R*)-1-{[(1*S*)-2-hydroxy-1-(1*H*-indol-3-ylmethyl)ethyl]amino}-2,3-dihydro-1*H*-inden-5-yl)-2-propenoate) (1.40 g, 3.59 mmol) and hydroxylamine hydrochloride (2.288g, 32.27 mmol) in 40 mL MeOH was stirred for 10 min at rt, and cooled to ca. 5 °C with ice bath. KOH pellets (3.78g, 57.3 mmol) was added to the cold reaction mixture. Ice bath was removed after 10 min. The reaction was allowed to warm to rt and was left stirring for 2 h. The reaction was quenched with 200 mL saturated aqueous NH_4Cl, extracted with EtOAc (5 x 200 mL). The combined extract was washed with saturated aqueous $NaHCO_3$, brine, and dried over Na_2SO_4. The solvent was removed under reduced pressure to yield (2*E*)-*N*-hydroxy-3-(1-{[(1S)-2-hydroxy-1-(1*H*-indol-3-ylmethyl)ethyl]amino}-2,3-dihydro-1*H*-inden-5-yl)-2-propenamide (1.10g, 78.%) as a white solid: LC/MS [M+H] 391.9, RT 1.65 min (method A); ^{1}H-NMR (DMSO-d6) δ 10.7(s, 1H), 10.6(broad, 1H), 9.0(broad, 1H), 7.51(d, 1H), 7.29-7.41(m, 5H), 7.13 (d, 1H), 7.05(t, 1H), 6.95 (t, 1H), 6.35 (d, 1H), 4.53 (d, 1H), 4.26 (t, 1H), 3.39 (s, 2H), 3.03 (m, 1H), 2.2.83-2.90 (m, 1H), 2.62-2.69 (m, 4H), 2.24-2.29 (m, 1H) and 1.35-1.41 (m, 1H).

Compound example 193

(-)-(2E)-N-hydroxy-3-(1-{(2-hydroxyethyl)[2-(1H-indol-3-yl)ethyl]amino}-2,3-dihydro-1H-inden-5-yl)but-2-enamide



Intermediate R3 [methyl (2E)-3-{(1S)-1-[(2-hydroxyethyl)amino]-2,3-dihydro-1H-inden-5-yl}but-2-enoate - 3-propyl-1H-indole] (0.445 g, 1.06 mmol) was dissolved in dioxane (10 mL) and cooled to 0 °C. NH_2OH (10 mL, 50% in water) was added to above mixture followed by 1N NaOH (10 mL). The resulting solution was stirred at 0 °C for 2 h and at rt for another hour. The reaction was quenched with NH_4Cl saturated solution, diluted with EtOAc (30 mL) and stirred until both layers become clear. The organic layer was separated, washed with brine, dried over Na_2SO4 and concentrated to obtain the desired product (0.31 g, 70 %): LC/MS [M+H] 420.2, RT 1.83 min (method A). ^{1}H-NMR (CD_3OD) δ 7.26 (m, 5H), 7.14 (m, 2H), 6.90 (t, 1H), 6.02 (s, 1H), 4.71 (s, 1H), 3.63 (m, 2H), 2.92 (m, 8H), 2.51 (s, 3H), 2.33 (m, 1H), 2.10 (m, 1H).

With the exception of compound example 43, 44, 45, 46, 181, 182, and 183, all other compound examples in table 1 are synthesized in a similar manner as described above for compound example 1 and 193.

Compound Example 43

(2*E*)-*N*-Hydroxy-3-(2-{[2-(1*H*-indol-3-yl)ethyl]amino}-2,3-dihydro-1*H*-inden-5-yl)-2-propenamide



Compound Example 10 (*tert*-Butyl 3-[2-((*tert*-butoxycarbonyl){5-[(1*E*)-3-(hydroxyamino)-3-oxo-1-propenyl]-2,3-dihydro-1*H*-inden-2-yl}amino)ethyl]-1*H*-indole-1-carboxylate) (119 mg, 0.21 mmol) was dissolved in CH_2Cl_2 (4 mL) and TFA (1 mL) was added. The solution was stirred for 1h before the solvent was removed under vacuum. The crude material was dissolved in a small amount of EtOAc. This solution was added to a stirring solution of 1:1 $NaHCO_3/Na_2CO_3$ (pH 9). The product precipitated out and the mixture was filtered. The solid was collected and dried to give (2*E*)-*N*-hydroxy-3-(2-{[2-(1*H*-indol-3-yl)ethyl]amino}-2,3-dihydro-1*H*-inden-5-yl)-2-propenamide as a white solid (46 mg,

60%): ^{1}H-NMR (DMSO-d6) δ 10.82 (s, 1H), 7.52 (d, 1H), 7.17-7.42 (m, 6H), 6.95-7.08 (m, 2H), 6.38 (d, 1H), 3.74 (m, 1H), 2.77-3.17 (m, 8H).

Examples 44, 45, and 46 are synthesized in a similar manner. In the case of examples 45 and 46, 95% TFA in water is used.

Compound Example 182

N-{(1R)-5-[(1E)-3-(Hydroxyamino)-3-oxoprop-1-en-1-yl]-2,3- dihydro-1H-inden-1-yl}-N-[(1S)-2-hydroxy-1-(1H-indol-3-ylmethyl)ethyl]benzamide



A mixture of intermediate E1 [methyl (2E)-3-((1R)-1-{[(1S)-2-hydroxy-1-(1H-indol-3-ylmethyl)ethyl]amino}-2,3-dihydro-1H-inden-5-yl)acrylate] (0.2g, 0.51mmol), benzoyl chloride (0.28 g, 2.05 mmol) and Et_3N (0.29 ml, 2.05 mmol) in CH_2Cl_2 (2 ml) was stirred at rt for 16h. To the crude mixture was added MeOH (2ml) and hydroxylamine hydrochloride salt (0.32 g, 4.61 mmol). The reaction mixture was stirred at rt for 10 min. and was cooled to 0 °C with an ice-water bath. Potassium hydroxide (0.67 g, 10.24 mmol) was added to the reaction mixture as pellets. The reaction was continued to stir for 1h. The reaction was quenched with saturated aqueous NH_4Cl, and extracted with EtOAc. The combined extract was washed with saturated aqueous $NaHCO_3$, brine, and dried over Na_2SO_4. The solvent was removed and the crude product was purified with reverse-phase preparative HPLC to give the desired product as an oil (4 mg, 1.5%). LC/MS [M+1] 496.0, RT 2.45 min (Method A).

Examples 181 and 183 are prepared in a similar manner as described above.

Pro-drugs of this invention in general may be made by conventional methods well known in the art. For example, the hydroxyl groups may be converted to esters by reacting the compounds with carboxylic acid chlorides or anhydrides under standard conditions. The hydroxyl groups may also be converted to carbonates by reacting the compounds with chloroformates under standard conditions.

Salts of the compounds identified herein can be obtained by isolating the compounds as hydrochloride salts, prepared by treatment of the free base with anhydrous

HCl in a suitable solvent such as THF. Generally, a desired salt of a compound of this invention can be prepared in situ during the final isolation and purification of a compound by means well known in the art. Or, a desired salt can be prepared by separately reacting the purified compound in its free base form with a suitable organic or inorganic acid and isolating the salt thus formed. These methods are conventional and would be readily apparent to one skilled in the art.

Additionally, sensitive or reactive groups on the compound of this invention may need to be protected and deprotected during any of the above methods. Protecting groups in general may be added and removed by conventional methods well known in the art (see, for example, T. W. Greene and P.G.M. Wuts, *Protective Groups in Organic Synthesis;* Wiley: New York, (1999).

Compositions of the compounds of this invention

The compounds of this invention can be utilized to achieve the desired pharmacological effect by administration to a patient in need thereof in an appropriately formulated pharmaceutical composition. The present invention includes pharmaceutical compositions that are comprised of a pharmaceutically acceptable carrier and a pharmaceutically effective amount of a compound, or salt thereof, of the present invention. A pharmaceutically acceptable carrier is any carrier that is relatively non-toxic and innocuous to a patient at concentrations consistent with effective activity of the active ingredient so that any side effects ascribable to the carrier do not vitiate the beneficial effects of the active ingredient. A pharmaceutically effective amount of compound is that amount which produces a result or exerts an influence on the particular condition being treated. The compounds of the present invention can be administered with pharmaceutically-acceptable carriers well known in the art using any effective conventional dosage unit forms, including immediate, slow and timed release preparations, orally, parenterally, topically, nasally, ophthalmically, otically, sublingually, rectally, vaginally, and the like.

For oral administration, the compounds can be formulated into solid or liquid preparations such as capsules, pills, tablets, troches, lozenges, melts, powders, solutions, suspensions, or emulsions, and may be prepared according to methods known to the art for the manufacture of pharmaceutical compositions. The solid unit dosage forms can be a capsule which can be of the ordinary hard- or soft-shelled gelatin type containing, for example, surfactants, lubricants, and inert fillers such as lactose, sucrose, calcium phosphate, and corn starch.

In another embodiment, the compounds of this invention may be tableted with conventional tablet bases such as lactose, sucrose and cornstarch in combination with

binders such as acacia, corn starch or gelatin, disintegrating agents intended to assist the break-up and dissolution of the tablet following administration such as potato starch, alginic acid, corn starch, and guar gum, gum tragacanth, acacia, lubricants intended to improve the flow of tablet granulation and to prevent the adhesion of tablet material to the surfaces of the tablet dies and punches, for example talc, stearic acid, or magnesium, calcium or zinc stearate, dyes, coloring agents, and flavoring agents such as peppermint, oil of wintergreen, or cherry flavoring, intended to enhance the aesthetic qualities of the tablets and make them more acceptable to the patient. Suitable excipients for use in oral liquid dosage forms include dicalcium phosphate and diluents such as water and alcohols, for example, ethanol, benzyl alcohol, and polyethylene alcohols, either with or without the addition of a pharmaceutically acceptable surfactant, suspending agent or emulsifying agent. Various other materials may be present as coatings or to otherwise modify the physical form of the dosage unit. For instance tablets, pills or capsules may be coated with shellac, sugar or both.

Dispersible powders and granules are suitable for the preparation of an aqueous suspension. They provide the active ingredient in admixture with a dispersing or wetting agent, a suspending agent and one or more preservatives. Suitable dispersing or wetting agents and suspending agents are exemplified by those already mentioned above. Additional excipients, for example those sweetening, flavoring and coloring agents described above, may also be present.

The pharmaceutical compositions of this invention may also be in the form of oil-in-water emulsions. The oily phase may be a vegetable oil such as liquid paraffin or a mixture of vegetable oils. Suitable emulsifying agents may be (1) naturally occurring gums such as gum acacia and gum tragacanth, (2) naturally occurring phosphatides such as soy bean and lecithin, (3) esters or partial esters derived form fatty acids and hexitol anhydrides, for example, sorbitan monooleate, (4) condensation products of said partial esters with ethylene oxide, for example, polyoxyethylene sorbitan monooleate. The emulsions may also contain sweetening and flavoring agents.

Oily suspensions may be formulated by suspending the active ingredient in a vegetable oil such as, for example, arachis oil, olive oil, sesame oil or coconut oil, or in a mineral oil such as liquid paraffin. The oily suspensions may contain a thickening agent such as, for example, beeswax, hard paraffin, or cetyl alcohol. The suspensions may also contain one or more preservatives, for example, ethyl or *n*-propyl p-hydroxybenzoate; one or more coloring agents; one or more flavoring agents; and one or more sweetening agents such as sucrose or saccharin.

Syrups and elixirs may be formulated with sweetening agents such as, for example,

glycerol, propylene glycol, sorbitol or sucrose. Such formulations may also contain a demulcent, and preservative, such as methyl and propyl parabens and flavoring and coloring agents.

The compounds of this invention may also be administered parenterally, that is, subcutaneously, intravenously, intraocularly, intrasynovially, intramuscularly, or interperitoneally, as injectable dosages of the compound in a physiologically acceptable diluent with a pharmaceutical carrier which can be a sterile liquid or mixture of liquids such as water, saline, aqueous dextrose and related sugar solutions, an alcohol such as ethanol, isopropanol, or hexadecyl alcohol, glycols such as propylene glycol or polyethylene glycol, glycerol ketals such as 2,2-dimethyl-1,1-dioxolane-4-methanol, ethers such as poly(ethylene glycol) 400, an oil, a fatty acid, a fatty acid ester or, a fatty acid glyceride, or an acetylated fatty acid glyceride, with or without the addition of a pharmaceutically acceptable surfactant such as a soap or a detergent, suspending agent such as pectin, carbomers, methycellulose, hydroxypropylmethylcellulose, or carboxymethylcellulose, or emulsifying agent and other pharmaceutical adjuvants.

Illustrative of oils which can be used in the parenteral formulations of this invention are those of petroleum, animal, vegetable, or synthetic origin, for example, peanut oil, soybean oil, sesame oil, cottonseed oil, corn oil, olive oil, petrolatum and mineral oil. Suitable fatty acids include oleic acid, stearic acid, isostearic acid and myristic acid. Suitable fatty acid esters are, for example, ethyl oleate and isopropyl myristate. Suitable soaps include fatty acid alkali metal, ammonium, and triethanolamine salts and suitable detergents include cationic detergents, for example dimethyl dialkyl ammonium halides, alkyl pyridinium halides, and alkylamine acetates; anionic detergents, for example, alkyl, aryl, and olefin sulfonates, alkyl, olefin, ether, and monoglyceride sulfates, and sulfosuccinates; non-ionic detergents, for example, fatty amine oxides, fatty acid alkanolamides, and poly(oxyethylene-oxypropylene)s or ethylene oxide or propylene oxide copolymers; and amphoteric detergents, for example, alkyl-beta-aminopropionates, and 2-alkylimidazoline quarternary ammonium salts, as well as mixtures.

The parenteral compositions of this invention will typically contain from about 0.5% to about 25% by weight of the active ingredient in solution. Preservatives and buffers may also be used advantageously. In order to minimize or eliminate irritation at the site of injection, such compositions may contain a non-ionic surfactant having a hydrophile-lipophile balance (HLB) of from about 12 to about 17. The quantity of surfactant in such formulation ranges from about 5% to about 15% by weight. The surfactant can be a single component having the above HLB or can be a mixture of two or more components having the desired HLB.

Illustrative of surfactants used in parenteral formulations are the class of polyethylene sorbitan fatty acid esters, for example, sorbitan monooleate and the high molecular weight adducts of ethylene oxide with a hydrophobic base, formed by the condensation of propylene oxide with propylene glycol.

The pharmaceutical compositions may be in the form of sterile injectable aqueous suspensions. Such suspensions may be formulated according to known methods using suitable dispersing or wetting agents and suspending agents such as, for example, sodium carboxymethylcellulose, methylcellulose, hydroxypropylmethyl-cellulose, sodium alginate, polyvinylpyrrolidone, gum tragacanth and gum acacia; dispersing or wetting agents which may be a naturally occurring phosphatide such as lecithin, a condensation product of an alkylene oxide with a fatty acid, for example, polyoxyethylene stearate, a condensation product of ethylene oxide with a long chain aliphatic alcohol, for example, heptadeca-ethyleneoxycetanol, a condensation product of ethylene oxide with a partial ester derived form a fatty acid and a hexitol such as polyoxyethylene sorbitol monooleate, or a condensation product of an ethylene oxide with a partial ester derived from a fatty acid and a hexitol anhydride, for example polyoxyethylene sorbitan monooleate.

The sterile injectable preparation may also be a sterile injectable solution or suspension in a non-toxic parenterally acceptable diluent or solvent. Diluents and solvents that may be employed are, for example, water, Ringer's solution, isotonic sodium chloride solutions and isotonic glucose solutions. In addition, sterile fixed oils are conventionally employed as solvents or suspending media. For this purpose, any bland, fixed oil may be employed including synthetic mono- or diglycerides. In addition, fatty acids such as oleic acid can be used in the preparation of injectables.

A composition of the invention may also be administered in the form of suppositories for rectal administration of the drug. These compositions can be prepared by mixing the drug with a suitable non-irritation excipient which is solid at ordinary temperatures but liquid at the rectal temperature and will therefore melt in the rectum to release the drug. Such material are, for example, cocoa butter and polyethylene glycol.

Another formulation employed in the methods of the present invention employs transdermal delivery devices ("patches"). Such transdermal patches may be used to provide continuous or discontinuous infusion of the compounds of the present invention in controlled amounts. The construction and use of transdermal patches for the delivery of pharmaceutical agents is well known in the art (see, e.g., US Patent No. 5,023,252, issued June 11, 1991, incorporated herein by reference). Such patches may be constructed for continuous, pulsatile, or on demand delivery of pharmaceutical agents.

Controlled release formulations for parenteral administration include liposomal,

polymeric microsphere and polymeric gel formulations which are known in the art.

It may be desirable or necessary to introduce the pharmaceutical composition to the patient via a mechanical delivery device. The construction and use of mechanical delivery devices for the delivery of pharmaceutical agents is well known in the art. Direct techniques for, for example, administering a drug directly to the brain usually involve placement of a drug delivery catheter into the patient's ventricular system to bypass the blood-brain barrier. One such implantable delivery system, used for the transport of agents to specific anatomical regions of the body, is described in US Patent No. 5,011,472, issued April 30, 1991.

The compositions of the invention can also contain other conventional pharmaceutically acceptable compounding ingredients, generally referred to as carriers or diluents, as necessary or desired. Conventional procedures for preparing such compositions in appropriate dosage forms can be utilized. Such ingredients and procedures include those described in the following references, each of which is incorporated herein by reference: Powell, M.F. *et al,* "Compendium of Excipients for Parenteral Formulations" *PDA Journal of Pharmaceutical Science & Technology* 1998, 52(5), 238-311; Strickley, R.G "Parenteral Formulations of Small Molecule Therapeutics Marketed in the United States (1999)-Part-1" *PDA Journal of Pharmaceutical Science & Technology* 1999, 53(6), 324-349; and Nema, S. *et al*, "Excipients and Their Use in Injectable Products" *PDA Journal of Pharmaceutical Science & Technology* 1997, 51(4), 166-171.

Commonly used pharmaceutical ingredients which can be used as appropriate to formulate the composition for its intended route of administration include:

acidifying agents (examples include but are not limited to acetic acid, citric acid, fumaric acid, hydrochloric acid, nitric acid);

alkalinizing agents (examples include but are not limited to ammonia solution, ammonium carbonate, diethanolamine, monoethanolamine, potassium hydroxide, sodium borate, sodium carbonate, sodium hydroxide, triethanolamine, trolamine);

adsorbents (examples include but are not limited to powdered cellulose and activated charcoal);

aerosol propellants (examples include but are not limited to carbon dioxide, CCl_2F_2, $F_2ClC\text{-}CClF_2$ and $CClF_3$)

air displacement agents (examples include but are not limited to nitrogen and argon);

antifungal preservatives (examples include but are not limited to benzoic acid, butylparaben, ethylparaben, methylparaben, propylparaben, sodium benzoate);

antimicrobial preservatives (examples include but are not limited to benzalkonium chloride, benzethonium chloride, benzyl alcohol, cetylpyridinium chloride, chlorobutanol, phenol, phenylethyl alcohol, phenylmercuric nitrate and thimerosal);

antioxidants (examples include but are not limited to ascorbic acid, ascorbyl palmitate, butylated hydroxyanisole, butylated hydroxytoluene, hypophosphorus acid, monothioglycerol, propyl gallate, sodium ascorbate, sodium bisulfite, sodium formaldehyde sulfoxylate, sodium metabisulfite);

binding materials (examples include but are not limited to block polymers, natural and synthetic rubber, polyacrylates, polyurethanes, silicones, polysiloxanes and styrene-butadiene copolymers);

buffering agents (examples include but are not limited to potassium metaphosphate, dipotassium phosphate, sodium acetate, sodium citrate anhydrous and sodium citrate dihydrate)

carrying agents (examples include but are not limited to acacia syrup, aromatic syrup, aromatic elixir, cherry syrup, cocoa syrup, orange syrup, syrup, corn oil, mineral oil, peanut oil, sesame oil, bacteriostatic sodium chloride injection and bacteriostatic water for injection)

chelating agents (examples include but are not limited to edetate disodium and edetic acid)

colorants (examples include but are not limited to FD&C Red No. 3, FD&C Red No. 20, FD&C Yellow No. 6, FD&C Blue No. 2, D&C Green No. 5, D&C Orange No. 5, D&C Red No. 8, caramel and ferric oxide red);

clarifying agents (examples include but are not limited to bentonite);

emulsifying agents (examples include but are not limited to acacia, cetomacrogol, cetyl alcohol, glyceryl monostearate, lecithin, sorbitan monooleate, polyoxyethylene 50 monostearate);

encapsulating agents (examples include but are not limited to gelatin and cellulose acetate phthalate)

flavorants (examples include but are not limited to anise oil, cinnamon oil, cocoa, menthol, orange oil, peppermint oil and vanillin);

humectants (examples include but are not limited to glycerol, propylene glycol and sorbitol);

levigating agents (examples include but are not limited to mineral oil and glycerin);

oils (examples include but are not limited to arachis oil, mineral oil, olive oil, peanut oil, sesame oil and vegetable oil);

ointment bases (examples include but are not limited to lanolin, hydrophilic ointment, polyethylene glycol ointment, petrolatum, hydrophilic petrolatum, white ointment, yellow ointment, and rose water ointment);

penetration enhancers (transdermal delivery) (examples include but are not limited to monohydroxy or polyhydroxy alcohols, mono-or polyvalent alcohols, saturated or unsaturated fatty alcohols, saturated or unsaturated fatty esters, saturated or unsaturated dicarboxylic acids, essential oils, phosphatidyl derivatives, cephalin, terpenes, amides, ethers, ketones and ureas)

plasticizers (examples include but are not limited to diethyl phthalate and glycerol);

solvents (examples include but are not limited to ethanol, corn oil, cottonseed oil, glycerol, isopropanol, mineral oil, oleic acid, peanut oil, purified water, water for injection, sterile water for injection and sterile water for irrigation);

stiffening agents (examples include but are not limited to cetyl alcohol, cetyl esters wax, microcrystalline wax, paraffin, stearyl alcohol, white wax and yellow wax);

suppository bases (examples include but are not limited to cocoa butter and polyethylene glycols (mixtures));

surfactants (examples include but are not limited to benzalkonium chloride, nonoxynol 10, oxtoxynol 9, polysorbate 80, sodium lauryl sulfate and sorbitan mono-palmitate);

suspending agents (examples include but are not limited to agar, bentonite, carbomers, carboxymethylcellulose sodium, hydroxyethyl cellulose, hydroxypropyl cellulose, hydroxypropyl methylcellulose, kaolin, methylcellulose, tragacanth and veegum);

sweetening agents (examples include but are not limited to aspartame, dextrose, glycerol, mannitol, propylene glycol, saccharin sodium, sorbitol and sucrose);

tablet anti-adherents (examples include but are not limited to magnesium stearate and talc);

tablet binders (examples include but are not limited to acacia, alginic acid, carboxymethylcellulose sodium, compressible sugar, ethylcellulose, gelatin, liquid glucose, methylcellulose, non-crosslinked polyvinyl pyrrolidone, and pregelatinized starch);

tablet and capsule diluents (examples include but are not limited to dibasic calcium phosphate, kaolin, lactose, mannitol, microcrystalline cellulose, powdered cellulose, precipitated calcium carbonate, sodium carbonate, sodium phosphate, sorbitol and starch);

tablet coating agents (examples include but are not limited to liquid glucose, hydroxyethyl cellulose, hydroxypropyl cellulose, hydroxypropyl methylcellulose, methylcellulose, ethylcellulose, cellulose acetate phthalate and shellac);

tablet direct compression excipients (examples include but are not limited to dibasic calcium phosphate);

tablet disintegrants (examples include but are not limited to alginic acid, carboxymethylcellulose calcium, microcrystalline cellulose, polacrillin potassium, cross-linked polyvinylpyrrolidone, sodium alginate, sodium starch glycollate and starch);

tablet glidants (examples include but are not limited to colloidal silica, corn starch and talc);

tablet lubricants (examples include but are not limited to calcium stearate, magnesium stearate, mineral oil, stearic acid and zinc stearate);

tablet/capsule opaquants (examples include but are not limited to titanium dioxide);

tablet polishing agents (examples include but are not limited to carnuba wax and white wax);

thickening agents (examples include but are not limited to beeswax, cetyl alcohol and paraffin);

tonicity agents (examples include but are not limited to dextrose and sodium chloride);

viscosity increasing agents (examples include but are not limited to alginic acid, bentonite, carbomers, carboxymethylcellulose sodium, methylcellulose, polyvinyl pyrrolidone, sodium alginate and tragacanth); and

wetting agents (examples include but are not limited to heptadecaethylene oxycetanol, lecithins, sorbitol monooleate, polyoxyethylene sorbitol monooleate, and polyoxyethylene stearate).

It is believed that one skilled in the art, using the preceding information, can utilize the present invention to its fullest extent. Nevertheless, the following are examples of pharmaceutical formulations that can be used in the composition of the present invention. They are for illustrative purposes only, and are not to be construed as limiting the invention in any way.

Pharmaceutical compositions according to the present invention can be illustrated as follows:

Sterile IV Solution: A 2 mg/mL solution of the desired compound of this invention is made using sterile, injectable water, and the pH is adjusted if necessary. The solution is diluted for administration to 0.2 - 1 mg/mL with sterile 5% dextrose and is administered as an IV infusion over 120 minutes.

Lyophilized powder for IV administration: A sterile preparation can be prepared with (i) 100 - 1000 mg of the desired compound of this invention as a lypholized powder, (ii) 32- 327

mg/mL sodium citrate, and (iii) 300 – 3000 mg Dextran 40. The formulation is reconstituted with sterile, injectable saline or dextrose 5% to a concentration of 10 to 20 mg/mL, which is further diluted with saline or dextrose 5% to 0.2 – 0.4 mg/mL, and is administered either IV bolus or by IV infusion over 15 – 120 min.

Intramuscular suspension: The following solution or suspension can be prepared, for intramuscular injection:

50 mg/mL of the desired, water-insoluble compound of this invention
5 mg/mL sodium carboxymethylcellulose
4 mg/mL TWEEN 80
9 mg/mL sodium chloride
9 mg/mL benzyl alcohol

Hard Shell Capsules: A large number of unit capsules are prepared by filling standard two-piece hard galantine capsules each with 100 mg of powdered active ingredient, 150 mg of lactose, 50 mg of cellulose and 6 mg of magnesium stearate.

Soft Gelatin Capsules: A mixture of active ingredient in a digestible oil such as soybean oil, cottonseed oil or olive oil is prepared and injected by means of a positive displacement pump into molten gelatin to form soft gelatin capsules containing 100 mg of the active ingredient. The capsules are washed and dried. The active ingredient can be dissolved in a mixture of polyethylene glycol, glycerin and sorbitol to prepare a water miscible medicine mix.

Tablets: A large number of tablets are prepared by conventional procedures so that the dosage unit was 100 mg of active ingredient, 0.2 mg. of colloidal silicon dioxide, 5 mg of magnesium stearate, 275 mg of microcrystalline cellulose, 11 mg. of starch, and 98.8 mg of lactose. Appropriate aqueous and non-aqueous coatings may be applied to increase palatability, improve elegance and stability or delay absorption.

Immediate Release Tablets/Capsules: These are solid oral dosage forms made by conventional and novel processes. These units are taken orally without water for immediate dissolution and delivery of the medication. The active ingredient is mixed in a liquid containing ingredient such as sugar, gelatin, pectin and sweeteners. These liquids are solidified into solid tablets or caplets by freeze drying and solid state extraction techniques. The drug compounds may be compressed with viscoelastic and thermoelastic sugars and

polymers or effervescent components to produce porous matrices intended for immediate release, without the need of water.

Method of treating hyper-proliferative disorders

Another embodiment of the present invention relates to a method of using the compounds described above, including salts and pro-drugs thereof and corresponding compositions thereof, to treat mammalian hyper-proliferative disorders. This method comprises administering to a patient an amount of a compound of this invention, or a pharmaceutically acceptable salt thereof, which is effective to treat the patient's hyper-proliferative disorder. A patient, for the purpose of this invention, is a mammal, including a human, in need of treatment for a particular hyper-proliferative disorder. Hyper-proliferative disorders include but are not limited to solid tumors, such as cancers of the breast, respiratory tract, brain, reproductive organs, digestive tract, urinary tract, eye, liver, skin, head and neck, thyroid, parathyroid and their distant metastases. Those disorders also include lymphomas, sarcomas, and leukemias.

Examples of breast cancer include, but are not limited to invasive ductal carcinoma, invasive lobular carcinoma, ductal carcinoma in situ, and lobular carcinoma in situ.

Examples of cancers of the respiratory tract include, but are not limited to small-cell and non-small-cell lung carcinoma, as well as bronchial adenoma and pleuropulmonary blastoma.

Examples of brain cancers include, but are not limited to brain stem and hypophtalmic glioma, cerebellar and cerebral astrocytoma, medulloblastoma, ependymoma, as well as neuroectodermal and pineal tumor.

Tumors of the male reproductive organs include, but are not limited to prostate and testicular cancer. Tumors of the female reproductive organs include, but are not limited to endometrial, cervical, ovarian, vaginal, and vulvar cancer, as well as sarcoma of the uterus.

Tumors of the digestive tract include, but are not limited to anal, colon, colorectal, esophageal, gallbladder, gastric, pancreatic, rectal, small-intestine, and salivary gland cancers.

Tumors of the urinary tract include, but are not limited to bladder, penile, kidney, renal pelvis, ureter, and urethral cancers.

Eye cancers include, but are not limited to intraocular melanoma and retinoblastoma.

Examples of liver cancers include, but are not limited to hepatocellular carcinoma (liver cell carcinomas with or without fibrolamellar variant), cholangiocarcinoma (intrahepatic bile duct carcinoma), and mixed hepatocellular cholangiocarcinoma.

Skin cancers include, but are not limited to squamous cell carcinoma, Kaposi's sarcoma, malignant melanoma, Merkel cell skin cancer, and non-melanoma skin cancer.

Head-and-neck cancers include, but are not limited to laryngeal / hypopharyngeal / nasopharyngeal / oropharyngeal cancer, and lip and oral cavity cancer.

Lymphomas include, but are not limited to AIDS-related lymphoma, non-Hodgkin's lymphoma, cutaneous T-cell lymphoma, Hodgkin's disease, and lymphoma of the central nervous system.

Sarcomas include, but are not limited to sarcoma of the soft tissue, osteosarcoma, malignant fibrous histiocytoma, lymphosarcoma, and rhabdomyosarcoma.

Leukemias include, but are not limited to acute myeloid leukemia, acute lymphoblastic leukemia, chronic lymphocytic leukemia, chronic myelogenous leukemia, and hairy cell leukemia.

These disorders have been well characterized in humans, but also exist with a similar etiology in other mammals, and can be treated by administering pharmaceutical compositions of the present invention.

The utility of the compounds of the present invention can be illustrated, for example, by their activity *in vitro* in the *in vitro* tumor cell proliferation assay described below. The link between activity in tumor cell proliferation assays *in vitro* and anti-tumor activity in the clinical setting has been very well established in the art. For example, the therapeutic utility of taxol (Silvestrini et al. *Stem Cells* 1993, 11(6), 528-35), taxotere (Bissery et al. *Anti Cancer Drugs* 1995, 6(3), 339), and topoisomerase inhibitors (Edelman et al. *Cancer Chemother. Pharmacol.* 1996, 37(5), 385-93) was demonstrated with the use of *in vitro* tumor proliferation assays.

The following assay is one of the methods by which compound activity relating to treatment of the disorders identified herein can be determined.

<u>In vitro tumor cell proliferation assay</u>

The adherent tumor cell proliferation assay used to test the compounds of the present invention involves a readout called Cell Titre-Glo developed by Promega (Cunningham, BA "A Growing Issue: Cell Proliferation Assays. Modern kits ease quantification of cell growth" *The Scientist* 2001, *15*(13), 26, and Crouch, SP *et al.*, "The use of ATP bioluminescence as a measure of cell proliferation and cytotoxicity" *Journal of Immunological Methods* 1993, *160*, 81-88).

HCT116 cells (colon carcinoma, purchased from ATCC) or A549 (lung carcinoma, purchased from ATCC) were plated in 96-well plates at 3000 cells/well in complete media with 10% Fetal Calf Serum and incubated 24 h at 37 °C. Twenty-four h after plating, test

compounds were added over a final concentration range of 10 nM to 20 μM in serial dilutions at a final DMSO concentration of 0.2 %. Cells were incubated for 72 h at 37 °C in complete growth media after addition of the test compound. On day 4, using a Promega Cell Titer Glo Luminescent® assay kit, the cells are lysed and 100 microliters of substrate/buffer mixture is added to each well, mixed and incubated at room temperature for 8 min. The samples were read on a luminometer to measure the amount of ATP present in the cell lysates from each well, which corresponds to the number of viable cells in that well. Values read at 24 h incubation were subtracted as Day 0. For determination of IC50's, a linear regression analysis were used to determine drug concentration which results in a 50% inhibition of cell proliferation using this assay format.

Representative compounds of this invention showed a significant inhibition of tumor cell proliferation in the assays with HCT116 cells (> 50% inhibition at 10 uM) and representative compounds were also studied with the A549 cells and found to be active. MDA-MB-231 (breast adenocarcinoma, purchased from ATCC), LnCaP (prostate carcinoma, purchased from ATCC), H460 (lung carcinoma, purchased from ATCC), or Hela (cervix adenocarcinoma) cells can also be used in similar assays.

Based upon the above and other standard laboratory techniques known to evaluate compounds useful for the treatment of hyper-proliferative disorders, by standard toxicity tests and by standard pharmacological assays for the determination of treatment of the conditions identified above in mammals, and by comparison of these results with the results of known medicaments that are used to treat these conditions, the effective dosage of the compounds of this invention can readily be determined for treatment of each desired indication. The amount of the active ingredient to be administered in the treatment of one of these conditions can vary widely according to such considerations as the particular compound and dosage unit employed, the mode of administration, the period of treatment, the age and sex of the patient treated, and the nature and extent of the condition treated.

The total amount of the active ingredient to be administered will generally range from about 0.01 mg/kg to about 200 mg/kg, and preferably from about 0.1 mg/kg to about 20 mg/kg body weight per day. A unit dosage may contain from about 0.5 mg to about 1500 mg of active ingredient, and can be administered one or more times per day. The daily dosage for administration by injection, including intravenous, intramuscular, subcutaneous and parenteral injections, and use of infusion techniques will preferably be from 0.01 to 200 mg/kg of total body weight. The daily rectal dosage regimen will preferably be from 0.01 to 200 mg/kg of total body weight. The daily vaginal dosage regimen will preferably be from 0.01 to 200 mg/kg of total body weight. The daily topical dosage regimen will preferably be from 0.1 to 200 mg administered between one to four times daily. The transdermal

concentration will preferably be that required to maintain a daily dose of from 0.01 to 200 mg/kg. The daily inhalation dosage regimen will preferably be from 0.01 to 100 mg/kg of total body weight.

Of course the specific initial and continuing dosage regimen for each patient will vary according to the nature and severity of the condition as determined by the attending diagnostician, the activity of the specific compound employed, the age and general condition of the patient, time of administration, route of administration, rate of excretion of the drug, drug combinations, and the like. The desired mode of treatment and number of doses of a compound of the present invention or a pharmaceutically acceptable salt or composition thereof can be ascertained by those skilled in the art using conventional treatment tests.

The compounds of this invention can be administered as the sole pharmaceutical agent or in combination with one or more other pharmaceutical agents where the combination causes no unacceptable adverse effects. For example, the compounds of this invention can be combined with known anti-hyper-proliferative or other indication agents, and the like, as well as with admixtures and combinations thereof.

Optional anti-hyper-proliferative agents which can be added to the composition include but are not limited to compounds listed on the cancer chemotherapy drug regimens in the 11th Edition of the *Merck Index*, (1996), which is hereby incorporated by reference, such as asparaginase, bleomycin, carboplatin, carmustine, chlorambucil, cisplatin, colaspase, cyclophosphamide, cytarabine, dacarbazine, dactinomycin, daunorubicin, doxorubicin (adriamycine), epirubicin, etoposide, 5-fluorouracil, hexamethylmelamine, hydroxyurea, ifosfamide, irinotecan, leucovorin, lomustine, mechlorethamine, 6-mercaptopurine, mesna, methotrexate, mitomycin C, mitoxantrone, prednisolone, prednisone, procarbazine, raloxifen, streptozocin, tamoxifen, thioguanine, topotecan, vinblastine, vincristine, and vindesine.

Other anti-hyper-proliferative agents suitable for use with this invention include but are not limited to those compounds acknowledged to be used in the treatment of neoplastic diseases in *Goodman and Gilman's The Pharmacological Basis of Therapeutics* (Ninth Edition), editor Molinoff et al., publ. by McGraw-Hill, pages 1225-1287, (1996), which is hereby incorporated by reference, such as aminoglutethimide, L-asparaginase, azathioprine, 5-azacytidine cladribine, busulfan, diethylstilbestrol, 2', 2'-difluorodeoxycytidine, docetaxel, erythrohydroxynonyladenine, ethinyl estradiol, 5-fluorodeoxyuridine, 5-fluorodeoxyuridine monophosphate, fludarabine phosphate, fluoxymesterone, flutamide, hydroxyprogesterone caproate, idarubicin, interferon, medroxyprogesterone acetate, megestrol acetate, melphalan, mitotane, paclitaxel,

pentostatin, *N*-phosphonoacetyl-L-aspartate (PALA), plicamycin, semustine, teniposide, testosterone propionate, thiotepa, trimethylmelamine, uridine, and vinorelbine. Other anti-hyper-proliferative agents suitable for use with this invention include but are not limited to other anti-cancer agents such as epothilone, irinotecan, raloxifen and topotecan.

It is believed that one skilled in the art, using the preceding information, can utilize the present invention to its fullest extent.

It should be apparent to one of ordinary skill in the art that changes and modifications can be made to this invention without departing from the spirit or scope of the invention as it is set forth herein.

What is claimed is:

1. A compound of Formula I



(I)

wherein

W is selected from H, $(C_1\text{-}C_6)$alkyl,

O-phenyl optionally substituted with up to 2 substituents each selected independently from R^{12},

phenyl optionally substituted with up to 2 substituents each selected independently from R^{12}, OH, $COOR^7$, $C(O)NHR^7$, $S(O)_2(C_1\text{-}C_3)$alkyl, $NHS(O)_2(C_1\text{-}C_3)$alkyl, $N[(C_1\text{-}C_3)alkyl]_2$, $NH(C_1\text{-}C_3)$alkyl, $NHC(O)(C_1\text{-}C_3)$alkyl,  , and $(C_1\text{-}C_3)$alkoxy substituted with 1 substituent selected from $N[(C_1\text{-}C_3)alkyl]_2$, $NH(C_1\text{-}C_3)$alkyl, and  ,

indolyl optionally substituted with 1 or 2 substituents each selected independently from R^{12}, OH, $C(O)O(C_1\text{-}C_4)$alkyl,

$(C_1\text{-}C_3)$alkyl substituted with 1 or 2 substituents each selected independently from OH, $C(O)R^8$, $(C_1\text{-}C_3)$alkoxy, pyrrolidinyl,  , imidazolyl, $NH(C_1\text{-}C_3)$alkyl, and $N[(C_1\text{-}C_3)alkyl]_2$, and

$(C_1\text{-}C_3)$alkoxy substituted with 1 substituent selected from $NH(C_1\text{-}C_3)$alkyl, $N[(C_1\text{-}C_3)alkyl]_2$, pyrrolidinyl, imidazolyl,  and $(C_1\text{-}C_3)$alkoxy, and

another heteroaryl optionally substituted with up to 3 substituents each independently selected from R^{12};

L is selected from CHR^4, $CHR^5\text{-}CHR^6$, and $CHR^5\text{-}CH_2\text{-}CHR^6$;

R^1 is selected from H, $C(O)R^{10}$, $C(O)OR^7$, tetrahydropyranyl, $(C_3\text{-}C_6)$cycloalkyl, phenyl optionally substituted with up to 2 substituents each independently

selected from R^{12},

pyridyl, optionally substituted with up to 2 substituents each independently selected from R^{12},

$S(O)_2$-phenyl where said phenyl is optionally substituted with 1 or 2 substituents each independently selected from R^{12}, NH_2, $NHC(O)(C_1\text{-}C_3)$alkyl, $NH(C_1\text{-}C_3)$alkyl-$N[(C_1\text{-}C_3)alkyl]_2$, $NH(C_1\text{-}C_3)$alkyl-OH, COOH, OH, and $(C_1\text{-}C_3)$alkoxy substituted with 1 substituent selected from $N[(C_1\text{-}C_3)alkyl]_2$, OH, and  ,

$S(O)_2(C_1\text{-}C_3)$alkyl optionally substituted with one phenyl ring,

$(C_1\text{-}C_6)$alkyl optionally substituted with 1 or 2 substituents each independently selected from OR^{11}, $C(O)R^{10}$, $C(O)OR^7$, $N[(C_1\text{-}C_3)alkyl]_2$, $(C_3\text{-}C_6)$cycloalkyl, dioxopyrrolidinyl,  , glucopyranosyl, glucopyranosylamino,

$(C_1\text{-}C_3)$alkoxy optionally substituted with 1 or 2 substituents each selected independently from OH,  , and imidazolyl,

O-phenyl optionally substituted with up to two substituents each independently selected from R^{12},

NH_2 where one H is optionally replaced with one substituent selected from $S(O)_2(C_1\text{-}C_3)$alkyl, $S(O)_2NH(C_1\text{-}C_3)$alkyl, $S(O)_2CF_3$, $C(O)R^7$, $S(O)_2N[(C_1\text{-}C_3)alkyl]_2$, $C(O)O(C_1\text{-}C_4)$alkyl, $C(O)NH(C_1\text{-}C_4)$alkyl, $C(O)N[(C_1\text{-}C_3)alkyl]_2$,  , and $(C_1\text{-}C_4)$alkyl optionally substituted with one OH group,

phenyl optionally substituted with 1 or 2 substituents each independently selected from R^{12}, OH, S-$(C_1\text{-}C_3)$alkyl, $C(O)NH_2$, $S(O)_2NH_2$, $C(O)N[(C_1\text{-}C_3)alkyl]_2$, $S(O)_2(C_1\text{-}C_3)$alkyl, $S(O)_2NHC(O)(C_1\text{-}C_3)$alkyl, $C(O)(C_1\text{-}C_3)$alkyl, $C(O)NH(C_1\text{-}C_3)$alkyl, $NHS(O)_2(C_1\text{-}C_3)$alkyl, $NHS(O)_2N[(C_1\text{-}C_3)alkyl]_2$, $NHC(O)NH(C_1\text{-}C_3)$alkyl, $NHC(O)N[(C_1\text{-}C_3)alkyl]_2$, $NHC(O)NH_2$, $S(O)_2N[(C_1\text{-}C_3)alkyl]_2$, $NHS(O)_2NH(C_1\text{-}C_3)$alkyl, $NHC(O)(C_1\text{-}C_3)$alkyl, $S(O)_2NH(C_1\text{-}C_3)$alkyl optionally substituted with 1 substituent selected from $(C_1\text{-}C_3)$alkoxy, $NH(C_1\text{-}C_3)$alkyl,

$N[(C_1\text{-}C_3)alkyl]_2$, and  ,

$(C_1\text{-}C_3)$alkyl substituted with one substituent selected from $NHS(O)_2(C_1\text{-}C_3)alkyl$, $NHS(O)_2N[(C_1\text{-}C_3)alkyl]_2$, $NHC(O)NH(C_1\text{-}C_3)alkyl$, $NHC(O)N[(C_1\text{-}C_3)alkyl]_2$, $NHS(O)_2NH(C_1\text{-}C_3)alkyl$, and $NHC(O)(C_1\text{-}C_3)alkyl$, and

$(C_1\text{-}C_3)$alkoxy substituted with 1 substituent selected from OH, $NH(C_1\text{-}C_3)alkyl$, $N[(C_1\text{-}C_3)alkyl]_2$, $(C_1\text{-}C_3)$alkoxy, and  ,

pyrrolyl optionally substituted with one substituent selected from R^{12}, $C(O)N[(C_1\text{-}C_3)alkyl]_2$, $C(O)NH(C_1\text{-}C_3)alkyl$, $C(O)(C_1\text{-}C_3)alkyl$,  , and $S(O)_2(C_1\text{-}C_3)alkyl$,

pyrazolyl optionally substituted with up to 3 substituents each selected independently from R^{12}, $C(O)N[(C_1\text{-}C_3)alkyl]_2$, $C(O)NH(C_1\text{-}C_3)alkyl$, and  , and

another heteroaryl optionally substituted with up to two substituents each independently selected from R^{12};

R^2 is in each instance selected independently from $(C_1\text{-}C_3)$alkyl, halo, $(C_1\text{-}C_3)$alkoxy, CF_3, NO_2, NH_2, CN, and COOH;

R^3 is selected from H, $(C_1\text{-}C_3)$alkyl, and halo;

R^4 is selected from H and $(C_1\text{-}C_3)$alkyl-OH;

R^5 is selected from H, OH and $(C_1\text{-}C_3)$alkyl;

R^6 is selected from H, $C(O)OR^7$, $C(O)R^9$, and

$(C_1\text{-}C_6)$alkyl optionally substituted with one substituent selected from OH, $NHS(O)_2(C_1\text{-}C_3)alkyl$, and $NHC(O)(C_1\text{-}C_3)alkyl$;

R^7 is selected from H and $(C_1\text{-}C_4)$alkyl;

R^8 is selected from OH, NH_2, $N[(C_1\text{-}C_3)alkyl]_2$, morpholinyl, and pyrrolidinyl;

R^9 is selected from NH_2, morpholinyl, $N[(C_1\text{-}C_3)alkyl]_2$, and

$NH(C_1\text{-}C_3)$alkyl optionally substituted with one substituent selected from OH, COOH, and $N[(C_1\text{-}C_3)alkyl]_2$;

R^{10} is selected from $(C_3\text{-}C_6)$cycloalkyl, morpholinyl, $N[(C_1\text{-}C_4)alkyl]_2$, $(C_1\text{-}C_3)$alkoxy, heteroaryl optionally substituted with 1 or 2 substituents each independently selected from $(C_1\text{-}C_3)$alkyl, $(C_1\text{-}C_3)$alkoxy, OH, halo and CF_3,

phenyl optionally substituted with 1 or 2 substituents each independently selected from $(C_1\text{-}C_3)$alkyl, $(C_1\text{-}C_3)$alkoxy, OH, halo and CF_3,

$(C_1\text{-}C_3)$alkyl optionally substituted with one substituent selected from phenyl, imidazolyl, and  ,

$NH(C_1\text{-}C_4)$alkyl optionally substituted with 1 phenyl ring optionally substituted with 1 or 2 substituents each independently selected from $(C_1\text{-}C_3)$alkyl, $(C_1\text{-}C_3)$alkoxy, halo and CF_3, and

NH-phenyl where said phenyl is optionally substituted with 1 or 2 substituents each independently selected from $(C_1\text{-}C_3)$alkyl, $(C_1\text{-}C_3)$alkoxy, halo and CF_3;

R^{11} is selected from H, $C(O)N[(C_1\text{-}C_3)alkyl]_2$, C(O)-pyrrolidinyl, C(O)NH-phenyl, and $C(O)NH(C_1\text{-}C_3)$alkyl optionally substituted with 1 phenyl ring;

R^{12} is selected from $(C_1\text{-}C_6)$alkyl, $(C_1\text{-}C_3)$alkoxy, halo, NO_2, CN, CF_3, O-CF_3, and phenyl optionally substituted with up to 2 substituents each selected independently from halo, $(C_1\text{-}C_3)$alkyl, and $(C_1\text{-}C_3)$alkoxy;

X is selected from O, S, CH_2, and NH, and

when X is NH, the H on NH is optionally replaced with $C(O)(C_1\text{-}C_3)$alkyl, $S(O)_2(C_1\text{-}C_3)$alkyl, or $(C_1\text{-}C_6)$alkyl

and when X is O, S, or CH_2, the  moiety is optionally substituted

by replacing any H atom in the  moiety with $(C_1\text{-}C_4)$alkyl;

m is selected from 0, 1 and 2;

n is selected from 1 and 2;

-- -- is selected from a double bond and a single bond;

or a pharmaceutically acceptable salt, ester or carbonate thereof.

2. A compound of claim 1 wherein

R^1 is selected from H, $C(O)R^{10}$, tetrahydropyranyl, $(C_3\text{-}C_6)$cycloalkyl,

$S(O)_2$-phenyl where said phenyl is optionally substituted with 1 or 2 substituents each independently selected from R^{12},-NH_2, $NHC(O)(C_1\text{-}C_3)$alkyl, $NH(C_1\text{-}C_3)alkyl\text{-}N[(C_1\text{-}C_3)alkyl]_2$, $NH(C_1\text{-}C_3)$alkyl-OH, COOH, OH, and $(C_1\text{-}C_3)$alkoxy substituted with 1 substituent selected from $N[(C_1\text{-}C_3)alkyl]_2$, OH, and  ,

$S(O)_2(C_1\text{-}C_3)$alkyl optionally substituted with one phenyl ring,

$(C_1\text{-}C_6)$alkyl optionally substituted with 1 or 2 substituents each independently selected from OR^{11}, $C(O)R^{10}$, $C(O)OR^7$, $N[(C_1\text{-}C_3)alkyl]_2$,



$(C_3\text{-}C_6)$cycloalkyl, dioxopyrrolidinyl,

$(C_1\text{-}C_3)$alkoxy optionally substituted with 1 or 2 substituents each



selected independently from OH, , and imidazolyl,

O-phenyl optionally substituted with up to two substituents each independently selected from R^{12},

NH_2 where one H is optionally replaced with one substituent selected from $S(O)_2(C_1\text{-}C_3)$alkyl, $S(O)_2NH(C_1\text{-}C_3)$alkyl, $S(O)_2CF_3$, $C(O)R^7$, $S(O)_2N[(C_1\text{-}C_3)alkyl]_2$, $C(O)NH(C_1\text{-}C_4)$alkyl,



$C(O)N[(C_1\text{-}C_3)alkyl]_2$, , and

$(C_1\text{-}C_4)$alkyl optionally substituted with one OH group,

phenyl optionally substituted with 1 or 2 substituents each independently selected from R^{12}, OH, S-$(C_1\text{-}C_3)$alkyl, $C(O)NH_2$, $S(O)_2NH_2$, $C(O)N[(C_1\text{-}C_3)alkyl]_2$, $S(O)_2(C_1\text{-}C_3)$alkyl, $S(O)_2NHC(O)(C_1\text{-}C_3)$alkyl, $C(O)(C_1\text{-}C_3)$alkyl, $C(O)NH(C_1\text{-}C_3)$alkyl, $NHS(O)_2(C_1\text{-}C_3)$alkyl, $NHS(O)_2N[(C_1\text{-}C_3)alkyl]_2$, $NHC(O)NH(C_1\text{-}C_3)$alkyl, $NHC(O)N[(C_1\text{-}C_3)alkyl]_2$, $NHC(O)NH_2$, $S(O)_2N[(C_1\text{-}C_3)alkyl]_2$, $NHS(O)_2NH(C_1\text{-}C_3)$alkyl, $NHC(O)(C_1\text{-}C_3)$alkyl,

$S(O)_2NH(C_1\text{-}C_3)$alkyl optionally substituted with 1 substituent selected from $(C_1\text{-}C_3)$alkoxy, $NH(C_1\text{-}C_3)$alkyl,



$N[(C_1\text{-}C_3)alkyl]_2$, and ,

$(C_1\text{-}C_3)$alkyl substituted with one substituent selected from $NHS(O)_2(C_1\text{-}C_3)$alkyl, $NHS(O)_2N[(C_1\text{-}C_3)alkyl]_2$, $NHC(O)NH(C_1\text{-}C_3)$alkyl, $NHC(O)N[(C_1\text{-}C_3)alkyl]_2$, $NHS(O)_2NH(C_1\text{-}C_3)$alkyl, and $NHC(O)(C_1\text{-}C_3)$alkyl, and

$(C_1\text{-}C_3)$alkoxy substituted with 1 substituent selected from OH, $NH(C_1\text{-}C_3)$alkyl, $N[(C_1\text{-}C_3)alkyl]_2$, $(C_1\text{-}C_3)$alkoxy,



and ,

pyrrolyl optionally substituted with one substituent selected from R^{12},

$C(O)N[(C_1\text{-}C_3)alkyl]_2$, $C(O)NH(C_1\text{-}C_3)alkyl$, $C(O)(C_1\text{-}C_3)alkyl$,


, and $S(O)_2(C_1\text{-}C_3)alkyl$,

pyrazolyl optionally substituted with up to 3 substituents each selected independently from R^{12}, $C(O)N[(C_1\text{-}C_3)alkyl]_2$, $C(O)NH(C_1\text{-}C_3)alkyl$,

and 
, and

another heteroaryl optionally substituted with up to two substituents each independently selected from R^{12};

R^{10} is selected from $(C_3\text{-}C_6)$cycloalkyl, $N[(C_1\text{-}C_4)alkyl]_2$, $(C_1\text{-}C_3)alkyl$, $NH(C_1\text{-}C_4)alkyl$, heteroaryl optionally substituted with 1 or 2 substituents each independently selected from $(C_1\text{-}C_3)alkyl$, $(C_1\text{-}C_3)alkoxy$, OH, halo and CF_3,

phenyl optionally substituted with 1 or 2 substituents each independently selected from $(C_1\text{-}C_3)alkyl$, $(C_1\text{-}C_3)alkoxy$, OH, halo and CF_3;

R^{11} is H;

R^{12} is selected from $(C_1\text{-}C_3)alkyl$, $(C_1\text{-}C_3)alkoxy$, halo, NO_2, CN, CF_3, and O-CF_3; and

m is selected from 0 and 1.

3. A compound of claim 1 wherein

W is selected from

O-phenyl optionally substituted with up to 2 substituents selected from R^{12},

phenyl optionally substituted with up to 2 substituents each selected independently from R^{12}, OH, $COOR^7$, $C(O)NHR^7$, $S(O)_2(C_1\text{-}C_3)alkyl$, $NHS(O)_2(C_1\text{-}C_3)alkyl$, $N[(C_1\text{-}C_3)alkyl]_2$, $NH(C_1\text{-}C_3)alkyl$,

$NHC(O)(C_1\text{-}C_3)alkyl$, 
, and

$(C_1\text{-}C_3)alkoxy$ substituted with 1 substituent selected from

$N[(C_1\text{-}C_3)alkyl]_2$, $NH(C_1\text{-}C_3)alkyl$, and 

indolyl optionally substituted with 1 or 2 substituents each selected independently from R^{12}, OH, $C(O)O(C_1\text{-}C_4)alkyl$,

$(C_1\text{-}C_3)alkyl$ substituted with 1 or 2 substituents each selected independently from OH, $C(O)R^8$, $(C_1\text{-}C_3)alkoxy$, pyrrolidinyl,


, imidazolyl, $NH(C_1\text{-}C_3)alkyl$, and $N[(C_1\text{-}C_3)alkyl]_2$, and

$(C_1\text{-}C_3)alkoxy$ substituted with 1 substituent selected from $NH(C_1\text{-}C_3)alkyl$,

$N[(C_1\text{-}C_3)alkyl]_2$, pyrrolidinyl, imidazolyl,  and $(C_1\text{-}C_3)alkoxy$, and

another heteroaryl optionally substituted with up to 3 substituents each independently selected from R^{12};

R^1 is selected from H, $C(O)R^{10}$, tetrahydropyranyl, $(C_3\text{-}C_6)cycloalkyl$,

$S(O)_2$-phenyl where said phenyl is optionally substituted with 1 or 2 substituents each independently selected from R^{12},-NH_2, $NHC(O)(C_1\text{-}C_3)alkyl$, $NH(C_1\text{-}C_3)alkyl\text{-}N[(C_1\text{-}C_3)alkyl]_2$, $NH(C_1\text{-}C_3)alkyl$-OH, COOH, OH, and $(C_1\text{-}C_3)alkoxy$ substituted with 1 substituent selected from $N[(C_1\text{-}C_3)alkyl]_2$, OH, and  ,

$S(O)_2(C_1\text{-}C_3)alkyl$ optionally substituted with one phenyl ring,

$(C_1\text{-}C_6)alkyl$ optionally substituted with 1 or 2 substituents each independently selected from OR^{11}, $C(O)R^{10}$, $C(O)OR^7$, $N[(C_1\text{-}C_3)alkyl]_2$, $(C_3\text{-}C_6)cycloalkyl$, dioxopyrrolidinyl,  ,

$(C_1\text{-}C_3)alkoxy$ optionally substituted with 1 or 2 substituents each selected independently from OH,  , and imidazolyl,

O-phenyl optionally substituted with up to two substituents each independently selected from R^{12},

NH_2 where one H is optionally replaced with one substituent selected from $S(O)_2(C_1\text{-}C_3)alkyl$, $S(O)_2NH(C_1\text{-}C_3)alkyl$, $S(O)_2CF_3$, $C(O)R^7$, $S(O)_2N[(C_1\text{-}C_3)alkyl]_2$, $C(O)NH(C_1\text{-}C_4)alkyl$, $C(O)N[(C_1\text{-}C_3)alkyl]_2$,  , and

$(C_1\text{-}C_4)alkyl$ optionally substituted with one OH group,

phenyl optionally substituted with 1 or 2 substituents each independently selected from R^{12}, OH, S-$(C_1\text{-}C_3)alkyl$, $C(O)NH_2$, $S(O)_2NH_2$, $C(O)N[(C_1\text{-}C_3)alkyl]_2$, $S(O)_2(C_1\text{-}C_3)alkyl$, $S(O)_2NHC(O)(C_1\text{-}C_3)alkyl$, $C(O)(C_1\text{-}C_3)alkyl$, $C(O)NH(C_1\text{-}C_3)alkyl$, $NHS(O)_2(C_1\text{-}C_3)alkyl$, $NHS(O)_2N[(C_1\text{-}C_3)alkyl]_2$, $NHC(O)NH(C_1\text{-}C_3)alkyl$, $NHC(O)N[(C_1\text{-}C_3)alkyl]_2$, $NHC(O)NH_2$, $S(O)_2N[(C_1\text{-}C_3)alkyl]_2$, $NHS(O)_2NH(C_1\text{-}C_3)alkyl$, $NHC(O)(C_1\text{-}C_3)alkyl$, $S(O)_2NH(C_1\text{-}C_3)alkyl$ optionally substituted with 1 substituent

selected from $(C_1\text{-}C_3)$alkoxy, $NH(C_1\text{-}C_3)$alkyl,

$N[(C_1\text{-}C_3)alkyl]_2$, and  ,

$(C_1\text{-}C_3)$alkyl substituted with one substituent selected from $NHS(O)_2(C_1\text{-}C_3)$alkyl, $NHS(O)_2N[(C_1\text{-}C_3)alkyl]_2$, $NHC(O)NH(C_1\text{-}C_3)$alkyl, $NHC(O)N[(C_1\text{-}C_3)alkyl]_2$, $NHS(O)_2NH(C_1\text{-}C_3)$alkyl, and $NHC(O)(C_1\text{-}C_3)$alkyl, and

$(C_1\text{-}C_3)$alkoxy substituted with 1 substituent selected from OH, $NH(C_1\text{-}C_3)$alkyl, $N[(C_1\text{-}C_3)alkyl]_2$, $(C_1\text{-}C_3)$alkoxy, and  ,

pyrrolyl optionally substituted with one substituent selected from R^{12}, $C(O)N[(C_1\text{-}C_3)alkyl]_2$, $C(O)NH(C_1\text{-}C_3)$alkyl, $C(O)(C_1\text{-}C_3)$alkyl,  , and $S(O)_2(C_1\text{-}C_3)$alkyl,

pyrazolyl optionally substituted with up to 3 substituents each selected independently from R^{12}, $C(O)N[(C_1\text{-}C_3)alkyl]_2$, $C(O)NH(C_1\text{-}C_3)$alkyl, and  , and

another heteroaryl optionally substituted with up to two substituents each independently selected from R^{12};

R^2 is in each instance selected independently from $(C_1\text{-}C_3)$alkyl, halo, $(C_1\text{-}C_3)$alkoxy or CF_3;

R^4 and R^5 are each H;

R^6 is selected from H, and

$(C_1\text{-}C_6)$alkyl optionally substituted with one substituent selected from OH, $NHS(O)_2(C_1\text{-}C_3)$alkyl, and $NHC(O)(C_1\text{-}C_3)$alkyl;

R^{10} is selected from $(C_3\text{-}C_6)$cycloalkyl, $N[(C_1\text{-}C_4)alkyl]_2$, $(C_1\text{-}C_3)$alkyl, $NH(C_1\text{-}C_4)$alkyl,

heteroaryl optionally substituted with 1 or 2 substituents each independently selected from $(C_1\text{-}C_3)$alkyl, $(C_1\text{-}C_3)$alkoxy, OH, halo and CF_3,

phenyl optionally substituted with 1 or 2 substituents each independently selected from $(C_1\text{-}C_3)$alkyl, $(C_1\text{-}C_3)$alkoxy, OH, halo and CF_3;

R^{11} is H;

R^{12} is selected from $(C_1\text{-}C_3)$alkyl, $(C_1\text{-}C_3)$alkoxy, halo, NO_2, CN, CF_3, and O-CF_3; and

m is selected from 0 and 1.

4. A compound of claim 3 wherein

W is selected from

phenyl optionally substituted with up to 2 substituents each selected independently from R^{12}, and

$(C_1$-$C_3)$alkoxy substituted with 1 substituent selected from

$N[(C_1$-$C_3)alkyl]_2$, $NH(C_1$-$C_3)$alkyl, and  ,

indolyl optionally substituted with 1 or 2 substituents each selected independently from R^{12},

$(C_1$-$C_3)$alkyl substituted with 1 or 2 substituents each selected independently from OH and $(C_1$-$C_3)$alkoxy, and

another heteroaryl optionally substituted with up to 3 substituents each independently selected from R^{12}.

5. A compound of claim 3 wherein L is CHR^5-CHR^6.

6. A compound of claim 3 wherein

R^1 is selected from H, $C(O)R^{10}$, tetrahydropyranyl,

$S(O)_2$-phenyl where said phenyl is optionally substituted with 1 or 2 substituents each independently selected from R^{12}, COOH, OH, and

$(C_1$-$C_3)$alkoxy substituted with 1 substituent selected from

$N[(C_1$-$C_3)alkyl]_2$, OH, and  ,

$(C_1$-$C_6)$alkyl optionally substituted with 1 or 2 substituents each independently selected from OR^{11}, $N[(C_1$-$C_3)alkyl]_2$,

$(C_3$-$C_6)$cycloalkyl,  ,

$(C_1$-$C_3)$alkoxy optionally substituted with 1 or 2 OH,

NH_2 where one H is replaced with one substituent selected from $S(O)_2(C_1$-$C_3)$alkyl, $S(O)_2NH(C_1$-$C_3)$alkyl, $S(O)_2CF_3$, $C(O)R^7$, $S(O)_2N[(C_1$-$C_3)alkyl]_2$, $C(O)NH(C_1$-$C_4)$alkyl,

$C(O)N[(C_1$-$C_3)alkyl]_2$,  , and

$(C_1$-$C_4)$alkyl optionally substituted with one OH group,

phenyl optionally substituted with 1 or 2 substituents each independently selected from R^{12}, OH, $C(O)NH_2$, $S(O)_2NH_2$,

$S(O)_2NHC(O)(C_1\text{-}C_3)$alkyl, $C(O)NH(C_1\text{-}C_3)$alkyl,
$NHS(O)_2(C_1\text{-}C_3)$alkyl, $NHS(O)_2N[(C_1\text{-}C_3)\text{alkyl}]_2$,
$NHC(O)NH(C_1\text{-}C_3)$alkyl, $NHC(O)N[(C_1\text{-}C_3)\text{alkyl}]_2$, $NHC(O)NH_2$,
$NHS(O)_2NH(C_1\text{-}C_3)$alkyl, $NHC(O)(C_1\text{-}C_3)$alkyl,
$S(O)_2NH(C_1\text{-}C_3)$alkyl optionally substituted with 1 substituent selected from $(C_1\text{-}C_3)$alkoxy, $NH(C_1\text{-}C_3)$alkyl, $N[(C_1\text{-}C_3)\text{alkyl}]_2$, and  ,
$(C_1\text{-}C_3)$alkyl substituted with one substituent selected from $NHS(O)_2(C_1\text{-}C_3)$alkyl, $NHS(O)_2N[(C_1\text{-}C_3)\text{alkyl}]_2$, $NHC(O)NH(C_1\text{-}C_3)$alkyl, $NHC(O)N[(C_1\text{-}C_3)\text{alkyl}]_2$, $NHS(O)_2NH(C_1\text{-}C_3)$alkyl, and $NHC(O)(C_1\text{-}C_3)$alkyl, and
$(C_1\text{-}C_3)$alkoxy substituted with 1 substituent selected from OH, $NH(C_1\text{-}C_3)$alkyl, $N[(C_1\text{-}C_3)\text{alkyl}]_2$, $(C_1\text{-}C_3)$alkoxy, and  ,

pyrrolyl optionally substituted with one substituent selected from R^{12}, $C(O)N[(C_1\text{-}C_3)\text{alkyl}]_2$, $C(O)NH(C_1\text{-}C_3)$alkyl, $C(O)(C_1\text{-}C_3)$alkyl,  , and $S(O)_2(C_1\text{-}C_3)$alkyl,

pyrazolyl optionally substituted with up to 3 substituents each selected independently from R^{12}, $C(O)N[(C_1\text{-}C_3)\text{alkyl}]_2$, $C(O)NH(C_1\text{-}C_3)$alkyl, and  , and

another heteroaryl optionally substituted with up to two substituents each independently selected from R^{12}.

7. A compound of claim 1 wherein

W is selected from

phenyl optionally substituted with up to 2 substituents each selected independently from R^{12}, and

$(C_1\text{-}C_3)$alkoxy substituted with 1 substituent selected from $N[(C_1\text{-}C_3)\text{alkyl}]_2$, $NH(C_1\text{-}C_3)$alkyl, and  ,

indolyl optionally substituted with 1 or 2 substituents each selected independently from R^{12},

$(C_1$-$C_3)$alkyl substituted with 1 or 2 substituents each selected independently from OH, $(C_1$-$C_3)$alkoxy,  ,

another heteroaryl optionally substituted with up to 3 substituents each independently selected from R^{12};

L is CHR^5-CHR^6;

R^1 is selected from H, $C(O)R^{10}$, tetrahydropyranyl,

$S(O)_2$-phenyl where said phenyl is optionally substituted with 1 or 2 substituents each independently selected from R^{12}, COOH, OH, and

$(C_1$-$C_3)$alkoxy substituted with 1 substituent selected from $N[(C_1$-$C_3)alkyl]_2$, OH, and  ,

$(C_1$-$C_6)$alkyl optionally substituted with 1 or 2 substituents each independently selected from OR^{11}, $N[(C_1$-$C_3)alkyl]_2$,

$(C_3$-$C_6)$cycloalkyl,  ,

$(C_1$-$C_3)$alkoxy optionally substituted with 1 or 2 OH groups,

NH_2 where one H is replaced with one substituent selected from $S(O)_2(C_1$-$C_3)$alkyl, $S(O)_2NH(C_1$-$C_3)$alkyl, $S(O)_2CF_3$, $C(O)R^7$, $S(O)_2N[(C_1$-$C_3)alkyl]_2$, $C(O)NH(C_1$-$C_4)$alkyl, $C(O)N[(C_1$-$C_3)alkyl]_2$,  , and

$(C_1$-$C_4)$alkyl optionally substituted with one OH group,

phenyl optionally substituted with 1 or 2 substituents each independently selected from R^{12}, OH, $C(O)NH_2$, $S(O)_2NH_2$, $S(O)_2NHC(O)(C_1$-$C_3)$alkyl, $C(O)NH(C_1$-$C_3)$alkyl, $NHS(O)_2(C_1$-$C_3)$alkyl, $NHS(O)_2N[(C_1$-$C_3)alkyl]_2$, $NHC(O)NH(C_1$-$C_3)$alkyl, $NHC(O)N[(C_1$-$C_3)alkyl]_2$, $NHC(O)NH_2$, $NHS(O)_2NH(C_1$-$C_3)$alkyl, $NHC(O)(C_1$-$C_3)$alkyl, $S(O)_2NH(C_1$-$C_3)$alkyl optionally substituted with 1 substituent selected from $(C_1$-$C_3)$alkoxy, $NH(C_1$-$C_3)$alkyl, $N[(C_1$-$C_3)alkyl]_2$, and  ,

$(C_1$-$C_3)$alkyl substituted with one substituent selected from $NHS(O)_2(C_1$-$C_3)$alkyl, $NHS(O)_2N[(C_1$-$C_3)alkyl]_2$, $NHC(O)NH(C_1$-$C_3)$alkyl, $NHC(O)N[(C_1$-$C_3)alkyl]_2$,

$NHS(O)_2NH(C_1\text{-}C_3)$alkyl, and $NHC(O)(C_1\text{-}C_3)$alkyl, and

$(C_1\text{-}C_3)$alkoxy substituted with 1 substituent selected

from OH, $NH(C_1\text{-}C_3)$alkyl, $N[(C_1\text{-}C_3)alkyl]_2$, $(C_1\text{-}C_3)$alkoxy,

and  ,

pyrrolyl optionally substituted with one substituent selected from R^{12},

$C(O)N[(C_1\text{-}C_3)alkyl]_2$, $C(O)NH(C_1\text{-}C_3)$alkyl, $C(O)(C_1\text{-}C_3)$alkyl,

 , and $S(O)_2(C_1\text{-}C_3)$alkyl,

pyrazolyl optionally substituted with up to 3 substituents each selected

independently from R^{12}, $C(O)N[(C_1\text{-}C_3)alkyl]_2$, $C(O)NH(C_1\text{-}C_3)$alkyl,

and  , and

another heteroaryl optionally substituted with up to two substituents each

independently selected from R^{12};

R^2 is halo;

R^5 is H;

R^6 is selected from H, and

$(C_1\text{-}C_6)$alkyl optionally substituted with one substituent selected from OH,

$NHS(O)_2(C_1\text{-}C_3)$alkyl, and $NHC(O)(C_1\text{-}C_3)$alkyl;

R^{10} is selected from $(C_3\text{-}C_6)$cycloalkyl, $N[(C_1\text{-}C_4)alkyl]_2$, $(C_1\text{-}C_3)$alkyl and $NH(C_1\text{-}C_4)$alkyl;

R^{11} is H;

R^{12} is selected from $(C_1\text{-}C_3)$alkyl, $(C_1\text{-}C_3)$alkoxy, halo, NO_2, CN, CF_3, and O-CF_3; and

m is selected from 0, and 1.

8. A compound of claim 7 wherein

W is selected from

phenyl optionally substituted with up to 2 substituents each selected

independently from R^{12}, and

$(C_1\text{-}C_3)$alkoxy substituted with 1 substituent selected from

$N[(C_1\text{-}C_3)alkyl]_2$, $NH(C_1\text{-}C_3)$alkyl, and  ,

indolyl optionally substituted with 1 or 2 substituents each selected independently

from R^{12},

$(C_1\text{-}C_3)$alkyl substituted with 1 or 2 substituents each selected

independently from OH, and $(C_1\text{-}C_3)$alkoxy.

9. A compound of claim 7 wherein

R^1 is selected from H,

$S(O)_2$-phenyl where said phenyl is optionally substituted with 1 or 2 substituents each independently selected from R^{12}, COOH, and OH,

$(C_1\text{-}C_6)$alkyl optionally substituted with 1 or 2 substituents each independently selected from OR^{11}, $(C_3\text{-}C_6)$cycloalkyl,  , and

$(C_1\text{-}C_3)$alkoxy optionally substituted with 1 or 2 OH groups,

NH_2 where one H is replaced with one substituent selected from

$S(O)_2(C_1\text{-}C_3)$alkyl, $S(O)_2NH(C_1\text{-}C_3)$alkyl, $S(O)_2CF_3$, $C(O)R^7$, $S(O)_2N[(C_1\text{-}C_3)\text{alkyl}]_2$, $C(O)NH(C_1\text{-}C_4)$alkyl, $C(O)N[(C_1\text{-}C_3)\text{alkyl}]_2$,  , and

$(C_1\text{-}C_4)$alkyl optionally substituted with one OH group,

phenyl optionally substituted with 1 or 2 substituents each independently selected from R^{12}, OH, $C(O)NH_2$, $S(O)_2NH_2$, $S(O)_2NHC(O)(C_1\text{-}C_3)$alkyl, $C(O)NH(C_1\text{-}C_3)$alkyl, $NHS(O)_2(C_1\text{-}C_3)$alkyl, $NHS(O)_2N[(C_1\text{-}C_3)\text{alkyl}]_2$, $NHC(O)NH(C_1\text{-}C_3)$alkyl, $NHC(O)N[(C_1\text{-}C_3)\text{alkyl}]_2$, $NHC(O)NH_2$, $NHS(O)_2NH(C_1\text{-}C_3)$alkyl, $NHC(O)(C_1\text{-}C_3)$alkyl, $S(O)_2NH(C_1\text{-}C_3)$alkyl optionally substituted with 1 substituent selected from $(C_1\text{-}C_3)$alkoxy, $NH(C_1\text{-}C_3)$alkyl, $N[(C_1\text{-}C_3)\text{alkyl}]_2$, and  ,

$(C_1\text{-}C_3)$alkyl substituted with one substituent selected from $NHS(O)_2(C_1\text{-}C_3)$alkyl, $NHS(O)_2N[(C_1\text{-}C_3)\text{alkyl}]_2$, $NHC(O)NH(C_1\text{-}C_3)$alkyl, $NHC(O)N[(C_1\text{-}C_3)\text{alkyl}]_2$, $NHS(O)_2NH(C_1\text{-}C_3)$alkyl, and $NHC(O)(C_1\text{-}C_3)$alkyl, and

$(C_1\text{-}C_3)$alkoxy substituted with 1 substituent selected from OH, $NH(C_1\text{-}C_3)$alkyl, $N[(C_1\text{-}C_3)\text{alkyl}]_2$, $(C_1\text{-}C_3)$alkoxy, and  ,

pyrrolyl optionally substituted with one substituent selected from R^{12}, $C(O)N[(C_1\text{-}C_3)\text{alkyl}]_2$, $C(O)NH(C_1\text{-}C_3)$alkyl, $C(O)(C_1\text{-}C_3)$alkyl, and



pyrazolyl optionally substituted with up to 3 substituents each selected independently from R^{12}, C(O)N[(C_1-C_3)alkyl]$_2$, C(O)NH(C_1-C_3)alkyl,

and  .

10. A compound of claim 1 wherein

W is selected from

phenyl optionally substituted with up to 2 substituents each selected independently from R^{12}, and

(C_1-C_3)alkoxy substituted with 1 substituent selected from

N[(C_1-C_3)alkyl]$_2$, NH(C_1-C_3)alkyl, and  ,

indolyl optionally substituted with 1 or 2 substituents each selected independently from R^{12},

(C_1-C_3)alkyl substituted with 1 or 2 substituents each selected independently from OH, and (C_1-C_3)alkoxy;

L is CHR^5-CHR^6;

R^1 is selected from H,

$S(O)_2$-phenyl where said phenyl is optionally substituted with 1 or 2 substituents each independently selected from R^{12}, COOH, and OH,

(C_1-C_6)alkyl optionally substituted with 1 or 2 substituents each independently selected from OR^{11}, (C_3-C_6)cycloalkyl,  , and

(C_1-C_3)alkoxy optionally substituted with 1 or 2 OH groups,

NH_2 where one H is replaced with one substituent selected from

$S(O)_2$(C_1-C_3)alkyl, $S(O)_2NH$(C_1-C_3)alkyl, $S(O)_2CF_3$, $C(O)R^7$,

$S(O)_2N$[(C_1-C_3)alkyl]$_2$, C(O)NH(C_1-C_4)alkyl, C(O)N[(C_1-C_3)alkyl]$_2$,

 , and

(C_1-C_4)alkyl optionally substituted with one OH group,

phenyl optionally substituted with 1 or 2 substituents each independently selected from R^{12}, OH, $C(O)NH_2$, $S(O)_2NH_2$,

$S(O)_2NHC(O)$(C_1-C_3)alkyl, C(O)NH(C_1-C_3)alkyl,

$NHS(O)_2$(C_1-C_3)alkyl, $NHS(O)_2N$[(C_1-C_3)alkyl]$_2$,

$NHC(O)NH(C_1\text{-}C_3)alkyl$, $NHC(O)N[(C_1\text{-}C_3)alkyl]_2$, $NHC(O)NH_2$, $NHS(O)_2NH(C_1\text{-}C_3)alkyl$, $NHC(O)(C_1\text{-}C_3)alkyl$, $S(O)_2NH(C_1\text{-}C_3)alkyl$ optionally substituted with 1 substituent selected from $(C_1\text{-}C_3)alkoxy$, $NH(C_1\text{-}C_3)alkyl$, $N[(C_1\text{-}C_3)alkyl]_2$, and  ,

$(C_1\text{-}C_3)alkyl$ substituted with one substituent selected from $NHS(O)_2(C_1\text{-}C_3)alkyl$, $NHS(O)_2N[(C_1\text{-}C_3)alkyl]_2$, $NHC(O)NH(C_1\text{-}C_3)alkyl$, $NHC(O)N[(C_1\text{-}C_3)alkyl]_2$, $NHS(O)_2NH(C_1\text{-}C_3)alkyl$, and $NHC(O)(C_1\text{-}C_3)alkyl$, and

$(C_1\text{-}C_3)alkoxy$ substituted with 1 substituent selected from OH, $NH(C_1\text{-}C_3)alkyl$, $N[(C_1\text{-}C_3)alkyl]_2$, $(C_1\text{-}C_3)alkoxy$, and  ,

pyrrolyl optionally substituted with one substituent selected from R^{12}, $C(O)N[(C_1\text{-}C_3)alkyl]_2$, $C(O)NH(C_1\text{-}C_3)alkyl$, $C(O)(C_1\text{-}C_3)alkyl$, and  ,

pyrazolyl optionally substituted with up to 3 substituents each selected independently from R^{12}, $C(O)N[(C_1\text{-}C_3)alkyl]_2$, $C(O)NH(C_1\text{-}C_3)alkyl$, and  ;

R^2 is halo;

R^3 is selected from H, and $(C_1)alkyl$;

R^5 is H;

R^6 is selected from H, and $(C_1\text{-}C_6)alkyl$ optionally substituted with one OH group;

R^7 is selected from H and $(C_1\text{-}C_4)alkyl$;

R^{11} is H;

R^{12} is selected from $(C_1\text{-}C_3)alkyl$, $(C_1\text{-}C_3)alkoxy$, halo, CN, and CF_3;

m is selected from 0, and 1; and

n is 1.

11. A compound of claim 10 wherein L is $CH_2\text{-}CH_2$.

12. A pharmaceutical composition comprising a compound of Claim 1.

13. A pharmaceutical composition comprising a compound of Claim 2.

14. A pharmaceutical composition comprising a compound of Claim 3.

15. A pharmaceutical composition comprising a compound of Claim 4.

16. A pharmaceutical composition comprising a compound of Claim 5.

17. A pharmaceutical composition comprising a compound of Claim 6.

18. A pharmaceutical composition comprising a compound of Claim 7.

19. A pharmaceutical composition comprising a compound of Claim 8.

20. A pharmaceutical composition comprising a compound of Claim 9.

21. A pharmaceutical composition comprising a compound of Claim 10.

22. A pharmaceutical composition comprising a compound of Claim 11.

23. A method of treating a hyper-proliferative disorder in a mammal comprising administering to a mammal in need thereof a pharmaceutically effective amount of a compound of Claim I.

24. A method of treating a hyper-proliferative disorder in a mammal comprising administering to a mammal in need thereof a pharmaceutically effective amount of a compound of Claim 2.

25. A method of treating a hyper-proliferative disorder in a mammal comprising administering to a mammal in need thereof a pharmaceutically effective amount of a compound of Claim 3.

26. A method of treating a hyper-proliferative disorder in a mammal comprising administering to a mammal in need thereof a pharmaceutically effective amount of a compound of Claim 4.

27. A method of treating a hyper-proliferative disorder in a mammal comprising administering to a mammal in need thereof a pharmaceutically effective amount of a compound of Claim 5.

28. A method of treating a hyper-proliferative disorder in a mammal comprising administering to a mammal in need thereof a pharmaceutically effective amount of a compound of Claim 6.

29. A method of treating a hyper-proliferative disorder in a mammal comprising administering to a mammal in need thereof a pharmaceutically effective amount of a compound of Claim 7.

30. A method of treating a hyper-proliferative disorder in a mammal comprising administering to a mammal in need thereof a pharmaceutically effective amount of a compound of Claim 8.

31. A method of treating a hyper-proliferative disorder in a mammal comprising administering to a mammal in need thereof a pharmaceutically effective amount of a compound of Claim 9.

32. A method of treating a hyper-proliferative disorder in a mammal comprising administering to a mammal in need thereof a pharmaceutically effective amount of a compound of Claim 10.

33. A method of treating a hyper-proliferative disorder in a mammal comprising administering to a mammal in need thereof a pharmaceutically effective amount of a compound of Claim 11.

34. A method of any of Claim 23, Claim 24, Claim 25, Claim 26, Claim 27, Claim 28, Claim 29, Claim 30, Claim 31, Claim 32, and Claim 33, wherein the hyper-proliferative disorder is selected from solid tumors, lymphomas, sarcomas and leukemias.

35. A method of claim 34 wherein the disorder is selected from solid tumors.

36. A method according to claim 35 wherein the tumor is selected from cancers of the breast, reproductive organs, respiratory tract, brain, head, neck, hematopoietic tissue, digestive tract and urinary tract.

37. A method according to claim 36 wherein the disorder is selected from cancers of the breast, prostate, ovary, lung, colon, head, neck and hematopoietic tissue.

INTERNATIONAL SEARCH REPORT

International Application No
PCT/US2004/011990

A. CLASSIFICATION OF SUBJECT MATTER
IPC 7 C07D209/16 C07D209/26 C07D213/38 C07C259/06 C07D403/12
A61K31/16 A61P35/00

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)
IPC 7 C07C C07D

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, CHEM ABS Data, BEILSTEIN Data, WPI Data, PAJ

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category °	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	EP 0 301 861 A1 (TAKEDA CHEMICAL INDUSTRIES, LTD., JAPAN) 1 February 1989 (1989-02-01) claim 1	1-37
A	US 5 929 097 A (DU MILA T ET AL) 27 July 1999 (1999-07-27) claim 1; example 94	1-37
A	PATENT ABSTRACTS OF JAPAN vol. 1998, no. 12, 31 October 1998 (1998-10-31) -& JP 10 182583 A (MITSUI CHEM INC.), 7 July 1998 (1998-07-07) pages 5-13 abstract	1-37

-/--

[X] Further documents are listed in the continuation of box C.

[X] Patent family members are listed in annex.

° Special categories of cited documents :

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier document but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"&" document member of the same patent family

Date of the actual completion of the international search	Date of mailing of the international search report
2 August 2004	09/08/2004

Name and mailing address of the ISA	Authorized officer
European Patent Office, P.B. 5818 Patentlaan 2 NL – 2280 HV Rijswijk Tel. (+31-70) 340-2040, Tx. 31 651 epo nl, Fax: (+31-70) 340-3016	Schuemacher, A

Form PCT/ISA/210 (second sheet) (January 2004)

INTERNATIONAL SEARCH REPORT

International Application No
PCT/US2004/011990

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category °	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	SUMMERS J B ET AL: "HYDROXAMIC ACID INHIBITORS OF 5-LIPOXYGENASE: QUANTITATIVE STRUCTURE-ACTIVITY RELATINSHIPS" JOURNAL OF MEDICINAL CHEMISTRY, AMERICAN CHEMICAL SOCIETY. WASHINGTON, US, vol. 33, no. 3, 1990, pages 992-998, XP001061790 ISSN: 0022-2623 charts II, III	1-37
A	MÜLLER K ET AL: "Antipsoriatic anthrones with modulated redox properties. 4. Synthesis and biological activity of novel 9,10-dihydro-1,8-dihydroxy-9-oxo-2-anthracenecarboxylic and -hydroxamic acids" JOURNAL OF MEDICINAL CHEMISTRY, AMERICAN CHEMICAL SOCIETY. WASHINGTON, US, vol. 40, no. 17, 15 August 1997 (1997-08-15), pages 2780-2787, XP002092385 ISSN: 0022-2623 table 1; compounds 4C-13C	1-37
P,A	WO 03/087066 A (SK CHEMICALS CO LTD ; IN2GEN CO LTD (KR); KIM DAE-KEE (KR); KIM JAE-SU) 23 October 2003 (2003-10-23) claim 1	1-37

Form PCT/ISA/210 (continuation of second sheet) (January 2004)

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US2004/011990

Box II Observations where certain claims were found unsearchable (Continuation of item 2 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. [X] Claims Nos.: –
because they relate to subject matter not required to be searched by this Authority, namely:

Although claims 23-37 are directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.

2. [ ] Claims Nos.:
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:

3. [ ] Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box III Observations where unity of invention is lacking (Continuation of item 3 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. [ ] As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.

2. [ ] As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.

3. [ ] As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:

4. [ ] No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

[ ] The additional search fees were accompanied by the applicant's protest.

[ ] No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

International Application No
PCT/US2004/011990

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
EP 0301861 A1	01-02-1989	AT 74269 T	15-04-1992
		CA 1317962 C	18-05-1993
		DE 3869692 D1	07-05-1992
		JP 1104033 A	21-04-1989
		JP 2748415 B2	06-05-1998
		JP 1110624 A	27-04-1989
		JP 2639568 B2	13-08-1997
		US 5272180 A	21-12-1993
US 5929097 A	27-07-1999	NONE	
JP 10182583 A	07-07-1998	NONE	
WO 03087066 A	23-10-2003	WO 03087066 A1	23-10-2003
		KR 2003081173 A	17-10-2003